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Type 1 diabetes mellitus (T1DM) results from auto-immune destruction of the insulin-
secreting β-cells of the pancreas. The most common treatment is injection of exogenous 
insulin, but this allows only partial control over blood glucose levels, so other therapies are 
needed. Pancreatic islet transplantation has shown proof of principle for cell replacement 
therapy to treat T1DM. There are several sources of cells which could be used, but much of 
the focus has been on pluripotent stem cells, which are able to self-renew indefinitely in 
culture and give rise to any cell in the body. Insulin-expressing cells have successfully been 
produced from embryonic stem cells (ESCs) by recapitulating embryonic development in 
vitro. However, problems associated with the use of ESCs mean that an alternative cell 
source is needed. In 2006, it was discovered that 4 transcription factors can reprogram 
somatic cells into induced pluripotent stem cells (iPSCs). iPSCs provide an alternative source 
of pluripotent stem cells and can be derived in a patient-specific manner. iPSCs have been 
shown to differentiate in vitro into insulin-expressing cells, but it is unknown whether iPSCs 
are truly equivalent to ESCs. Important differences have been shown to exist between iPSCs 
and ESCs which may affect the ability of iPSCs to give rise to cells of a pancreatic lineage 
and therefore limit their usefulness for the treatment of T1DM. The aim of this project is to 
identify whether iPSCs are a viable alternative to ESCs for generating β-cells in vitro for cell 
replacement therapy to treat type 1 diabetes. The differentiation potential of iPSCs and ESCs 
to give rise to first definitive endoderm (the first stage in differentiation towards a pancreatic 
lineage) in vitro will be compared, and the involvement of miRNAs in differentiation of 
ESCs and iPSCs to definitive endoderm will be investigated.  
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Chapter 1: Introduction 
 
1.1 Diabetes Mellitus  
Diabetes mellitus is defined as “a group of metabolic diseases characterized by 
hyperglycaemia resulting from defects in insulin secretion, insulin action, or both.” In 2000, 
there were around 171 million people with diabetes worldwide, and this is expected to rise to 
366 million by 2030 (World Health Organisation, 2006). 
 
1.1.1 Type 1 Diabetes Mellitus (T1DM) 
Type 1 diabetes mellitus (T1DM) accounts for around 10% of cases of adult-onset diabetes, 
and results from T cell-mediated auto-immune destruction of the insulin-secreting β-cells of 
the pancreas, leading to insufficient insulin production and causing chronic hyperglycaemia 
(Anderson & Bluestone, 2005). Long-term complications associated with the microvascular 
damage caused by chronic hyperglycaemia include retinopathy, nephropathy, neuropathy, 
and cardiovascular disease (Report of the Expert Committee on the Diagnosis & 
Classification of Diabetes Mellitus, 2003).  
Susceptibility to T1DM is largely inherited, with genetic susceptibility residing mainly in the 
HLA complexes, as well as in several other genetic loci termed insulin-dependent diabetes 
mellitus (IDDM) susceptibility genes, which are thought to be important regulators of the 
immune response. The HLA locus is thought to confer about 50% of the genetic 
susceptibility, with roughly 15% contribution from two other genes: insulin-VNTR (IDDM2) 
and CTLA-4 (IDDM12), and minor contributions from the other IDDM genes (reviewed in 
Bluestone et al., 2010). However, although a number of susceptibility alleles have been 
identified through genome-wide association studies, these have not identified monogenic 
defects relating directly to disease onset: instead, it seems more likely that a global defect in 
immune regulation may underlie disease susceptibility. Onset of the disease may also require 
exposure to environmental factors, many of which are still poorly understood, but which are 
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thought to include certain viruses e.g. congenital rubella; environmental toxins; or certain 
foods (reviewed in Daneman, 2006). 
The abnormal activation of the immune system in susceptible individuals leads to an 
inflammatory response within the pancreatic islets, termed insulitis. Histology of the 
pancreatic islets shows infiltration by macrophages and T cells. Islet antigen-reactive T cells 
have been identified both in the NOD mouse model and in human patients (Bluestone et al, 
2010). There is also a humoral response with production of antibodies by B cells to β-cell 
antigens such as insulin (Atkinson et al., 1986), glutamic acid decarboxylase (Kaufman et al., 
1992; Schott et al., 1994), and the protein tyrosine phosphatase IA2 (Lan et al., 1996; Lu et 
al., 1996). The presence of one or more of these antibodies is present in 85-90% of 
individuals diagnosed with T1DM, and can precede the clinical onset of T1DM by years 
(Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003). Other 
immune cell types are also involved in the pathogenesis of T1DM, including natural killer 
cells and monocytes (Bluestone et al., 2010).  
 
1.1.2 Type 2 Diabetes Mellitus (T2DM)  
T2DM is a complex disease, usually of late onset, which comprises around 90% of all 
diabetics. It is more heterogeneous than T1DM, as its aetiology involves not only a loss of 
responsiveness of β-cells to glucose, resulting in insufficient insulin production, but also end-
organ insulin resistance. This results in a compensatory demand for increased β-cell insulin 
production, eventually leading to β-cell death (Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 2003).  
T2DM is a complex polygenic disease, and is linked to polymorphisms in several genes 
(McCarthy & Zeggini, 2009). Environmental factors, especially obesity and other associated 
lifestyle factors such as physical inactivity and poor diet, are also known to contribute to 
T2DM pathogenesis. Obesity itself causes insulin resistance through increased release of non-
esterified fatty acids, glycerol, hormones (including leptin and adiponectin), and pro-
inflammatory cytokines from adipose tissue (Kahn et al., 2006).  
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Treatment for T2DM includes diet control and exercise, sometimes supplemented with oral 
hypoglycaemic agents. Exercise decreases hyperglycaemia as skeletal muscle activity does 
not require insulin for glucose uptake. Some oral hypoglycaemic agents used in T2DM 
treatment act to stimulate insulin secretion from the β-cells, while others act by slowing 
degradation of carbohydrates in the intestine, inhibiting hepatic glucose output, or increasing 
target-tissue responsiveness to insulin. Insulin therapy may also be needed in cases where 
first-line treatment fails to adequately control blood glucose levels (reviewed in Derosa & 
Sibilla, 2007).  
 
1.1.3 Other Types of Diabetes 
Gestational diabetes mellitus (GDM) is any degree of glucose intolerance which first occurs 
during pregnancy, and is associated with an increased risk of perinatal morbidity and 
mortality. It is caused by several hormones, including oestrogen, progesterone, and human 
placental lactogen, which cause insulin resistance, keeping blood glucose levels high so that 
adequate amounts can be taken up by the foetus. In order to compensate, β-cell numbers in 
the pregnant woman increase, resulting in higher insulin release, but in some cases this 
response is inadequate, resulting in hyperglycaemia. In the majority of cases, glucose 
regulation will return to normal after delivery (Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 2003). 
Several forms of diabetes are associated with monogenic defects in β-cell function, which are 
inherited in an autosomal dominant pattern. Several common sites of mutation have been 
identified, and include HNF-1α, HNF-4α and glucokinase. These forms of diabetes result in 
the onset of hyperglycaemia at an early age, and are referred as maturity-onset diabetes of the 
young (MODY). They are characterised by impaired insulin secretion with no defects in 
insulin action. Conversely, some rare cases of diabetes are caused by genetically determined 
abnormalities of insulin action e.g. mutations of the insulin receptor, or inability to convert 
proinsulin to insulin. Other uncommon causes of diabetes include disease of the pancreas, 
endocrinopathies, and certain drugs or chemicals (Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 2003). 
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1.2 Structure of the Pancreas 
 
Figure 1.1. Structure of the Pancreas (Encyclopaedia Britannica, 2014). Available from 
www.britannica.com/EBchecked/media/68636/Structures-of-the-pancreas-Acinar-cells-produce-digestive-
enzymes-which. 
The mature pancreas (figure 1.1) has two distinct homeostatic functions. The larger exocrine 
part consists of acinar cells which produce and secrete digestive enzymes into the intestine 
via a highly branched ductal tree, while the endocrine part consists of the highly vascularised 
islets of Langerhans which contain the hormone-producing cells that control blood glucose 
levels. These are scattered throughout the pancreatic tissue and make up less than 2% of the 
pancreas’s mass. The islets contain five cell types: insulin-secreting β-cells are the most 
abundant, making up an estimated 60-80% of the islet cells; the glucagon-secreting α-cells 
make up approximately 15-20% of the islet cells; followed by small numbers of somatostatin-
secreting δ-cells, pancreatic polypeptide-secreting PP-cells and ghrelin-secreting ε-cells 
(Martini, 2006).  
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1.3 Developmental Biology of the Pancreas  
Pancreatic development is a complicated process of morphological events accompanied by an 
elaborate pattern of cellular differentiation and lineage selection. These events are mediated 
by tissue interactions, signalling pathways and cascades of gene expression that determine 
cell fate. The expression of transcription factors throughout gastrulation and the formation of 
definitive endoderm (DE) are complex and overlapping due to the proximity of the three 
germ layers. Much of our knowledge of pancreatic development comes from studies in model 
organisms such as the mouse, chicken, zebrafish, and Xenopus and, despite differences in 
scale, pancreas development is highly conserved among these vertebrates.  
 
1.3.1 Formation of Definitive Endoderm 
Around 3-5 days post-fertilisation, the mouse embryo develops into a blastocyst which is 
comprised of an outer shell of trophoblast cells (the trophoectoderm) encasing the inner cell 
mass (ICM) and a hollow cavity known as the blastocoele. The ICM cells closer to the 
blastocoele are known as the visceral endoderm and contribute only to the formation of extra-
embryonic tissue, while the cells closer to the trophoectoderm are known as the epiblast and 
give rise to the entire embryo (Rossant & Tam, 2004). The ICM is characterised by the 
expression of a number of transcription factors, such as OCT4, SOX2 and NANOG, each of 
which is required for its establishment and maintenance (Niwa et al., 2000; Avilion et al., 
2003; Mitsui et al., 2003).  
The process of gastrulation, which begins at approximately embryonic day (E) 6.5, 
subdivides the mouse embryo into the three germ layers: the ectoderm, which gives rise to the 
skin and central nervous system; the mesoderm, which gives rise to blood, bone, and muscle; 
and the endoderm, which gives rise to the respiratory and digestive tracts and their associated 
organs. The first sign of gastrulation is the formation of the primitive streak. The epiblast, at 
this stage, is a cup-shaped epithelial layer covered on its basal surface by the visceral 
endoderm. Cells that aggregate at the anterior primitive streak near the node have the 
potential to generate both endoderm and mesoderm, suggesting that they represent 
mesendoderm progenitors (Kimelman & Griffin, 2000; Rodaway & Patient, 2001). The 
transcription factor BRACHYURY is expressed in precursor cells throughout the primitive 
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streak, making this a marker of the putative mesendoderm population, but its expression is 
subsequently restricted to mesoderm and not endoderm cells (Kubo et al., 2004). These cells 
migrate through the primitive streak and then move laterally and anteriorly to develop into 
mesoderm and endoderm respectively. The endoderm cells emerge from the anterior segment 
of the primitive streak and are incorporated into the visceral endoderm, progressively 
displacing it to extra-embryonic sites (Lawson et al., 1991). Cells that migrate early give rise 
to anterior endoderm, and cells that migrate later give rise to posterior endoderm, suggesting 
that different regions of the primitive streak constitute different signalling environments that 
are responsible for the induction of specific lineages (Murry & Keller, 2008).  
While the later stages of pancreas development have been extensively studied, relatively little 
is known about how endoderm is initially formed and specified in higher vertebrates: for 
example, which signals and genes direct the totipotent cells of the early mouse embryo to 
form a sheet of endoderm by the end of gastrulation, and how endoderm cells obtain 
positional identity and form a primitive gut tube. However, it is likely that other germ layers 
provide positional identity through soluble signalling factors. The primitive streak and node 
produce numerous growth factors, including FGF4, TGF-β family members and WNT3A, 
which have been implicated in patterning of the endoderm, although a direct role has not been 
demonstrated. FGF4 is expressed by the primitive streak (Wells & Melton, 2000), and the 
pancreas appears to arise from cells that receive intermediate levels of FGF4. Manipulations 
of FGF4 levels in the early embryo can expand or contract the pre-pancreatic domain 
(Dessimoz et al., 2006). Cells lacking FGFR1 fail to migrate through the PS and form 
endoderm/mesoderm. WNT3A is essential for primitive streak induction and germ layer 
formation. It inhibits the formation of ectoderm and induces posterior primitive streak. The 
TGF-β family of signalling molecules includes Nodal and BMP4. Nodal signalling is 
essential for primitive streak induction and germ layer formation (Murry & Keller, 2008), 
while BMP4 signalling is not essential but increases the efficiency of primitive streak 
formation through the induction of Nodal and WNT3A (Wells & Melton, 2000).  
The two earliest markers of DE are SOX17 and CER1 (Lewis & Tam, 2006). CER1 
expression in DE is transient and restricted to anterior DE (Belo et al., 1997; Biben et al., 
1998). SOX17 is essential for appropriate formation of DE, as mice lacking SOX17 do not 
develop gut endoderm (Kanai-Azuma et al., 2002). FOXA2 also plays an important role in 
DE formation, as homozygous knockout in mice is lethal due to a lack of endoderm (Sasaki 
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& Hogan, 1993; Monaghan et al., 1993). The expression of CXCR4 is also observed on the 
cell surface of DE cells (McGrath et al., 1999; Nair & Schilling, 2008). Visceral endoderm 
also expresses BRACHYURY, FOXA2 and SOX17 (Wilkinson et al., 1990) but can be 
distinguished from DE by the expression of CXCR4 (Yasunaga et al., 2005).  
 
1.3.2 Pancreatic Specification 
By the end of gastrulation, at approximately E7.5, the DE consists of a flat sheet of cells with 
anterior-posterior patterning which covers the mesoderm and ectoderm of the embryo. This 
flat sheet begins to roll up to form the primitive gut tube, while regionally distinct gene 
expression patterns emerge to specify the various endoderm organs. The DE is in contact 
with different structures along its anterior-posterior axis, including ectoderm, notochord 
plate, node, lateral mesoderm and primitive streak, which are likely to be a source of signals 
for patterning (Wells & Melton, 1999)  
By E8.5, DE cells in the region of the foregut/midgut junction are already committed to a 
pancreatic fate, as demonstrated by their ability to differentiate into all cells of the pancreatic 
lineage (Wessels & Cohen, 1967). However, the first morphological evidence of pancreas 
development is not distinguishable until approximately E9.5, with the formation of two 
independent thickenings of the primitive gut tube, first dorsal, and then ventral (Pictet et al., 
1972).  
 
Figure 1.2. Early development of the dorsal pancreas. (A) At E9, the gut endoderm is in contact with the 
notochord; (B) At E 9.5, the dorsal aortae fuse between the notochord and gut endoderm; (C) At E10, the 
mesenchyme surrounds the gut endoderm and the dorsal pancreatic bud has formed. (Slack, 1985). 
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The dorsal pancreatic bud develops in close proximity to the notochord (figure 1.2) and this 
proximity is essential for dorsal bud development. Kim et al. (1997) showed that notochord 
removal from early chicken embryos in vitro prevented proper dorsal pancreas formation and 
inhibited the expression of pancreas-specific genes. Further studies showed that the 
morphogen sonic hedgehog (SHH) was absent from the pre-pancreatic endoderm, and 
grafting experiments with chicken endoderm showed that notochord proximity to the 
endoderm could suppress SHH expression (Hebrok et al., 1998). Analysis of the notochord-
produced morphogens FGF2 and activin βB, a member of the TGFβ family, found that they 
were able to replace the notochord effect by inhibiting SHH expression (Hebrok et al., 1998; 
Kim & Melton, 1998). By E8.5-9.0, the notochord is no longer in contact with the dorsal 
pancreas due to the fusion of the two dorsal aortae between the notochord and gut endoderm 
(figure 1.2). Interaction between blood vessels and pancreatic endoderm has been shown to 
be critical for endocrine differentiation in the pancreas. In vitro studies of E8.5 dorsal 
endoderm revealed that it requires co-culture with adjacent dorsal aorta in order to 
differentiate into endocrine cells and express insulin (Lammert et al., 2001).  
After this early dependence on the dorsal aorta, pancreatic epithelium becomes enveloped in 
pancreatic mesenchyme, separating it from the dorsal aorta. Condensation of the pancreatic 
mesenchyme and evagination of the underlying endoderm forms the pancreatic buds at 
around E9.5 and signals from the surrounding mesenchyme, including FGF10, TGF-β family 
members, and retinoic acid, are essential for the further proliferation and branching of the 
pancreatic buds. FGF10 enhances Notch signalling, which restricts expression of the 
transcription factor NGN3 to pancreatic progenitors (Apelqvist et al., 1999). Mice lacking 
FGF10 display impaired pancreatic epithelial growth, confirming the importance of signals 
from the surrounding mesenchyme (Bhushan et al., 2001). TGF-β signals are also important 
for organising and regulating the growth and relative proportions of the endocrine and 
exocrine pancreas. Inactivation of the activin receptors has severe effects on endocrine 
development resulting in islet hypoplasia (Jorgensen et al., 2007). Retinoic acid (RA) 
signalling is also essential for pancreas development, as RA-deficient zebrafish fail to 
develop a pancreas or liver. In the mouse and Xenopus, RA signalling appears to be essential 
for dorsal pancreas formation (Stafford et al., 2004).  
In contrast, the notochord plays no role in the development of the ventral pancreas, as they 
are not in contact with one another. Instead, ventral pancreatic development is closely linked 
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to liver development, with liver development being promoted by instructive signalling, such 
as FGF signalling, from the adjacent cardiac mesoderm. At the same time, in the absence of 
FGF signalling and cardiac mesoderm, the ventral pancreatic program is initiated. Thus, it 
appears that the default fate of the ventral endoderm is pancreatic and that signals from the 
cardiac mesoderm actively induce a hepatic state (Deutsch et al., 2001). 
The gut endoderm widely expresses a number of transcription factors such as HNF1β (Ott et 
al., 1991), FOXA1 and FOXA2 (previously known as HNF3α and β; Monaghan et al., 1993) 
and HNF4α (Duncan et al., 1994; Taraviras et al. 1994), which delineate the region of the 
foregut endoderm which gives rise to the pancreas. The pancreatic domain is further refined 
by the expression of markers specifying a pancreatic fate, including HLXB9, PDX1 and 
ISL1.  
One of the key components of pancreatic specification is the expression of PDX1, a 
transcription factor which is first expressed at E8.5 in the pre-pancreatic endoderm and 
throughout the developing ductal trees during pancreatic bud formation (Offield et al., 1996) 
until E13, when it becomes mainly restricted to the β-cells and some δ cells, although low 
expression of PDX1 is maintained in some duct and exocrine cells (Wilson et al., 2003). In 
the adult pancreas, PDX1 plays a critical role in the regulation of the transcription of genes 
associated with β-cell identity, such as insulin, GLUT2, islet amyloid polypeptide (IAPP) and 
glucokinase (Leonard et al., 1993; Ohlsson et al., 1993; Miller et al., 1994; Watada et al., 
1996a; Watada et al., 1996b; MacFarlane et al., 2000; Chakrabarti et al., 2002). Lineage 
tracing experiments have demonstrated that mature pancreatic cells derive from PDX1-
expressing progenitor cells (Gu et al., 2003). It has been suggested that members of the 
HNF1 and FOXA families of transcription factors may play a role in the control of PDX1 
expression. Mice null for FOXA2 or HNF1β die before pancreas formation (Ang & Rossant, 
1994; Weinstein et al., 1994; Coffinier et al., 1999), but embryoid bodies lacking FOXA2 fail 
to activate the Pdx1 gene, which suggests that FOXA2 may be an upstream activator of Pdx1 
expression (Gerrish et al., 2000). PDX1 plays a critical role in early pancreas development: 
removal of PDX1 by gene targeting arrests pancreatic development after initial bud formation 
(Jonsson et al., 1994; Ahlgren et al., 1996; Offield et al., 1996), indicating that PDX1 is 
necessary for growth of the pancreatic buds but not for the initial induction of bud formation. 
Conversely, ectopic expression of PDX1 in non-pancreatic chick gut endoderm was also 
shown to induce the formation of pancreatic bud-like structures (Grapin-Botton et al., 2001).  
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The expression of HLXB9 is initiated around E8.0 in the gut endoderm and the notochord, 
and maintained in mature β-cells. Mice deficient for HLXB9 fail to express PDX1 in the 
dorsal pancreas, resulting in dorsal pancreatic agenesis (Harrison et al., 1999; Li et al., 1999). 
In the remaining ventral pancreas of HLXB9-deficient animals, islet malformations were 
observed, suggesting essential functions for HLXB9 in islet cell development. These studies 
demonstrate that HLXB9 is necessary for bud formation and its expression precedes that of 
PDX1 in the dorsal pre-pancreatic endoderm.  
ISL1 is expressed in the developing pancreas and the central nervous system (Karlsson et al., 
1990; Thor et al., 1991). Targeted disruption of the Isl1 gene results in failure of development 
of the dorsal pancreatic mesenchyme and the complete absence of endocrine cells, while the 
ventral pancreatic epithelium and associated mesenchyme is unaffected. ISL1 has also been 
shown to play a role in the differentiation of islet cells and is expressed in mature β-cells 
(Ahlgren et al., 1997).  
The specification of endocrine cells in the developing pancreatic endoderm is dependent on 
appropriate Notch signalling and expression of the pro-endocrine transcription factor NGN3 
(figure 1.3). Although NGN3 is exclusively expressed in scattered cells in the pancreatic 
epithelium and not in differentiated endocrine cells (Apelqvist et al., 1999), lineage tracing 
has demonstrated that NGN3-positive cells function as endocrine precursors from which all 
four endocrine subtypes differentiate (Gu et al., 2002). NGN3 expression occurs in 2 distinct 
temporal waves, thereby generating “early” and “late” endocrine cells which have different 
developmental potential. Early NGN3-expressing cells exclusively give rise to α-cells, while 
NGN expression at later stages gives rise to β- and PP-cells after E11.5, and δ-cells after 
E14.5.  
In the pancreas, the downstream target of Notch signalling is the Hes1 gene, which in turn 
inhibits the expression of Ngn3 by binding to several sites on the Ngn3 promoter (Jensen et 
al., 2000; Lee et al., 2001). Animals lacking NGN3 failed to develop any endocrine cells 
while exocrine tissue and pancreatic ducts were nearly normal (Gradwohl et al., 2000). In 
addition, ectopic expression of NGN3 in the pancreatic epithelium caused premature 
differentiation of the pancreas into endocrine cells, resulting in nearly exclusive production of 
glucagon-expressing α-cells (Apelqvist et al., 1999; Schwitzgebel et al., 2000). These studies 
demonstrated that, in the absence of Notch signalling, NGN3 is essential for the initiation of 
endocrine differentiation in the pancreas. As Notch signalling restricts NGN3 expression to a 
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few scattered cells, other mechanisms must play a role in the upregulation of NGN3 
expression. The NGN3 promoter has been shown to contain binding sites for a number of 
transcription factors, including HNF1, FOXA and HNF6 (Jacquemin et al., 2000; Lee et al., 
2001). HNF6 is initially expressed throughout the pancreatic buds but is subsequently 
excluded from the mature pancreas (Rausa et al., 1997). Mice lacking HNF6 had severely 
reduced NGN3 expression in the developing pancreas leading to a severely reduced number 
of endocrine cells (Jacquemin et al., 2000), supporting a role for HNF6 as an upstream 
activator of NGN3 expression.  




Figure 1.3.Endocrine specification of the developing pancreas. The transcription factors expressed at each 
stage are labelled in black, and the instructive signals that specify certain cell types are shown in red. Adapted 
from Van Hoof et al,. 2009. 
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NGN3 has also been shown to activate NEUROD1 (figure 1.3), which is expressed slightly 
later than NGN3 during pancreatic development. Unlike NGN3, its expression is maintained 
in mature islet cells and plays a role in the expression of a number of endocrine products 
including insulin (Naya et al., 1995; Qiu et al., 2002). The expression of NEUROD1 is 
dependent on NGN3 expression as NGN3-null mutant mice do not express NEUROD1 
(Gradwohl et al., 2000), whilst NGN3 expression is unchanged in NEUROD1 null embryos. 
Similarly to NGN3, ectopic expression of NEUROD1 induces premature differentiation of 
endocrine cells in the pancreas, demonstrating that NEUROD1 is also a pro-endocrine gene 
(Schwitzgebel et al., 2000). However, unlike NGN3-null mutant mice, mice lacking 
NEUROD1 are still able to form all pancreatic endocrine cell types, but the number of cells is 
drastically reduced due to increased apoptosis (Huang et al., 2002).  
Following initiation of the endocrine program, a set of transcription factors is necessary to 
convert NGN3-positive cells into the four mature endocrine cell types (figure 1.3). These 
factors can be divided into early factors such as PAX4, NKX2.2 and NKX6.1, which are co-
expressed with NGN3 in endocrine precursors, and late factors such as PAX6, ISL1, MAFA 
and PDX1, which are found in more mature cells.  
NKX2.2 expression is initiated at E9.5 throughout the dorsal pancreatic epithelium, and is 
expressed until E13 when it becomes localised to NGN3-positive cells. NKX2.2 expression 
persists in mature α-, β- and PP-cell types but not δ-cells. Mice lacking NKX2.2 display a 
complete absence of β-cells as well as a reduction in α- and PP-cells, whereas the number of 
δ-cells remained unaffected. Interestingly, NKX2.2 mutant islets contain a number of 
immature endocrine cells expressing IAPP and PDX1 but lacking other β-cell markers such 
as GLUT2 and glucokinase. Thus, it appears that in the absence of NKX2.2, β-cells are 
specified but are unable to differentiate to fully mature, insulin-producing cells. 
PAX4/NKX2.2 double deficient mice show a similar phenotype to NKX2.2 deficient mice, 
suggesting that PAX4 acts downstream of NKX2.2. This is further supported by the lack of 
alteration of NKX2.2 expression levels in PAX4-deficient mice (Sussel et al., 1998).  
Expression of PAX4 is initiated at around E9.5 in the pancreatic buds and becomes 
progressively restricted to β-cells until approximately E15. However, little or no PAX4 can 
be detected in the mature pancreas (Smith et al., 1999). ARX and PAX4 play antagonistic 
roles in the specification of the endocrine cell subtypes, with ARX promoting specification of 
α- and PP-cells and PAX4 promoting specification of β- and δ-cells. Knockout of one of the 
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factors leads to a change in the proportion of cells of each lineage, although the total number 
of endocrine cells is unchanged. PAX4 inhibits the α/PP-cell fate through inhibition of ARX.  
NKX6.1 is first detected at E9.5 in both pancreatic buds, where it persists until E13. After 
this, NKX6.1 expression becomes specifically restricted to β-cells where it is required for 
insulin secretion (Oster et al., 1998). A lack of NKX6.1 results in reduced β-cell numbers, 
while other endocrine cell types are unaffected. The islets of mice deficient in NKX2.2 
expression also fail to express NKX6.1, suggesting that NKX2.2 is upstream from NKX6.1 in 
the β-cell differentiation pathway. In support of this, NKX2.2 expression is unaffected in 
NKX6.1-null mice and the pancreatic phenotype of mice lacking both NKX2.2 and NKX6.1 
is identical to the phenotype of mice solely lacking NKX2.2, demonstrating that the lack of 
NKX6.1 expression has no effect on β-cell differentiation in the absence of NKX2.2 (Sander 
et al., 2000). NKX6.2, a paralogue of NKX6.1 shows a similar expression pattern but is not 
expressed in mature β-cells. NKX6.2-deficient mice do not display any obvious phenotype, 
while NKX6.1/NKX6.2 double mutants show a similar phenotype to the NKX6.1 knockout, 
apart from a reduction in glucagon-expressing cells, suggesting an additional role for 
NKX6.2 in α-cell formation. The misexpression of NKX6.1 in PDX1-producing cells in 
NKX6.2 deficient mice was found to rescue β-cell development, indicating that these factors 
have redundant roles in β-cell development (Binot et al., 2010).  
The late factors are involved in the final steps of islet differentiation, after NGN3 expression 
and in conjunction with hormone expression. PAX6 is expressed in all hormone-producing 
cells throughout pancreatic morphogenesis, and plays an important role in islet cell 
differentiation. Conventional knockout experiments revealed its importance in the 
development of all islet cell types, as well as in the formation of well-structured islets of 
Langerhans (St-Onge et al., 1997). An additional role of this gene in maintaining postnatal β-
cell phenotype was revealed as conditional ablation of PAX6 resulted in a diabetic condition 
with hypoinsulinaemia.  
MAFA, MAFB and cMAF have all been shown to act in the terminal differentiation of α and 
β-cells. MAFA has been identified as specific to pancreatic β-cells, where it was found to 
directly interact with the promoter of the insulin gene and activate insulin expression 
(Matsuoka et al., 2003; Zhao et al., 2005). MAFA-deficient insulin-expressing cells are 
unable to release insulin in response to glucose. In contrast, ectopic expression of MAFA in 
embryonic chicken endoderm, as well as in non-pancreatic cell cultures, was found to be 
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sufficient to promote insulin secretion. Expression of MAFA is initiated at E13.5 and is 
restricted to insulin-positive cells throughout embryogenesis and adulthood (Matsuoka et al., 
2004). Mice deficient for MAFA develop diabetes accompanied by a significant decrease in 
circulating insulin levels and abnormal islet architecture (Zhang et al., 2005).  
As previously mentioned, PDX1 plays a role in the final differentiation of mature islets in 
addition to its early role in bud formation. After its early expression in the pre-pancreatic 
endoderm, PDX1 is downregulated as it cannot be detected in the NGN3 expressing 
endocrine progenitors (Schwitzgebel et al., 2000). Its expression is reactivated in most 
mature β-cells and in some δ-cells, where it plays a role in maintaining the differentiated 
phenotype and in the regulation of expression of a number of β-cell genes.  
 
1.3.3 Human Pancreatic Development  
 
Figure 1.4. Approximate timescale of mouse and human pancreatic development. Developmental stages are 
indicated as embryonic days of development (E) for mice and weeks of development (WD) for humans. Adapted 
from Van Hoof et al., 2009. 
 
Much of our current understanding of pancreatic development originates from mouse studies, 
as studies of human pancreatic development are limited by ethical constraints. However, 
development of the human pancreas may differ considerably from that of the murine model. 
In the mouse, the end of gastrulation and the formation of DE are completed by 
approximately E7.5 (figure 1.4). Pancreatic budding occurs by E9.5 and gut rotation brings 
the two buds in closer proximity around E12.5 (Van Hoof et al., 2009). In human 
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development, the first appearance of the pancreatic buds occurs just before 4 weeks of 
development and the two buds fuse at around week 6 of development. The first insulin-
expressing cells appear very early in mouse development at approximately E10.5 and a 
second wave of β-cell differentiation occurs at birth which results in properly formed islets. 
In contrast, in human development, the first insulin-expressing cells do not appear until week 
8 of development and the islets are formed by week 12-13 of development (Slack, 1995). The 
morphology of the pancreas also varies between mice and humans, as the murine pancreas 
consists of multiple lobes, whereas the human pancreas in a single solid organ. Arrangement 
of the endocrine islets also differs: in rodents, the β-cells tend to aggregate in the centre of the 
islets with the other cell types around the edge. However, in humans the β-cells are scattered 
throughout the islet (Brissova et al., 2005; Cabrera et al., 2006). Although the basic 
developmental program may be similar in humans and mice, the timing and/or activation of 
factors may differ which would be fundamental for the development in vitro differentiation 
protocols.  
 
1.4 Insulin and Its Mechanisms of Action  
 
1.4.1 Insulin Biosynthesis  
Insulin is a 6kDa polypeptide hormone which is synthesised and released from the β-cells of 
the islets of Langerhans in the pancreas. The initial product of gene transcription is a pre-
proinsulin molecule which is rapidly cleaved in the rough endoplasmic reticulum to 
proinsulin, a 9kDa precursor peptide consisting of 2 short peptide chains (A and B chains) 
and a connecting (C) peptide. The A and B chains are linked by two disulphide bonds 
between cysteine amino acid residues. The proinsulin molecules are then transported to the 
Golgi apparatus where they are packaged into secretory granules in which they are cleaved by 
converting proteases, removing the C-peptide and leaving the bound A and B chains to form 
the active insulin molecule. Insulin and C-peptide are stored in secretory vesicles and co-
secreted in equal proportions by exocytosis in response to secretory stimuli (Steiner et al., 
1985).  
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1.4.2 Insulin Secretion 
The primary stimulus for insulin secretion is plasma glucose concentration. Glucose absorbed 
from the small intestine reaches the β-cells through the circulatory system and is transported 
into the cell by the GLUT2 transporter, where it is metabolised to glucose-6-phosphate by the 
enzyme glucokinase. This causes a rise in intracellular ATP concentration which in turn 
promotes the closure of the ATP-sensitive potassium (KATP) channels. Retention of potassium 
ions (K
+
) within the cell depolarises the cell membrane causing the opening of voltage-
sensitive calcium ion (Ca
2+
) channels (VDCCs) leading to an influx of Ca
2+
. The resulting 
rise in intracellular Ca
2+
 levels causes insulin secretion by exocytosis, where the insulin-
containing secretory granules fuse with the plasma membrane and release insulin into the 
circulation (figure 1.5). High concentrations of extracellular Ca
2+
 have been shown to be a 
substitute for stimulatory levels of glucose demonstrating the critical role of Ca
2+
 ion influx 
in insulin release (Hedeskov, 1980).  
 
Figure 1.5. Signal transduction in β-cells. Insulin secretion is activated primarily by glucose but also by other 
stimuli, including amino acids, neurotransmitters and hormones. Jones et al., 2008. 
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Insulin secretion is not solely dependent on a rise in plasma glucose levels; it can also be 
triggered by a number of other substances, such as amino acids, neurotransmitters and 
hormones, most of which require the presence of non-stimulatory blood glucose 
concentrations in order to be able to stimulate insulin secretion (figure 1.5). The autonomic 
neurons innervating the islets of Langerhans also influence insulin secretion: activation of the 
parasympathetic neurons, which occurs during a meal, stimulates insulin secretion; while 
activation of the sympathetic neurons, or an increase in the plasma concentration of 
adrenaline, inhibits insulin secretion. Neurotransmitters stimulate insulin secretion from the 
β-cell by activating the G protein Gq, which in turn activates the membrane-bound enzyme 
phospholipase C (PLC). PLC acts on phosphatidylinositol 4,5-biphosphate (PIP2), which is 
present in small amounts in the inner half of the plasma membrane lipid bilayer. Activated 
PLC cleaves PIP2 to generate inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 
leaves the plasma membrane and diffuses through the cytosol to the endoplasmic reticulum 
(ER) where it binds to and opens IP3-gated Ca
2+
-release channels in the ER membrane. Ca
2+
 
stored in the ER is released through the open channels, quickly raising intracellular Ca
2+
 
which in turn triggers insulin release (Jones et al., 2008). Insulin release is also partly under 
hormonal control. Glucose-independent insulinotropic peptide (GIP) and glucagon-like 
peptide (GLP) are secreted by the gastrointestinal tract in response to eating, and stimulate 
the secretion of insulin. This results in an earlier and greater release of insulin during a meal 
than would occur if plasma glucose concentration were the only stimulus (Vander et al., 
1998, p596-600). 
 
1.4.3 Insulin Action 
Insulin induces its effects by binding to specific receptors in the plasma membrane of its 
target cells: muscle (both cardiac and skeletal), adipose tissue and liver. In these cells, insulin 
activates glycolysis, glycogenesis and lipogenesis, whilst simultaneously inhibiting 
glycogenolysis, gluconeogenesis, and lipolysis. Long-term regulation of insulin expression is 
mediated by glucose both through stimulation of insulin gene expression and inhibition of 
insulin mRNA degradation. Glucose also stimulates proinsulin biosynthesis preferentially 
over other islet proteins (Vander et al, 1998, p596-600). 
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Insulin binding to its tyrosine kinase receptor on the surface of its target cells triggers a 
number of signal transduction pathways (figure 1.6). Insulin binding first induces 
autophosphorylation at several tyrosine residues on the intracellular part of the receptor. This 
results in the recruitment of PI3-kinase to the plasma membrane of the cell, bringing it within 
reach of its substrate, PtdIns(4.5)P2, which is then phosphorylated. These events occur within 
the first minute of insulin binding to its receptor, and result in a significant increase in the 
concentration of PtdIns(3,4,5)P3. Protein kinase B (PKB) binds to PtdIns(3,4,5)P3, resulting in 
the recruitment of PKB from the cytosol to the plasma membrane, where it is phosphorylated 
by two other protein kinases, PDK1 and PDK2, resulting in its activation. Once activated, 
PKB dissociates from the plasma membrane and phosphorylates numerous substrates in both 
the cytoplasm and the nucleus which are important for regulating insulin-dependent 
processes.  
 
Figure 1.6. The Insulin Signalling Pathway. Insulin binding to its receptor triggers signalling cascades that 
activates glycolysis, glycogenesis and lipogenesis, whilst simultaneously inhibiting glycogenolysis, 
gluconeogenesis, and lipolysis. Adapted from (Lizcano & Alessi, 2002). 
One of these substrates is glycogen synthase kinase 3 (GSK3), which is inactivated by PKB. 
This results in dephosphorylation of glycogen synthase, leading to the activation of 
glycogenesis. Inactivation of GSK3 also results in the dephosphorylation of eIF2B, which 
controls the initiation stage of protein synthesis, stimulating the synthesis of protein from 
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amino acids. Insulin also inhibits lipid metabolism in adipocytes by decreasing intracellular 
concentrations of cAMP, a process which appears to also be mediated by PKB through the 
phosphorylation and activation of PDE3B. 
Another key action of insulin is to stimulate glucose uptake into its target cells by inducing 
the translocation of the glucose transporter GLUT4 to the plasma membrane, allowing uptake 
of glucose from the interstitial fluid by facilitated diffusion. Glucose transport into the liver is 
not directly insulin-dependent as hepatocytes have GLUT2 transporters in their cell 
membranes. Insulin activates hexokinase which phosphorylates glucose into glucose-6-
phosphate. The lowered intracellular glucose concentration relative to the plasma allows the 
diffusion of glucose into hepatocytes via the GLUT2 transporters (Lizcano & Alessi, 2002). 
In T1DM, the lack of insulin affects nutrient uptake and metabolism by the liver, skeletal 
muscle, and adipose tissue, resulting in hyperglycaemia. Without glucose to metabolise, these 
cells enter a fasting state. The liver initiates gluconeogenesis, resulting in a further increase in 
blood glucose; the adipose tissue breaks down its fat stores causing abnormal fat metabolism; 
the skeletal muscle breaks down its proteins to provide a substrate for ATP production. 
Abnormal fat metabolism results in ketone production from the liver which is poorly secreted 
by the kidneys resulting in diabetic ketoacidosis. High blood glucose concentrations can also 
saturate reabsorption from the kidney tubules resulting in a loss of glucose in the urine, 
causing less water to be reabsorbed and more to be excreted (known as osmotic diuresis) 
(Vander et al., 1998, p604-606). 
 
1.5 Treatment of Type 1 Diabetes 
 
1.5.1 Insulin Replacement 
The discovery of insulin was the result of Nobel-prize winning experiments by Banting and 
Best in the 1920s. They found that removing the pancreas from a dog resulted in the 
development of diabetes, and that treatment with a pancreatic extract ameliorated the 
symptoms. Bertram Collip then joined the team and began the work of trying to purify the 
insulin from the pancreatic extracts. In 1922, the first patient, a fourteen-year-old boy, was 
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successfully treated with the purified insulin (Banting et al., 1922). More volunteers were 
recruited and as soon as 1923, insulin was being produced on a commercial scale, providing a 
life-saving treatment to many patients.   
Since then, the most common treatment for T1DM has been injection of exogenous insulin, 
which, although lifesaving, is an invasive treatment regime that involves repeated testing of 
blood sugar levels and several injections daily. Up until the 1980s, animal insulins, obtained 
from pancreatic extracts of cows and pigs, were the only sources of insulin available. These 
were associated with complications such as variable pharmacokinetics, skin reactions at the 
sites of injection and immunogenicity. More recently, recombinant human insulin produced 
in genetically modified micro-organisms, has been more commonly used.  
Different insulin regimens exist for the treatment of T1DM to permit individualisation of 
insulin therapy, and different biosynthetic insulin analogues are available which enable fine-
tuning of the treatment: for example, “rapid-acting” insulin have an onset of 5-10 minutes,  
while “long-acting” insulin provides continuous activity for up to 36 hours (Crasto et al., 
2009). The twice-daily regimen consists of twice-daily injections of short-acting and 
intermediate-acting insulin the doses of which can be adjusted according to blood glucose 
levels, meal times and exercise. However, this regimen requires a relatively rigid timing of 
meals and exercise. In an attempt to offer a more physiological replacement of insulin, the 
basal bolus regimen involves basal (“long-acting”) insulin, used as background insulin to 
cover fasting, and short-acting insulin used at each meal. This therapy offers more flexibility 
for the patients but requires frequent blood glucose monitoring. Continuous subcutaneous 
insulin infusion (CSII) involves an insulin pump worn by the patient which delivers a 
continuous infusion of short-action insulin. The continuous infusion of insulin provides for 
background insulin requirement and pre-programmed infusion rates cover periods of activity, 
exercise or inactivity. Although reports indicate an improvement in quality of life with the 
use of CSII (Weinzimer et al., 2006), most randomised controlled studies did not demonstrate 
improvement in glycaemic control (DiMeglio et al., 2004; Fox et al., 2005).  
When a major clinical trial was undertaken to compare intensive and conventional insulin 
therapies with regard to their effects on the development and progression of long-term 
complications associated with T1DM, it was found that keeping glucose levels as close to the 
normal range as possible slows the onset and progression of complications (Rohlfing et al., 
2002). Although treatment with a mixture of long- and rapid-acting synthetic insulin 
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analogues, or with CSII, has improved control over blood glucose levels, the National 
Diabetes Audit for 2008-2009 found that only 28.6% of patients were achieving the NICE-
recommended target level of glycated haemoglobin of 7.5% or less. In addition, these patients 
are more likely to suffer from episodes of hypoglycaemia. For these reasons, other therapies 
are needed.  
 
1.5.2 Pancreas Transplantation 
Even before the discovery of insulin, physicians were exploring the possibility of treating 
T1DM via pancreatic replacement strategies. The first successful whole pancreas transplant 
was carried out in 1966 (Kelly et al., 1967), and resulted in insulin independence. Although 
initial success rates were low, with methodological improvements and the use of 
immunosuppression the procedure started to become more widespread in the mid-1980s 
(Gaglia et al., 2005). However, there are problems associated with it: the shortage of suitable 
donors, the highly invasive nature of the procedure, and the requirement for lifelong 
immunosuppression afterwards. For these reasons, it is currently only carried out in diabetic 
patients with end-stage renal disease as a simultaneous pancreas and kidney transplant.  
 
1.5.3 Islet Transplantation 
Islet transplantation is a less invasive alternative to whole pancreas transplantation. It was 
first shown to be a viable approach for treating T1DM by reversing chemically induced 
diabetes in a rodent model (Ballinger & Lacy, 1972). However, technical limitations in islet 
isolation techniques, immunosuppression regimens, and low success rates, precluded its 
widespread use until protocols were optimised in a landmark study, where seven patients 
were treated with islet transplants, and all maintained insulin independence for up to one year 
(Shapiro et al., 2000). This approach was dubbed the ‘Edmonton protocol’ and included the 
selection of patients that suffered from severe hypoglycaemia, a steroid-free 
immunosuppressive protocol, islet preparation in the absence of xenogenic proteins, and an 
increase in the transplanted islet mass with islets from up to four donors used per recipient. 
More than 100 islet transplants are now carried out every year, with 44% of patients 
achieving insulin independence (Barton et al., 2012).  However, although a clinical review in 
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the British Medical Journal in 2001 (Serup et al., 2001) anticipated that by 2010, islet 
transplantation would be the treatment of choice for most patients with type 1 diabetes, islet 
transplantation is still regarded as an experimental procedure, and is therefore currently only 
an option for type 1 diabetics with severe glycaemic lability, recurrent hypoglycaemia, or 
hypoglycaemia unawareness (de Kort et al., 2011), or those undergoing a simultaneous 
transplant, as these are the only patients for whom the significant side effects resulting from 
immunosuppression and islet perfusion are considered to outweigh the poor quality of life 
caused by diabetes.   
One of the reasons why islet transplantation is still not widely used is because of the shortage 
of suitable donors. Currently, the only source of islets is heart-beating brain-dead donors. 
There have been suggestions that the use of non-heart-beating donors could widen the donor 
pool, but there would still be a shortfall. Pancreata that do become available are first offered 
for whole organ transplant, as this is an established procedure with recognised long-term 
benefit. In addition, islets from up to four donors are needed for each islet transplantation 
(Langer, 2010) due to the fact that as many as 50-60% of the transplanted islets may be lost 
immediately after transplantation (Harlan et al., 2009). 
Another problem facing islet transplantation is graft deterioration, with only 10% of patients 
achieving insulin independence after 5 years due to loss of function of the transplanted islets. 
This failure has been attributed to both anti-donor antibodies and increased alloantibody 
titres, suggesting that some form of immunomodulatory therapy to control the auto-immune 
aspect of the disease will be needed. There is a need for better assays for monitoring these 
autoimmune and alloimmune responses (Harlan et al., 2009). It has been suggested that 
selecting other sites for transplantation, such as under the gastric or intestinal mucosa, or 
immunologically privileged sites such as the brain, thymus or testis, might better preserve the 
function of the transplanted islets. Currently, islets are infused into the liver via the portal 
vein, as this is the only site that has routinely shown success in large animals, and the 
pancreas would normally secrete insulin into the portal vein (Langer, 2010). Complications 
resulting from islet transplantation have been more common than originally thought, largely 
due to side effects of immunosuppression regimes, as well as peritoneal haemorrhage and 
partial portal vein thrombosis resulting from islet infusion into the portal vein (Gaglia et al., 
2005). 
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There have been improvements in islet transplantation techniques since the Edmonton 
protocol, but the necessity of life-long immunosuppression, the scarcity of cadaveric donors 
and technical inefficiencies in islet isolation preclude widespread use of this therapy today as 
a replacement for insulin. Therefore there is a need for research into alternative sources of 
functionally competent, insulin-secreting β-cells as substitutes for donor islets to meet the 
clinical need for transplantation therapy. 
 
1.5.4 Xenotransplantation 
One solution to the problem of donor shortages is to use islets from other species. Much of 
the focus has been on pig islets, as they have several advantages. Firstly, high yields can be 
obtained using similar techniques to human islet isolation. Secondly, porcine insulin is very 
similar to human insulin, with only one amino acid difference (Trucco et al., 2007; Jones et 
al., 2008). Finally, pigs are amenable to genetic modification in order to promote 
cryoprotective or immunomodulatory properties, or to produce human insulin (Hering & 
Walawalkar, 2009).  
However, two main obstacles prevent the widespread use of porcine islets in humans. Firstly, 
the hyper-immune response to xenografts due to the presence of the α1,3-galactosyl antigen 
on porcine cells has proved difficult to avoid, although in contrast to whole organ 
xenotransplants, this may not play a major role in the rejection of pig islet transplants in non-
human primates (Hering & Walawalkar, 2009). The currently used intensive 
immunosuppressive regimen in pig islet transplantation may have severe side effects in 
humans, and is unlikely to be considered for routine clinical practice. However, advances 
have now been made in the breeding of genetically modified pigs which are free of this 
antigen: islets isolated from these pigs show decreased antigenicity and increased survival in 
non-human primate models of islet transplantation (Trucco et al., 2007). A study by Klymiuk 
et al. (2012) reported the transplantation of islets from transgenic pigs which had been 
engineered to express LEA29Y, a high-affinity variant of the T-cell co-stimulation inhibitor 
CTL4-4Ig, under the control of the insulin gene promoter. When these islets were 
transplanted into humanised mice, they were protected from immune rejection and were able 
to normalise hyperglycaemia, suggesting that this may represent a new approach to 
controlling the immune response to xenografts. 
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Secondly, the demonstration that porcine endogenous retroviral (PERV) sequences in the 
porcine DNA may become activated on xenotransplantation (van der Laan et al., 2000) has 
raised concerns over viral infections in humans receiving porcine islet transplants. However, 
another study has suggested that the potential threat of PERVs to xenotransplant recipients 
may have been over-estimated, because prolonged immunosuppression and exposure to 
porcine islet xenografts caused no detectable transmission of PERVs in in vitro or in vivo 
studies (Denner et al., 2008).  
The interest in xenotransplantation has led to some controversial clinical trials. An Australian 
company, Living Cell Technologies Ltd., reported a clinical trial in Moscow in 1996, in 
which encapsulated porcine islet cells (DIABECELL®) were transplanted into two patients 
with diabetes, leading to reduced insulin requirements. Follow up work on this trial revealed 
evidence of residual, viable, encapsulated pig β-cells being retrieved from a transplant 
recipient almost a decade after xenotransplantation (Elliott et al., 2007). The approach used in 
this trial was subsequently strongly criticised by the International Xenotransplantation 
Association for being premature and potentially risky (Grose, 2007). Similarly, earlier 
clinical trials of porcine islet transplantation in Mexico (Valdes-Gonzalez et al., 2007) have 
been the subject of extensive criticism about the preclinical data used in justification of the 
trials, and about the reported efficacy of the trials (Sykes & Cozzi, 2006).  
However, Living Cell Technologies Ltd. reported in a press release dated 5 May 2009 
(www.lctglobal.com/latest-news.php), that in a clinical trial in Russia, insulin independence 
was observed for 2 of the 7 patients who received DIABECELL® and no adverse effects 
were reported. Patients had a reduction in insulin requirements of 6-25% and a reduction in 
both the severity and number of hypoglycaemic events. A subsequent phase II trial carried 
out in Argentina showed that patients treated with DIABECELL® also had reduced insulin 
requirements, and a reduced risk of hypoglycaemic incidents (www.lctglobal.com/latest-
news.php, press release dated 22 November 2012). Another trial is due to start in New 
Zealand within the next few years. The commercial and clinical potential of pig islets as a 
source of transplant material for the treatment of T1DM is driving larger and more controlled 
clinical trials and the outcome of these will determine whether a future exists for the use of 
porcine islets as a substitute for human islets. 
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1.6 Cell Replacement Therapy 
Islet transplantation has shown proof of principle for cell replacement therapy to treat type 1 
diabetes. There are numerous different sources of tissue that could potentially be used, but 
there are certain requirements in order for them to be suitable for transplantation. First, they 
must be able to synthesise and store insulin, and release sufficient amounts in response to 
changes in circulating nutrients and a variety of hormones and neurotransmitters. Second, any 
source of replacement β-cells will also have to be able to generate large numbers of cells in 
vitro to meet the requirement of transplantation therapy, but this proliferative capacity must 
be tightly regulated to avoid post-transplantation expansion. Thirdly, they must show 
persistent engraftment and survival. 
 
1.6.1 Human β-cells 
An obvious starting point in the generation of replacement tissue is the expansion of mature 
islet β-cells, as studies have shown that, even many years after diagnosis, patients with 
T1DM still retain some β-cell mass and function (Wang et al., 2012). However, expansion of 
these cells in vivo or in vitro has proved to be a difficult task as, although β-cells are the 
predominant cell within pancreatic islets, they still only comprise around 2% of the total 
pancreatic cells, so that isolating a homogeneous population of β-cells has proven difficult. In 
addition, β-cells have a very limited proliferative capacity, and human β-cells are even less 
proliferative than rodent β-cells (Bonner-Weir et al, 2000b).  
Although β-cells can be stimulated to proliferate in vitro by certain growth factors (Hayek et 
al., 1995; Beattie et al., 2002), their proliferation was accompanied by dedifferentiation and 
loss of function. A number of attempts have been made to restore insulin production in these 
expanded cells, but insulin expression was limited or inconsistent (Gershengorn et al., 2004; 
Lechner et al., 2005; Ouziel-Yahalom et al., 2006). A study by Bar et al. (2012) showed that 
these dedifferentiated cells can be redifferentiated to insulin-producing cells using HES1 
shRNA to inhibit the Notch pathway, raising the possibility of producing functional β-cells in 
vitro. Similarly, Aly et al. (2013) showed increased proliferation of adult β-cells in vitro 
through manipulation of the Wnt signalling pathway. Another recent study identified a small 
molecule capable of inducing β-cell proliferation both in a rodent cell line, as well as in a 
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mouse model of diabetes (Shen et al., 2013). Despite this, it seems unlikely that expansion of 
human adult β-cells by in vitro manipulation will be able to generate the quantity of 
replacement β-cells required for cell replacement therapies.  
During the past 30 years, a number of rodent β-cell lines have been established from x-ray 
induced insulinomas in adult rats (Gazdar et al., 1980; Asfari et al., 1992), or derived by 
transformation of adult hamster islet cells (Santerre et al., 1981). Other rodent β-cell lines 
have been generated by targeted oncogenesis in transgenic mice that have expressed the 
SV40LT under the control of the insulin promoter (Efrat et al., 1988; Miyazaki et al., 1990). 
These cell lines have been extremely useful for the study of rodent β-cells, but since there are 
many differences between rodent and human β-cells, attempts have been made to generate 
human β-cell lines.  
Human β-cell lines have been generated from many different sources, including adult islets, 
foetal pancreases, or insulinomas (Levine et al., 1995; de la Tour et al., 2001; Demeterco et 
al., 2002) but insulin production by these cells was either extremely low or could only be 
maintained  over a few passages. In 2005, a reversibly immortalised human β-cell line was 
established through the introduction and subsequent removal by Cre-recombinase-mediated 
excision of immortalising genes (Narushima et al., 2005). These cells expressed a mature β-
cell phenotype, secreted insulin in response to glucose stimulation and rectified 
streptozotocin-induced hyperglycaemia in mice. Disappointingly, no new reports on the use 
of this line have since been published. In 2011, (Ravassard et al., 2011) reported 
establishment of a stable, functional β-cell line with glucose-inducible insulin secretion using 
targeted oncogenesis in human foetal pancreatic tissue. These cells were capable of 
proliferation and were stable over at least 80 passages. They expressed many specific β-cell 
markers without expression of markers of other pancreatic cell types, and were also capable 
of expressing insulin in response to glucose and other insulin secretagogues. In addition, 
transplantation of these cells in mice reversed chemically induced diabetes. However, after 
transplantation of these cells, the mice eventually became hypoglycaemic due to continued 
proliferation of these cells in vivo. Transformed β-cell lines derived from human β-cells offer 
the potential of generating in vitro the huge numbers of cells that would be required for 
transplantation therapy. However, while the establishment of a human β-cell line will be 
extremely useful for studying human β-cells, the use of genetically manipulated cells is 
unlikely to be acceptable for cell replacement therapy.  
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1.6.2 Pancreatic Stem Cells 
The adult β-cell mass is not static but fluctuates in response to changing physiological 
conditions such as pregnancy (Sorenson & Brelje, 1997) and obesity (Butler et al., 2003). In 
addition, several approaches, including surgical ablation of pancreatic tissue and pancreatic 
duct ligation (PDL), were found to initiate endogenous regenerative programmes acting to 
replace the missing cells. β-cell regeneration could potentially occur through one of several 
mechanisms: replication of existing β-cells, neogenesis of β-cells from multipotent duct 
progenitor cells, or conversion of α-cells or non-endocrine cells into β-cells. However, the 
existence of stem cells in the adult pancreas remains controversial. Although stem cells have 
been proposed to exist in the adult exocrine pancreas, pancreatic ducts and in the islets 
themselves, they remain poorly characterised and their proliferative capacity in vitro is quite 
limited. In the case of exocrine and duct cells, it is not clear whether the mature cells can 
transdifferentiate directly into insulin-expressing cells or whether a step of dedifferentiation 
is required first.  
Lineage tracing studies in mice suggest that, under most circumstances including acute 
pancreatic regeneration, new β-cells arise by a slow regeneration of existing β-cells. Dor et 
al. (2004) used pulse-chase labelling of β-cells to show that throughout adult life, or 
following partial pancreatectomy, new β-cells arise from pre-existing β-cells. Another study 
showed that, several weeks after toxin application, treated mice recovered from 
hyperglycaemia through the genesis of new β-cells that mainly originated from surviving β-
cells (Nir et al., 2007). Teta et al. (2007) provided more insight into the mitotic behaviour of 
β-cells under normal physiological conditions, after partial pancreatectomy, and during 
pregnancy, and showed that new β-cells arose from a pre-existing population of β-cells, and 
not from repeatedly dividing pancreatic progenitors. This was also seen by another study, 
which demonstrated β-cell replication following PDL and its subsequent reversal, suggesting 
that once the disease state is removed, the β-cells can replicate and restore endocrine function 
(Hao et al., 2013).  
However, several other studies have suggested alternative origins of β-cells during pancreas 
regeneration, most notably neogenesis of cells from multipotent duct progenitor cells. 
However, the evidence for this is conflicting, with several studies using lineage tracing 
techniques to support this hypothesis, and other studies using similar techniques to 
demonstrate that this is not the case. An early study by Wang et al. (1995) noted significant 
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islet hyperplasia following PDL. Pulse chase labelling indicated that proliferation of existing 
β-cells could not fully account for the hyperplasia, and it was therefore concluded that 
multipotent precursors and/or stem cells may be involved in these regenerative events. The 
concomitant increase in the numbers of β-cells and pancreatic duct cells suggested that newly 
formed β-cells may have a ductal origin. Since then, several studies have shown that 
pancreatic duct cells are able to give rise to insulin-expressing cells in vitro (Bonner-Weir et 
al., 2000a; Yatoh et al., 2007). Lineage tracing experiments on newly formed β-cells 
following PDL determined that duct cells could indeed give rise to islet and acinar cells, and 
that this conversion was accompanied by several rounds of replication followed by 
dedifferentiation and redifferentiation. In non-injured neonates, the naturally occurring 
postnatal increase in islet cell mass was also partially attributed to duct cell conversion (Inada 
et al., 2008). A study by Xu et al. (2008) provided evidence of β-cell renewal from existing 
β-cells and cells in the ductal lining of adult pancreas, which re-expressed the pro-endocrine 
gene NGN3 following  PDL, as when these cells were isolated, they were found to be capable 
of giving rise to all 4 endocrine subtypes. Following partial pancreatectomy or PDL, PDX1 
was found to be ectopically expressed in mature ductal structures, suggesting that it may play 
a crucial role in regenerative processes and direct the conversion of different pancreatic cell 
types (Li et al., 2010). More recently, a mechanism for this neogenesis has been proposed, 
through the activation of the Wnt target gene Lgr5 following PDL, which marks progenitor 
cells in self-renewing tissues (Huch et al., 2013).  
Several studies have demonstrated using lineage-tracing techniques that exocrine duct and 
acinar cells do give rise to endocrine cells, including β-cells, during embryonic development, 
but that after birth there is no detectable contribution of exocrine cells to β-cell growth in 
either the uninjured mouse (Kopinke & Murtaugh, 2010) or following PDL (Solar et al., 
2009; Rankin et al., 2013; Xiao et al., 2013).Similarly, other studies showed that both 
endocrine and exocrine cells arise from SOX9-expressing cells during embryogenesis, but 
that this does not occur during adulthood, or following injury (Furuyama et al., 2011; Kopp et 
al., 2011). Studies also showed that although PDL did result in ectopic expression of NGN3 
in ductal cells, this did not result in subsequent β-cell neogenesis (Kopp et al., 2011; Xiao et 
al., 2013). A more recent study which used PDL in combination with STZ treatment to 
remove all pre-existing β-cells found no evidence for β-cell regeneration, even after 10 
months, but that the exocrine compartment of the pancreas did undergo regeneration (Cavelti-
Weder et al., 2013). Some of these discrepancies in results may be due to the methods used to 
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measure β-cell mass (Chintinne et al., 2012; Rankin et al., 2013), misinterpretation of 
existing β-cells as new β-cells, or species-specific differences between mouse and rat.  
Other studies have demonstrated the plasticity of pancreatic cells to transdifferentiate from 
one cell type to another. Thorel et al. (2010) generated a transgenic mouse model in which 
more than 99% of endogenous β-cells were chemically destroyed. Then, using a β-cell 
tracking system, the authors observed increased β-cell mass over time, and demonstrated that 
these new β-cells arose from healthy α-cells through transdifferentiation, showing a 
previously unappreciated flexibility of cell fate conversion of endocrine cells. Although the 
cells generated frequently secreted both insulin and glucagon, indicating an incomplete 
conversion, this study significantly extended knowledge of pancreatic cell plasticity and 
regeneration.  
PDX1 is thought to play a crucial role in regenerative processes in the pancreas, and its 
ectopic expression has been shown to result in transdifferentiation of pancreatic cells 
(Taniguchi et al., 2003; Miyatsuka et al., 2006). Other transcription factors have also been 
shown to be important. Ectopic expression of ARX in adult β-cells forces them to adopt α- or 
PP-cell phenotypes, suggesting that the opposite conversion might be achieved in order to 
generate β-cells from other pancreatic cell types by the misexpression of PAX4 (Collombat et 
al., 2003). Indeed, the same group later showed that inactivation of ARX, which has an 
opposing role to PAX4, in α-cells leads to their conversion into functional β-cells which were 
capable of normalising STZ-induced hyperglycaemia. In addition, this conversion also 
triggered islet cell neogenesis from pancreatic duct cells, with a reactivation of Ngn3 
expression (Courtney et al, 2013). Zhou et al. (2008) demonstrated 9 transcription factors 
that, when misexpressed, caused alterations in β-cell number or function. Overexpression of 
combinations of some of these factors in the exocrine pancreas of mice resulted in the 
conversion of acinar cells to insulin-secreting cells. The combination with the highest 
efficiency was PDX1, NGN3 and MAFA. This reprogramming did not involve any 
dedifferentiation or proliferating steps, suggesting direct transdifferentiation. The insulin-
secreting cells produced were morphologically indistinguishable from endogenous β-cells, 
expressed all known β-cell markers, and were able to cure diabetes in streptozotocin-treated 
mice. PDX1 and MAFA were needed only transiently as they activated their endogenous 
homologues, while NGN3 expression was down-regulated one month post-infection, 
mimicking its transient expression pattern as normally seen during embryonic development. 
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It was not possible to use the same factors to force other cell types to acquire β-cell identity, 
suggesting that the close relation and epigenetic similarities of acinar and β-cells might be a 
prerequisite for a successful conversion. This combination of transcription factors was also 
used to convert pancreatic exocrine cells to β-cells in vitro (Akinci et al., 2012). Another 
study showed that transient treatment of acinar cells with EGF and CNTF resulted in their in 
vivo conversion to functional β-cells, providing further evidence for the plasticity of these 
cells (Baeyens et al, 2014).  
 
1.6.3 Other Adult Stem Cells  
Many adult tissues have been shown to contain progenitor/stem cells, which are responsible 
for the normal maintenance and renewal of tissue. The proliferation capacity of these cells is 
limited and although this could restrict their utility as a source of replacement β-cells, it could 
also represent a safety advantage. In addition, these cells provide a source of autologous cells 
which may reduce the risk of graft rejection compared with an allograft. Tissue stem cells 
have been found in tissues characterised by high turnover such as bone marrow (Jiang et al., 
2002; Grove et al., 2004), intestinal epithelium (Potten et al., 1998) and liver (Theise et al., 
1999), as well as in tissues with low regenerative potential, such as brain (Galli et al., 2003), 
kidney (Oliver et al., 2004) and the retina (Tropepe et al., 2000).  
 
Liver Progenitor Cells: As the pancreas is derived from endoderm tissue, a logical place to 
start looking for stem cells able to give rise to insulin-expressing cells is in other endoderm-
derived organs.  The liver and the pancreas not only have a common developmental origin in 
the foregut (Pictet, 1972) but also share the expression of a number of transcription factors, 
such as the hepatic nuclear factors (Odom et al., 2004). Furthermore, both liver and β-cells 
express the GLUT2 high-capacity glucose transporter and high specificity/low affinity 
glucokinase. In addition, the liver is one of the primary target sites for insulin, which is 
delivered from the pancreas through the portal vein. Finally, the liver is relatively accessible 
for biopsy and can regenerate after partial hepatectomy. Taken together, these properties 
make the liver a clinically attractive option for autologous cell grafting of liver-derived β-
cells in patients with T1DM, thus avoiding the requirement for immunosuppression. Early 
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studies of the liver uncovered multipotent cells, termed hepatic oval cells, which have been 
shown to differentiate in vivo into a number of hepatic, pancreatic and intestinal cell types 
(Suzuki et al., 2002) and in vitro into cells expressing pancreatic β-cell markers (Yang et al., 
2002; Nakajima-Nagata et al., 2004; Yechoor et al., 2009). For many of the same reasons, 
biliary tree stem cells may prove a promising source of adult stem cells for differentiation 
into endodermal lineages. The promise of these cells has been demonstrated for improving 
liver function (reviewed in Lanzoni et al, 2013).  
Rodent and human hepatocytes can be induced to express pancreatic markers and adopt some 
functional aspects of β-cells (Yang et al., 2002; Zalzman et al., 2003; Cao et al., 2004; 
Kaneto et al., 2005; Kim et al., 2007) via multiple approaches, including adenovirus-
mediated gene transfer (Ferber et al., 2000; Ber et al., 2003; Kojima et al., 2003; Sapir et al., 
2005). Some of these genetically modified cells had the capacity to improve hyperglycaemia 
in diabetic mice and expressed significant amounts of insulin. In many cases, the pancreatic 
transcription factor PDX1 was used to induce a pancreatic phenotype (Ferber et al., 2000; 
Horb et al., 2003; Ber et al., 2003; Kaneto et al., 2005; Yang et al., 2006; Fodor et al., 2007; 
Shternhall-Ron et al., 2007). Similarly, the overexpression of another β-cell transcription 
factor, NEUROD-betacellulin, in mouse liver cells in vivo was reported to cause reversal of 
hyperglycaemia (Kojima et al., 2003; Yatoh et al., 2007). Another study showed that the 
forced expression of NGN3 alone was insufficient to transdifferentiate mature hepatocytes 
but was competent to convert hepatic progenitor cells into a functional β-cell lineage 
(Yechoor et al., 2009). More recently, improved glucose control was shown, without 
transdifferentiation, by lentiviral delivery of an insulin gene construct to rat liver in vivo 
(Elsner et al., 2008). Taken together, these studies demonstrate that liver and pancreatic cells 
may possess the plasticity of converting into each other under certain circumstances. 
However, there is so far not enough evidence that modified liver cells are able to undergo the 
in vitro expansion required to create the amounts of cells needed for cell replacement therapy.  
 
Bone Marrow-Derived Stem Cells: Bone marrow contains two different types of stem cells: 
haematopoietic stem cells (HSCs), which can be isolated from bone marrow, peripheral blood 
or umbilical cord blood; and mesenchymal stem cells (MSCs), which can be found in bone 
marrow and umbilical cord blood. HSCs are responsible for the production of all blood cell 
types, while MSCs are involved in the formation of mesenchymal tissues e.g. bone, muscle, 
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and fat. It has been shown that bone marrow-derived stem cells possess a high plasticity and 
are able to transdifferentiate into a number of different cell lineages (Jiang et al., 2002; Grove 
et al., 2004). Bone marrow cells are already routinely collected for current medical 
procedures, so clinical harvesting procedures are already in place. Bone marrow could also 
potentially serve as an autologous source of stem cells, minimising the problem of immune 
rejection. All of these factors make bone marrow stem cells an attractive source of stem cells 
for cell replacement therapy.  
An initial study reported the ability of transplanted bone marrow stem cells to migrate to the 
pancreas and to differentiate in vivo into endocrine pancreatic cells (Ianus et al., 2003) but 
this was later contested by several studies (Choi et al., 2003; Hess et al., 2003; Lechner et al., 
2004; Taneera et al., 2006) that failed to show evidence of transdifferentiation but suggested 
that bone marrow stem cells instead contributed to pancreatic regeneration by enhancing 
existing β-cell replication. Similarly, studies in the non-obese diabetic (NOD) mouse, a 
model of auto-immune diabetes, showed that bone marrow stem cell transplantation resulted 
in a proportion of mice regaining endogenous β-cell function but could not find any evidence 
that the bone marrow stem cells themselves replenished the β-cell mass (Nishio et al., 2006; 
Suri et al., 2006). Hasegawa et al. (2006) examined the role of bone marrow transplantation 
in the stimulation of insulin production in more depth, showing that, consistent with previous 
results, acute pancreatic injury was required to improve hyperglycaemia and restore islet cell 
numbers. In addition, although no bone marrow-derived insulin-producing cells were seen, 
regenerated islets were surrounded by bone marrow stem cell-derived haematopoietic cells, 
suggesting that they may have a supportive role in β-cell regeneration after injury.  
Some advances have also been made in the differentiation of bone marrow stem cells into 
insulin-producing cells in vitro, either by manipulating the culture environment (Tang et al., 
2004; Hisanaga et al., 2008) or by forced reprogramming of bone marrow stem cells using 
pancreatic transcription factors such as PDX1 (Li et al., 2007). There have also been reports 
of MSCs in human umbilical cord blood which can differentiate in vitro into cells expressing 
markers of the endocrine pancreas (Pessina et al., 2004) and into insulin-expressing cells 
(Sun et al., 2007). In vivo studies have shown that transplantation of MSCs improved insulitis 
in a type 1 diabetic mouse model (Ende et al., 2004). Although there appears to be promise in 
the generation of insulin-producing cells from bone marrow MSCs, further work is needed to 
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determine the efficiency of this differentiation process and the functional properties of the 
bone marrow stem cell-derived cells. 
The immunosuppressive qualities of MSCs cells may also be advantageous in treating type 1 
diabetes. A study by Urban et al. (2008) showed that transplantation of bone marrow-derived 
MSCs resulted in significant suppression of β-cell-specific T cell proliferation in the 
pancreas, which may allow β-cell regeneration. The first clinical attempt to use autologous 
stem cells to treat T1DM showed that, following transplantation of autologous HSCs in 
newly diagnosed patients undergoing immunosuppression, patients showed increased levels 
of c-peptide and achieved insulin independence. The rationale was to preserve residual β-cell 
mass and facilitate endogenous mechanisms of β-cell regeneration. However, this study used 
very aggressive immunosuppression which is unlikely to be acceptable for routinely treating 
patients with T1DM (Voltarelli et al., 2007; Couri et al., 2009). Bone marrow stem cells 
probably do not have the capacity to differentiate in vivo into reasonable numbers of β-cells 
and therefore may re-establish β-cell tolerance through immunosuppression and the 
regeneration of regulatory T cells. 
 
Other Tissue Stem Cells: There have been sporadic reports of differentiation of insulin-
expressing cells from a number of other tissues, including intestine, which shares an 
endodermal origin with the pancreas. The enteroendocrine K-cells in the intestinal epithelium 
possess a regulated secretory pathway, and secrete the insulinotropic hormone GIP in a 
glucose-regulated manner. In addition, some of the transcription factors involved in the 
development of intestinal endocrine cells are also involved in islet development. These 
properties make them attractive candidates for engineering insulin expression and regulated 
secretion. On the other hand, intestinal enteroendocrine cells are quite rare and the intestinal 
epithelium is not readily accessible for biopsy.  
Early studies showed that primary mouse intestinal cells could be induced to produce insulin 
through treatment with GLP-1, which activated the expression of NGN3. Cells contained 
insulin secretory granules and could normalise hyperglycaemia in diabetic mice (Suzuki et 
al., 2003; Yoshida et al.; 2002) but insulin production was constitutive rather than in 
response to glucose.  Ectopic expression of PDX1 in combination with treatment with 
betacellulin or co-expression of ISL1 in the rat enterocyte cell line IEC-6 also resulted in the 
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activation of insulin expression (Kojima et al., 2002). More recently, a study by Talchai et al. 
(2012) showed that Foxo1 ablation in the gut epithelium of both adult and neonatal mice 
results in the formation of insulin-expressing cells, as well as other pancreatic hormone-
expressing cells. These insulin-expressing cells expressed markers highly enriched in 
pancreatic β-cells but which are normally absent in the gut e.g. C-peptide, MAFA, PDX1 and 
NKX6.1. Immunocytochemistry revealed that insulin-expressing cells were distinct from 
cells producing PP, GCG and SST, indicating that they are not mixed lineage pancreatic 
progenitors. Unlike pancreatic endocrine cells, enteroendocrine cells arise from NGN3-
expresing progenitors throughout life. Therefore, insulin-expressing cells in the gut should 
have greater regenerative capacity than islet β-cells. In this study, following ablation of 
insulin-expressing cells using streptozotocin, mice initially developed hyperglycaemia, but 
after 9 days, hyperglycaemia began to decrease, and most were able to survive without 
exogenous insulin. This improvement could not be attributed to β-cell regeneration in the 
pancreas but was instead due to regeneration of insulin-secreting cells in the gut. Another 
study using transient overexpression of the pancreatic transcription factors PDX1, MAFA and 
MGN3 showed conversion of intestinal crypt cells into glucose-responsive β-like cells (Chen 
et al, 2014).  
Neural stem cells have been shown to differentiate into cells of all three germ layers (Clarke 
et al., 2000) and subpopulations of neurons express functional elements that are characteristic 
of β-cells, including the KIR6.2 and SUR1 subunits of the KATP channel, voltage-operated 
Ca
2+
 channels, GLUT2 glucose transporters and glucokinase (Yang et al., 1999). In separate 
studies, rat primary neural stem cells (Burns et al., 2005) and a transformed human neural 
cell line (Hori et al., 2005) were differentiated towards an insulin-expressing phenotype and 
demonstrated expression of a number of pancreatic markers including PDX1, NKX2.2, 
NKX6.2, NGN3, NEUROD/BETA2, PAX4, PAX6 and ISL1. Although the number of 
reports on the use of neural stem cells as β-cell precursors is limited, neural stem cells are 
amenable to expansion in vitro (Minger et al., 1996) and the biology of human neural stem 
cells is becoming increasingly well understood, suggesting a potential future source of 
replacement β-cells. However, the inaccessibility of these cells remains a problem.  
Other reports have suggested the production of insulin-producing cells from diverse tissue 
sources such as dermis (Shi et al., 2004), blood monocytes (Ruhnke et al., 2005) and mouse 
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salivary glands (Hisatomi et al., 2004). However, these studies have yet to be shown to be 
reproducible and further work is required to determine the functional capacity of these cells. 
 
1.7 Embryonic Stem Cells 
Embryonic stem cells (ESCs) have two key 
characteristics which make them appealing for 
use in cell replacement therapy. Firstly, they can 
self-renew in culture indefinitely, providing a 
potentially unlimited source of cells, and 
secondly, they are pluripotent i.e. they are able to 
give rise to any cell in the body given the 
appropriate signals.  
ESCs are derived from blastocyst-stage embryos, 
3-5 days post-fertilisation (figure 1.7). The 
blastocyst is comprised of an outer layer of cells 
enclosing the inner cell mass and a hollow cavity 
called the blastocoele. The cells of the inner cell 
mass have the potential to develop into any cell 
type of the body, but after implantation, rapidly 
differentiate to other cell types with limited 
developmental potential. However, if these cells 
are removed from the blastocyst and cultured in 
vitro under appropriate conditions, they continue 
to proliferate indefinitely and maintain the ability 
to differentiate into any cell type.  
The derivation of mouse ESCs (mESCs) was first reported in 1981 (Evans & Kaufman, 1981; 
Martin, 1981). The term “embryonic stem cell” was introduced to distinguish these embryo-
derived pluripotent cells from embryonal carcinoma (EC) cells, which were the first 
pluripotent cell lines to be established, derived from the undifferentiated compartment of both 
murine and human germ cell tumours (Finch & Ephrussi, 1967). Mouse ESCs express genes 
Figure 1.7. Derivation of ESC lines from 
cleavage-stage embryos. The National 
Institutes of Health resource for stem cell 
research.  Available online from:  
stemcells.nih.gov/info/2001report/appendixC.
asp 
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characteristic of the early blastocyst such as OCT4 (Rosner et al., 1990; Scholer et al., 1990), 
SOX2 (Yuan et al., 1995), REX1 (Rogers et al., 1991) and UTF1 (Okuda et al., 1998). These 
cells also express the cell surface antigen SSEA-1 (Krupnick et al., 1994). 
It took a further 17 years for the first derivation of human ESC (hESCs) lines to be reported 
(Thomson et al., 1998). The cells displayed cell surface markers including SSEA-3, SSEA-4, 
the keratan sulphate antigens TRA-1-60 and TRA-1-81, and alkaline phosphatase (Thomson 
et al., 1995; Thomson et al., 1996). These cells also expressed high telomerase activity, 
showing that they are capable of extensive replication. These ESC lines maintained the 
capability of forming derivatives of all three germ layers when injected into severe combined 
immunodeficient (SCID) mice.  
However, significant differences have been shown between mouse and human ESCs in terms 
of their culture conditions and gene expression. While the growth of mESCs in leukaemia 
inhibitory factor (LIF) and serum-containing media is sufficient to maintain them in an 
undifferentiated state in the absence of a feeder cell layer, this is not the case for hESCs 
(Thomson et al., 1998; Reubinoff et al., 2000). In addition, mouse and human ESCs differ in 
the expression of several cell surface antigens: SSEA-1 is expressed in undifferentiated 
mESCs where it is down-regulated upon differentiation, but it is not expressed in hESCs until 
these cells are differentiated. In addition SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 are 
expressed in undifferentiated hESCs but not in mESCs. Investigation into the gene expression 
of undifferentiated human and mouse ESCs revealed that hESCs expressed the transcription 
factors OCT4 and SOX2 in common with their mouse counterparts (Reubinoff et al., 2000), 
though the expression levels of these genes, as well as of REX1 and UTF1 were found to be 
much higher in hESCs than in mESCs. hESCs share many characteristics with mouse epiblast 
stem cells (EpiSCs) which are derived from post-implantation epiblasts (Brons et al., 2007), 
which are considered ‘primed’ pluripotent cells (unlike mESCs, which are considered ‘naive’ 
pluripotent cells), suggesting that they may not have the full developmental potential of 
mESCs. Despite these differences, the signalling pathways which control differentiation are 
very similar (Murray & Keller, 2008). 
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1.7.1 Differentiation of ESCs into Pancreatic β-cells 
The first studies describing differentiation of mESCs into insulin-expressing cells used an 
antibiotic resistance gene driven by the insulin promoter to allow selection of cells that 
spontaneously differentiated into insulin expressing cells (Soria et al., 2000). Soon 
afterwards, it was shown that hESCs could also spontaneously differentiate into insulin-
expressing cells (Assady et al., 2001), although the efficiency was very low. An early study 
described generation of insulin-producing cells from differentiated mESCs using a protocol 
modified from neural differentiation protocols (Lumelsky et al. , 2001), but there is now 
evidence that the insulin-positive cells produced were in fact of a neuronal lineage and that 
the insulin immunoreactivity observed resulted from insulin uptake from the medium 
(Rajagopal et al., 2003). Naujok et al. (2009) extensively characterised ESCs differentiated 
using the protocols developed by Lumelsky et al. (2001) and D’Amour et al. (2006), showing 
that the cells produced by the first protocol have the characteristics of a neuronal lineage, 
while the second protocol produced cells with endodermal characteristics. 
One strategy used to differentiate ESCs into insulin-expressing cells has been the over-
expression of pancreas-associated transcription factors such as PDX1 (Miyazaki et al, 2004; 
Lavon et al, 2006) and PAX4 (Lin et al., 2007; Liew et al., 2008). Although these cells 
released marginal amounts of C-peptide in response to the insulin secretagogue tolbutamide, 
they did not respond to glucose (Liew et al., 2008). More recently, Chen et al. (2011) showed 
that over-expression of SOX17, NGN3 and MAFA in mESCs resulted in increased 
expression of pancreatic genes, and, in the case of MAFA, enhanced glucose-stimulated 
insulin release. This was confirmed by another study in mESCs using over-expression of 
PDX1 and MAFA, together with either NGN3 or NEUROD (Xu et al, 2013). Other studies 
used over-expression of SOX17 to increase expression of DE markers (Qu et al., 2008) or to 
establish stable endoderm progenitors which showed increased differentiation into DE and 
pancreatic lineages (Seguin et al., 2008). However, the therapeutic scope of such genetically 
modified cells may be very limited. Li et al (2014) developed an approach that combined 
transient expression of reprogramming factors with small molecules to induce direct 
reprogramming of mouse fibroblasts into definitive endoderm-like cells, which could 
subsequently differentiate into pancreatic progenitor cells and insulin-expressing cells. The 
cells did not express pluripotency genes at any point, suggesting that they may be safer in 
terms of tumorigenicity than traditionally differentiated iPSCs.  
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Differentiation into Definitive Endoderm 
More recently, the most successful protocols for generating insulin-expressing cells in vitro 
have been those which have recapitulated the signalling pathways important during in vivo 
pancreatic development, including TGF-β, Wnt, Hedgehog and Notch signalling (see section 
1.3.2). The first step in the differentiation of ESCs into β-cells is the production of definitive 
endoderm (DE), a stage which has been extensively investigated and characterised in order to 
identify signals capable of inducing endoderm differentiation. Early studies found that DE 
could be induced in Xenopus embryos by activin A (Smith et al, 1990; Gurdon et al, 1994), 
which is often used as a replacement for Nodal in differentiation protocols as they both 
belong to the TGF-β family of signalling molecules, and this was further demonstrated in 
experiments in zebrafish and chicken (Grapin-Botton et al, 2007; Tam et al, 2003). The 
ability of Activin A to induce DE formation in ESCs was first demonstrated by Kubo et al 
(2004), who used a GFP reporter in the locus of the Brachyury gene to show that DE arises 
from a Brachyury
+
 population capable of giving rise to both endoderm and mesoderm. 
Subsequent studies similarly used reporter ESC lines containing the GFP and IL2Rα reporter 
genes in the Goosecoid and Sox17 loci respectively, to allow identification of culture methods 
capable of generating DE, and to distinguish DE from visceral endoderm (Yasunaga et al., 
2005; Tada et al., 2005). Another study used an ESC reporter line that expressed CD4 in the 
Foxa2 gene locus to show that both Wnt and TGF-β signalling are also important for DE 
formation (Gadue et al., 2006).  
In 2005, D’Amour et al published an influential protocol for the differentiation of DE that 
involved treatment with high concentrations of Activin A and low serum levels, resulting in a 
yield of Sox17-expressing cells of over 80%. Other markers of DE, including Foxa2, Cxcr4, 
and Cer1 were also upregulated, while Sox7, a marker of visceral endoderm, was not. This 
protocol was further optimised in a later study (Kroon et al, 2008). It has now been 
established that Activin A has different effects depending on the concentrations used, with 
low concentrations (5-20ng/ml) able to maintain stem cells in an undifferentiated state under 
feeder-free conditions, intermediate concentrations (20-50ng/ml) resulting in the induction of 
mesoderm, and high concentrations (50-100ng/ml) resulting in the induction of DE. In 
addition, the timing of Activin A treatment also has an impact on the cells produced, with 
immediate inhibition of TGF-β signalling after endoderm formation resulting in induction of 
anterior foregut, and sustained TGF-β signalling resulting in posterior foregut and hepatic 
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development (Vallier et al, 2005). This may reflect the in vivo situation, where cells which 
migrate through the primitive streak earlier give rise to anterior DE, while cells which 
migrate later give rise to posterior DE. It has also been shown that inhibition of Activin 
A/Nodal signalling is required for further pancreatic specification of DE cells, further 
elucidating the timing needed for optimal differentiation (Cho et al, 2012).  
While the role of Activin A has been extensively characterised, studies have also identified 
the roles of other signalling pathways in endoderm formation, including PI3K (McLean et al., 
2007), BMP4 (Teo et al, 2011; Xu et al, 2011), FGF (Sui et al, 2012), and Wnt (D’Amour et 
al, 2006) signalling. In a follow-up to the study published by D’Amour et al (2005), Nostro et 
al (2011) further optimised differentiation conditions in order to enhance the efficiency of 
differentiation, both at the DE stage, and at the final insulin-producing cell stage. This study 
further elucidated the temporal requirements for TGF-β, Wnt and BMP4 signalling, and 
showed that BMP4, bFGF and VEGF could replace serum in differentiation. Being able to 
carry out differentiation in serum-free conditions is an advantage, both in terms of 
reproducibility and in being more clinically relevant. More recently, a comprehensive study 
by Loh et al (2014) further elucidated the developmental signals and timing required for high 
efficiency differentiation into DE. 
Culture conditions also play an important role in differentiation to DE, as demonstrated by 
Kubo et al (2004), who showed that high serum concentrations resulted in a lower efficiency 
of differentiation into DE, due to the presence of undefined growth factors and hormones in 
serum. Reduction of serum concentration to 0.2-0.5% was shown to be the most successful 
for generating DE (D’Amour et al, 2005). Whether the cells are differentiated in monolayer 
culture or as embryoid bodies is also likely to affect the differentiation process, and the 
necessary dose and timing of signalling factors (Sulzbacher et al, 2009). In an attempt to 
recreate more physiological conditions, and improve the quality of the cells produced, Van 
Hoof et al (2011) developed a protocol for the differentiation of ESCs into DE in adherent, 
size-controlled, clusters, which were able to give rise to homogenous clusters of pancreatic 
progenitors. However, Nostro et al (2011) found that differentiation kinetics were faster in 
monolayer cultures vs. embryoid bodies, with endodermal gene expression arising by day 3 
in monolayer but not until day in embryoid bodies. However, embryoid body culture has the 
advantage of being more easily scaled up. Chetty et al (2013) found that the differentiation 
efficiency varied depending on the density of the cells at the start of the protocol, with cells 
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plated at higher densities forming more DE than those at low densities, suggesting that 
contact-mediated growth inhibition might improve the cells’ response to differentiation 
signals. Treating low density cells with DMSO prior to differentiation improved the 
efficiency of differentiation to a level comparable with high-density cells. This was true for 
differentiation into several lineages, including DE. Another study linked differences in 
propensity of stem cells to form DE to the cell cycle state of the cells, and showed that the 
activity of Activin signalling during cell cycle progression is controlled by cyclin D proteins. 
Using small molecules to manipulate CDK4/cyclin D could improve differentiation 
efficiency, even to the extent where Activin A was not required (Pauklin & Vallier, 2013). 
Taylor-Weiner et al (2013) showed the role of extracellular matrix components, such as 
fibronectin and lamimin, in DE formation. 
  
Differentiation into Insulin-Expressing Cells 
 
 
Figure 1.8. In vitro directed differentiation of pluripotent stem cells toward insulin-producing β-cells 
recapitulates in vivo development. During embryonic development, pluripotent cells in the inner cell mass are 
progressively differentiated toward pancreatic endocrine cells, through sequential formation of definitive 
endoderm, pancreatic progenitors, and endocrine progenitors. Adapted from Maehr, 2011. 
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In a follow-up of their previous study, and using knowledge of in vivo pancreas development, 
D’Amour et al. (2006) developed a 5-stage differentiation protocol that guided ESCs to 
differentiate into β-cells through the sequential formation of DE, primitive foregut, pancreatic 
endoderm, endocrine progenitors and finally pancreatic endoderm cells (figure 1.8). The cells 
produced using this protocol had an insulin content similar to that of human islets, and were 
positive for both insulin and C-peptide (although at very low efficiency, with only 7.3% of 
cells positive for insulin). The cells released insulin in response to various secretagogues, 
although not glucose. In addition, some cells were polyhormonal, suggesting that the cells 
produced had an immature phenotype.  
Several other studies have adopted a similar sequential approach, but used different 
combinations of growth factors to induce differentiation. Jiang et al (2007) used a feeder- and 
serum-free protocol to differentiate ESCs into insulin-expressing cells using slightly different 
factors. 4% of the cells within the islet-like clusters were positive for c-peptide, and these 
were also capable of releasing insulin in response to glucose. These cells were further 
characterised in a subsequent study by the same group, which found that the islet-like clusters 
generated using this protocol contained cells which expressed insulin, glucagon and c-
peptide, which were occasionally co-expressed in the same cells. However, when 
transplanted into diabetic mice, these islet-like clusters were unable to completely normalise 
hyperglycaemia, although they did extend survival and showed evidence of c-peptide release 
in response to glucose (Eshpeter et al, 2008). Shim et al. (2007) used a shorter protocol, 





 population indicative of pancreatic endoderm, but did not produce 
significant numbers of insulin-expressing cells in vitro. However, when the precursor cells 
were transplanted into mice, they were able to reverse STZ-induced diabetes, and insulin-
positive cells were observed when the graft was removed, suggesting further maturation in 
vivo. This was confirmed by another study, in which transplanted cells were able to correct 
hyperglycaemia in diabetic mice (Jiang et al, 2007). Cho et al. (2008) reproduced the 
protocol developed by D’Amour et al (2006), but added betacellulin and nicotinamide to the 
final stage, which allowed sustained expression of PDX1, but the efficiency of differentiation 
was lower, with very few insulin-expressing cells observed, and little or no insulin release in 
response to glucose. Shiraki et al. (2008) used a reporter ESC line expressing GFP in the 
Pdx1 gene locus to investigate pancreatic differentiation, showing that co-culture of ESCs 
with a mesodermal cell line was able to induce differentiation into DE and PDX1-expressing 
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cells. They then elucidated the signalling molecules, concentrations and timings involved in 
differentiation to produce higher yields of DE and PDX1-expressing pancreatic progenitors 
which were able to give rise to both endocrine (including insulin-expressing) and exocrine 
cell types when transplanted into immunodeficient mice. An additional study that further 
elucidated the roles of signalling molecules in differentiation into pancreatic progenitors 
showed that retinoic acid plays a role in the differentiation of ESC-derived DE cells into 
PDX1
+
 progenitors, and allows differentiation at a high efficiency by inhibiting hepatic 
differentiation (Cai et al., 2010). Sui et al (2013) elucidated the role of BMP4 signalling in 
the later stages of pancreatic differentiation, while Nostro et al (2011) further elucidated the 
timing and doses of signalling molecules required at each stage of differentiation, and 
produced populations of cells containing more than 25% c-peptide-positive cells. A study 
using treatment with Activin A, retinoic acid, bFGF and nicotinamide resulted in the 
production of islet-like structures with distinct monohormonal cells, including insulin-
expressing cells. These cells showed low levels of insulin release in response to glucose when 
cultured in monolayer, but this was increased when the cells were grown in suspension (Liu 
& Lee, 2012). 
Despite these promising results demonstrating that ESCs can give rise to pancreatic endocrine 
cells in vitro, most of these studies produced cells that were functionally restricted, either 
having a polyhormonal phenotype, or lacking appropriate insulin release in response to 
glucose. Many of the cells had characteristics more reminiscent of foetal pancreatic cells. 
Perhaps this is not surprising, given that most protocols allow around 20 days for the 
differentiation of ESCs into insulin-expressing cells, even though insulin-expressing cells are 
not detected in the human foetal pancreas until around 8 weeks of development. A study by 
Patterson et al (2012) showed that this is a common feature of several in vitro differentiation 
protocols, with the differentiated progeny showing more similarity in terms of morphology 
and gene expression to cells normally found at very early stages of development in vivo. 
While increasing the length of time in culture did allow the cells to mature somewhat, they 
were still very different from the equivalent adult cells, suggesting that increased time in 
culture alone is not enough to drive maturation, and that additional signals are needed. 
However, Kroon et al. (2008) succeeded in producing a population of pancreatic progenitor 
cells which, several weeks after transplantation into immunodeficient mice, were shown to 
release C-peptide and insulin in response to glucose, demonstrating that unknown factors in 
the in vivo environment were capable of inducing these cells to complete differentiation into a 
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more mature β-cell phenotype. However, only a few mice were able to normalise 
hyperglycaemia. This result was confirmed by another group using a different differentiation 
protocol (Shim et al., 2007).  
Since then, there have been efforts to elucidate the factors needed for β-cell maturation. One 
study demonstrated that ESCs did not optimally differentiate in vitro until the cells were 
grown layered with other islet cells, showing a need for either growth factors or direct cell 
contact from α- or δ-cells for β-cell maturation in vivo (Kahan et al., 2003). A more recent 
study elucidated the differences between immature and mature β-cells from postnatal mice, 
and found differences in glucose-stimulated insulin secretion (GSIS) between them. 
Comparison of gene expression between mature and immature β-cells showed that this is 
very similar between them, but that some genes, including MafB and Ucn3, showed 
differential expression. Ucn3 expression was also different in immature β-cells derived from 
ESCs compared to those that had been allowed to mature through transplantation into mice, 
suggesting that this gene is a good marker to distinguish between immature and mature β-
cells derived from ESCs in vitro (Blum et al, 2012). Another study identified aberrant 
chromatin remodelling in insulin-expressing cells derived in vitro compared to those matured 
in mice (Xie et al, 2013). However, the precise factors involved in β-cell maturation remain 
unknown, and, until they are elucidated, it is unlikely that fully functional mature β-cells will 
be generated in vitro.  
Another problem facing the differentiation of β-cells from ESCs is the variability in the cells 
produced, even when using the same protocol. This clearly demonstrates that culture 
conditions and differentiation protocols still need to be optimised. The efficiency of 
differentiation also depends on the cell lines used, as cell lines have different propensities to 
differentiate into a pancreatic lineage (Osafune et al., 2008), making it difficult to compare 
different studies. Nostro et al (2011) suggested that this was due to different levels of 
endogenous BMP4 signalling between different cell lines, and could be controlled by 
manipulating BMP4 levels.  
In addition to the variability noticed between different cell lines, another problem facing the 
differentiation of pluripotent stem cells into insulin-expressing cells is the low efficiency of 
current differentiation protocols, with most studies reporting a final yield of around 4-7% 
insulin-expressing cells, and an optimised protocol still only resulting in a 25% yield (Nostro 
et al, 2011). If these cells are to be produced on a large scale for clinical use, the efficiency 
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will need to be improved. An appealing alternative may be to propagate intermediate 
progenitor cells, as was recently demonstrated by Cheng et al. (2012), who generated self-
renewing endoderm progenitor (EP) cell lines from both human ESCs and iPSCs, which 
expressed key endodermal genes such as FOXA2 and SOX17, and were able to differentiate 
into both hepatic and pancreatic cells. The β-cells generated from these progenitors produced 
insulin at around 20% of levels seen in adult human islets in response to glucose, and in 
addition showed low expression of other endocrine hormones e.g. SST, GCG. Despite their 
extensive proliferative capacity in vitro, when injected into immunodeficient mice they did 
not form teratomas. A similar cell line has also been described in mice (Morrison et al., 
2008). Sneddon et al (2012) described the self-renewal in vitro of both endoderm and 
endocrine progenitors when co-cultured with mesenchymal cells. Although they were unable 
to identify which growth factors released by the mesenchymal cells were responsible for this 
effect, it is likely to be due to a combination of signalling pathways, including BMP, EGF 
and FGF signalling (Sui et al, 2013). Importantly, continued passage of endoderm or 
endocrine progenitors in vitro had no detrimental effect on later stages of differentiation, and 
insulin-expressing cells could still be detected after maturation in vivo (Sneddon et al, 2013). 
Greggio et al (2013) described a three-dimensional culture system allowing the expansion of 
pancreatic progenitors in vitro.  
Something else that may contribute to the variability of the β-cells produced is that the 
protocols have typically used recombinant growth factors to induce differentiation, and these 
may vary in their biological activity. The use of small molecules to control differentiation is a 
promising alternative, as they can be chemically synthesised and purified, allowing 
standardisation. In addition, they are more easily produced and therefore less expensive. 
Studies have identified small molecules that can induce differentiation into DE (Borowiak et 
al., 2009; Zhu et al., 2009) and pancreatic progenitors (Chen et al., 2009). More recently, 
Kunisada et al. (2012) replaced several growth factors used in differentiation protocols with 
small molecules, replacing Wnt3A with CHIR00921 (a GSK3β inhibitor) in DE formation, 
and Noggin with Dorsomorphin (an inhibitor of BMP type 1 receptors) in pancreatic 
specification. Addition of SB431542 (a TGF-β type 1 receptor inhibitor) was able to increase 
NGN3 expression, as well as that of other pancreatic markers.  
The culture conditions may also have an impact on the quality of the cells produced. An early 
report showed that EB differentiation of ESCs resulted in higher endodermal and pancreatic 
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gene expression than differentiation of monolayer cultures (Xu et al, 2006). It has been 
suggested that the size of β-cell clusters may affect their insulin-releasing ability: clusters 
containing multiple β-cells release more insulin than single β-cells (Meda et al., 1990), and in 
vitro-derived β-cells secrete more insulin when in three-dimensional clusters than when 
grown in monolayer (Brereton et al., 2006). This was also shown when pancreatic 
progenitors derived from ESCs were transplanted into mice: a study by Van Hoof et al. 
(2011) developed a method for controlling the size of cell clusters and determined the 
optimum number of cells within each cluster for differentiation into pancreatic endoderm.  
Before these cells can be considered for a clinical application, there are concerns that need to 
be addressed. Firstly, the potential tumorigenicity of the cells produced, as the many rounds 
of replication in culture that stem cells or cell lines undergo before transplantation may lead 
to accumulation of abnormalities that could potentially be oncogenic (Ben-David et al., 
2011). In addition, the differentiation protocols are inefficient, and usually lead to a 
heterogeneous population of cells which may include pluripotent cells, which could give rise 
to teratomas if included in the transplant. It is therefore important to find strategies to avoid 
tumorigenesis, including the elimination of undifferentiated cells, since contamination could 
lead to the formation of teratomas. This is further discussed in section 1.8.2.  
Secondly, there are concerns about the immune challenges faced by transplanted cells. There 
are two immune challenges facing the transplantation of β-cells derived from ESCs. The first 
is allograft rejection due to immunological mismatches between donor and recipient, and it 
seems likely that some form of immunomodulatory therapy will be needed to prevent graft 
failure. In solid organ and bone marrow transplants, it has been well established that the best 
strategy for reducing graft rejection is to minimise mismatching between donor and recipient. 
ABO blood typing is particularly important, as a mismatch will result in graft rejection, but in 
terms of HLA matching, the matching of HLA-A, HLA-B and HLA-DR is most important. 
However, the better the match, the greater the chance of graft survival, and the lower the 
requirement for immunosuppression (Grinnemo et al, 2008). Techniques developed in the 
field of whole organ transplantation to reduce graft rejection can also be applied to stem cell 
transplantation, including the use of immunomodulatory drugs and antibodies, co-stimulatory 
blockade to inhibit activation of T cells (Huber et al, 2013), or the induction of mixed 
haematopoietic chimerism by simultaneous transplantation of haematopoietic stem cells from 
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the same donor to induce tolerance to the transplanted cells (reviewed in Boyd & Fairchild, 
2010.) 
Some research has suggested that national or international banks of HLA-typed ESC lines 
could provide HLA- and ABO blood group-matched cells for the majority of individuals. 
Although a large number of ESC lines would be needed to provide every potential recipient 
with a perfect HLA match, one study has suggested that a bank of just 150 ESC lines could 
provide a beneficial match for the majority of the UK population (Taylor et al, 2005). For 
less genetically diverse populations, such as the Japanese population, as few as 50 ESC lines 
may provide a beneficial match. However, most ESC lines are derived from surplus embryos 
generated for IVF, so the MHC haplotypes are unknown at the time of ESC derivation and 
rare haplotypes may not become available. In addition, ethnic minorities are poorly 
represented in this pool of embryos (Fairchild, 2010). One way around this may be to 
generate ESC lines using somatic cell nuclear transfer, in which the nucleus from a somatic 
cell is transferred into an enucleated oocyte, which is then cultured to the blastocyst stage, 
from which ESCs of a known genetic background can be derived. This was only recently 
achieved in human cells (Tachibana et al, 2013).  
The second immune challenge is the problem of auto-immunity in T1DM. This has been the 
subject of much research, and can be divided into antigen-specific immunomodulation, 
including vaccination with antigens associated with the onset of T1DM e.g. GAD65; and 
non-antigen-specific immunomodulation, which aim to more generally suppress the 
autoimmune response, including treatment with T cell-inhibiting drugs e.g. cyclosporine A; T 
cell-inhibiting antibodies; thymoglobulin, which inhibits not only T cells but also B cells, 
dendritic cells, NK cells and endothelial cells; B cell-specific antibodies; cytokines; and co-
transplantation of autologous bone marrow stem cells (reviewed in Waldron-Lynch & 
Herold, 2011).  
One method which could be used to protect transplanted cells from the immune system, 
potentially providing a solution to both immune challenges, is encapsulation of the 
transplanted cells. This method has been tested repeatedly in previous years, initially with 
poor cell survival (Lacy et al., 1991; De Vos et al., 2002), although more recently, improved 
methods of  encapsulation have shown better results (Kirk et al., 2014; Yahknenko et al., 
2014). As described in section 1.5.4, encapsulation of pig islets has been suggested to prevent 
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their rejection by the immune system. Survival and function of stem cell-derived insulin-
expressing cells in capsules has also been demonstrated (Bruin et al, 2013).  
 
1.8 Induced Pluripotent Stem Cells  
In 2006, a significant advance in the field of stem cell research was made with the discovery 
that 4 transcription factors could reprogram somatic cells into induced pluripotent stem cells 
(iPSCs). Reprogramming was initially carried out in mouse fibroblasts through screening of 
24 candidate genes that had all been implicated in the establishment and maintenance of 
pluripotency in ESCs. This pool of candidates was subsequently narrowed down to 4 
transcription factors: OCT4, KLF4, c-MYC and SOX2, which were sufficient to enable 
reprogramming (Takahashi & Yamanaka, 2006). These reprogrammed cells were shown to 
be similar to ESCs in terms of their morphology and gene expression, and were 
karyotypically normal. Although iPSCs from this first experiment were not germline-
competent, they were able to give rise to all three germ layers in vitro. Germline-competent 
iPSCs have since been generated (Okita et al., 2007). Reprogramming of human fibroblasts 
was achieved a year later (Takahashi et al., 2007; Yu et al., 2007), and since then, iPSCs 
have been generated from numerous different human cell types (Aasen et al., 2008; Aoi et 
al., 2008; Haase et al., 2009; Giorgetti et al., 2009; Loh et al., 2010; Maherali et al., 2008; 
Utikal et al., 2009; Sun et al., 2009), including pancreatic β-cells (Stadtfeld et al., 2008), as 
well as from several other species, including rhesus monkey (Liu et al., 2008).  
Reprogramming of somatic cells into iPSCs holds great promise for the treatment of a range 
of diseases, including T1DM, through cell replacement therapy (figure 1.9). As an alternative 
source of pluripotent cells, iPSCs have advantages over ESCs, as they are patient-specific, 
and do not require the use of human embryos or oocytes in their derivation. iPSCs also have 
potential for the treatment of genetic defects through gene therapy in combination with cell 
replacement therapy, as the cells can be extensively characterised to ensure that gene repair is 
specific, reducing the risks of random, viral-mediated gene therapy. Proof-of-principle for 
gene therapy in combination with cell replacement therapy was shown by a study in which 
iPSCs were generated from mice models of sickle cell anaemia and the human sickle 
haemoglobin allele was corrected using gene-specific targeting. Haematopoietic progenitors 
were obtained from these corrected iPSCs and were able to reconstitute the haematopoietic 
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system and cure sickle cell anaemia when transplanted into irradiated mice (Hanna et al., 
2007).  
In addition to their promise in cell replacement therapy, iPSCs are also extremely useful for 
disease modelling and drug screening in vitro (figure 1.9). iPSCs can be differentiated in vitro 
into several types of cells which will be useful for drug screening, including hepatocytes, 
cardiomyocytes and neurons. These should help to predict whether drugs have toxic effects 
on the liver, heart and brain at an early stage of research and development.  
 
 
Figure 1.9. Derivation of iPSCs & their applications in cell replacement therapy, disease modelling and gene 
therapy. Fairchild, 2010. 
 
Many cells affected by disease have defied attempts to culture them in vitro, or their 
phenotype has been changed by adaptation to tissue culture. Embryos shown to carry genetic 
disease using pre-implantation genetic diagnosis can yield ESC lines that model genetic 
disorders, but the vast majority of diseases that show more complex genetic patterns of 
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inheritance are not accessible in this way. The increased accessibility of disease-specific 
iPSCs compared to ESCs means that numerous iPSC lines derived from patients of different 
ages and with specific diseases are now available. These provide an extremely useful tool for 
disease modelling and drug screening. Although early studies focussed on diseases with 
monogenic defects, more recently iPSCs have been generated from patients with more 
genetically complex diseases, including T1DM (Maehr et al., 2009). Currently, insights into 
T1DM come largely from rodent models such as the non-obese diabetic (NOD) mouse 
model, which although extremely useful, have limitations as they are rarely fully 
representative of the disease in humans. Given that T1DM seems to result from auto-immune 
interaction between T cells and β-cells, it may be useful to differentiate iPSCs from diabetic 
patients into β-cells and observe their interaction with the patient’s T cells in vitro so that the 
auto-immune aspect of the disease can be recapitulated in vitro.  
However, the usefulness of iPSCs for disease modelling is limited by current differentiation 
protocols. Although iPSCs can in theory give rise to any cell in the body, so far in vitro 
differentiation protocols have only been developed for a small subset of cell types. In 
addition, it is difficult to achieve a pure population using current differentiation protocols, 
and the cells produced frequently have an immature phenotype characteristic of foetal cells. 
This limits their usefulness for modelling adult diseases. In some cases, iPSCs may not be 
suitable for disease modelling: for example, iPSCs derived from patients with fragile X 
syndrome continued to silence the Fmr1 gene after differentiation, in contrast to ESCs 
derived from pre-implantation genetic diagnosis, which reactivate Fmr1 after differentiation 
(Urbach et al, 2010). Also, iPSCs could not be generated from patients with Fanconi anaemia 
unless the genetic defect was repaired first, so are unsuitable for modelling this disease in 
vitro (Muller et al, 2012). 
 
1.8.1 Differentiation of iPSCs into Pancreatic β-cells 
β-cells have been derived from iPSCs generated both from normal human fibroblasts 
(Tateishi et al., 2008; Zhang et al., 2009; Alipio et al., 2010), as well as from fibroblasts from 
both a mouse model of T1DM (Jeon et al., 2012) and human patients with T1DM (Maehr et 
al., 2009). In addition, insulin-expressing cells have also been produced from rhesus monkey 
iPSCs (Zhu et al., 2011) which may be useful for pre-clinical trials of iPSC-based therapies 
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for T1DM. The protocols used have been developed from those used to generate β-cells from 
ESCs, starting with the formation of DE. These studies have shown that not only do the cells 
produced demonstrate specific markers of the pancreatic lineage, such as expression of 
PDX1, HNF6, HNF4α and NKX6.1; they are also able to release insulin in response to 
glucose, suggesting that they may be functional. Saito et al. (2011) showed that both ESCs 
and iPSCs were able to form islet-like structures in vivo, which were able to release insulin in 
response to glucose and were able to normalise hyperglycaemia when transplanted into mice.  
However, the same problems associated with β-cells differentiated from ESCs also apply to 
those derived from iPSCs, such as the variability in the cells produced, their potential 
tumorigenicity and the problem of the auto-immune aspect of the disease. In addition, there 
are still issues specific to iPSCs that need to be resolved before they can be considered as an 
alternative to ESCs for a therapeutic application, which are discussed below. 
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Table 1.1. Developments in the techniques for reprogramming somatic cells into iPSCs, and their respective advantages and disadvantages. Abbreviations: O = OCT4, S = SOX2, 
K = KLF4, M = C-MYC, N = NANOG, L = LIN28, VPA = valproic acid, NaB = sodium butyrate. Adapted from Robinton & Daley, 2012.  
 
 
1.8.2 Considerations Prior to Clinical Application of iPSCs 
 
Reprogramming Method 
All four factors used in initial reprogramming experiments are overexpressed in at least some types 
of tumour, and c-Myc in particular is known to play a central role in both pluripotency and cancer 
pathways (Lee et al, 2013), raising concerns about a potential increase in tumorigenicity in these 
cells, and leading to efforts to remove or replace these factors with less oncogenic factors (table 1.1). 
For example, in mouse fibroblasts, SOX1 and SOX3 can replace SOX2; KLF2 can replace KLF4; 
and L-MYC and N-MYC can replace C-MYC (Blelloch et al., 2007; Nakagawa et al., 2008). A 
different combination of factors (OCT4, SOX2, NANOG and LIN28) has also been shown to 
reprogram neonatal human fibroblasts (Yu et al., 2007). In addition, some cell types have 
endogenous expression of one or more of the reprogramming factors, removing the need for 
exogenous expression in reprogramming e.g. fibroblasts express C-MYC and KLF4, and it has been 
shown that C-MYC can be omitted from the reprogramming mix (Nakagawa et al., 2008; Wernig et 
al., 2008); while neural progenitor cells have high endogenous expression of SOX2 and C-MYC and 
have been reprogrammed initially in the absence of SOX2 (Eminli et al., 2008; Kim et al., 2008) and 
then using only OCT4 (Kim et al., 2009), although the efficiency of reprogramming is reduced, and 
the inaccessibility of these cells make it unlikely that they will ever be widely used. In addition, 
iPSCs generated using one or two reprogramming factors showed a marked reduction in efficiency of 
differentiation into neural and haematopoietic lineages compared to ESCs and iPSCs generated using 
four factors (Löhle et al., 2012).  
Another concern is the use of integrating viral vectors to deliver the reprogramming factors. The first 
reprogramming experiments used retroviral (Takahashi & Yamanaka, 2006; Takahashi et al., 2007) 
and lentiviral vectors (Blelloch et al., 2007; Yu et al., 2007; Brambrink et al., 2008; Hockemeyer et 
al., 2008; Maherali et al., 2008; Stadtfeld et al., 2008). However, both lentiviruses and retroviruses 
lead to integration of the viral transgenes into the genome which may not be completely silenced in 
the iPSCs generated (Lois et al., 2002). Genomic integration has been shown to alter gene function 
(Kustikova et al., 2005) and viral transgene re-activation in iPSC-derived chimeric mice has been 
implicated in tumorigenesis (Nakagawa et al., 2008).  Also, random integration may influence the 
molecular signature of iPSCs by disrupting regulatory regions in the human genome. Transcriptional 
analysis showed that transgene expression from incompletely silenced viral vectors could perturb 
global gene expression in iPSCs (Soldner et al, 2009). A recent study demonstrated a propensity for 
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virally-reprogrammed iPSCs to revert to pluripotency following differentiation, leading to teratoma 
formation following transplantation into mice (Polanco et al., 2013). For these reasons, it is unlikely 
that these cells would be acceptable for clinical applications.  
Attempts to make iPSCs more clinically applicable have led to the development of non-integrating 
reprogramming methods (summarised in table 1.1), such as reprogramming using chemical 
compounds in place of the reprogramming factors (Zhu et al., 2010), as well as the use of expression 
plasmids (Okita et al., 2008), episomal vectors (Yu et al., 2009), piggyBac transposition (Woltjen et 
al., 2009), Cre-recombinase-based excisable viruses (Soldner et al., 2009), membrane-soluble 
protein-induced reprogramming (Zhou et al., 2009), transient transfection with plasmid DNA (Si-
Tayeb et al., 2010), delivery of reprogramming factors conjugated with cell-penetrating peptide 
(Kim et al., 2009) and reprogramming using synthetic modified mRNA (Warren et al., 2010).  
Reprogramming strategies using small interfering RNAs (siRNAs) or microRNAs (miRNAs) may 
offer an alternative reprogramming strategy to generate more clinically relevant iPSCs. Zhao et al. 
(2008) showed that siRNA targeting p53 and Utf1 dramatically increases reprogramming efficiency. 
More recently, a lentiviral vector encoding stem cell-specific miRNAs were used to reprogram 
somatic cells to pluripotency at a higher efficiency than the traditional reprogramming factors. The 
reasons for this increase in efficiency may include the fact that miRNA expression does not require 
protein translation, leading to a fast response, and also that miRNAs are able to target hundreds of 
mRNAs which can lead to a rapid phenotypic change (Anokye-Danso et al., 2011). This was quickly 
followed by reprogramming by direct transfection of mature double-stranded miRNAs (Miyoshi et 
al., 2011) which has the additional advantage of avoiding viral integration. iPSCs generated in this 
way have been reported to be less tumorigenic when compared with iPSCs generated by other 
approaches. This may be due to the fact that miRNA-mediated reprogramming does not require 
exogenous expression of c-MYC; that the miRNAs used are known to target several cell cycle 
regulators, resulting in the attenuation of the G1/S phase transition; and that these miRNAs result in 
the upregulation of tumour suppressor genes such as p16Ink4a and p14/19Arf (Lin et al., 2010). 
However, there may also be disadvantages to using this approach: firstly, in order to provide the 
necessary amount of miRNAs over the course of reprogramming it was necessary to carry out 
repeated transfections; and secondly, the need for such large amounts of synthetic nucleotides may 
greatly increase the cost of large-scale reprogramming needed for the use of iPSCs in a clinical 
setting.  
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Choice of Donor Cell Type 
The efficiency and kinetics of reprogramming vary depending on the starting cell type: for example, 
retroviral reprogramming of mouse embryonic fibroblasts can be achieved in 8-12 days, while 
human fibroblasts typically take around 20-25 days. Fibroblasts were used in early reprogramming 
experiments, and are still the most popular cell type due to their accessibility, commercial 
availability, and ease of maintenance in culture. However, reprogramming of fibroblasts is relatively 
slow and inefficient. Since then, many different cells have been reprogrammed into iPSCs, each with 
their own advantages and disadvantages (table 1.1). 
Keratinocytes (Aasen et al., 2008; Maherali et al., 2008) represent an easily accessible source of 
cells (obtained from plucked hair follicles) that can be reprogrammed with ~100-fold increase in 
efficiency and ~2-fold increase in speed compared to fibroblasts, although this was only reported for 
juvenile cells, and the efficiency is likely to be less for older cells. In addition, they require extended 
culture in vitro to obtain enough cells for reprogramming, which increases their likelihood of 
accumulating genetic abnormalities. Furthermore, due to their physical location, keratinocytes have 
prolonged exposure to UV light, which further increases their risk of DNA damage. Melanocytes 
(Utikal et al., 2009) have many of the same advantages and disadvantages of keratinocytes, in that 
they are accessible and can be reprogrammed at a higher efficiency and speed, but they may have 
accumulated genetic abnormalities.  
Adipose stem cells from patients of a range of ages have also been reprogrammed at a higher 
efficiency (~ 20-fold increase) and speed (~2-fold faster) than fibroblasts. They are readily available 
through lipoaspiration, which is a more invasive procedure, but a small amount of tissue provides 
large numbers of cells for reprogramming, removing the need for their expansion in vitro. In 
addition, the derivation of iPSCs from adipose stem cells does not require the support of feeder cells 
(Sun et al., 2009).  
iPSCs derived from blood cells are an appealing prospect, as they can be obtained through a 
minimally invasive procedure, or through existing blood banks, and does not require the extended 
expansion in culture that fibroblasts do. The first study to show that haematopoietic cells can be 
successfully reprogrammed into iPSCs used CD34
+
 cells from the peripheral blood of patients 
undergoing G-CSF mobilisation. While this increases the yield of CD34
+
 progenitor cells, which 
have been suggested to be more amenable to reprogramming than terminally differentiated peripheral 
blood cells, it is also associated with side effects such as headache, nausea, and bone pain. This study 
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used retroviral reprogramming, which requires cells to be dividing, so cells were expanded in culture 
prior to reprogramming. However, this led to a decrease in the numbers of progenitor cells and an 
increase in numbers of differentiated cells over time. The reprogramming efficiency was still 
relatively low (0.01-0.02%) (Loh et al., 2009). Subsequent studies reprogrammed peripheral 
terminally differentiated T cells, which are abundant in peripheral blood, so that only 1ml of blood 
was needed to provide sufficient cells for reprogramming, and which can be easily expanded in 
culture (Brown et al., 2010; Seki et al., 2010; Staerk et al., 2010). A potential concern of using T 
cell-derived iPSCs is the persistence of T cell receptor gene rearrangements in the iPSC genome, and 
their potential effects on subsequent differentiation, but so far, no significant differences in 
differentiation potential have been observed between ESCs and T cell-derived iPSCs. A considerable 
advance was made by Seki et al. (2010), who used a non-integrating approach by using Sendai virus 
to deliver the reprogramming factors, which resulted in higher reprogramming efficiency. More 
recently, Chou et al. (2011) used an episomal vector to reprogram both peripheral blood and cord 
blood cells.  
Another potential source of haematopoietic cells for reprogramming is cord blood (Haase et al., 
2009; Giorgetti et al., 2009: Chou et al., 2011), which is routinely available from commercial and 
public banks, covering a wide range of haplotypes. In addition, the isolation of progenitors is more 
efficient from cord blood than peripheral blood, and cord blood cells have higher proliferation 
potential than peripheral blood cells. The fact that the cells are younger also means that they are less 
likely to have acquired potentially harmful genetic abnormalities. However, the availability of 
autologous cells is restricted to those who had their cord blood banked at birth. It is also unclear how 
long these cells can be cryopreserved for and still generate iPSCs: one study used cord blood that had 
been cryopreserved for more than 5 years (Giorgetti et al., 2009), but many patients who could 
potentially benefit from cell replacement therapy using cord blood-derived iPSCs would not need 
them until much later in life. In addition, cord blood cells have been reprogrammed using just OCT4 
and SOX2 without the need for the oncogenes c-MYC and KLF4, which makes them more clinically 
relevant (Giorgetti et al., 2009). The differentiation status of the starting cell type also has an impact 
on reprogramming: for example, haematopoietic progenitor cells can generate 300 times more iPSC 
colonies than terminally differentiated T or B cells (Kim et al., 2010).  
An additional consideration when choosing a starting cell type for reprogramming is that there is 
emerging evidence that iPSCs retain an epigenetic memory of their starting cell type (Polo et al, 
2010). This may adversely affect their ability to differentiate into cells of other lineages, with some 
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studies showing that iPSCs have lower efficiencies of differentiation into haematopoietic, 
neuroepithelial, neuronal and cardiac lineages than ESCs (Feng et al, 2010; Hu et al, 2010). 
However, in some cases, epigenetic memory may be advantageous for generating cells that are 
difficult to generate through in vitro differentiation, such as pancreatic β-cells: a study in which 
iPSCs were generated from pancreatic β-cells showed that these iPSCs could differentiate into β-
cells in vitro at considerably higher efficiencies than iPSCs derived from other sources (Bar-Nur et 
al, 2011).  
 
Efficiency and Speed of Reprogramming 
The reprogramming process is very slow (~ 4 weeks) and inefficient (~0.01%) making it difficult to 
scale up this technology to the level needed for use of autologous cells for cell replacement therapy. 
The use of small molecules and soluble factors to increase the efficiency of reprogramming is 
appealing given their ease of use, ready availability, potential for standardisation, and lack of 
permanent genome modification. Numerous small molecules (and other factors) which improve the 
efficiency of reprogramming or replace some of the reprogramming factors have now been identified 
(reviewed in Feng et al, 2009). It has recently been shown that a combination of several chemical 
compounds is sufficient to reprogram mouse fibroblasts and adipose stem cells into iPSCs without 
the need for any additional reprogramming factors (Hou et al, 2013), although it has yet to be shown 
whether this is possible for human cells. Certain culture conditions, such as carrying out 
reprogramming in hypoxic conditions (Yoshida et al., 2009), have also been shown to improve 
efficiency.  
Since reprogramming depends on the resetting of the epigenetic state, numerous epigenetic modifiers 
have been identified which increase the efficiency of reprogramming (Mikkelsen et al, 2008; Shi et 
al., 2008), including valproic acid (Huangfu et al., 2008). However, the broad and non-specific 
effects of these epigenetic modifiers may result in global dysregulation of gene expression: for 
example, the demethylating agent 5-azacytidine (5-AZA) is mutagenic (Jackson-Grusby et al., 
1997), and mice with global alterations in DNA methylation develop tumours at a high frequency 
(Gaudet et al., 2003).  
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Culture Methods and Standardisation 
In the past few years, standards for the identification of iPSCs and for the assessment of their 
functional equivalence to ESCs have become widely accepted. Assessing the success of 
reprogramming into iPSCs starts with the identification of compact colonies that have distinct 
borders and well-defined edges, and that consist of cells which have a large nucleus, large nucleoli 
and little cytoplasm. Reprogramming is a stochastic process that results in the production of a wide 
range of colony morphologies, and while some of them may appear similar to ESCs, further 
characterisation is needed to identify true, fully reprogrammed iPSCs, including the expression of 
certain molecular markers, as well as functional assays. 
Molecular markers which allow the identification of fully reprogrammed iPSCs include the 
expression of a network of pluripotency genes, including Oct4, Sox2 and Nanog, at comparable 
levels to ESCs; as well as the expression of a number of cell surface markers including SSEA-3/4, 
TRA-1-81 and TRA-1-60 (Maherali & Hochedlinger, 2008). Alkaline phosphatase has been widely 
used as a marker for pluripotency, but recent evidence shows this to be insufficient to identify iPSCs, 
as cells that have been only partially reprogrammed may also stain  positive (Chan et al, 2009). 
iPSCs must be able to grow and maintain pluripotency independently of transgene expression. iPSCs 
must also be epigenetically similar to ESCs, with DNA demethylation at the promoters of 
pluripotency genes, X chromosome reactivation in female cells, and the presence of bivalent 
chromatin domains at developmental genes (Maherali & Hochedlinger, 2008).  
Analysis of the pluripotency of mouse iPSCs can be rigorously assessed through the generation of 
chimaeric mice, which evaluates the potential of iPSCs to contribute to the normal development of 
adult tissues when injected into the blastocyst. Germline transmission is assessed by the ability of 
these chimaeras to give rise to offspring derived entirely from iPSCs (Okita et al., 2007). The test 
with the highest stringency is tetraploid complementation, which involves the generation of extra-
embryonic tissue such as the placenta by fusion of embryonic cells at the two-cell stage. The 
resulting tetraploid embryo can then be combined with normal diploid iPSCs, giving rise to a foetus 
in which all extra-embryonic tissue is derived from the tetraploid cells and the foetus is derived from 
the diploid iPSCs. This measures the ability of the iPSCs to direct the normal development of an 
entire organism. This test has only been accomplished for a small number of iPSC lines, and it 
appears that not all iPSC lines are able to contribute to all-iPSC mice (Stadtfeld et al, 2010). Due to 
obvious ethical constraints, these tests for pluripotency cannot be carried out for human iPSCs. The 
most commonly used method of assessing the pluripotency of human iPSCs is differentiation in 
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vitro, either as embryoid bodies (compact balls of cells that form loosely organised tissues which 
resemble the gastrulating embryo) or in monolayer cultures, in order to assess the differentiated cells 
for markers of all three embryonic germ layers. The teratoma formation assay involves measuring 
the ability of iPSCs to differentiate into all three germ layers in vivo, following injection of 
undifferentiated cells into immunodeficient mice. Although this is the most stringent assay available 
for testing the pluripotency of human iPSCs, it does not assess whether the iPSCs are able to give 
rise to every cell in the body, nor does it assess the contribution of the iPSCs to the germline 
(Robinton & Daley, 2012).  
In order to be clinically relevant, iPSCs need to be generated and cultured using defined media 
components that are free of animal components. Many cell lines are grown on a feeder layer of 
mouse fibroblasts, which has the possibility of contaminating iPSCs with animal pathogens, as well 
as transferring potentially immunogenic antigens to the stem cells (Martin et al, 2005). Currently, the 
only ESC lines licensed for clinical use were not derived under xeno-free conditions (Crook et al, 
2007), although they were subsequently maintained in culture under xeno-free conditions. In 2012, 
another group developed the first animal-component free and good manufacturing practice (GMP)-
compliant ESCs (Tannenbaum et al, 2012). One possible alternative to mouse feeders is to use 
autologous skin fibroblasts from the same patient as a source of feeder cells (Takahashi et al, 2009). 
Another possibility is the use of synthetic basement membranes such as Matrigel™, which is a 
soluble basement membrane extract of the mouse Engelbreth-Holm-Swarm tumour that gels at room 
temperature, forming a reconstituted basement membrane which can be used to maintain pluripotent 
stem cells without a feeder cell layer. However, this is still not a completely defined formula, and is 
derived from a mouse cell line, so is not compatible with xeno-free culture. Extracellular matrix 
prepared from human fibroblasts in combination with xeno-free medium has also been reported 
(Meng et al, 2010), and several other groups have developed synthetic surfaces capable of 
maintaining pluripotent stem cells (reviewed in Villa-Doaz et al, 2012).  
There has also been a move towards more defined cell culture medium, with Rajala et al (2010) 
reporting the development of a fully defined xeno-free medium, capable of supporting the expansion 
of ESCs and iPSCs. In addition, mTeSR-2 is a defined, xeno-free medium for the maintenance of 
pluripotent stem cells in culture (www.stemcelltechnolgies.com). A study by Bergstrom et al (2011) 
compared four xeno-free culture systems. Many of the advances in GMP culture of ESCs will also 
apply to iPSCs, and recent studies have reported reprogramming under feeder- and xeno-free 
conditions (MacArthur et al, 2012; Warren et al, 2012), which is a big step towards the derivation of 
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clinical grade iPSCs.  However, the scale up of stem cell culture to the levels required for clinical 
application remains challenging.  
Several studies have described the use of suspension culture for large-scale growth of pluripotent 
stem cells in culture (Andang et al, 2008; Amit et al, 2011; Zweigerdt et al, 2011), while more 
recently a study by Fluri et al (2012) reported the derivation and expansion of iPSCs in suspension 
culture, which would allow large-scale production using bioreactors. However, they used 
reprogrammable mouse embryonic fibroblasts, which just require the addition of doxycycline for the 
reactivation of pluripotency genes and subsequent reprogramming, so it is unclear whether the 
reprogramming efficiency would be high enough when using cells that have not been genetically 
modified in this way. A subsequent study carried out reprogramming of unmodified cells in stirred 
suspension bioreactors, but they used retroviral vectors for reprogramming, making the study less 
clinically relevant than if they had used a non-integrating method (Shafa et al, 2012). Again, it is 
unclear whether the reprogramming efficiency would be high enough.  
In addition, new strategies will also need to be developed for the differentiation of pluripotent stem 
cells into insulin-expressing for cell replacement therapy, as currently many protocols rely on 
undefined products such as recombinant growth factors for the direction of cell fate. Commercial 
products for differentiation are now becoming available which have the advantages of being fully 
defined, serum- and animal product-free, and less variable in their biological activity, making them 
more clinically applicable. 
 
Tumorigenicity 
There are two concerns regarding the tumour-forming capacity of iPSCs: malignant transformation 
of the transplanted differentiated cells due to the use of integrating vectors or oncogenic 
reprogramming factors, and benign teratoma formation resulting from the transplantation of grafts 
contaminated with undifferentiated cells. Studies in both mouse (Miura et al, 2009) and human 
(Gutierrez-Aranda et al, 2010) cells found that transplantation of embryoid bodies derived from 
iPSCs gave rise to teratomas at higher efficiencies than those derived from ESCs, and that this was 
due to the presence of higher numbers of undifferentiated cells in the transplant. This makes finding 
strategies to remove any undifferentiated cells from the transplant even more important.  
Chapter 1: Introduction 
69 
 
Early reports reported the removal of teratomas retrospectively through the use of suicide genes and 
chemotherapy (Schuldiner et al., 2003; Cao et al., 2007; Vazquez-Martin et al, 2012), but these 
methods have several disadvantages including adverse effects, drug resistance, and the fact that they 
were used retrospectively. Removal of undifferentiated cells prior to graft transplantation is 
preferable, as this reduces the risk to patients, as well as reducing the need for post-transplantation 
monitoring. Several techniques have been developed, including antibody-induced cytotoxicity (Choo 
et al, 2008; Tan et al, 2009), lectin binding for the selection of pluripotent cells (Wang et al, 2011), 
fluorescence-activated cell sorting (FACS), and magnetic-activated cell sorting (MACS) (Tang et al, 
2011). The last two methods can be used either to eliminate pluripotent cells (Ben-David et al, 2013) 
or enrich differentiated cells based on their cell surface marker expression. Enrichment of 
differentiated cells has the advantage of purifying the graft to include only a single cell type, but this 
relies on knowledge of cell surface markers that can adequately distinguish the cells of interest from 
any other cells which may have arisen during directed differentiation, and usually requires a 
combination of markers. Recent studies identified novel surface markers for cells at different stages 
of the pancreatic differentiation process cells (Kelly et al, 2011; Fishman et al, 2012). However, 
these approaches have disadvantages including the loss of cells during sorting, and possible changes 
in cellular properties (Wang et al, 2012). The use of small molecules for selectively inducing cell 
death in pluripotent stem cells is also of interest: high-throughput screening identified two drugs 
capable of inducing death of undifferentiated ESCs (Conesa et al., 2012; Lee et al, 2013). Another 
study identified differences in adhesion strengths between pluripotent stem cells and differentiated 
cells which could be used to eliminate pluripotent cells from mixed cultures (Singh et al, 2013).  
Another recent study raised another safety issue, by showing that virally-reprogrammed iPSCs may 
reactivate pluripotency genes after differentiation, leading to the formation of teratomas. However, 
this study only looked at early stages of differentiation, and iPSCs reprogrammed using episomal 
vectors did not have this problem (Polanco et al, 2013). However, this is another issue that will need 
to be considered before iPSCs can be considered for clinical use. 
 
Immunogenicity 
Although it has been generally assumed that iPSCs, because they can be derived from an autologous 
source, would be immune-tolerated by the patient, recent evidence has shown that in mice, iPSCs 
generated by either retroviral or episomal approaches are rejected by the recipient’s immune system 
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more often than equivalent ESCs due to abnormal gene expression which contributes to increased 
immunogenicity of the cells (Zhao et al., 2011). However, this study only looked at the immune 
response to undifferentiated cells. A more clinically relevant study looked at terminally differentiated 
cells derived from ESCs and iPSCs, and found that cells derived from syngeneic iPSCs were no 
more immunogenic than those derived from syngeneic ESCs, either in vivo or in vitro (Guha et al, 
2013). This study found no differences in the expression of the genes identified by Zhao et al (2011) 
between ESCs and iPSCs. These results were confirmed by a subsequent study which again found no 
evidence of immune rejection of syngeneic ESC- or iPSC-derived tissues (Araki et al, 2013).  
The immunogenicity of iPSCs may depend on the cell type and the developmental stage of the 
starting material used for reprogramming, as iPSCs derived from some cell types (e.g. cord blood) 
appear to be innately less immunogenic than iPSCs derived from others (e.g. adult skin) (Liu et al, 
2013), suggesting that epigenetic mechanisms may be involved in immunogenicity. In addition, 
iPSCs reprogrammed using retroviral reprogramming have been suggested to be more immunogenic 
than those generated using non-integrating methods (Zhao et al, 2011). This may be due to the fact 
that the retroviral transgenes can alter gene expression. However, due to the time it takes to 
differentiate a patient’s own cells for therapy, and the expense of making these cells, it may be more 
appropriate to turn to banking of iPSCs. With the diversity of starting material available from donors, 
it is considerably easier to generate cell lines of a known genetic background that would provide an 
immunological match for most of the population compared to an ESC bank, although it is unlikely 
that even the best possible match from an iPSC bank will be able to entirely escape immune 
recognition following transplant.  
 
1.9 Differences Between iPSCs and ESCs 
Although early reports of iPSCs demonstrated that they were equivalent to ESCs in terms of their 
expression of pluripotency markers and ability to differentiate into cells from all three germ layers 
(Maherali et al, 2007; Wernig et al, 2007), recent in-depth analyses have revealed numerous subtle 
differences between the two cell types. Disparities were first observed in the differentiation abilities 
of ESCs and iPSCs, in both teratoma formation and in vitro differentiation assays. Just like ESC 
lines, iPSC lines have considerable heterogeneity and show different propensities for differentiation 
(Abeyta et al, 2004; Osafune et al, 2008; Martinez et al, 2012; Mills et al, 2013), and some studies 
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have shown that iPSCs have lower efficiencies of differentiation into haematopoietic, 
neuroepithelial, neuronal and cardiac lineages compared to ESCs (Feng et al, 2010; Hu et al, 2010; 
Narsinh et al, 2011). Studies in both mouse (Miura et al, 2009) and human (Gutierrez-Aranda et al, 
2010) cells found that transplantation of embryoid bodies derived from iPSCs gave rise to teratomas 
at higher efficiencies than those derived from ESCs, and that this was due to the presence of higher 
numbers of undifferentiated cells in the transplant. iPSCs are generally less successful in generating 
high percentage chimaeras and live mice through tetraploid complementation than ESCs (Stadtfeld et 
al, 2010). While some researchers argued that these results show that iPSCs have an intrinsically 
lower capacity to differentiate into certain lineages in vitro than ESCs, others have shown otherwise. 
A more recent large-scale study compared the propensity of 49 iPSC lines and 10 ESC lines to 
differentiate into a neural lineage, and found that seven iPSC lines showed significantly reduced 
differentiation capacity, which corresponded to differences in the expression levels of several genes. 
However, the majority of iPSC lines could not be distinguished from ESC lines (Koyanagi-Aoi et al, 
2013). In contrast, Kwon et al (2014) found that iPSCs differentiated into dopaminergic neurons at a 
higher efficiency than ESCs. These studies have led to questions about whether iPSCs are indeed 
identical to ESCs, and if they are not, what the functional implications of this might be for the use of 
iPSCs for in vitro applications such as disease modelling and drug screening, and in vivo use for cell 
replacement therapy.  
 
1.9.1 Gene Expression 
Early studies comparing the gene expression signatures of ESCs and iPSCs found that they were 
very similar, and distinct from other cell types (Muller et al, 2008). However, more recent studies 
have identified differences between the two cell types, although there has been disagreement over 
whether these are stochastic differences present between different cell lines, or indicative of a unique 
iPSC gene expression signature that separates them from ESCs. One study suggested that iPSCs have 
a unique gene expression signature that is shared among different iPSCs from different labs, 
generated using different reprogramming techniques (Chin et al, 2009). This study argued that the 
overlap in the gene expression signatures of iPSCs from different reprogramming experiments shows 
that the iPSC state is not stochastic. However, a subsequent study criticised these results, arguing that 
although Chin et al (2009) had identified 15 genes that were consistently differentially expressed 
between iPSCs and ESCs from several laboratories, these genes were not always consistently up- or 
downregulated across the iPSC lines. Meta-analysis showed that the transcriptomes of ESCs and 
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iPSCs do not cluster together; neither do they form two separate clusters separating iPSCs and ESCs. 
Instead, the transcriptomes generally form distinct clusters representing the lab of origin. This lab-
specific clustering was not observed for the fibroblast lines from which the iPSCs were derived, 
which clustered together irrespective of the lab of origin. In addition, many of the genes that are 
differentially expressed between stem cells from different laboratories have also been previously 
reported to differ between ESCs and iPSCs. This study suggests that culture conditions may have a 
large impact on iPSCs and ESCs, resulting in lab-specific gene expression patterns that overshadow 
differences in gene expression between ESCs and iPSCs (Newman & Cooper, 2010). Interestingly, a 
large scale comparison of ESCs and iPSCs found that ESCs derived at Kyoto University could be 
distinguished from the other cell lines included in the analysis, providing further evidence for lab-
specific differences between cell lines (Koyanagi-Aoi et al, 2013). Contradictory to this, another 
study argued that the lab-specific differences that were observed were due to analysis of array data 
without statistical correction of batch effects. When analysis was performed with statistical 
correction of batch effects, the lab of origin ceased to be the main difference between the cell lines, 
and differences between iPSCs and ESCs was seen to be the main difference (Wang et al, 2011). In 
addition, when genes that were differentially expressed were grouped into functional modules 
(groups of genes with similar functions), it was found that several of these were consistently different 
between ESCs and iPSCs, providing further evidence for an iPSC state that is distinct from ESCs, 
and suggesting that there may be a functional effect of these differences. However, a recent study 
carried out at the human pluripotent stem cell database showed that there were no genes that were 
consistently differentially expressed between ESCs and iPSCs, although there were genes that were 
differentially expressed between cell lines (Mallon et al, 2013), so there is still no consensus on 
whether iPSCs have a unique gene expression signature that can distinguish them from ESCs.  
Investigating DNA methylation patterns of ESCs and iPSCs showed that a very small number of 
genes were differentially methylated between ESCs and iPSCs from different sources, and suggested 
that these perhaps represented a set of aberrantly methylated genes than can distinguish between 
ESCs and iPSCs (Ruiz et al, 2012). Analysis of data from previous studies confirmed that this subset 
of genes was also aberrantly methylated in these studies. These epigenetic aberrations were 
associated with changes in gene expression, and 20-50% of these aberrations persisted after 
differentiation. Differentiated samples segregated based on whether the starting cell type was an ESC 
or iPSC, which could explain functional differences observed between ESCs and iPSCs.  
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A study by Narsinh et al (2011) investigated expression of genes known to be involved in 
pluripotency and early lineage commitment in 3 ESC lines and 4 iPSC lines (derived from several 
cell types using different reprogramming methods), and found that, although the populations of both 
ESCs and iPSCs meet pluripotency criteria, when individual cells were analysed, iPSCs showed 
significantly higher variability than ESCs in expression of pluripotency-associated marker genes and 
surface antigens. This was still true for iPSC populations that were selected for using TRA-1-
60/SSEA-4 surface antigen expression, suggesting that the variability is not due to the presence of 
higher numbers of differentiated cells in the population. This study did not report passage numbers, 
but if the cells were analysed at early passages, the higher variability observed in iPSC population 
could be due to the presence of incompletely reprogrammed cells in the iPSC population.  
A handful of studies have analysed differences in gene expression between genetically identical 
mouse ESCs and iPSCs. A study by Stadtfeld et al (2010) assessed their pluripotency through their 
ability to contribute to all-iPSC mice through tetraploid complementation. This study found that, 
although all ESCs were able to give rise to tetraploid embryos, most iPSCs could not. Comparison of 
mRNA and miRNA expression levels showed that only one region was differentially expressed 
between the two cell types: the Dlk1-Dio3 region on chromosome 12. This region, containing the 
genes Gtl2 and Rian, as well as 26 miRNAs, was aberrantly silenced in most iPSCs compared to 
ESCs, and only iPSCs that express this region are able to support the development of all-iPSC mice. 
Silencing of this region is due to hypermethylation and hyperacetylation, but is not due to aberrant 
expression in the somatic cell of origin, and is maintained upon differentiation. However, treatment 
with histone deacetylase inhibitor VPA was able to rescue the defect, and the iPSCs were thereafter 
able to give rise to all-iPSC mice. This study suggests that a relatively small subset of transcripts 
distinguishes miPSCs from mESCs, and that differences seen in other studies are likely to be due to 
variation in genetic background or insertion of viral transgenes.  
A study by Liu et al (2010) showed that expression of miRNAs encoded in the Dlk1-Dio3 imprinted 
region, including miR-134, -323-5p, -409-5p, -495, and -543, in iPSCs that were not able to give rise 
to all-iPSC mice compared to fully pluripotent stem cell lines. Among the targets of these miRNAs 
were several components of the polycomb repressive complex 2 (PRC2). Decreased repression of 
these components in partially pluripotent cells may result in the maintenance of histone acetylation 
and failure to demethylate the Dlk1-Dio3 region, which would be consistent with the reduced gene 
and miRNA expression levels. The authors of this study suggested that the expression levels of this 
region may provide a fast and effective method to characterise the pluripotency of iPSCs. 
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Stadtfeld et al (2012) further elucidated the timing of repression of maternal Dlk1-Dio3 transcripts 
during reprogramming, with transcriptional downregulation preceding the acquisition of aberrant 
DNA methylation and gene silencing. This process is dependent on DNMT3A, and promoted by 
DNMT3l. They also investigated different culture conditions that were able to prevent aberrant 
silencing of this region, and showed that treatment with ascorbic acid can prevent but not reverse 
aberrant DNA methylation of the Dlk1-Dio3 region. Cells treated with ascorbic acid maintained 
activating histone marks which are otherwise frequently lost during reprogramming. These cells then 
maintained normal DNA methylation levels, whereas cells that were not treated with ascorbic acid 
frequently lost activating histone marks, facilitating the recruitment of DNMT3A, and leading to 
progressive hypermethylation during reprogramming. Interestingly, ascorbic acid did not appear to 
affect methylation of any other genes other than in this region. 
However, it is unknown whether this is also true for human cells: an evaluation of published data did 
not indicate aberrant regulation of the Gtl2 homologue Meg3 in hiPSCs (Yu et al, 2009). In addition, 
mouse and human iPSCs and ESCs are significantly different to one another, likely representing 
different developmental stages of the embryo, and for this reason any conclusions drawn from 
miPSCs are not necessarily applicable to hiPSCs. Very recently, a comparison of isogenic hESC and 
iPSC lines was carried out, differentiating an ESC line into neural progenitors, and then 
reprogramming these cells into iPSCs. This study found no differences in gene expression or DNA 
methylation between the ESC and iPSC lines tested, in either differentiated or undifferentiated cells, 
although the sample group was small (Mallon et al, 2014).  
While there is still no definitive answer as to whether there are any consistent differences in gene 
expression between ESCs and iPSCs, it is clear that there is variability between cell lines which may 
have a functional impact on their pluripotency and ability to differentiate. The differences in gene 
expression observed between different cells lines could be due to several factors, including the 
presence of genomic and epigenomic aberrations, the presence of an “epigenetic memory” of the 
somatic cell of origin in iPSCs, and differences in microRNA expression.  
 
1.9.2 Genomic Stability 
It has long been established that ESCs are susceptible to acquiring chromosomal abnormalities with 
prolonged culture. The fact that the inner cell mass from which ESCs are derived is a transient state 
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existing only for a few days, may mean that genetic changes as a result of adaptation to culture 
cannot be avoided. The most common mutations in ESCs are aneuploidy of chromosomes 17, 12, 20 
and X (Draper et al, 2004; Maitra et al, 2005; Baker et al, 2007; Spits et al, 2008), and these changes 
correspond with changes in gene expression (Narva et al, 2010; Mayshar et al, 2010), and have been 
suggested to be advantageous for growth. This is supported by the fact that many genes on these 
chromosomes are involved in processes such as self-renewal, differentiation and apoptosis (Draper et 
al, 2004), and also that aneuploid ESCs grow faster and are highly clonogenic (Baker et al, 2007). 
Despite these differences, aneuploid ESCs seem to maintain expression of pluripotency genes, and 
the ability to differentiate in vitro. However, chromosomal abnormalities are not observed in all ESC 
cultures, and it is unclear whether certain cell lines are more prone to developing abnormalities, or 
whether the instability is a result of certain culture methods: for example, it has been shown that the 
passage of ESCs by mechanical dissection preserves genomic integrity better than enzymatic 
passaging (Maitra et al, 2005), and one report only observed abnormalities in cells cultured in 
knockout serum replacement and not in those cultured in serum (Spits et al, 2008). A larger study 
carried out by Mayshar et al (2010) showed that cell lines prone to aberrations did not necessarily 
cluster together; instead, the main contribution seemed to be the laboratory of origin, suggesting that 
culture conditions have an effect. In addition, several studies have linked these abnormalities to an 
increased risk of oncogenesis, as several of these genes are also linked to cancer (Baker et al, 2007;  
Lefort et al, 2008; Narva et al, 2010), emphasising the importance of carefully characterising ESCs 
that are to be used for clinical applications, and keeping time in culture to a minimum.  
While some chromosomal aberrations, such as gains at chromosomes 12, are common to both iPSCs 
and ESCs that are maintained in culture over long periods of time, some are specific to each cell 
type: for example, gains of chromosome 17 were observed only in ESCs and gains of chromosome 8 
were seen only in iPSCs (Mayshar et al, 2010; Taapken et al, 2011). The question is whether iPSCs 
are more prone to genetic abnormalities than ESCs. The evidence seems to suggest that, in addition 
to chromosomal abnormalities acquired as a result of extended time in culture, iPSCs are also prone 
to develop aberrations as a result of the reprogramming process itself, or from mutations already 
present in the somatic cells of origin, as large numbers of genomic aberrations are seen in new iPSC 
lines shortly after reprogramming. These could result from a number of sources: mutations in the cell 
of origin that have been carried over through the reprogramming process; mutations acquired during 
reprogramming due to replication and metabolic stress; mutations resulting from the integration of 
the viral reprogramming transgenes; and mutations that arise as a result of adaptation to culture. 
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There is disagreement about which factor is the main contributor to genomic abnormalities in iPSCs, 
and also about whether iPSCs are more prone to genomic abnormalities than ESCs.  
A study by Mayshar et al (2010) identified aberrations in early passage iPSCs that are likely to result 
from selection during the reprogramming process and initial adaptation to culture. These are unlikely 
to result from the starting population, as the aberrations could not be identified in the somatic cells, 
and multiple iPSC lines from the same starting population did not develop the same aberrations. It is 
also unlikely to be entirely due to the reprogramming method, as iPSCs derived without using viral 
vectors were also prone to aberrations. This was also observed in a study by Laurent et al (2011) 
who showed that in iPSCs, deletions appeared at the earliest passage numbers and often decreased 
over time in culture, suggesting that they are positively selected for during reprogramming and 
negatively selected against during culture. Several of the deletions involved tumour-suppressor 
genes. In addition, duplications arose over long-term passage, and these genes, which were often 
associated with tumorigenicity or cell proliferation, were positively selected for during culture. This 
was also observed by Hussein et al (2011), who found that the number of copy number variations 
(CNVs) in iPSCs was about twofold higher than in either ESCs or fibroblasts. Many of these CNVs 
fell outside ‘normal’ CNVs identified in large-scale screening of healthy individuals, and were 
observed at early passage numbers, suggesting that they arose as a result of reprogramming or early 
adaptation to culture. However, the number of CNVs decreased over extended passaging to a level 
similar to that seen in ESCs, presumably due to negative selection of these abnormalities during 
extended culture. A study which performed karyotype analysis on a large number of iPSCs and ESCs 
found no difference in the incidence of chromosomal aberrations between ESCs and iPSCs (Taapken 
et al, 2011), which is in contrast to other reports (Martins-Taylor et al, 2011).  
iPSCs that are generated from adult somatic cells may have an increased mutational load due to pre-
existing mutations. This is especially a concern with iPSCs generated from skin fibroblasts, as the 
skin is exposed to UV light which may increase DNA damage and subsequent mutations. For this 
reason, the age of the donor is also likely to affect the mutational load of the cells used to generate 
iPSCs. Several studies have showed that some mutations observed in iPSCs could also be observed 
in the fibroblast populations (Gore et al, 2011; Young et al, 2012). However, iPSCs had a 
significantly higher mutational load than fibroblasts, which indicates that genomic abnormalities 
observed in iPSCs are not entirely due to mutations in their cells of origin, but instead are likely to 
also arise during reprogramming or early adaptation to culture. Evidence for this includes the fact 
that early passage iPSCs contained new mutations not found in the fibroblast population (Gore et al, 
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2011). These mutations often became fixed in the iPSC line, as they could also be observed after 
extended passaging. New mutations were observed in the later passage cells, which are likely due to 
adaptation to culture. This is in contrast to previous studies (Laurent et al, 2011; Hussein et al, 2011) 
which showed that iPSCs initially had high levels of mutations that were likely to result from the 
reprogramming process, but that these were selected against over passaging until the mutational load 
was similar to that of ESCs.  
Another possible reason for differences between ESCs and iPSCs may be due to differences in 
mitochondrial DNA. A study using a mouse model with an error-prone mitochondrial DNA 
polymerase demonstrated that iPSCs could be generated from somatic cells with a high 
mitochondrial mutational load, but that these cells had defects in both proliferation and 
differentiation (Wahlestedt et al., 2014).  
While most of these studies looked only at genomic abnormalities in undifferentiated stem cells, a 
study by Laurent et al (2011) found that the most rapidly arising genomic aberrations were identified 
in cells undergoing directed differentiation. This shows that differentiation can be a highly selective 
process, and that genomically aberrant cells can rapidly take over a differentiating population. This 
stresses the importance of assessing the genomic integrity of differentiated cells as well as 
pluripotent cells, as this may have an impact on the function of these cells.  
 
1.9.3 Epigenomic Stability 
Differences between ESCs and iPSCs are not confined to genetic differences, but also include 
epigenetic differences. Detailed analysis of the epigenetic differences between ESCs and iPSCs was 
made possible by the development of high-throughput sequencing technologies and the generation of 
single nucleotide genome-wide maps of DNA methylation. The main features of the ESC epigenome 
are also seen in iPSCs, including genome-wide DNA methylation patterns and the establishment of 
bivalent histone marks at specific loci. However, despite these similarities, a core set of differentially 
methylated regions (DMRs) that seems to represent hot spots of failed epigenetic reprogramming has 
been identified (Lister et al, 2011). The DMRs are enriched for genes that are important for 
developmental processes. In the most exhaustive comparison so far, Kim et al (2010) reported that 
there were more DMRs in iPSCs than in ESCs. However, these DMRs were not linked to specific 
loci and therefore do not represent consistent differences between iPSCs and ESCs. The high 
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incidence of DMRs in iPSCs that are not present either in somatic cells or in ESCs suggests that they 
are stochastic and arise during reprogramming.  
Several studies have looked at histone modifications in ESCs and iPSCs and showed that although 
reprograming results in a reduction of repressive chromatin marks, resulting in an epigenome that is 
more similar to that of ESCs than the starting cell type, there are some differences between the two 
cell types: some differences are due to residual histone modifications that are also seen in the cell of 
origin, while others are unique to iPSCs and are likely to result from aberrant reprogramming. These 
patterns correspond to differences in gene expression between ESCs and iPSCs (Pick et al, 2009; 
Hawkins et al, 2010). However, in contrast to these results, a study by Guenther et al (2010) showed 
that no more variation was observed between ESCs and iPSCs than within ESC lines or iPSCs lines, 
and also found no evidence that iPSCs contain histone marks reflective of their cell of origin. 
Although some variation in histone modifications was noticed between cell lines, these differences 
had little or no effect on gene expression. A study by Pick et al (2009) investigated differences in 
genomic imprinting in ESCs and iPSCs. In general, ESCs show a substantial degree of genomic 
imprinting stability but aberrant biallelic expression of some genes was observed in some iPSC lines. 
This biallelic expression was due to significant DNA demethylation in the promoter in the affected 
iPSC lines. 
 
1.9.4 Epigenetic Memory 
Another factor which has been proposed to result in differences in gene expression between ESCs 
and iPSCs is the presence of an “epigenetic memory” of the somatic cell of origin in iPSCs. This 
may lead to significant and persistent donor-cell gene expression, due to aberrant silencing of 
somatic genes during the reprogramming process, and may affect the differentiation potential of 
iPSCs. This phenomenon was first noticed when studies were carried out to investigate differences in 
gene expression between ESCs and iPSCs. Chin et al (2009) carried out genome-wide expression 
analysis in both ESCs and iPSCs, and found that genes expressed at a higher level in ESCs vs. iPSCs 
are also expressed at higher levels in ESCs vs. fibroblasts. Of genes that are expressed at higher 
levels in iPSCs than ESCs, many appear to be inefficiently silenced from the fibroblast state. This 
suggests that iPSCs have not fully silenced the expression pattern of the somatic cell from which 
they are derived, and failed to fully activate genes characteristic of ESCs. This was corroborated in 
another study looking at iPSCs generated from fibroblasts (Doi et al, 2009), and it was subsequently 
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shown that this effect is not limited to fibroblast-derived iPSCs (Marchetto et al. 2009; Ghosh et al, 
2010). iPSCs were more similar to their donor cell type than to any other donor cell type, with 
significant residual gene expression. In addition, these iPSCs also showed incomplete induction of 
genes important for pluripotency compared to ESCs. These results suggest that differences in gene 
expression between ESCs and iPSCs may be due to incomplete reprogramming resulting in 
incomplete silencing of genes expressed in the donor cell. However, this study also pointed out that 
another possible source of variation could be due to a heterogeneous population of iPSCs, some of 
which are fully reprogrammed and some of which are not. This would skew the results towards an 
intermediate state of gene expression. 
In order to remove any potentially confounding effects of donor-specific differences in gene 
expression, Polo et al (2010) compared the transcriptional and epigenetic patterns, as well as the 
differentiation potential, of genetically identical, transgene-free iPSCs derived from different somatic 
cell types. They found that iPSCs derived from different cell types exhibit different gene expression 
patterns, and in particular that iPSCs retained gene expression patterns indicative of their cell of 
origin. iPSCs derived from different cell types were also distinguishable based on their DNA 
methylation patterns, although the promoter regions of genes that had been shown to be differentially 
expressed between iPSCs from different origins were not differentially methylated. This suggests 
that methylation differences are more subtle than gene expression differences, and that other 
epigenetic mechanisms may be involved. The promoters of differentially expressed genes did show 
different patterns of histone modification. This has subsequently been shown by several other 
studies, using iPSCs derived from various different somatic cell types (Kim et al, 2011; Ruiz et al, 
2012). 
In contrast to previous studies, a study by Ohi et al (2011) found no starting cell type-specific 
differences between iPSCs; instead, they reported that while some of the differentially expressed 
genes were specific to one type of somatic cell, most were found to be expressed in all three somatic 
cell types analysed, suggesting that the epigenetic memory is general and not specific to the starting 
cell type. They also did not identify any differences in differentiation efficiency between the iPSCs 
derived from different somatic cell types. Unlike many of the previous studies which identified 
epigenetic memory in iPSCs, this study attempted to correlate the differences in gene expression 
between ESCs and iPSCs with epigenetic differences, and showed that differential gene expression 
between ESCs and iPSCs was due to differences in promoter DNA methylation, with genes that are 
overexpressed in iPSCs compared to ESCs showing hypomethylation in iPSCs, suggesting that 
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establishment of DNA methylation during reprogramming may be insufficient. This could not be 
attributed to differences in expression levels of de novo methyl transferases (DNMTs), but the 
authors did note that the affected genes tended to be isolated from other genes, suggesting that the 
recruitment of the DNA methylation machinery to these isolated genes may be inefficient.  
Several studies have shown a reduced differentiation efficiency of iPSCs compared to ESCs, and 
have suggested that this may be due to epigenetic memory. A study by Polo et al (2010) showed that 
genetically identical iPSCs derived from different cell types exhibit different differentiation 
potential: for example, iPSCs derived from fibroblasts were less able to give rise to haematopoietic 
lineage cells than iPSCs derived from B cells. This was also shown in a study by Kim et al (2010), 
who demonstrated that iPSCs retain a memory of their cell of origin, which translates into 
differences in differentiation propensity, and that this is due to residual DNA methylation at loci 
required for haematopoietic differentiation. Importantly, they also showed that the epigenetic 
memory of these cells can be reset, through subsequent rounds of differentiation and reprogramming, 
or through treatment with epigenetic-modifying drugs. In some cases, epigenetic memory may be 
advantageous for generating cells that are difficult to generate through in vitro differentiation, such 
as pancreatic β-cells: for example, Bar-Nur et al (2011) showed that iPSCs generated from human 
pancreatic β-cells maintained open chromatin structure at key β-cell genes together with a unique 
DNA methylation signature that distinguished them from other PSCs, and that these iPSCs had an 
increased ability to differentiate into insulin-producing cells in vivo and in vitro. 
Some studies have argued that the main factor influencing the differentiation propensity of iPSCs is 
not the cell type used for reprogramming, but instead is due to the genetic background of the donor 
(Kajiwara et al, 2012; Shao et al., 2013; Mills et al., 2013). However, a study by Thatava et al (2012) 
found that the differences between iPSC clones from the same donor were greater than the 
differences between iPSCs from different donors.  
Differences between ESCs and iPSCs may be attenuated after continued passaging (Chin et al, 2009; 
Polo et al, 2010) and not passed on to the differentiated progeny of the iPSCs (Patterson et al, 2012). 
This is likely to be due to early-passage iPSC lines gradually resolving transcriptional and epigenetic 
differences, and provides evidence that the reprogramming process may take longer than previously 
thought. This shows the importance of reporting the passage numbers of cells used in these 
comparisons. In contrast, other studies have shown that differentially methylated regions in iPSCs 
are transmitted to differentiated progeny, and cannot be erased through continued passaging (Chan et 
al, 2009; Mikkelsen et al, 2008; Hu et al, 2010; Lister et al, 2011).  
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It is becoming clear that the heterogeneity and behaviour of stem cells is more complex than had 
previously been thought, and that iPSCs and ESCs are neither identical nor distinct populations; 
instead, they seem to overlap, with greater variability within each population than is observed 
between the populations. This variability is likely to have functional implications for the cells. It may 
be more useful to consider each cell line in terms of its quality and utility, in order to choose the best 
cell line for the application. With a view to this end, some researchers have produced a ‘scorecard’ to 
evaluate the character of both iPSCs and ESCs, and to predict the quality and utility of any 
pluripotent cell in a high-throughput manner: a large-scale study by Bock et al (2011) used gene 
expression profiling, DNA methylation mapping, and a high-throughput quantitative differentiation 
assay to establish  genome-wide reference maps for patterns of gene expression and DNA 
methylation in order to provide a baseline against which comparisons of new ES and iPS cell lines 
can be made in order to assess their quality and utility.  
 
1.9.5 miRNA Expression 
There have been several studies which have investigated differences in miRNA expression between 
ESCs and iPSCs, but although there has been some overlap in the miRNAs identified, so far there is 
little evidence for consistent differences between ESCs and iPSCs. Wilson et al (2009) found that, 
although ESCs and iPSCs had very similar miRNA expression profiles, there were subtle differences 
between the 2 cell types. Specifically, although some stem cell-specific miRNAs (e.g. the miR-302, 
miR-17 and miR-106 clusters) were highly expressed in both ESCs and iPSCs, others, including the 
miR-520 and miR-371 clusters, were more highly expressed in ESCs than in iPSCs. In addition, 
some miRNAs, including miR-886-5p and let-7a, which are associated with differentiated cells, were 
more highly expressed in iPSCs than ESCs, suggesting that they may be incompletely silenced 
during reprogramming. This study observed a downward trend in miRNA expression when 
transitioning from fibroblast to iPSC, but the expression levels of many miRNAs did not decrease in 
iPSCs to the levels observed in ESCs. However, this study did not report the passage numbers of the 
cells used, and if they were low, reprogramming may have been incomplete. In a meta-analysis 
focussing on differences in gene expression between ESCs and iPSCs, Chin et al (2009) also carried 
out miRNA profiling, and found little difference in miRNA expression between ESCs and iPSCs; 
however a few miRNAs were consistently differentially expressed between ESCs and iPSCs. These 
included some of the miRNAs identified by Wilson et al (2009), suggesting that iPSCs may have a 
miRNA expression signature unique from that of ESCs. Some of these differences were alleviated 
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over time in culture. However, another study, using a larger sample group, also carried out miRNA 
profiling, and found that pluripotent stem cells could be divided into two distinct groups based on 
their miRNA expression levels, but that this segregation was not dependent on cell type:  one group 
consisted of mainly ESCs with some virally reprogrammed iPSCs, while the other consisted of 
iPSCs generated in a number of ways, as well as the ESC line H9. These groups differed in the 
expression of a group of miRNAs including miR-199a* and miR-302a, whose targets include pro-
proliferative cyclins and oncogenes, and the p53-regulating miRNAs miR-92 and miR-141 (Neveu et 
al, 2010). This study did not report differences in expression of miR-302, miR-371 or miR-502 
clusters between ESCs and iPSCs, as reported by other studies (Chin et al, 2009; Wilson et al, 2009), 
although there was some variability in their expression between cell lines. An analysis of miRNA 
expression in genetically identical miPSCs and mESCs showed reduced expression of the miRNAs 
encoded in the Dlk1-Dio3 imprinted region in some iPSCs (Liu et al, 2008). In contrast to these 
results, a large-scale comparison of 49 iPSC lines and 10 ESC lines found no significant differences 
in miRNA expression between the two cell types (Koyanagi-Aoi et al, 2013), and another study 
found that hierarchical clustering could not segregate ESCs and iPSCs, although further investigation 
revealed there were some miRNAs that were differentially expressed between ESCs and iPSCs. 
However, these differences were not consistent with previous studies (Razak et al, 2013).   
There have been fewer studies investigating differences in the differentiated progeny of ESCs and 
iPSCs. Wilson et al (2009) reported differences in miRNA expression in embryoid bodies derived 
from ESCs and iPSCs. Christodoulou et al (2011) reported differential expression of BMP4 during 
differentiation to DE, possibly linked to aberrant silencing of the Dlk1-Dio3 region, but this did not 
appear to be associated with any reduction in differentiation propensity. The functional significance 
of differences between ESCs and iPSCs is still unclear, and it is worth noting that although 
differences in miRNA expression may be statistically significant, they may not be biologically 
relevant, and this is something that needs to be investigated further before iPSCs can be considered 
for a clinical application.  
 
1.10 MicroRNA 
MicroRNAs (miRNAs) are small (18-25 nucleotides), non-coding RNAs that regulate gene 
expression post-transcriptionally. Although miRNAs predominantly negatively regulate mRNA 
expression, a few examples of positive regulation of target genes by miRNAs through activation of 
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translation have been described (Place et al., 2008; Vasudevan et al., 2007).  miRNAs were first 
identified in studies of Caenorhabditis elegans, where they play an important role in regulating the 
timing of larval development (Lee et al., 1993; Wightman et al., 1993; Reinhart et al., 2000). Since 
then, over 21,000 miRNAs have been identified in numerous different species (www.mirbase.org), 
and they are involved in almost every biological process, including development, metabolism, and 
ageing, as well as in many human diseases, most notably cancer (Slack, 2010). Cells express a 
miRNA signature characteristic of their lineage and developmental state (Strauss et al., 2006). 
 
1.10.1 Biosynthesis and Action of miRNAs 
miRNAs are present in the genome either as independent transcription units or as clusters. Their 
coding sequences can be either intragenic (i.e. located in the exons or introns of so-called “host” 
genes) or intergenic. Intragenic miRNAs may be co-transcribed with the host genes or regulated by 
their own specific promoters. However, the majority of characterised miRNAs are intergenic and 
orientated antisense to neighbouring genes, suggesting that they are transcribed independently 
(Bartel, 2004).  
The biogenesis of miRNAs is shown in figure 1.10. Most miRNAs are transcribed by RNA 
polymerase II. Primary miRNA (pri-miRNA) transcripts in the nucleus are recognised and cleaved 
into precursor miRNA (pre-miRNA) by a complex containing RNase III enzyme Drosha and RNA 
binding protein DGCR8. Pre-miRNAs are transported into the cytoplasm by Exportin5, where they 
are processed by DICER into double stranded mature miRNA. Although it was initially thought that 
one of the strands of the mature duplex, the “guide” strand, was preferentially incorporated into the 
Argonaute-containing RISC complex to induce degradation or repress translation of target mRNA, 
while the other strand (designated with a *) was released and degraded, it is now recognised that 
either one of the strands of the miRNA duplex can have biological activity, and they are more 
commonly denoted as 3p and 5p. miRNAs recognise and bind specific sequences in target mRNAs, 
usually in the 3’ untranslated region (3’UTR) (Bartel, 2004). Although the number of miRNAs is 
small compared to that of mRNAs (the human genome is thought to encode around 1,000 miRNAs, 
while the number of mRNAs is estimated to be around 30,000), a single miRNA is able to target 
hundreds of mRNAs, and one mRNA may be targeted by several miRNAs. As a result, the potential 
for fine tuning translation of mRNAs by miRNAs is enormous.  




Figure 1.10  miRNA biogenesis. pri-miRNA transcripts in the nucleus are cleaved into pre-miRNA, which are 
transported into the cytoplasm by Exportin5, where they are processed by DICER into double stranded mature miRNA. 
The guide strand is incorporated into the RISC complex to induce degradation or repress translation of target mRNA. 
Adapted from Winter et al, 2009. 
 
 
1.10.2 The Role of miRNAs in Pluripotency  
Experiments disrupting the miRNA processing enzymes DICER and DGCR8 show the importance 
of miRNAs in ESC proliferation, cell cycle and differentiation. DICER-null ESCs show defects in 
proliferation and differentiation, including prolonged G0 and G1 phases in the cell cycle, failure to 
express differentiation markers, decreased levels of DNA methylation and DNMTs, and increased 
telomere recombination and elongation (Kanellopoulou et al., 2005). DGCR8-null ESCs arrest in the 
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G1 phase, cannot silence self-renewal genes e.g. Oct4, Rex1, Nanog and Sox2, and show reduced 
expression of differentiation markers. They also do not form teratomas (Wang et al., 2007). The 
differences in phenotype between DICER- and DGCR8-null ESCs suggest that other small RNAs 
may play a role in ESC proliferation, cell cycle and differentiation.  
There is an overall trend of increasing miRNA expression complexity through differentiation, with 
PSCs expressing relatively few miRNAs, and more differentiated cells expressing more miRNAs. 
This is in contrast to the pattern of mRNA expression, which has been shown to be restricted with 
increasing development, with fewer genes expressed in more mature cells (Strauss et al., 2006). 
Early experiments in human and mouse ESCs showed that a small number of miRNAs are 
specifically expressed in pluripotent stem cells, and are quickly downregulated upon differentiation. 
These miRNAs are highly conserved between mice and humans, and include the miR-290 family 
(miR-290, -291a, 291b, -292, -293, 294 &- 295) in mice (Houbaviy et al., 2003), its human 
homologues the miR-371 family (miR-371, -372, -373), and the miR-302 cluster (miR-302a, -302b, -
302c, -302d and -367) which is present in both in mice and humans (Suh et al., 2004). Many ESC-
specific miRNAs are present in the genome in clusters, which are co-transcribed as polycistronic 
transcripts, suggesting common upstream regulation and co-ordinated expression patterns. They 
often have similar seed sequences, suggesting common mRNA targets (Martinez & Gregory, 2010). 
Such a high degree of functional redundancy suggests that they play a critical role in maintaining the 
pluripotent state of ESCs. The targets of these miRNAs included many genes with promoters bound 
by the ESC-associated transcription factors NANOG, SOX2 and OCT4, suggesting an important role 
in pluripotency and self-renewal.  
These results were confirmed by larger microarray profiling experiments (Laurent et al., 2008), 
which also identified an additional cluster of miRNAs on chromosome 19, the miR-520 family, 
present in ESCs, as well as the miR-17 cluster and its paralogous miRNAs in the miR-106 cluster. 
Even larger scale experiments were made possible with the advent of next-generation sequencing 
methods, which allowed high-throughput analysis of both previously identified and novel miRNAs 
(Morin et al., 2008; Bar et al., 2008). In addition, they showed that miRNAs frequently showed 
variation from their ‘reference’ sequences, producing multiple mature miRNAs termed “isomiRs”. 
Much of this variability can be explained by variability in DICER1 or Drosha cleavage positions in 
the pre-miRNA hairpin structure. The relative abundance of different isomiRs may vary across 
tissues; however the functional implications of these modifications are still unclear.  
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miRNAs and Gene Regulation 
The core molecular circuitry of stem cells, composed of pluripotency-associated transcription 
factors, interacts with miRNAs to activate genes involved in pluripotency and self-renewal and 
suppress genes involved in differentiation. The transcription factors OCT4, SOX2 and NANOG act 
co-ordinately and are central to the establishment and maintenance of the pluripotent state. They 
form a positive auto-regulatory circuit in which each factor binds to and activates its own promoter, 
as well as the promoters of the other pluripotency factors, resulting in maintenance of high levels of 
expression. They also co-occupy the regulatory regions of hundreds of different genes which are 
divided into two groups: one group are transcriptionally active in ESCs and include transcription 
factors, chromatin modifiers and components of stem cell-specific signalling pathways, while the 
other group of genes are silenced in ESCs due to the co-occupation of their promoters by members of 
the Polycomb group proteins (transcriptional repressors that regulate lineage choices during 
development and differentiation), and include a number of transcription factors involved in 
differentiation and fate commitment (Lakshmipathy et al., 2010; Tiscornia & Belmonte, 2010). 
miRNAs are an integral part of the gene networks regulated by the pluripotency factors OCT4, 
SOX2 and NANOG, and help to poise ESCs for rapid and efficient differentiation. OCT4, SOX2, 
and NANOG occupy the promoters of most ESC-specific miRNAs, as well as another subset of 
miRNAs that are normally silenced by Polycomb group proteins in ESCs but are upregulated during 
differentiation into certain lineages (Marson et al, 2008). In the undifferentiated state, both OCT4 
and OCT4-induced miR-302 directly repress NR2F2 (a transcription factor expressed in 
differentiated cells) at the transcriptional and post-transcriptional level respectively. During 
differentiation, NR2F2 directly inhibits OCT4, triggering a positive feedback loop for its own 
expression (Rosa et al., 2011). Exogenous expression of c-MYC induces the expression of miRNAs 
involved in negatively regulating genes involved in differentiation, resulting in the attenuation of 
differentiation, and therefore the maintenance of pluripotency, in these cells (Lin et al, 2009).  
The ESC-specific miR-290 family of miRNAs (which includes miR-291-3p, miR-294 and miR-295) 
can also enhance the efficiency of somatic cell reprogramming in murine cells using 3 
reprogramming factors, OCT4, SOX2 and KLF4, but not the efficiency of reprogramming with 4 
factors, including c-MYC, suggesting that these miRNAs enhance reprogramming through acting 
downstream of c-MYC (Judson et al., 2009). Lentiviral transfection of the miR-302 cluster of 
miRNAs, which includes miR-302a-d and miR-367, can replace all the previously defined factors to 
reprogram somatic cells to iPSCs at a higher efficiency (Anokye-Danso et al., 2011). 
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Reprogramming by direct transfection of mature double-stranded miRNAs (Miyoshi et al., 2011) has 
the additional advantage of avoiding viral integration. 
“Incoherent feed-forward” regulation, where a transcription factor both activates and represses its 
target, is important in fine-tuning expression in ESCs. For example, Lefty1 and Lefty2 are both 
actively expressed in ESCs, and are directly occupied at their promoters by OCT4, SOX2, and 
NANOG. However, these transcription factors also occupy the promoter of the miR-290 cluster, 
which repress Lefty1 and Lefty2. Therefore ESC transcription factors activate expression of Lefty1 
and Lefty2, but also fine-tune its expression by activating a family of miRNAs that repress Lefty1 and 
Lefty2 (Marson et al., 2008). 
 
miRNAs and Cell Cycle Regulation 
 ESCs are able to undergo infinite and rapid self-renewal due to their unique cell cycle, in particular 
their shortened G1 phase. Small RNAs have been implicated in ESC proliferation based on the 
phenotype of DICER- and DGCR8-null ESCs, which show reduced proliferation ability, suggesting 
that miRNAs normally suppress inhibitors of the G1/S phase transition. Many ESC-specific miRNAs 
are involved in regulation of the cell cycle, and are often referred to as the ESC cell cycle-regulating 
(ESCC) miRNAs. Wang et al. (2008) used a screening strategy to investigate whether miRNAs 
introduced into DGCR8-null ESCs could rescue the defects in proliferation. Several miRNAs, 
including the miR-290 family, were able to do so. These miRNAs shared a similar seed sequence, 
suggesting that they target the same mRNAs, and using a combination of these miRNAs did not 
show any further improvement, suggesting that they may be functionally redundant. This study 
showed that ESC-specific cell cycle regulating miRNAs increase ESC proliferation through 
repression of cell cycle inhibitors, including p21, CDKN1A, RB1, RBL1, RBL2 and LATS2, 
resulting in increased G1/S transition.  
Card et al. (2008) first showed a connection between the pluripotency genes and regulation of the 
cell cycle, through the activity of the miR-302 cluster of miRNAs. OCT4, SOX2 and NANOG bind 
to the promoter region of the miR-302 cluster and are required for its expression. Increased 
expression of miR-302 results in an increase in S-phase cells and a decrease in G-phase cells through 
regulation of cell cycle regulators including CyclinD1 and Cdk4, while reduced expression has the 
opposite effect (Card et al, 2008). It is now known that many of the stem cell-specific miRNAs, 
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including the miR-21 cluster, the miR-17 cluster, and the miR-15b cluster, are involved in promoting 
the G1-S phase transition of the cell cycle through repression of cell cycle inhibitors including 
p21cip, Rbl2, and Lats2, which increases activity of cyclinE/cdk2 activity (Gangaraju & Lin, 2009; 
Sengupta et al., 2009; Tiscornia & Belmonte, 2010). The ESCC miRNAs, which include the miR-
302 cluster, the miR-371-373 cluster, and the miR-106a~363 cluster, can also enhance the efficiency 
of reprogramming of human cells (Subramanyam et al., 2011; Liao et al., 2011).  
Melton et al. (2010) showed that the cell cycle in pluripotent stem cells is regulated by two families 
of miRNAs that play opposing roles: the ESCC miRNAs are expressed in ESCs, and the let-7 family 
of miRNAs are expressed in somatic cells. In Dicer-null ESCs, introduction of ESCC miRNAs 
rescued the cell cycle defects associated with Dicer knockout, while introduction of let-7 miRNAs 
rescued the differentiation defects. However in wild-type ESCs, introduction of let-7 had no effect on 
pluripotency, suggesting that the ESCC miRNAs normally antagonise its effects, and the let-7 
miRNAs are not able to induce differentiation until the ESCC miRNAs are downregulated. Ectopic 
expression of LIN28 is also able to enhance reprogramming efficiency through inhibition of let-7 
biogenesis (Melton et al., 2010).  
 
1.10.3 The Role of miRNAs in Differentiation 
The switch from pluripotency to differentiation requires downregulation of pluripotency genes, 
decreased self-renewal and activation of lineage-specific gene expression. The fact that ESC-specific 
miRNAs involved in maintaining pluripotency do not rescue the differentiation defects of DICER1- 
or DGCR8-deficient cells indicates that different miRNAs are involved in differentiation.  
One of the most important regulators of differentiation is the let-7 family of miRNAs, members of 
which are widely expressed in differentiated cells, but not in pluripotent cells (Chen et al., 2007; 
Morin et al., 2008). As ESCs differentiate, expression of the pluripotency genes are downregulated, 
resulting in decreased expression of the ESCC family of miRNAs, and therefore decreased 
expression of LIN28. This decrease in LIN28 expression allows de-repression of let-7 expression. 
This is enhanced by a positive feedback loop, where let-7 suppresses its own negative regulator 
LIN28. This interaction between LIN28 and let-7 provides robustness to the differentiation switch. 
The let-7 family directly target numerous genes involved in promoting the G1/S phase transition 
such as Cdk6, Cdc25a and Ccnd2, and indirectly target several oncogenes which normally promote 
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proliferation, such as Nras, Kras, Hmga2 and c-Myc). Other miRNAs also play a role in cell cycle 
regulation during differentiation: the miR-15a/16 cluster also represses several genes involved in 
promoting the G1/S phase transition, including Cdk6, Card10 and Cdc27 (Ivey & Srivastava, 2010).  
The let-7 family is also involved in silencing the self-renewal programme by directly targeting the 
expression of several pluripotency factors, including c-MYC and LIN28. Let-7 also inhibits the 
downstream targets of the pluripotency factors in order to stabilise the differentiated state (Melton et 
al., 2010). Tissue-specific miRNAs often play a role in the switch from pluripotency to 
differentiation through the repression of pluripotency genes. In mice, miR-134, -296 and -470 repress 
the pluripotency factors NANOG, OCT4 and SOX2, and miR-200c, -203 and -182 repress SOX2 
and KLF4 (Tay et al., 2008). In humans, miR-145 directly represses the expression of pluripotency 
factors OCT4, SOX2 and KLF4 (Xu et al., 2009).  
Some miRNAs associated with pluripotency also play a role in differentiation. The miR-290 cluster 
of miRNAs, which plays a role in maintenance of self-renewal in stem cells, also plays a role in 
differentiation through repression of another target gene, Rbl2, leading to increased expression of 
DNMTs and increased methylation of the OCT4 promoter, preventing its expression (Benetti et al., 
2008). Ectopic expression of the miR-290 cluster in DICER-deficient ESCs can also rescue 
differentiation defects. A recent study has shown that the miR-290 cluster promotes mesendoderm 
formation through repression of Pax6 and therefore ectoderm formation (Kaspi et al, 2013).  
As pluripotent cells adopt certain fates, lineage-specific genes are transcriptionally activated and 
genes that would drive differentiation towards other fates are suppressed. Active repression of 
lineage-specific genes is important for pluripotency and is largely mediated by Polycomb group 
proteins. One Polycomb protein, EZH2, is highly expressed in pluripotent cells but is downregulated 
during skeletal muscle differentiation through the action of miR-214, allowing activation of lineage-
specific genes (Juan et al, 2009). Similar mechanisms almost certainly exist in differentiation to 
other lineages.  
A number of studies have demonstrated the importance of miRNAs in commitment to a specific 
embryonic germ layer during development. In mouse ESCs, elevated levels of miR-296 and miR-134 
enhanced the expression of genes associated with differentiation toward ectoderm (Tay et al., 2008). 
In human ESCs, members of the miR-30 family have been shown to regulate the embryonic 
ectoderm development protein which is important in the development of the neural tube (Song et al., 
2011), and miR-125 isoforms have been shown to potentiate early neural specification (Boissart et 
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al., 2012). The miR-302 family is expressed in undifferentiated ESCs and has been shown to be 
critical in the maintenance of pluripotency. In addition, a study by Rosa & Brivanlou (2011) 
demonstrated that this family also plays a role in the earliest stages of differentiation, as in humans, 
repression of the Lefty1 and Lefty2 genes by miR-302 results in increased TGF-β signalling, leading 
to increased endoderm and mesoderm formation, and decreased neuroectoderm formation. The miR-
17-92 cluster plays an important role in mesoderm differentiation and knockout in mouse embryos 
results in severe developmental defects affecting the heart and lungs (Ventura et al., 2008). Foshay et 
al. (2009) demonstrated the importance of one member of this cluster, miR-93, in the regulation of 
both endoderm and mesoderm differentiation through its regulation of Stat3. miR-124 is highly 
expressed in human ESCs and targets two regulators of cytoskeletal rearrangement important in cell 
migration during mesodermal differentiation(Berardi et al. 2012). Another cluster of pluripotency-
associated miRNAs, the miR-290 cluster, regulate Pax6 expression in early lineage commitment, and 
knockout of these miRNAs in mice resulted in an increased propensity to form ectoderm at the 
expense of mesoderm and endoderm (Kaspi et al. 2013). 
One early event that is critical in the commitment of differentiating cells to an endodermal or 
mesodermal lineage is epithelial-to-mesenchymal transition (EMT). Members of the miR-200 family 
of miRNAs have been implicated in EMT and have been shown to be important in targeting Smad 
interacting protein-1 (SIP1) (Korpal et al, 2008; Chng et al, 2010). SIP1 promotes neuroectoderm 
formation at the expense of mesendoderm and so its inhibition has a positive effect on mesendoderm 
commitment (Chng et al, 2010). In addition, downregulation of miR-200a is important in definitive 
endoderm formation, as it results in reduced repression of ZEB2, leading to downregulation of E-
cadherin and subsequently allowing EMT (Liao et al, 2013). Other miR-200 family members also 
regulate EMT through their targets ZEB1 and ZEB2 (Gregory et al, 2008). 
 
miRNAs Involved in Pancreatic Development 
Full knockout of the miRNA processing enzyme, DICER1, in murine embryos results in embryonic 
lethality, whereas partial knockdown allows the development of mice which are histologically 
normal apart from the pancreas (Morita et al. 2009). Conditional deletion of DICER1 in the 
developing pancreas results in defects in all pancreatic lineages, but it particularly affects the insulin-
secreting β-cells (Lynn et al. 2007). These studies demonstrate the critical role that miRNAs play in 
pancreatic development. 
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Numerous miRNAs have been identified as playing a role in pancreatic development (figure 1.12). 
Several groups (Tzur et al. 2008; Hinton et al. 2010; Kim et al. 2011; Tsai et al. 2010; Porciuncula et 
al. 2013) have investigated miRNA expression at the DE stage of pancreatic development. Although 
there is relatively little overlap in the miRNAs identified in these studies, which is likely to be due to 
the wide range of cell lines and differentiation protocols used, some miRNAs, including miR-375, 
miR-708 and miR-744, were identified in several of the studies, providing strong evidence for their 
involvement in DE formation. However these studies have, so far, only identified a few targets for 
these miRNAs. An early study identified Timm8a as a target of miR-375 but the authors were unable 
to elucidate a function for this pathway in the formation of endoderm (Hinton, et al., 2010). More 
recently, a study by Liao et al (2013) identified a direct relationship between miR-200a and Sox17, 
but not Foxa2 (another predicted target of miR-200a), and postulated that downregulation of miR-
200a promotes endoderm formation through promotion of EMT and de-repression of Sox17.  
 
 
Figure 1.11. miRNAs expressed at the different stages of pancreatic development. Adapted from Van Hoof et al., 2009. 
 
The role of miRNAs in the later stages of pancreatic development has been better elucidated. miR-
375 was one of the first miRNAs identified in the pancreas (Poy et al., 2004), and remains one of the 
best characterised. It is expressed in the pancreas and pituitary gland, organs linked by their role in 
hormone secretion, and expression levels increase throughout pancreas organogenesis. Loss-of-
function studies showed that miR-375 is essential for β-cell formation in zebrafish (Kloosterman et 
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al., 2007), and that miR-375 knockout mice have decreased numbers of β-cells and increased 
numbers of α-cells. This shows the importance of miR-375 in the establishment of normal pancreatic 
cell mass through the targeting of a group of genes which control cellular growth and proliferation in 
the developing pancreas (Poy et al., 2009). Further evidence for the involvement of miR-375 in 
pancreas development is provided by the fact that its expression is regulated by several transcription 
factors important in pancreatic development and function, including HNF6, INSM1, NGN3, 
NEUROD1, and PDX-1 (Keller et al., 2007). A recent study showed that overexpression of miR-375 
in differentiating embryoid bodies resulted in formation of islet-like clusters, upregulation of 
endocrine genes including insulin, glucagon, and somatostatin, and release of insulin in response to 
glucose. Interestingly, the cells produced using this protocol were reported not to be polyhormonal, 
and the fact that they produced insulin in response to glucose suggests that they are more mature than 
insulin-expressing cells produced using previously reported (Lahmy et al, 2013).  
miR-124a shows a similar expression pattern to miR-375, increasing during pancreas development. 
Its targets include FOXA2, a transcription factor important for β-cell differentiation, pancreatic 
development, glucose metabolism and insulin secretion. Other predicted targets of miR-124a include 
NEUROD1 (Baroukh et al., 2007). miR-124a and miR-23b have also been shown to be involved in 
regulation of HES1 during neuronal development (Wang et al, 2010), and might have a similar role 
in pancreatic development, as HES1 plays an important role in endocrine specification by controlling 
the numbers of NGN3
+
 cells.  
miR-7 is highly and specifically expressed in the endocrine pancreas where it is co-localised with 
glucagon and insulin in mature α- and β-cells, respectively. At E12.5, 13.5 and 14.5, miR-7 is co-
localised with NGN3-expressing cells, suggesting that it is induced in newly specified endocrine 
cells. miR-7 expression is also abolished in NGN3 knockout mice (Kredo-Russo et al., 2012). miR-
127 and miR-382 showed a similar pattern of expression (Correa-Medina et al., 2009). miR-7 
regulates expression of PAX6, a transcription factor important in the development of the endocrine 
pancreas. This is important since under-expression of PAX6 results in glucose intolerance, as well as 
having effects on the eye, while over-expression causes eye abnormalities and induces apoptosis in 
the brain and the endocrine pancreas. Knockdown of miR-7 led to increased expression of PAX6, 
leading to increased expression of ARX, which is specifically expressed in α-cells, as well as PAX4 
and MAFB, which are expressed in β cells. Insulin and glucagon levels were also increased, due to 
an increase in the numbers of α- and β-cells. There was a decrease in the number of ε-cells, 
suggesting that miR-7 knockdown acts upstream of PAX6 to promote differentiation of α- and β-
Chapter 1: Introduction 
93 
 
cells at the expense of ε-cells. Conversely, overexpression of miR-7 led to a decrease in PAX6 and 
downregulation of insulin and MAFB, both direct targets of PAX6, while ghrelin expression was 
increased (Kredo-Russo et al., 2012).  
Several other miRNAs are also expressed during pancreatic development: miR-495 and miR-218 are 
involved in early pancreas morphogenesis and endocrine specification (Simion et al. 2010); miR-23a 
and miR-23b are co-expressed in the developing pancreas, and repress HNF6 expression (Joglekar et 
al., 2007); miR-19b is highly expressed in pancreatic progenitor cells and regulates Neurod1(Zhang 
et al. 2011); overexpression of miR-26a during pancreatic development increased islet numbers, 
expression of endocrine genes, and cell proliferation (Fu et al. 2013). miR-15a, miR-15b, miR-16 
and miR-195a regulate translation of Ngn3 during pancreas regeneration, and may play a similar role 
during development, although no direct interaction of these miRNAs with Ngn3 mRNA could be 
found.  
 
miRNAs Involved in Pancreas Function 
The deletion of DiCER1 in mature β-cells has less effect on islet morphology than deletion in the 
developing pancreas, although both the number of β-cells and the release of insulin were reduced 
(Kalis et al. 2011; Melkman-Zehavi et al. 2011) demonstrating the importance of miRNAs for 
mature β-cell maintenance and function through regulation of both insulin biosynthesis and 
exocytosis.  
miR-375 is required for normal glucose homeostasis through its control of insulin secretion in mature 
β-cells. It negatively regulates Mtpn expression (Poy et al., 2004), which may control insulin 
exocytosis either through the actin network, or through NFκB signalling. miR-375 also regulates 
Pdk1 expression, which is involved in regulation of insulin gene expression, as well as cell signalling 
downstream of the insulin receptor (El Ouaamari et al., 2008), showing that miR-375 regulates β-cell 
function through at least two mechanisms. Knockout of miR-375 also results in reduced β-cell 
proliferation, and a number of predicted targets of miR-375 are genes regulating cellular growth (Poy 
et al., 2009). Other miRNAs involved in β-cell proliferation include miR-29a (Bagge et al., 2012) 
and miR-7, which inhibits components of the mTOR signalling pathway(Wang et al., 2013).  
Similarly to miR-375, miR-124a also regulates Mtpn expression (Krek et al. 2005), but additionally 
regulates insulin secretion through its regulation of Foxa2, downstream targets of which include 
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components of the β-cell KATP channel, which is involved in insulin exocytosis. miR-124a is also 
predicted to directly target other components of the exocytotic machinery, including Rab27a, 
Snap25, Rab3a, Syn1, and Noc2 (Lovis et al. 2008), as well as Creb-1, Isl-1, and Vamp-3, which are 
part of the transcriptional network downstream of the insulin receptor (Baroukh et al., 2007). miR-
124, miR-29a and miR-29b have each been shown to be important regulators of the pyruvate/lactate 
(monocarboxylate) transporter MCT1 in β-cells. This transporter is a member of a group of 
housekeeping genes which are usually highly selectively suppressed in these cells (Sekine et al. 
2012).  However, levels of miR-124a have been reported to be low or undetectable in mouse and 
human islets, suggesting that miR-29a and miR-29b may be the most important in this context 
(Pullen et al. 2011), although the levels of miR-124a may increase during aging, at least in the rat 
(Tugay & Regazzi, 2013).  
miR-9 regulates insulin secretion through inhibition of both Oc-2, leading to increased levels of 
granuphilin (Plaisance et al., 2006), and Sirt1 (Ramachandran et al., 2011) . Similarly, mir-96 also 
regulates insulin secretion in β-cells through increased levels of granuphilin, but through a pathway 
that does not involve Oc-2. Overexpression of miR-96 also resulted in decreased levels of Noc2, a 
protein which plays a positive role in insulin exocytosis (Lovis et al., 2008). Several miRNAs, 
including miR-7 (Melkman-Zehavi et al., 2011), miR-30d (Tang et al., 2009; Zhao et al., 2012), 
miR-133a (Fred et al., 2010), and miR-15a (Sun et al., 2011), regulate β-cell function through the 
control of insulin gene expression and biosynthesis. The expression of many of these miRNAs is 
controlled by glucose concentration, demonstrating how these miRNAs form part of the regulatory 
network controlling β-cell function.   
Recent studies have demonstrated the importance of miRNAs in maintaining β-cell function, as their 
dysregulation in T2DM contributes to a loss of pancreatic β-cell phenotype (Talchai et al., 2012). 
Locke et al (2014) recently demonstrated that miR-187 is strongly up-regulated in islets from T2DM 
human donors compared to healthy control donors, leading to reduced expression of the Hipk3 gene, 
and a subsequent reduction in glucose-stimulated insulin secretion. Another study comparing 
miRNA expression between T2DM human donors and healthy control donors demonstrated aberrant 
repression of a cluster of miRNAs expressed in the Dlk1-Meg3 gene locus, including miR-376a, 
miR-432 and miR-495, in T2DM, and subsequently demonstrated that this downregulation was 
linked to increased β-cell apoptosis through the gene targets Iapp and Tp53inp1 (Kameswaran et al. 
2014). 
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In addition to its importance during early lineage commitment, EMT is also important for 
maintaining mature pancreas function. Isolated human pancreatic islet cells undergo EMT in culture, 
a process which coincides with a loss of function including a lack of insulin secretion. Several 
proteins, including VIMENTIN, N-CADHERIN, β-CATENIN, SNAIL1, SNAIL2 and TWIST, are 
overexpressed during EMT and have been shown to play a role in this process (Ouziel-Yahalom et 
al., 2006). Interestingly, analysis of human pancreatic islets showed that, although mesenchymal 
proteins are not detected, mesenchymal gene transcripts are present at very high levels. This suggests 
that EMT is controlled by post-transcriptional regulation of these mesenchymal genes, and a study 
demonstrated that members of the miR-30 family negatively regulate transcription of mesenchymal 
genes to maintain the epithelial phenotype of islet endocrine cells. During EMT, expression of the 
miR-30 family is reduced, allowing increased transcription of mesenchymal genes and an alteration 
in cell phenotype (Joglekar et al, 2009). While this process is important for in vitro culture of 
isolated islets, it is also likely to contribute to the maintenance of the mature, islet cell phenotype. 
DiCER1 deletion in mature β-cells has a smaller effect on islet morphology than deletion in the 
developing pancreas, although both the number of β-cells and insulin release were reduced (Kalis et 
al., 2011; Melkman-Zehavi et al., 2011), demonstrating the importance of miRNAs for mature β-cell 
maintenance and function through regulation of both insulin biosynthesis and exocytosis, as well as 
cell signalling downstream of the insulin receptor .  
 
1.11 Hypothesis & Aims 
The aim of this project is to identify whether iPSCs are a viable alternative to ESCs for generating β-
cells in vitro for cell replacement therapy to treat type 1 diabetes. The differentiation potential of 
iPSCs and ESCs to give rise to DE (the first stage in differentiation towards a pancreatic lineage) in 
vitro will be compared, and mechanisms important in the differentiation of ESCs and iPSCs to DE 
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2.1 Generation of Induced Pluripotent Stem Cell (iPSC) Lines 
Although there are a number of ways of generating iPSCs (as previously described in chapter 
1), for the purposes of this project new iPSC lines were generated using retroviral 
transduction of four reprogramming factors (Oct4, Sox2, Klf4 and c-Myc) as described by 
Takahashi & Yamanaka (2007) (see figure 2.1 for an overview of the process). While this 
approach results in integration of the viral transgenes into the genome of the iPSCs generated, 
rendering the cells unsuitable for clinical applications, it also has one of the highest 
efficiencies of reprogramming.  
 
2.1.1 Preparation of Cell Lines  
 
Fibroblast Cell Culture: 2 human fibroblast cell lines, human foreskin fibroblasts (HFF) 
and neonatal human dermal fibroblasts (HDFn) were used for reprogramming into iPSCs. 
These cell lines were obtained from the UK Stem Cell Bank (www.ukstemcellbank.org.uk). 
Cryopreserved cells were thawed in a 37°C water bath and transferred into warmed fibroblast 
medium (table 2.1) in a cell culture flask and incubated at 37°C, 5% CO2. When the cells 
reached 80-90% confluence, the cells were passaged. The medium was aspirated and the cells 
washed once with PBS. 0.25% trypsin/1mM EDTA was added to the flask, which was then 
incubated until the cells detached from the surface of the flask. The trypsin was inactivated 
by the addition of medium, and the cells were then transferred into another flask. When 
making frozen stocks, the cells were counted after trypsinisation, using 4% trypan blue 
solution to ensure that only live cells were included in the count. The cells were spun down 
and the medium removed. 1x10
6
 cells were cryopreserved in 1ml of cryopreservation solution 
(10% DMSO in foetal calf serum). 
 




Reagent Volume (ml) Final Concentration 
DMEM 440 
 
Foetal Calf Serum 50 10% 
200mM L-Glutamine 5 2mM 
1% Penicillin-Streptomycin 5 1mg/ml 
Total 500  
Table 2.1. Volumes and final concentrations of each component of fibroblast medium. 
 
293FT Cell Culture: The 293FT cell line is supplied with the ViraPower™ Lentiviral 
Expression System, and is useful for generating high-titre lentivirus. It is a fast-growing, 
highly transfectable clone derived from human embryonal kidney cells transformed with the 
SV40 large T antigen from the pCMVSPORT6Tag.neo plasmid, controlled by the human 
cytomegalovirus promoter which is high-level and constitutive. Presence of the SV40 large T 
antigen allows very high levels of protein to be expressed from vectors containing the SV40 
origin, allowing maximal production of a replication-incompetent HIV-1-based lentivirus that 
is used to deliver a mouse retrovirus receptor (Slc7a1) to the fibroblasts, which then allows 
the retroviruses carrying the pluripotency factors needed for reprogramming to infect the 
fibroblasts (figure 2.1). Cryopreserved cells were thawed in a 37°C water bath and transferred 
into warmed 293FT medium (table 2.2) in a T25 cell culture flask and incubated at 37°C, 5% 
CO2. The next day, the medium was changed to 293FT medium containing Geneticin 
(50µg/ml), which is important for selecting the pCMVSPORT6Tag.neo plasmid-containing 
cells, as they contain a resistance gene. The cells were maintained in this medium until 
confluent, when they were passaged as described above. Frozen stocks were made as 
described above. 
293FT Medium 
Reagent Volume (ml) Final Concentration 
DMEM 430 
 
Foetal Calf Serum 50 10% 
100x Non-Essential Amino Acids 5 0.1mM 
200mM L-Glutamine 5 2mM 
100mM Sodium Pyruvate 5 1mM 
1% Penicillin-Streptomycin 5 1mg/ml 
Total 500  
Table 2.2. Volumes and final concentrations of each component of 293FT medium. 
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Plat-E Cell Culture: The Plat-E cell line is a retrovirus packaging line based on the 293FT cell 
line. It allows high and stable expression of viral structural proteins (Morita et al., 2000). In 
iPSC generation, it is used to package retroviruses containing pMX plasmid DNA (prepared 
as described in section 2.1.2) encoding the 4 transcription factors needed for reprogramming 
to pluripotency (OCT4, KLF4, SOX2 and c-MYC), as well as one encoding GFP to enable 
monitoring of transfection efficiency. These retroviruses are capable of infecting fibroblasts 
expressing the mouse retrovirus receptor Slc7a1. Cryopreserved cells were thawed in a 37°C 
water bath and transferred into warmed FP medium (table 2.3) in a T25 cell culture flask and 
incubated at 37°C, 5% CO2. The next day, the medium was changed to FP medium 
containing Blasticidin (1µg/ml) and Puromycin (0.1µg/ml), as these cells include a resistance 
gene that allows antibiotic selection of the cells containing the packaging constructs. The 
cells were maintained in this medium until confluent, when they were passaged as described 
above. Frozen stocks were made as described above.  
 
FP Medium 
Reagent Volume (ml) Final Concentration 
DMEM 447.5 
 
Foetal Calf Serum 50 10% 
1% Penicillin-Streptomycin 2.5 0.5mg/ml 
Total 500  
Table 2.3. Volumes and final concentrations of each component of FP medium 
 
2.1.2 Preparation of pMX Plasmids 
Glycerol stocks of E. coli containing plasmids for each of the reprogramming factors and 
GFP (Takahashi & Yamanaka, 2006) were obtained from AddGene (www.addgene.org).  
Plate Preparation: Luria broth (LB) was melted in the microwave using low power and then 
incubated in a 50°C water bath until cool. 40µg Ampicillin with sodium salt was added to 
400ml LB to give a final concentration of 0.4μg/ml.  20ml of LB was poured into a 100mm 
dish, which was then left to cool and set. One plate was prepared for each plasmid. 
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Recovery of Single Colonies from Stored Cultures: A sterile wire loop was used to streak an 
inoculum of bacteria from a glycerol stock onto the LB plate. The plate was incubated upside 
down at 37°C for 12 hours.  
Preparation of Bacteria for Plasmid Preparations: A starter colony was prepared by 
inoculating a single colony from the freshly streaked plate into 10ml LB medium containing 
0.4μg/ml Ampicillin. The starter culture was grown up for 8 hours with vigorous shaking. 
The starter culture was then diluted 1:500 in LB medium containing 0.4μg/ml Ampicillin, 
and the culture was grown up overnight at 37°C with vigorous shaking.  
Isolation of Plasmid DNA: The SNAP midiPrep Kit was used to lyse, precipitate and isolate 
the plasmid DNA. The bacterial culture was harvested by centrifugation at 6000 x g for 
15min at 4°C and the medium was poured off. The cell pellet was resuspended in 4ml of 
resuspension buffer, then 4ml of lysis solution was added. The solution was mixed by 
inverting 5-6 times and incubated at room temperature for 3min. 4ml of precipitation salt was 
added, and the solution was mixed by inverting 6-8 times before being placed on ice for 
5min. The tubes were inverted several times to ensure even formation of precipitate. A SNAP 
MidiPrep Column A (filtering) was placed inside a 50ml conical tube, and the solution was 
transferred onto this column and centrifuged for 5min at 3000 x g. The column was 
discarded, and 12ml of binding buffer was added to the filtrate, which was transferred to a 
SNAP MidiPrep Column B (binding) and centrifuged at 1000 x g for 1min. The flow-through 
was discarded. 5ml of wash buffer was added, and the tube was centrifuged at 2000 x g for 
1min. The flow-through was discarded. 5ml of final wash buffer was added and the tube was 
centrifuged at 2000 x g for 2min. 10ml of final wash buffer was added to the column and the 
tube was centrifuged at 2000 x g for 2min. The flow-through was discarded. The tube was 
then centrifuged at 4000 x g for 5min to dry the column. The column was then transferred to 
a new 50ml conical tube and 750µl of sterile water was added directly to the column. The 
column was incubated at room temperature for 3min, and then centrifuged at 4000 x g for 
5min. The column was discarded and the purified plasmid DNA was stored at -20°C until 
needed. The DNA was quantified using the Nanodrop spectrophotometer.  
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2.1.3 Reprogramming of Fibroblasts 
 
Day 1: Seeding of 293FT Cells: Cells were seeded to three 100mm dishes at a density of 
4x10
6
 cells per dish in 10ml 293FT medium and incubated overnight at 37°C, 5% CO2. 
Day 2: Transfection of 293FT Cells: 9µg ViraPower™ packaging mix (supplied as part of 
the ViraPower™ Lentiviral Expression System), containing plasmids that supply the cellular 
machinery needed to produce lentivirus, and 3µg of pLenti6-mSlc7a1 plasmid were added to 
1.5ml Opti-MEM low serum medium and mixed. 36µl of Lipofectamine 2000, which 
improves transfection efficiency, were added to 1.5ml Opti-MEM and incubated at room 
temperature for 5 minutes. The DNA and lipofectamine were combined and incubated at 
room temperature for 20 minutes. The medium on each dish of the 293FT cells was replaced 
and 3ml of the DNA mixture was added drop-wise to the cells, which were incubated at 
37°C, 5% CO2 overnight. The medium was changed after 24 hours.  
Day 3: Seeding Fibroblasts: Fibroblasts were seeded at a density of 1.5x10
5
 cells per well in 
four 6-well plates for each cell line.  
Day 4: Lentiviral Transduction of Fibroblasts: The supernatant containing the lentivirus 
was aspirated from the 293FT cells and filtered through a 0.45µm cellulose acetate filter to 
remove any cells that may have been aspirated with the supernatant. The supernatant was 
diluted 1:2 with Opti-MEM, and 4µg/ml Polybrene (a cationic polymer used to increase the 
efficiency of infection) was added. The lentivirus-containing supernatant was added to 20 
wells of each fibroblast line, and the remaining 4 wells were left untreated as a negative 
control. The cells were incubated at 37°C, 5% CO2 and after 5-6 hours the medium was 
replaced with 2ml of FP media per well. The medium was replaced again the next day. 
Day 9: Seeding of PlatE Cells: Cells were seeded to five 100mm dishes at a density of 
3.6x10
6
 cells per dish in 10ml FP medium.  
Day 10: Transfection of PlatE Cells: 27µl Fugene6 transfection reagent (a non-liposomal 
reagent that transfects DNA into cells with high efficiency and low toxicity) was added to 
0.3ml Opti-MEM and incubated for 5 minutes at room temperature in a 1.5ml tube for each 
plasmid. 9µg of plasmid pMX DNA encoding OCT4, SOX2, KLF4, c-MYC and GFP was 
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added drop-wise to each tube containing the Fugene 6/Opti-MEM mix and incubated at room 
temperature for 15 minutes. Each plasmid was added drop-wise to the PlatE cells, which were 
incubated overnight at 37°C, 5% CO2. The medium was replaced the next day.  
Day 11: Seeding Transduced Fibroblasts: The fibroblasts transduced with the mSlc 
receptor (HDFn/mSlc and HFF/mSlc) and the negative controls (HDFn/neg and HFF/neg) 
were seeded to 4x 6-well plates at a density of 1.5x10
5
 cells per well.  
Day 12: Retroviral Transduction of Fibroblasts: The supernatant containing the retrovirus 
was removed from each dish of PlatE cells and filtered through a 0.45µm cellulose acetate 
filter. 4µg/ml Polybrene was added, and the 4 retrovirus-containing mixtures were combined 
in equal parts. The supernatant from the GFP-infected cells was kept separate. The medium 
was removed from the fibroblasts and replaced with 1ml of retrovirus-containing supernatant 
per well. Some wells were left untreated as a negative control, while some were treated with 
GFP-containing supernatant. The cells were incubated at 37°C, 5% CO2 and after 5-6 hours 
the medium was replaced with 2ml of FP medium per well. The medium was changed again 
the next day.  
Day 15: The medium on the cells was replaced with FP media containing 5µM valproic acid 
(VPA), which is a histone deacetylase inhibitor that improves the efficiency of 
reprogramming (Huangfu et al., 2008).  
Day 16: Mitomycin C-inactivated iSNL feeder cells (see section 2.2.1) were seeded to 6 
gelatine-coated 6-well plates at a density of 1.5x10
6
 cells per well.  
Day 17: The potential iPS cells (piPSCs) and uninfected controls were seeded to iSNL feeder 
plates at a density of 1-2x10
4
 cells per well, and RNA was isolated. This was later used to 
check for exogenous transgene expression by qRT-PCR.  
The medium on the piPSCs and uninfected controls was replaced every other day with 
knockout serum replacement medium (table 2.5) containing 5µM VPA until the appearance 
of colonies 2-3 weeks after transfection. When large enough, the colonies were manually 
passaged onto new feeder cells and maintained as described in section 2.2. 




Figure 2 1.Overview of the process of reprogramming of fibroblasts to induced pluripotent stem cells.   
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2.2. Maintenance of Pluripotent Stem Cells in Culture  
2.2.1 SNL Feeder Cell Culture & Inactivation 
Feeder cell layers consist of adherent growth-arrested but viable cells. These cells act as a 
substratum on which stem cells can be grown in a co-culture system. Stem cells are 
dependent on contact with a feeder layer for survival and expansion, as the feeder layer 
provides an extracellular matrix and matrix-associated factors, and also secrete nutrients and 
signalling molecules into the medium. In this case, SNL cells, which are immortalised cells 
clonally derived from a mouse fibroblast cell line transformed with neomycin resistance and 
murine LIF genes, were used as feeders. These cells are frequently used as feeders when 
culturing mouse pluripotent stem cells, as they constitutively express LIF which these cells 
require for their maintenance in culture, but can also support the growth of human pluripotent 
stem cells (Pan et al., 2010). As these cells are immortal, they are easy to culture and can be 
expanded over many passages, unlike human and mouse embryonic fibroblasts, which are an 
alternative source of feeder cells.  
Cell culture dishes were coated with 0.1% gelatine, which improves adherence of cells, and 
incubated at 37°C for an hour. Excess gelatine was then removed. Cryopreserved cells were 
thawed in a 37°C water bath and transferred in 10ml warmed SNL medium (table 2.4) onto a 
gelatine-coated 100mm dish and incubated at 37°C, 5% CO2 until confluent, when they were 
passaged. The medium was aspirated and the cells washed once with PBS. 0.25% 
trypsin/1mM EDTA was added to the dish, which was incubated until the cells detached from 
the surface of the flask. The trypsin was inactivated by the addition of medium. The volume 
was adjusted to 200ml by adding medium and 10ml of the cell suspension was transferred to 
each gelatine-coated 100mm dish and incubated at 37°C, 5% CO2 until confluent.  
 
SNL Medium 
Reagent Volume (ml) Final Concentration 
DMEM 460 
 
Foetal Calf Serum 35 7% 
200mM L-Glutamine 5 2mM 
Total 500  
Table 2.4. Volumes and final concentrations of each component of SNL medium. 
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16 of these dishes were mitotically inactivated using Mitomycin-C (once inactivated, they are 
referred to as iSNL cells). 0.3ml of 0.4mg/ml Mitomycin-C solution was added to each dish, 
giving a final concentration of 12µg/ml. The dish was incubated for 2 hours 15 minutes at 
37°C, 5% CO2. The medium was removed and the dishes washed with PBS twice. The cells 
were trypsinised as described above and the cells were then resuspended in 2.5 ml media. The 
cells were counted, using 4% trypan blue solution to ensure that only live cells were included 
in the count, and then centrifuged and the medium aspirated. Cells were frozen at a 
concentration of 1.5x10
6
 cells in 1ml of freezing solution (10% DMSO in foetal calf serum) 
and stored at -80°C. The remaining 4 dishes were not inactivated and the SNL cells were 
cryopreserved as replacement stocks.  
Cryopreserved iSNL cells were thawed into 10-12ml warmed SNL medium and mixed gently 
by pipetting up and down. 1ml of this cell suspension was added to a gelatine-coated IVF 
dish and the cells were incubated overnight at 37°C, 5% CO2. The next day the medium was 
replaced with knockout serum replacement medium in order to optimise attachment of stem 
cell colonies.   
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Figure 2.2. Passage of stem cell colonies. (A) Hooked cutting tool used for manual dissection of colonies. (B) 
Undifferentiated stem cell colony grown on iSNL feeders. (C) Undifferentiated colony manually dissected into 
approximately equal pieces for passage. 
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Stem cells were thawed into warmed knockout serum replacement (KOSR) medium (table 
2.5) and transferred to an IVF dish containing iSNL feeder cells. Stem cells start to 
differentiate around the outside and from the centre of the colonies as they are maintained in 
culture. To preserve the stem cells in an undifferentiated state, undifferentiated sections of the 
colony were manually excised using a hooked cutting tool (figure 2.2) under a dissecting 
microscope and transferred to a new layer of iSNL cells, evenly spaced to avoid the colonies 
merging. The plate was transferred very carefully to the incubator (37°C, 5% CO2). Once the 
colonies had adhered (after about 24 hours), the medium was changed every 2-3 days. 
 
Knockout Serum Replacement (KOSR) Medium  
Reagent Volume (ml) Final Concentration 
Knockout DMEM 383.8 
 
Knockout serum replacement 100 20% 
200mM L-glutamine 5 2mM 
0.1mM non-essential amino acids 5 1% 
β-mercaptoethanol 1 0.1mM 
bFGF 0.2 4ng/ml 
1% Penicillin-streptomycin 5 1mg/ml 
Total 500  
Table 2.5. Volumes and final concentrations of each component of KOSR medium. 
 
2.2.3 Preparation of Matrigel™-Coated Plates  
Matrigel™ is a soluble basement membrane extract of the mouse Engelbreth-Holm-Swarm 
tumour that gels at room temperature, forming a reconstituted basement membrane which can 
be used to maintain pluripotent stem cells without a feeder cell layer. The major components 
of Matrigel™ are laminin, collagen IV, entactin, and heparan sulfate proteoglycan. Growth 
factors, collagenases, plasminogen activators and other undefined components are also 
present in Matrigel™.  
Matrigel™ was thawed at room temperature or overnight at 4°C, and then aliquoted into the 
dilution factor specified by the manufacturer. An aliquot was thawed on ice and added to 
25ml of cold DMEM medium to coat four 6-well plates (1ml/well). All pipette tips, tubes and 
plates were kept at 4°C prior to use in order to prevent the Matrigel™ from adhering to them. 
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Diluted Matrigel™ was added immediately to the plates, ensuring that the surface of the 
wells was fully coated, and left at room temperature for one hour prior to use. Coated plates 
could be kept for 7 days at 4°C. Matrigel™ was removed immediately before use and 2ml 
mTeSR-1™ medium were added to each well. 
 
2.2.4 Maintenance of Pluripotent Stem Cells on Matrigel™  
Undifferentiated hESCs were maintained in mTeSR-1™ medium, which is a defined, serum-
free medium developed for stem cell research, supplemented with 100ml mTeSR™1 5X 
Supplement per 400ml. Cells were incubated at 37°C, 5% CO2 and the media was changed 
every 2-3 days. The hESC colonies were passaged every 5-7 days by manual dissection using 
a hooked tool (figure 2.2) under a dissecting microscope and transferred onto a new 
Matrigel™-coated 6-well plate. Undifferentiated colonies were cut and fragments were re-
plated into 2-3 wells for each colony. 
 
2.2.5 Cryopreservation of Stem Cells 
Pluripotent stem cells were stored at -196°C in liquid nitrogen as vitrified cells in open-pulled 
straws. Vitrification accompanied by rapid freezing and thawing avoids the formation of ice 
crystals that could be potentially harmful to the cells. The vitrification protocol involves the 
stepwise exposure of colony fragments to two vitrification solutions with increasing 
cryoprotectant concentration; in this case DMSO and ethylene glycol. Vitrification solution 2 
contains sucrose as an osmotic buffer to protect the colony fragments from the cryopreservant 
for long-term storage. Direct immersion of open-pulled straws containing the colony 
fragments in small droplets of vitrification solution allows rapid cooling rates, which is 
required to avoid the formation of ice crystals.  
The holding medium (table 2.6) was prepared aseptically and used to prepare VS1 and VS2 
(tables 2.7 & 2.8, respectively) which were sterile filtered through a 0.2μM filter, aliquoted 
and stored at -20°C. Each thawed aliquot was used once and then discarded. VS1 and VS2 
were warmed to 37°C and a 200μl drop of VS1 and two 100μl drops of VS2 were placed on a 
sterile culture dish. Under the dissecting microscope, small colony fragments were 
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mechanically dissected as described previously and approximately 4-6 fragments were 
transferred to the VS1 drop in a minimum volume  of medium (approximately 4-5μl) for 
1min, before transferring the colony fragments to the first drop of VS2, then to the second 
drop after 25 seconds. The cells were recovered in a minimum volume (4-5μl) as a drop on 
the culture dish. The open-pulled straw was touched to the drop, which was aspirated by 
capillary action. The straw containing the cells was then plunged into a 5ml cryovial which 
had been previously pierced and immersed into the liquid nitrogen. The cryovial was then 
transferred to a liquid nitrogen container for long-term storage. 
 
Holding Medium 
Reagent Volume (ml) Final Concentration 
DMEM 86.5 
 
Foetal calf serum 10 10% 
L-glutamine 1 2mM 
1M HEPES Buffer 2.5 25mM 
Total 100  
Table 2.6. Volumes and final concentrations of each component of holding medium. 
 
Vitrification Solution 1 (VS1) 
Reagent Volume (ml) Concentration 
Holding medium 32 80% 
DMSO 4 10% 
Ethylene glycol 4 10% 
Total 40  
Table 2.7. Volumes and final concentrations of each component of vitrification solution 1 
 
Vitrification Solution (VS2) 
Reagent Volume (ml) Concentration 
Holding medium To 40ml 80% 
DMSO 4 10% 
Ethylene glycol 4 10% 
Sucrose 6.84g 
 
Total 40  
Table 2.8. Volumes and final concentrations of each component of vitrification solution 2. 
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2.3. In Vitro Differentiation of Stem Cells 
2.3.1 Differentiation to Definitive Endoderm  
The formation of definitive endoderm (DE) is a key step in the differentiation of pluripotent 
stem cells towards a pancreatic lineage (Courtney et al., 2010). Given that the successful 
generation of pancreatic progenitors and subsequently the development of more mature 
hormone-expressing cells is critically dependent on this stage, we have focussed our 
experiments on the generation of definitive endoderm. In order to optimise the yield of 
definitive endoderm, I have tested three different protocols.  
 Stage 1 
Formation of definitive endoderm 








Activin A (100ng/ml) 









Wnt3A  (3ng/ml)  





Table 2.9. Reagents and concentrations used to direct differentiation of stem cells to definitive endoderm 
using protocols developed by D’Amour et al, 2005; Nostro et al, 2011; or Borowiak et al, 2009. 
 
The use of small molecules in directed differentiation protocols is of great interest, as they 
can be chemically synthesised and purified, allowing a greater degree of standardisation than 
recombinant growth factors. In addition, they are often cheaper to produce. A study by 
Borowiak et al. (2009) described the use of the small molecules IDE1 and IDE2 to improve 
the efficiency of DE formation in comparison to an Activin A-based protocol (D’Amour et al, 
2005). As a result, I have investigated the effect of IDE1 on the efficiency of DE formation in 
iPSC and ESC lines. In 2011, Nostro et al. reported an optimised protocol for the 
differentiation of pluripotent stem cells into DE, and I have also investigated the efficiency of 
this protocol for DE formation in iPSC and ESC lines. 
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Stem cells were maintained in culture as previously described in section 2.2. Before the start 
of the differentiation protocol on day 1, RNA from colonies containing undifferentiated cells 
was taken. Colonies undergoing differentiation were washed with PBS before being exposed 
to either the D’Amour protocol, the Nostro protocol, or the Borowial protocol according to 
the time scale shown in table 2.9. The medium was prepared aseptically as described in table 
2.9 and sterile filtered through a 0.2μm filter. Cells that were allowed to spontaneously 
differentiate over the same timescale were also included in the comparison as a control, and 
were treated with RPMI only. Cells were harvested at the end of stage 1 and analysed as 
described in section 2.4. 
 
2.4. Characterisation of iPS Cells 
2.4.1 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
RT-PCR for the analysis of mRNA levels is a combination of 3 steps: i) reverse transcription 
of RNA into cDNA, ii) amplification of cDNA using the polymerase chain reaction, and iii) 
detection and quantification of amplification products. Traditional methods relied on end-
point analysis, where the cDNA is amplified for a specified number of cycles, and then the 
products visualised through gel electrophoresis. However, there are several disadvantages to 
this method, including poor precision and low sensitivity. More recently, the advent of real-
time PCR (qPCR) allows quantitative analysis of RNA in real time, using fluorescent reporter 
dyes to combine the amplification and detection stages of the PCR reaction. In this case, 
SYBRGreen, a double-stranded DNA-binding dye which fluoresces when it intercalates into 
a double stranded DNA molecule, was used. The increase in fluorescent signal after each 
PCR cycle is proportional to the amount of DNA produced. Intercalating dyes are 
inexpensive and simple to use, and, because they are not sequence specific, they can be used 
in any reaction. However, since SYBRGreen binds indiscriminately to double-stranded DNA, 
primer-dimer artefacts and amplification errors can contribute to the detected fluorescence. In 
addition, multiplexing (analysis of several different genes in one PCR reaction) is not 
possible using this system.  
Isolation of Total RNA: Total RNA was isolated using the RNeasy Mini Kit. Stem cell 
colonies were isolated by mechanical dissection into 350μl lysis buffer containing Buffer 
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RLT and 1% (v/v) β-mercaptoethanol. This is a highly denaturing guanidine thiocyanate-
containing buffer, which inactivates RNases to ensure purification of intact RNA. The cells 
were homogenised by vortexing before an equal volume of 70% ethanol was added to the 
lysate to optimise RNA binding to the RNeasy membrane. The lysate was applied to the 
RNeasy spin column and spun at 8000 x g for 1min to bind the RNA to the membrane and 
350μl Buffer RW1 was then added to the column. The column was centrifuged at 8000 x g 
for 1min and the flow-through was discarded.  
On-column DNase digestion was performed using the RNase-free DNase kit. The lyophilised 
DNase I was dissolved in 550μl PCR-grade water and mixed gently by inverting the vial. For 
long-term storage of DNase I, the stock solution was divided into 50μl aliquots and stored at -
20°C. A working solution of DNase I was freshly prepared by adding 10μl DNase I stock 
solution to 70μl Buffer RDD, mixed by gently inverting the tube. 80μl DNase I incubation 
mix were then added directly to the RNeasy spin column membrane and incubated for 15min 
at room temperature.  
The RNeasy spin column was washed with 350μl Buffer RW1, centrifuged at 8000 x g for 
1min and the flow through was discarded. 500μl Buffer RPE was added to the RNeasy spin 
column and centrifuged at 8000 x g for 1min and the flow-through was discarded. A further 
500μl Buffer RPE was added to the spin column, centrifuged at 8000 x g for 2min and the 
flow through was again discarded. The column was spun dry at 8000 x g for 1min and then 
placed in an RNase, DNase-free 1.5ml tube. 30μl of RNase-, DNase-free water were added 
directly to the membrane. The column was incubated for 1min at room temperature before 
being centrifuged at 8000 x g for 1min to elute the RNA. The eluate was reapplied to the spin 
column membrane and centrifuged at 8000 x g for 1min to maximise RNA concentration. 
The RNA was analysed using the Nanodrop spectrophotometer to check the yield and quality 
of RNA isolated. Isolated RNA was stored at -80°C. 
 
Reverse Transcription of Total RNA into cDNA: 9.5μl total RNA, 1μl Oligo(dT)15 primers 
(0.5μg/μl) and 1μl random primers (0.5μg/μl) were added to a sterile 0.5ml microcentrifuge 
tube and the mixture was incubated at 70°C for 5min to melt secondary structure within the 
template then immediately cooled on ice for 5min to prevent secondary structure from 
reforming. Oligo(dT)15 primers bind to the polyA tail of the mRNA, while random primers 
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bind to random sequences in the mRNA. A master mix was prepared according to table 2.11 
and 8.5μl was added to each sample. The samples were then incubated for 50 min at 42°C to 
allow the activation of the MMLV-RT enzyme and the synthesis of cDNA, followed by 
15min at 70°C to inactivate the enzyme. Newly synthesised cDNA was stored at -20°C. 
Reverse Transcription Mix 
Reagent Volume Needed For 1 Reaction (µl) 
5x Reaction Buffer 4 
10mM dNTPs 1 
40U/µl RNAsin 2 
400mM DTT 0.5 
MMLV-RT 1 
Total 8.5 
Table 2.10. Reagents and volume needed for the reverse transcription reaction. 
 
Amplification of cDNA by PCR: Forward and reverse oligonucleotide primers, complementary 
to the sequence to be amplified, were chemically synthesised by Integrated DNA 
Technologies and are detailed in table 2.12.  The primers were supplied lyophilised, and a 
100µM stock solution was made and diluted to a working concentration of 10μM. 
 
RT-PCR Reaction Mix 
Reagent Volume Needed For 1 Reaction (µl) Concentration 
5x Reaction Buffer 4 1x 
10mM dNTPs 0.5 250µM of each nucleotide 
25mM MgCl2 1.2 1.5mM 
10µM Forward Primer 1 0.5µM 
10µM Reverse Primer 1 0.5µM 
GoTaq Polymerase 0.2 1U 
cDNA 2 - 
PCR-grade Water 10.1 - 
Total 20 
 
Table 2.11. RT-PCR reaction mix. 
 
The cDNA samples were diluted 1:3 to remove any potential inhibitors of the PCR from the 
reverse transcription reaction. A PCR mix was prepared as described in table 2.11 in a sterile 
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microcentrifuge tube and briefly vortexed and centrifuged. As a negative control, the cDNA 
was replaced with water. The tubes were placed into a PCR thermo-cycler and the PCR 
cycles were performed using the following parameters: incubation at 94°C for 2min to 
activate the GoTaq® polymerase; 40 cycles of 94°C for 45sec (denaturation), 58°C for 30sec 
(annealing) and 72°C for 1min (elongation); and a final 10 minutes at 72°C to allow PCR 
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Table 2.12. Oligonucleotide primers used in PCR reactions. 
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2.4.2 Gel Electrophoresis 
Preparation of Agarose Gels: 2% agarose gels were made by dissolving 1g electrophoresis 
grade agarose in 50ml of 1X TBE buffer (table 2.13) and the mixture was heated in a 
microwave for approximately 2min until the agarose had dissolved. The solution was cooled 
and 5μl of 10mg/ml ethidium bromide (to give a final concentration of 1μg/ml) was added. 
The mixture was poured into a gel tray and allowed to set.  
 
10x Tris Borate EDTA (TBE) Buffer (1L) 
Reagent Amount (g/L) 
Tris-(hydroxymethyl) methylamine 109.3 
Boric Acid 55.65 
EDTA 9.31 
Table 2.13. Mass of each component of TBE buffer. TBE buffer was used to make the gels and as a running 
buffer in electrophoresis. The volume was made up to 1L with water and the buffer was stored at room 
temperature. For use, the 10X buffer was diluted 10-fold to obtain a 1X TBE buffer. 
 
Gel Electrophoresis: 6X blue/orange loading dye was added to the PCR products in a ratio of 
1:6. The samples were then loaded onto an agarose gel in an electrophoresis tank filled with 
1x TBE buffer. Electrophoresis was carried out at 70V for around 15 minutes. Afterwards, 
DNA was visualised under UV light using a transilluminator. Images were captured using a 
gel imaging system (InGenius LHR-Syngene). An estimation of DNA band size was obtained 
by comparison with DNA markers (e.g. 100bp DNA ladder) run in parallel with the samples. 
 
Purification of DNA from Agarose Gels: DNA was purified from agarose gels using the 
QIAquick gel extraction kit. The DNA fragment was excised from the gel using a clean 
scalpel blade and transferred to a DNase-, RNase-free tube. The mass of the DNA-containing 
gel slice was determined and 5 volumes of buffer PB, containing a pH indicator, were added 
for every 1 volume of gel (500μl/0.1g gel) and the gel slice was incubated in the buffer at 
55°C for approximately 5-10min to allow the gel to melt. The mixture was transferred to a 
spin column which was centrifuged for 1min at 13,000rpm to bind the DNA to the silica-
based membrane and the flow-through was discarded. The DNA was then washed twice with 
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750μl wash buffer PE and after centrifugation (1min at 13,000rpm) the flow-through was 
again discarded, and the column further centrifuged for 4min at 13,000rpm to dry the 
membrane. The column was then placed into a 1.5ml microcentrifuge tube and the bound 
DNA was eluted with 30μl of PCR-grade water, which was added directly to the silica 
membrane and incubated for 1min at room temperature, followed by centrifugation for 1min 
at 13,000rpm. Purified DNA was stored at -20°C. 
 
Preparation of Standard Curves for qRT-PCR: qRT-PR relies on the generation of standard 
curves for each gene of interest. To generate a template from which serial dilutions could be 
made to construct a standard cure, a PCR reaction was then performed, as described above, to 
create a standard curve for each gene of interest in subsequent qRT-PCR experiments. A 
standard curve for a reference gene was carried out in parallel in order to enable 
normalisation of any results. Cyclophilin G (CYCG) was chosen as a reference gene for these 
experiments as it has previously been shown that expression levels are not altered upon 
differentiation of stem cells (D’Amour et al., 2006), and this had previously been internally 
validated in our lab (Courtney, 2010).  
 
2.4.3 Quantitative PCR (qRT-PCR) for Detection of mRNA Expression 
 PCR reactions were set up in 20μl reactions as described in table 2.14, using either target 
cDNA or standard cDNA. Standard dilutions were prepared as in section 2.4.2 and run 
together with the samples of interest. A negative control in which the template cDNA was 
replaced with water was also included in each reaction. PCR reactions were carried out on the 
Qiagen Rotor-Gene™ 6000 using the following PCR cycling conditions: 10min at 95°C; 
followed by 40 repeated cycles of 5sec at 95°C, 15sec at 58°C and 10sec at 72°C. The 
fluorescence was acquired at the end of the elongation step. A melt curve analysis was carried 
out to ensure amplification of a single product, and the products were run on a gel to confirm 
the amplicon was the correct size (table 2.12).  
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qRT-PCR Reaction Mix 
Reagent 
Volume Needed For 1 
Reaction (µl) 
2x Sensimix Plus 
(containing reaction buffer, heat-activated Taq Polymerase, dNTPs, 6mM MgCl2, 
internal reference and stabilisers, and SYBR green) 
10 
10µM Forward Primer 1 
10µM Reverse Primer 1 
cDNA 2 
PCR-grade H2O 6 
Total 20 
Table 2.14. qRT-PCR reaction mix. 
 
Data Analysis: Individual reactions are characterised by the PCR cycle at which 
fluorescence first rises above a defined threshold background fluorescence (figure 2.3), 
known as the threshold cycle (CT). The more target cDNA there is in the starting material, the 
lower the CT. Plotting the concentration for a set of known standards versus the CT gives the 
standard curve (figure 2.4). In these experiments, the standards were assigned arbitrary 
concentrations and the amount of target in the unknown samples of interest is determined by 
measuring the CT of the samples and using the standard curve to determine their starting 
concentration.  To normalise gene expression for variation in the amount of RNA between 
different samples, the concentration for the gene of interest is divided by the concentration 
from a reference gene in the same sample. 
 




Figure 2.3. Amplification plot of fluorescence versus cycle number for seven serially-diluted standards, 
showing the cycle at which fluorescence first rises above a defined threshold background fluorescence (CT). 
 
Figure 2.4. Standard curve generated by plotting the assigned concentration of the standards against the CT. 
This can then be used to determine the concentration of the unknown samples relative to the standards. 




Immunocytochemistry is used to visualise the cellular location and abundance of a specific 
protein within a cell using antibodies that specifically bind to the protein of interest. These 
antibodies are labelled with a fluorescent tag, such as fluorescein isothiocyanate (FITC), that 
will absorb light and emit at a different wavelength. Direct immunofluorescence uses 
fluorescently-labelled primary antibodies whilst indirect immunofluorescence uses 
fluorescently-labelled secondary antibodies specific to the primary antibody. A list of the 
primary and secondary antibodies used is shown in table 2.15. 
 
Primary Antibody Dilution Specificity 
Goat anti-human Oct4 IgG 1:500 Primary 
Goat anti-human Sox17 IgG 1:500 Primary 
Mouse anti-human SSEA-3 IgM 1:100 Primary 
Mouse anti-human TRA-1-81 IgM 1:100 Primary 
Rabbit anti-human Nanog IgG 1:500 Primary 
Rabbit anti-goat AlexaFluor® 488 1:100 Secondary 
Goat anti-mouse IgG + IgM (FITC) 1:100 Secondary 
Goat anti-rabbit IgG (FITC) 1:100 Secondary 
Goat IgG 1:500 Isotype Control 
Mouse IgG 1:500 Isotype Control 
Rabbit IgG 1:500 Isotype control 
Table 2.15. List of antibodies used. 
 
Immunocytochemistry on Formalin-Fixed Cells: Immunofluorescence measurements of 
intracellular proteins require the cells to be fixed and permeabalised to allow the antibody 
inside the cell. The medium was aspirated and the cell colonies were washed twice with PBS. 
The cells were fixed with 500µl of 4% paraformaldehyde and incubated for 20min at room 
temperature before being washed 3 times with PBST (PBS containing 0.01% TritonX 100), 
and then incubated in 1ml PBST at room temperature for 15min. 500μl of primary antibody 
(table 2.15), diluted appropriately in PBST, was added to the cells which were then incubated 
in the dark overnight at 4°C. The cells were washed 3 times with PBST and 500μl secondary 
antibody at the appropriate dilution (table 2.15) was then added to the cells and left to 
incubate at room temperature for 1hr. 200µl of 5µg/ml Hoescht DNA stain solution was 
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added to the cells and incubated for 1min at room temperature. The cells were then washed 
twice for 5min in PBST. Control dishes were also prepared, by omitting the primary antibody 
to ascertain the specificity of the antibody, and also using an isotype control together with the 
secondary antibody to ascertain the degree of non-specific binding. The cells were visualised 
using a Nikon Eclipse TS100 inverted microscope.  
 
Live Cell Immunocytochemistry: If the proteins of interest are on the surface of the cell, as is 
the case with the pluripotent stem cell-specific keratan sulphate antigen TRA-1-60, the cells 
do not need to be fixed or permeabalised, allowing live cell staining. Cells were cultured as 
described in section 2.2 for at least 5 days before staining. 2µl of 0.5ng/ml TRA-1-60 
StainAlive dye was diluted in 198µl of medium to give a final concentration of 5pg/ml. The 
medium was aspirated and 200µl of antibody solution was added. After 30mins incubation at 
37°C, 5% CO2, the cells were washed twice with medium and left covered with 1ml of 
medium. The cells were visualised using a Nikon Eclipse TS100 inverted microscope. 
 
Alkaline Phosphatase Staining: Undifferentiated pluripotent stem cells are characterised by 
high levels of expression of alkaline phosphatase, which can be visualised using a 
Napthol/Fast Red Violet staining solution. The cells were cultured for at least 5 days before 
staining. The media was aspirated and the cells were fixed with 4% formaldehyde for 2 
minutes. The cells were washed with TBST (20mM Tris-HCl, pH7.4; 0.15M NaCl, 0.05% 
Tween-20). The staining solution was prepared by mixing Fast Red Violet, Napthol AS-BI 
phosphate and water in a ratio of 2:1:1. This was added to the cells which were then 
incubated at room temperature in the dark for 15min. The cells were washed with TBST and 
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2.5 Investigation of microRNA Expression 
Several characteristics of miRNAs make investigating their expression challenging. Unlike 
mRNAs, which all have a poly(A) tail, miRNAs do not have a common sequence which can 
be used to selectively enrich miRNAs in the sample. This is important as miRNAs make up 
only about 0.01% of the total RNA in a sample, and profiling needs to be able to distinguish 
mature miRNAs from other RNA species, as well as from pre- and pri-miRNA sequences, 
which will contain the mature miRNA sequence. Different mature miRNAs can be produced 
from the same pre-miRNA: distinct miRNAs are generated from the 5’ and 3’ arms of the 
pre-miRNA, and mature miRNAs can vary in length due to post-transcriptional 
modifications, giving rise to different “isomiRs” which may have differences in stability of 
function. In addition, miRNAs within a family may vary from each other by as little as one 
nucleotide in the sequence, so profiling methods need to be highly sensitive to be able to 
detect these differences. The copy number of different miRNA species within a cell varies 
over several orders of magnitude, and while the average copy number of a miRNA has been 
estimated to be around 500 per cells, some cell type-specific miRNAs are present at over 
10,000 copies per cells. Finally, due to their short length, variance in the CG content of 
miRNAs leads to a wide variance in melting temperatures for annealing reactions, creating 
miRNA-specific bias. There are three main techniques used for profiling miRNA expression, 
each with their own advantages and disadvantages: microarray, qRT-PCR, and high-
throughput RNA sequencing.  
 
2.5.1 Microarray Analysis 
A microarray works on the basis that RNA can hybridise specifically to complementary 
oligonucleotide target sequences which are printed onto a glass slide. Sample RNA is labelled 
with a fluorescent tag and the labelled RNA hybridises to complementary probes on the 
microarray slide. When the slide is scanned with a laser, a measurement of the fluorescence 
allows a measurement of the amount of RNA bound to that target (figure 2.5). 
Microarray analysis has the advantage of being a high-throughput method for profiling 
miRNA expression, allowing investigation of thousands of miRNAs in parallel: in this case, 
the microarray contains capture probes for all the microRNAs annotated in miRBase version 
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18. It is also relatively inexpensive. However, limitations of this approach include the fact 
that the labelling reaction can result in the addition of a large and variable number of 
nucleotides, and other RNA species may also be labelled, contributing to background noise, 
and may cross-hybridise with miRNA probes. The variation in the CG content of miRNAs 
can lead to different annealing temperatures for different miRNAs. To avoid this problem, 
LNA (locked nucleic acids) were incorporated into the array, as they have an increased 
affinity for complementary miRNA sequences. In addition, a limited range of quantification, 
imperfect specificity for some closely related miRNAs, and the inability to absolutely 
quantify miRNA means that this technique is most suited to carrying out comparisons 
between two states e.g. differentiated and undifferentiated stem cells, rather than absolute 
quantification of miRNA expression levels.  
In a traditional two-colour array, two different samples to be compared are labelled with two 
different colour fluorescent dyes, usually Cy3 (green) and Cy5 (red). The two labelled 
samples are mixed together and hybridised to a single microarray. Relative intensities of each 
fluorophore bound to each capture probe may then be used to identify up-regulated and 
down-regulated genes. In the experiments described here, a common reference approach was 
used, allowing comparison of all samples against each other. Each sample is hybridized on 
the same slide as a common reference sample, which is a mixture of all the samples used in 
the array, therefore reflecting their complexity. One colour dye is used for the sample, and the 
other for the common reference. As the reference sample is the same in all the arrays carried 
out, all samples can be directly compared with each other. This is similar in principle to 
single colour experiments, but allows for optimal inter-array performance monitoring and 
normalization, since the common reference gives a common baseline. It also minimizes the 
influence of dye specific differences on data analysis. 
Microarray analysis was used to analyse microRNA expression in samples of undifferentiated 
ESCs and iPSCs, as well as in ESCs and iPSCs that had undergone differentiation to 
definitive endoderm, as described in section 2.3. Samples were taken in triplicate, and total 
RNA, including the small RNA fraction, was isolated as described in section 2.5.2. 
Microarray hybridisation and image scanning was carried out by Exiqon Services, Denmark, 
who then supplied the raw data for analysis at NIBSC.  




Figure 2.5. Overview of microarray analysis of microRNA expression. 
 
Prior to microarray analysis, RNA yield and quality was analysed using RNA 6000 Nano 
chips on the Agilent 2100 Bioanalyzer, which is a microfluidics-based platform for sizing, 
quantification and quality control of DNA, RNA, proteins and cells. The chips contain 
sample wells, gel wells and a well for an external standard (ladder). Micro-channels create 
interconnected networks among these wells. During chip preparation, the micro-channels are 
filled with a sieving polymer (“gel”) and fluorescence dye. Then, samples and ladder with 
marker are loaded in each well. Once the wells and channels are filled, the chip becomes an 
integrated electrical circuit. Charged molecules like DNA or RNA are electrophoretically 
driven by a voltage gradient, similar to gel electrophoresis. Dye molecules intercalate into 
RNA strands and these complexes are detected by laser-induced fluorescence. Data is 
translated into gel-like images (bands) and electropherograms (peaks). The software 
automatically compares the unknown samples to the ladder fragments to determine the 
concentration of the unknown samples and to identify the ribosomal RNA peaks. The 
software also assigns an RNA integrity number (RIN) which is a measure of the quality of the 
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sample. A RIN of higher than 8 (out of maximum possible score of 10) is required for use in 
downstream applications such as microarray analysis, as a RIN lower than this indicates that 
the RNA is at least partially degraded, and this can compromise results. A typical 
electropherogram from an RNA 6000 Nano chip is shown in figure 2.6, which shows clearly 
defined peaks for the ladder, and the 18S and 28S ribosomal subunits. In a more degraded 
RNA sample, the 18S and 28S peaks would be lower, and other small peaks would also be 
present throughout the electropherogram. 
 
 
Figure 2.6. Typical electropherogram from an RNA 6000 Nano Bioanalyzer chip used to analyse RNA 
quantity and quality. The first peak shows the RNA ladder used as an external standard, while the two smaller 
peaks show the ribosomal subunits. There is little degradation of the sample, and it has a RIN of 9.5, which is 
adequate for use in further analysis. 
 
Data Analysis: The microarray slides were analysed using the NimbleGen MS200 scanner 
(Roche). Signal intensity data were extracted from the scanned images of each array using 
ImaGene9 software. Background correction, normalisation and miRNA expression analysis 
was carried out using Nexus Expression software.  
Background correction was carried out for each array slide using the Normexp background 
correction algorithm (Ritchie et al, 2007). This is based on signal intensity calculations that 
do not use subtraction to obtain a background corrected value. Using this algorithm, the 
background threshold was calculated for each array slide as 1.2x the 25
th
 percentile of the 
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overall signal intensity of the slide. miRNAs with intensities above background level in less 
than 4 of the 24 samples were removed from subsequent analysis, as when selecting 
candidates for validation, it is important to ensure that the signal intensity of the probes is 
well above the background. If microRNA capture probe signals are close to the background, 
this indicates that the microRNAs are present at a concentration that is close to or below the 
detection level of the array. For these probes, calculation of expression levels becomes 
unreliable.   
 
Figure 2.7. Before (left panel) and after (right panel) normalisation of data using Lowess normalisation. 
 
Normalisation is a mathematical adjustment of data to eliminate systemic errors such as dye 
bias and differences in labelling, hybridisation and scanning which can occur when 
performing a microarray experiment. The aim of normalisation is to enable comparison of 
data from different samples. When performing dual-colour arrays, it must be taken into 
account that the two dyes used have a different dynamic range for their concentration-
dependent light emission: for example, for low intensity signals, green fluorescent dyes show 
higher signal intensity compared to red fluorescent dues.  In these experiments, normalisation 
was performed using Lowess normalisation, which smooths the log ratio/log mean-intensity 
scatterplot to a linear distribution (figure 2.7). It works under the assumption that the majority 
of the signals between samples do not differ and enforces an equal overall mean on all signal 
intensities.  
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Comparison of miRNA Expression: For comparisons of miRNA expression between 
samples, the log fold change was calculated and compared. For this comparison, the 
calculated p-values were based on Students’ T-test. Due to the high numbers of miRNAs 
being tested in parallel, microarrays are prone to give false results. This can be controlled by 
using a multiple testing correction (Benjamini-Hochberg method) which adjusts p-values 
derived from multiple statistical tests.  
 
2.5.2 qRT-PCR for Detection of miRNA Expression 
Due to the high chance of false positives occurring during microarray analysis, the results 
need to be validated by qRT-PCR, as this is a more reliable method of analysing miRNA 
expression. Several features of miRNAs make profiling their expression levels using qRT-
PCR challenging. They are short (~22 nucleotides), which makes primer design difficult; the 
GC content of different miRNAs is heterogeneous, leading to variability in melting 
temperatures of nucleic acid duplexes between different miRNAs; mature miRNAs lack a 
common sequence feature allowing their selective purification from other RNA species e.g. a 
poly(A) tail; and the target sequence of a mature miRNA is also present in the primary and 
precursor miRNAs (for an overview of miRNA biosynthesis and processing see figure 1.10).  
In order to solve these problems, a poly(A) tail is added to miRNAs during the  reverse 
transcription of RNA to cDNA, which allows selective amplification. Addition of a universal 
tag sequence during reverse transcription allows the use of a universal primer for all miRNA 
PCR assays, together with a primer specific for the miRNA of interest. This makes primer 
design easier, and also increases the length of the amplicon so that variability in melting 
temperature can be reduced. 
  
miRNA Isolation: Total RNA, including the miRNA-containing fraction, was isolated from 
samples using the miRNeasy™ Mini Kit. Stem cell colonies were isolated by mechanical 
dissection (see section 2.2) into 700µl QIAzol lysis reagent, which contains phenol and 
guanidine thiocyanate, and is designed to facilitate cell lysis, inhibit RNases and remove 
DNA and proteins from the lysate. Lysates were incubated at room temperature for 5min. 
140µl chloroform was added to each tube, which was shaken vigorously for 15sec and then 
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incubated at room temperature for 2-3 minutes. The samples were centrifuged at 4°C for 15 
min at 12,000 x g, allowing them to separate into phases: a clear colourless aqueous phase 
(containing RNA), a white interphase (containing DNA) and a red organic phase (containing 
proteins). The upper aqueous phase (around 350µl) was transferred to a new collection tube 
and 1.5 volumes (usually 525µl) of 100% ethanol were added and mixed thoroughly by 
pipetting up and down. The sample was transferred into an RNeasy mini spin column and 
centrifuged at 8000 x g for 1 minute. The flow-through was discarded. On-column DNase 
digestion was performed as previously described.  
500µl Buffer RPE was added to the RNeasy spin column, which was centrifuged at 8000 x g 
for 1 minute to wash the column. Another 500µl was added to the RNeasy spin column, 
which was centrifuged at 8000 x g for 2 minutes to dry the column. The column was 
transferred to a new 2ml collection tube and centrifuged at 13000rpm for 1 minute. The 
column was transferred to a 1.5ml collection tube and 30µl of RNase-free, DNase-free PCR-
grade water was pipetted directly onto the spin column membrane. The tube was centrifuged 
for 1 minute at 8,000 x g to elute the RNA. The eluate was reapplied to the spin column 
membrane and centrifuged at 8000 x g for 1min to maximise RNA concentration. Isolated 
total RNA was stored at -80°C. 
 
Reverse Transcription Of microRNA into cDNA: The miScript™ reverse transcription kit was 
used to reverse transcribe miRNA into cDNA. The reverse transcription kit includes miScript 
reverse transcriptase mix, which is a blend of enzymes comprising a poly(A) polymerase and 
a reverse transcriptase, and miScript RT buffer, which contains Mg
2+
, dNTPs, Oligo-dT 
primers and random primers. The poly(A) polymerase adds a poly(A) tail to the miRNA, 
while the Oligo-dT primers add a universal tag sequence on the 5’ end, which allows binding 
of the universal primer during the PCR step. Polyadenylation of miRNAs and reverse 
transcription are carried out in parallel in the same step.  
Total RNA and reverse transcriptase were thawed on ice. MiScript™ RT buffer and RNase-
free water were thawed at room temperature. The reverse transcription master mix was 
prepared on ice according to table 2.16 and added to template RNA. The reverse transcription 
reaction was carried out at 37°C for 60minutes followed by 95°C for 5 minutes to inactivate 
the reverse transcriptase. The cDNA samples were stored at -20°C.  
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Reverse Transcription Mix 
Reagent Volume Needed For One Reaction (µl) 
5x miScript™ RT Buffer 4 
RNase-free water 5 
miScript™ Reverse Transcriptase Mix 1 
RNA 10 
Total 20 
Table 2.16. Reagents and volumes needed for the reverse transcription reaction. 
 
qRT-PCR For Detection Of miRNA Expression: PCR analysis of mature miRNA was carried 
out using a forward primer specific for the miRNA of interest in combination with the 
miScript™ SYBR Green PCR kit, which contains a universal primer used in all miRNA 
PCRs, using the reaction mix shown in table 2.17. 18µl of master mix was added to 2µl of 
cDNA. Standard dilutions were prepared as described in section 2.4.2 and run together with 
the samples of interest. A standard curve for a reference gene was also set up following the 
same procedure in order to enable normalisation of any results. A negative control in which 
the template cDNA was replaced with water was also included in each reaction. PCR 
reactions were carried out on the Qiagen Rotor-Gene™ 6000 using the reaction conditions as 
follows: 15min at 95°C; 40 repeated cycles of 15sec at 94°C, 30sec at 55°C and 30sec at 
70°C. The fluorescence was acquired at the end of the extension step. A melt curve analysis 
was carried out to ensure amplification of a single product. 
 
PCR Master Mix 
Reagent Volume Needed For One Reaction (µl) 
2x QuantiTect SYBR Green PCR Master Mix 10 
10x miScript Universal Primer 2 
10 miScript Primer Assay 2 
PCR-grade Water 4 
cDNA 2 
Total 20 
Table 2.17. qRT-PCR reaction mix for detection of miRNA 
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2.5.3 Identification of Gene Targets of miRNAs 
Identifying miRNA targets in mammals is challenging, largely due the limited 
complementarity between miRNAs and their target mRNAs, and the fact that the interactions 
between miRNAs and their target genes are still not entirely understood. The lack of high 
throughput experimental methods for miRNA target identification means relying on target 
prediction algorithms. Several independent groups have established computational algorithms 
designed to predict target genes of miRNAs (reviewed in Rajewsky, 2006) 
miRNA targets usually have at least one region that has complementary base pairing to the 
“seed” sequence at the 5’ end of the miRNA. Most miRNA recognition sites can be found 
within the 3’ untranslated region (UTR) of the target mRNA, although in theory miRNAs 
could bind to any part of the mRNA (Saito & Saetrom, 2010). Complete complementarity 
between a miRNA and a target mRNA is rare, but as little as a 6-base pair match is sufficient 
to suppress gene expression, because RISC can tolerate small mismatches within the seed 
region (Thomson et al., 2011).  
No existing target prediction software has been able to include all the currently known 
features of miRNA-target interactions, which include: 1) Complementarity to the miRNA 
seed sequence: when predicting targets of miRNAs, considering only perfectly 
complementary seed types increases specificity but might miss many potential targets, while 
considering moderately complementary seed types as well increases sensitivity but is also 
likely to increase the number of false positives; 2) Evolutionary conservation of the target site 
among different species by comparative sequence analysis: in order to reduce the number of 
false positives, several target prediction algorithms perform conservation analysis across 
species. However, even conserved miRNAs have a large number of non-conserved targets. 
There are also numerous miRNAs that are not conserved between species (Witkos et al., 
2011); 3) Free energy of the miRNA-mRNA complex: this can help determine the likelihood 
of binding between a miRNA and an mRNA, although since data sets of identified miRNA-
mRNA duplexes are very limited, and a low free energy of hybridisation does not guarantee 
accurate prediction of miRNA target genes, it is difficult to resolve appropriate thresholds of 
free energy; 4) mRNA sequence features outside the target site: some target prediction 
algorithms take into account target site accessibility i.e. the free energy cost of unfolding the 
mRNA secondary structure surrounding the target site to assess the likelihood of binding 
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between a miRNA and an mRNA; 5) The presence of multiple target sites: strong miRNA 
targets tend to have multiple target sites within their mRNA sequence (Saito & Saetrom, 
2010), as many miRNAs are co-expressed and are likely to regulate the same mRNA co-
ordinately. Multiple target sites in the same 3’ UTR can potentially increase translation 
suppression and enhance specificity of gene regulation (Min & Yoon, 2010). Although the 
effect of multiple target sites generally seems to be additive, miRNA targeting can also be 
synergistic (Saito & Saetrom, 2010).  
Different target prediction programs use different combinations of these features in order to 
predict miRNA targets. TargetScanS requires perfect complementarity with 7 or more bases 
of the miRNA seed region, and conservation between at least 5 species for the portion of the 
target site that binds to the miRNA seed. The seed match must occur at exactly corresponding 
positions in a cross-species UTR alignment. In addition, it adds a context score which takes 
mRNA sequence features outside of the target site into account. The estimated false positive 
rate is 22%, and all known miRNA-target interactions were successfully predicted (with no 
false negatives) (Min & Yoon, 2010).  
PicTar combines base-pairing and thermodynamic stability by allowing targets with 
imperfect seed matching providing they pass a strict free energy cut-off for imperfect 
matches. It also requires that the seed match occur at overlapping positions in a cross-species 
UTR alignment for at least 5 species. In addition, it considers clustering of co-expressed 
miRNAs, matching miRNAs with targets that are expressed in the same context and requires 
binding sites that are co-regulated by multiple miRNAs across species. It has an estimated 
precision level of >60% (Min & Yoon, 2010). 
miRanda selects target genes on the basis of three properties: 1) sequence complementarity, 
using a modified dynamic programming approach that recognises the importance of seed 
binding but does not require perfect seed complementarity; 2) the free energy of miRNA-
mRNA complexes; and 3) the conservation of target sites. The entire target site must occur 
with at least 90% identity at exactly corresponding positions in a cross-species UTR 
alignment. It only requires conservation between human and rodent genomes, but also has the 
additional option of including more extensive species conservation. miRanda has an 
estimated false-positive rate of ~24% and was able to correctly identify 9/10 previously 
validated targets (Min & Yoon, 2010).  
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DIANA-microT uses a sequence of 38 nucleotides to progressively go through a 3’UTR of a 
potential target in order to identify possible miRNA recognition elements (MREs). It 
calculates the minimum binding energy at each step, which is compared with the outcomes 
obtained from scrambled sequences with the same dinucleotide content as real 3’ UTRs. 
DIANA-microT allows a weak binding at the 5’ seed region, unlike TargetScan and PicTar, if 
there is additional base pairing between the 3’ end of the miRNA and the target gene. In 
addition, it only requires conservation between human and rodent. DIANA-microT is 
reported to have the highest precision level of all prediction software at 66% (Min & Yoon, 
2010), and its web server contains links to UniProt for protein information; iHOP for 
functional and bibliographic information; miRBase for miRNA information; and KEGG 
pathway for pathway analysis.  
PITA combines the free energy cost of unfolding the secondary structure of the mRNA 
surrounding the target site with the free energy cost of miRNA-mRNA pairing in order to 
predict miRNA targets, and does not rely on conservation between species.  
Algorithms used for predicting targets typically predict hundreds if not thousands of target 
genes for each miRNA, most of which are not true targets (Thomas et al., 2010). The false 
positive rate of prediction algorithms has been variously reported as between 24-70% 
(Thomson et al., 2011). This underscores the need for experimental data to demonstrate 
genuine miRNA targets and functions. Combining results from multiple prediction programs 
is encouraged in order to reduce the probability of false positives/negatives. TargetScanS, 
miRanda and PicTar are the most commonly used (Min & Yoon, 2010). In a comparison of 
target prediction programs, TargetScanS, PicTar and miRanda used either alone or in 
combination had the best trade-off between sensitivity and specificity (Witkos et al., 2011). 
Although the union of all target prediction programs achieves the highest sensitivity, it also 
achieves the lowest specificity. Conversely, although the intersection of all programmes 
achieves the highest specificity, it also achieves the lowest sensitivity (Sethupathy et al., 
2006). Target prediction algorithms also sometimes fail to predict biologically relevant 
targets. Many genes identified by overexpression or silencing of miRNAs in combination 
with microarray analysis were not predicted by target prediction software, which can largely 
be explained by the application of stringent criteria regarding the evolutionary conservation 
of putative binding sites (Krutzfeldt et al., 2006).  
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In addition, many resources are now available to extend the usefulness of target prediction 
programs. TarBase is a database containing miRNA targets that have been experimentally 
validated, and is linked to other databases to extend information about miRNAs and their 
target genes. miRecords curates predicted targets generated by 11 different prediction 
programs, and also includes validated targets together with their prediction results. miRGator 
integrates target prediction (combining TargetScan, MiRanda and PicTar), functional 
analysis, gene expression data and genome annotation. GoMir combines JTarget and 
TAGGO. JTarget integrates target prediction from 4 programs (TargetScan, miRanda, 
RNAhybrid, PicTar) and an experimental database (TarBase) while TAGGO performs GO 
clustering with the common genes obtained from JTarget and analyses how many target 
genes share a common GO category. MMIA finds target mRNAs by combining 
computational prediction results and expression data analysis, based on the fact that the 
expression of a miRNA must be reciprocal to that of its target mRNA. 
 
2.5.4 Luciferase Assay in 293FT Cells 
In order to determine whether miRNAs were acting directly by binding to genes which had 
been identified as putative targets, a luciferase assay was carried out in which a miRNA 
mimic or inhibitor were co-transfected into 293FT cells together with a reporter plasmid 
carrying a Gaussia luciferase gene and the 3’UTR of the gene of interest, which is where the 
majority of miRNA-target interactions occur. The 3’UTR plasmid is shown in figure 2.8. The 
plasmids encoded in the lentiviral vectors used to knockdown or overexpress miRNAs are 
shown in figures 2.9 and 2.10, respectively. Both vectors contain a reporter gene (eGFP for 
the mimic, and mCherry for the miRNA inhibitor), allowing monitoring of transfection 
efficiency. The effects of manipulating miRNA expression were analysed using qRT-PCR, as 
described in section 2.4.3. 
An overview of the luciferase assay is shown in figure 2.11. If the gene is a direct target of 
the miRNA of interest, the miRNA (either transfected or present endogenously in the cell) 
binds to the 3’UTR and degrades it. The luciferase gene is not translated and no luminescence 
is observed.  However, when an inhibitor of the miRNA is transfected into the cells, it 
prevents miRNA binding to the 3’UTR. The luciferase gene is translated, resulting in 
luminescence which can be detected using a luminometer. In this case, a plasmid was used 
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which also contained a reporter gene, secreted alkaline phosphatase (seAP), which allows 
normalisation of luminescence measurements between different samples. In addition to the 
3’UTR plasmid, a control plasmid was also used which has a scrambled sequence in place of 
the 3’UTR which does not correspond to any known miRNA binding sites. Scrambled 
miRNA mimic and inhibitor lentiviral vectors were also included as negative controls. 
 293FT cells were maintained in culture as described in section 2.1.1. 24hrs prior to infection, 
293FT cells were trypsinised and plated at a density of 3x10
4
 cells per well of a 24-well plate 
in 293FT medium, giving a confluency of 60-70%. After 24hrs, the medium was removed 
from the cells, and they were washed once with Opti-MEM reduced serum medium. 0.5ml of 
Opti-MEM supplemented with 4µg/ml Polybrene was added to each well, and 10µl of 
lentivirus or 1µl of control lentivirus (giving a MOI of approximately 10) was added to the 
cells according to the plate map shown in table 2.20. After 5-6 hours, the medium on the cells 
was replaced with 293FT medium. The medium was changed again the next day. 72hrs after 
infection with lentivirus, cells were transfected with the 3’UTR-containing plasmid. Cells 
were washed once with Opti-MEM and 0.5ml of Opti-MEM was added to the cells. 2.5µl of 
Lipofectamine 2000 transfection reagent was diluted in 25µl of Opti-MEM. 500ng of plasmid 
DNA was diluted in 50µl of Opti-MEM and the DNA and Lipofectamine were combined and 
incubated at room temperature for 5mins. The DNA-Lipofectamine mixture was then added 
to the cells according to the plate map shown in table 2.19. The cells were incubated for 5-
6hrs at 37C, 5% CO2 before the medium on the cells was replaced with 293FT medium. The 










Figure 2.8. Plasmid used in luciferase assays to determine miRNA-target relationships. The plasmid contains 
the 3’UTR of the gene of interest coupled to a luciferase gene which allows monitoring of miRNA binding to this 
region. This plasmid also contains a constitutively expressed reporter gene (alkaline phosphatase) which allows 
normalisation of luminescence measurements between different samples. 
 
 
Figure 2.9 miArrest™ lentiviral vector used to repress expression of miRNAs of interest. The vector contains 
the miRNA inhibitor sequence, as well as a mCherry reporter gene and an antibiotic resistance gene 
(hygromycin) which allows stable selection of transfected cells. 
 
 
Figure 2.10 miExpress™ lentiviral vector used to overexpress miRNAs of interest. The vector contains the 
precursor miRNA sequence, as well as an eGFP reporter gene and an antibiotic resistance gene (puromycin) 
which allows stable selection of transfected cells. 
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Table 2.18. Plate map used in luciferase assays. 
 
72hrs after plasmid transfection, the culture medium was collected and analysed for 
luminescence using the SecretePair™ Dual Luminescence Assay Kit. Two luminescence 
measurements were taken, one for Gaussia luciferase (GLuc), which is the reporter for 
miRNA binding, and one for secreted alkaline phosphatase (seAP), which is constitutively 
expressed and can be used to normalise GLuc measurements between samples.  
For measurement of GLuc, the GL-S buffer was used. The 10x buffer was thawed at room 
temperature and then vortexed to mix. 100µl of 1x buffer was prepared per sample by 
diluting 1:10 in distilled water. The GLuc assay working solution was prepared by adding 
10µl of substrate GL to 1ml of buffer GL-S. This was mixed well and incubated at room 
temperature in the dark for 25mins. 10µl of each sample was added to a well of a 96-well 
plate. 100µl of GLuc assay working solution was added to each well and gently mixed. The 
plate was incubated at room temperature for 1min before measuring luminescence.  
For measurement of seAP, 50ul of medium from each sample was heated at 65ºC for 10-
15min and then cooled on ice. 10x buffer AP was thawed at room temperature and then 
vortexed to mix. 100µl of 1x buffer was prepared per sample by diluting 1:10 in distilled 
water. The seAP assay working solution was prepared by adding 10µl of Substrate AP to 1 
ml of 1x buffer AP. This was mixed well and incubated at room temperature in the dark for 
5-10mins. 10µl of each sample was added to a well of a 96-well plate. 100µl of seAP assay 
working solution was added to each well and gently mixed. The plate was incubated at room 
temperature for 5-10mins before measuring luminescence with the luminometer. To obtain 
normalised luminescence measurements, the GLuc readings were divided by the seAP 





Figure 2.11. Overview of luciferase assay to detect miRNA-target interactions. Cells are transfected with a plasmid containing a luciferase gene and the 3’UTR of the gene 
of interest. The cells are then transfeted with i) a miRNA mimic; ii) a miRNA inhibitor; iii) both a miRNA mimic and inhibitor. When the miRNA of interest (either transfected 
or present endogenously in the cell) binds to the 3’UTR, it is degraded and there is no luciferase expression. However when the miRNA of interest is prevented from binding 
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Chapter 3: Generation & Characterisation 
of Induced Pluripotent Stem Cell Lines 
 
3.1 Introduction 
Embryonic stem cells (ESCs) were first derived from blastocyst-stage mouse embryos in 
1981 (Evans & Kaufman, 1981; Martin, 1981), although it took a further 17 years for the first 
derivation of human ESC (hESC) lines to be reported (Thomson et al., 1998). These cells 
have two defining characteristics: firstly, they can self-renew in culture indefinitely, and 
secondly, they are pluripotent i.e. they can give rise to any cell in the body. They also display 
cell surface markers including SSEA-3, SSEA-4, the keratan sulphate antigens TRA-1-60 and 
TRA-1-81, and alkaline phosphatase, and also have high telomerase activity, showing that 
these cells are capable of extensive replication (Thomson et al., 1995; Thomson et al., 1996).  
In 2006, a significant advance in the field of stem cell research was made with the discovery 
that 4 pluripotency-associated transcription factors (OCT4, KLF4, c-MYC and SOX2) could 
reprogram somatic cells into induced pluripotent stem cells (iPSCs). Reprogramming was 
initially carried out in mouse fibroblasts (Takahashi and Yamanaka, 2006), and 
reprogramming of human fibroblasts was achieved a year later (Takahashi et al., 2007; Yu et 
al., 2007). Since then, iPSCs have been generated from numerous different human cell types, 
as well as from several other species, including rhesus monkey. These cells were shown to be 
similar to ESCs in terms of their morphology and gene expression, and were karyotypically 
normal. Although iPSCs from this first experiment were not germline-competent, they were 
able to give rise to all three germ layers in vitro. Germline-competent iPSCs have since been 
generated (Okita et al., 2007). 
In the past few years, standards for the characterisation of ESCs and iPSCs have become 
widely accepted (Brivanlou et al, 2003; Maherali & Hochedlinger, 2008). Assessing the 
success of reprogramming into iPSCs starts with the identification of compact colonies that 
have distinct borders and well-defined edges, which consist of cells which have a large 
nucleus, large nucleoli and little cytoplasm. Pluripotent stem cells also have a short cell cycle 
with a truncated G1 phase, resulting in rapid growth (Smith et al, 2009). Molecular markers 
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which allow the identification of fully reprogrammed iPSCs include the expression of a 
network of pluripotency genes, including Oct4, Sox2 and Nanog, at comparable levels to 
ESCs; as well as the expression of a number of extracellular markers including SSEA-3/4, 
TRA-1-81 and TRA-1-60 (Maherali & Hochedlinger, 2008). Alkaline phosphatase has been 
widely used as a marker for pluripotency, but evidence shows this to be insufficient to 
identify fully reprogrammed iPSCs, as cells that have been only partially reprogrammed may 
also stain  positive (Chan et al, 2009). iPSCs must also be able to maintain their pluripotency 
independently of viral transgene expression, and be epigenetically similar to ESCs, with 
DNA demethylation at the promoters of pluripotency genes, X chromosome reactivation in 
female cells, and the presence of bivalent chromatin domains at developmental genes 
(Maherali & Hochedlinger, 2008). In addition, profiling of microRNA expression in 
pluripotent stem cells revealed a set of miRNAs that are uniquely expressed in pluripotent 
stem cells (Suh et al, 2004) which could potentially be used as an additional test for 
pluripotency.  
Analysis of the pluripotency of mouse iPSCs can be rigorously assessed through the 
generation of chimaeric mice, which evaluates the potential of iPSCs to contribute to the 
normal development of adult tissues when injected into the blastocyst. Germline transmission 
is assessed by the ability of these chimaeras to give rise to offspring derived entirely from 
iPSCs which have the genomic integrity of the injected iPSC line and the ability to form 
functional germ cells (Okita et al., 2007). The test with the highest stringency is tetraploid 
complementation, which involves the injection of iPSCs into blastocysts to measure the 
ability of iPSCs to direct the normal development of an entire organism. This test has only 
been accomplished for a small number of iPSC lines, and it appears that not all iPSC lines are 
able to contribute to all-iPSC mice (Stadtfeld et al, 2010). Due to ethical constraints, these 
tests for pluripotency cannot be carried out for human iPSCs. The most common method of 
assessing the pluripotency of hiPSCs is differentiation in vitro, either as embryoid bodies 
(compact balls of cells that form loosely organised tissues which resemble the gastrulating 
embryo) or in monolayer cultures, in order to assess the differentiated cells for markers of all 
three embryonic germ layers. The teratoma formation assay involves measuring the ability of 
iPSCs to differentiate into all three germ layers in vivo following injection of undifferentiated 
cells into immunodeficient mice. Although this is the most stringent assay available for 
testing the pluripotency of human iPSCs, it does not assess whether the iPSCs are able to give 
rise to every cell in the body, nor does it assess the contribution of the iPSCs to the germline 
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(Robinton & Daley, 2012). In addition, the ethical considerations of using lab animals for a 
routine pluripotency test, particularly where numerous iPSC lines need to be assessed, means 
that there has been a move away from the teratoma formation assay in favour of in vitro tests.  
Reprogramming to pluripotency is a stochastic process that results in the production of a wide 
range of colony morphologies, and while some of them may initially appear similar to ESCs, 
morphology alone cannot be used to identify pluripotent stem cells. It is important to fully 
characterise cells in order to identify true, fully reprogrammed iPSCs with which to conduct 
further experiments.  
 
3.2 Methods 
3.2.1 Generation of induced pluripotent stem cells 
iPSCs were generated using retroviral infection of HFF1 fibroblasts, which were obtained 
from the UK Stem Cell Bank, as described in section 2.1. Briefly, fibroblasts were infected 
first with a lentiviral vector carrying the mSlc7a1 retroviral receptor, and subsequently with 
retroviral vectors carrying the four reprogramming factors (OCT4, SOX2, KLF4 and C-
MYC) and GFP. Infected cells were treated with valproic acid and seeded onto iSNL feeder 
cells. Pluripotent stem cell colonies typically appeared 2-3 weeks following retroviral 
infection. ESC lines were also obtained from the UK Stem Cell Bank. Full details of these 
ESC lines can be found in the NIH registry 
(www.grants.nih.gov/stem_cells/registry/current.htm). A full summary of the lines used in 
this project and the characterisation carried out on them is shown in table 3.1.  
 
3.2.2 Maintenance of pluripotent stem cells in culture 
Stem cells were grown either on mitotically-inactivated feeder cells (iSNLs), which were 
inactivated as described in section 2.2.1, or on the soluble basement membrane extract 
Matrigel™, which was prepared as described in section 2.2.3. Stem cells grown on feeders 
were maintained in knockout serum replacement medium, while stem cells grown on 
Matrigel™ were maintained in mTeSR1™ defined medium. Stem cells were kept at 37°C, 
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5% CO2. Undifferentiated stem cells were passaged using manual dissection as described in 
section 2.2.2, and were cryopreserved as described in section 2.2.5. 
 
3.2.2 Characterisation of pluripotent stem cells 
In order to confirm the pluripotency of the stem cell lines used in this study, qRT-PCR was 
used to analyse expression levels of genes associated with pluripotency and differentiation 
into the three embryonic germ layers. Briefly, total RNA was isolated using the RNeasy Mini 
Kit. Reverse transcription of total RNA into cDNA was carried out as described in section 
2.4.1. qRT-PCR was carried out using the cycling conditions described in section 2.4.3. 
Expression of pluripotency genes was also confirmed using immunocytochemistry. The 
antibodies used are listed in table 2.16. Cells were either fixed with 4% paraformaldehyde 
before staining or were stained using a live cell stain, as described in section 2.4.4. Alkaline 
phosphatase expression levels were visualised using the alkaline phosphatase detection kit. 
Colonies were visualised using a Nikon Eclipse TS100 inverted microscope.  
  


















H9 ESC n/a n/a n/a 
Matrigel 
mTeSR-1™ 
TRA-1-60 live cell stain 
qRT-PCR for pluripotency genes 
Immunocytochemistry for pluripotency 
genes 
qRT-PCR for exogenous transgenes 
qRT-PCR for spontaneous differentiation. 
Alkaline phosphatase staining 
Used as positive control in characterisation 
experiments (chapter 3). 
Used in differentiation experiments (chapter 4) 
Used in miRNA microarray and validation 
experiments (chapter 5) 
Used in miRNA functional experiments (chapter 6) 
H7 ESC n/a n/a n/a 
Matrigel 
mTeSR-1™ 
TRA-1-60 live cell stain 
qRT-PCR for pluripotency genes 
Immunocytochemistry for pluripotency 
genes 
qRT-PCR for exogenous transgenes 
qRT-PCR for spontaneous differentiation 
Used in differentiation experiments (chapter 4) 
Used in miRNA microarray and validation 
experiments (chapter 5) 
H1 ESC n/a n/a n/a 
iSNL feeders 
KOSR medium 
TRA-1-60 live cell stain 
qRT-PCR for pluripotency genes 
Immunocytochemistry for pluripotency 
genes 
qRT-PCR for exogenous transgenes 
qRT-PCR for spontaneous differentiation 
Alkaline phosphatase staining 
Used in differentiation experiments (chapter 4) 
Used in miRNA microarray and validation 
experiments (chapter 5) 







TRA-1-60 live cell stain 
qRT-PCR for pluripotency genes 
Immunocytochemistry for pluripotency 
genes 
qRT-PCR for exogenous transgenes 
qRT-PCR for spontaneous differentiation 
Alkaline phosphatase staining 
Used in differentiation experiments (chapter 4) 
Used in miRNA microarray and validation 
experiments (chapter 5) 







qRT-PCR for pluripotency genes 
Immunocytochemistry for pluripotency 
genes 
qRT-PCR for exogenous transgenes 
qRT-PCR for spontaneous differentiation 
Alkaline phosphatase staining 
Used in differentiation experiments (chapter 4) 
Used in miRNA microarray and validation 
experiments (chapter 5) 







TRA-1-60 live cell stain 
Incompletely reprogrammed 
Passage discontinued after p6 
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TRA-1-60 live cell stain 
Incompletely reprogrammed 










TRA-1-60 live cell stain 
qRT-PCR for pluripotency genes 
Immunocytochemistry for pluripotency 
genes 
qRT-PCR for exogenous transgenes 
qRT-PCR for spontaneous differentiation 
Alkaline phosphatase staining 
Used in characterisation experiments (chapter 3) 










TRA-1-60 live cell stain 
qRT-PCR for pluripotency genes 
Immunocytochemistry for pluripotency 
genes 
qRT-PCR for exogenous transgenes 
qRT-PCR for spontaneous differentiation 
Alkaline phosphatase staining 
Used in characterisation experiments (chapter 3) 







TRA-1-60 live cell stain 
qRT-PCR for pluripotency genes 
Immunocytochemistry for pluripotency 
genes 
qRT-PCR for exogenous transgenes 
qRT-PCR for spontaneous differentiation 
Alkaline phosphatase staining 
Used in characterisation experiments (chapter 3) 







TRA-1-60 live cell stain 
qRT-PCR for pluripotency genes 
Immunocytochemistry for pluripotency 
genes 
qRT-PCR for exogenous transgenes 
qRT-PCR for spontaneous differentiation 
Alkaline phosphatase staining 
Used in characterisation experiments (chapter 3) 
 
Table 3.1. Summary of pluripotent stem cell lines used and characterisation carried out. 
 





3.3.1 Generation of New iPS Cell Lines 
iPSCs were generated from HFF1 fibroblasts by retroviral infection of four reprogramming 
factors: OCT4, SOX2, KLF4, and C-MYC. During reprogramming, a sub-population of cells 
was also infected with retroviral vector encoding GFP, which allows monitoring of infection 
efficiency in both PlatE cells and fibroblasts. Infection efficiency must be high in order for 
fibroblasts to receive adequate levels of all four of the reprogramming factors. Figure 3.1 
shows that both PlatE packaging cells and infected fibroblasts express high levels of GFP 
using these infection conditions. Expression of GFP is maintained after the infected 
fibroblasts are passaged onto feeder cells. 
 
Figure 3.1 GFP expression during reprogramming shows that both PlatE cells (day 12) and fibroblasts (day 
15) have been successfully infected with the GFP plasmid. Expression of GFP is maintained after the infected 
fibroblasts are passaged onto feeder cells (day 19). 10x magnification, scale bar 100µm. 
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During reprogramming, fibroblasts were either infected with both the mouse Slc7a1 
retrovirus receptor and the reprogramming factors (mSlc OKSM), reprogramming factors 
only (neg OKSM) or not infected at all (neg neg).  Twelve days post-infection, cells 
expressing the mSlc receptor which had been infected with the reprogramming factors had 
changed their morphology and were starting to form colonies that closely resembled 
pluripotent stem cells, while the cells which did not express the Slc receptor remained 
fibroblastic in appearance (figure 3.2, panel A). This demonstrates the importance of 
infecting the fibroblasts with the mouse retrovirus receptor during the reprogramming 
process, as it allows subsequent infection with the retroviral vectors containing the 
reprogramming factors. The cells that formed stem cell-like colonies could be cultured and 
passaged onto new feeders (figure 3.2, panel B) and subsequently maintained in culture as 
described in section 2.2.  
 
 
Figure 3.2. Formation of stem cell-like colonies after transfection of HFF1 fibroblasts with reprogramming 
factors. A) Fibroblasts expressing the mSlc receptor and infected with the reprogramming factors (mSlc OKSM) 
formed stem cell-like colonies, while those infected with only the reprogramming factors (neg OKSM) or not 
infected at all (neg neg) did not. B) Stem cell-like colonies could be passaged. 10x magnification, scale bar 
100µm. 
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3.3.2 Characterisation of New iPSC Lines 
A summary of the pluripotent stem cell lines used in subsequent experiments and the 
characterisation carried out for each line is shown in table 3.1.  
 
Characterisation of Newly Reprogrammed Lines Identifies Incomplete Reprogramming 
iPSCs cannot be identified by their morphology alone, since reprogramming of somatic cells 
results in a wide range of cells that are at different stages of the reprogramming process. 
Some are fully reprogrammed true iPSCs, but others are only partially reprogrammed and do 
not fulfil all of the criteria for pluripotency. This was demonstrated by an early 
reprogramming experiment, in which fibroblasts were reprogrammed and formed colonies 
that strongly resembled iPSC colonies (HFFA and HFFB lines), but which on further 
investigation were found to be incompletely reprogrammed.  
 
Immunocytochemistry  
The first check for pluripotency is live cell staining to investigate expression of TRA-1-60, a 
surface marker characteristic of pluripotent stem cells. Since this marker is expressed on the 
cell surface, the cells do not need to be fixed and permeabalised prior to staining, allowing 
continued culture and passage of the cells after staining. This is particularly useful at early 
stages of characterisation, when numbers of cells available for analysis are limited. Cells 
were cultured as described in section 2.2.2 for at least 5 days before staining with TRA-1-60 
StainAlive dye as described in section 2.4.4. Figure 3.3 shows high levels of TRA-1-60 
expression in an ESC line (H1), but no expression in the newly reprogrammed lines HFFA 
and HFFB, indicating that these cells are not true pluripotent iPSCs.  
 
Figure 3.3. Immunocytochemistry for TRA-1-60 expression using live cell stain. 10x magnification, scale bar 
10µm 





Figure 3.4. qRT-PCR showing expression levels of key pluripotency genes in an ESC line (H1), an established 
iPSC line (MRC5I), two newly reprogrammed cell lines (HFFA and HFFB), and the starting fibroblast cell line 
(HFF1).  
 
Cells were further characterised using qRT-PCR as described in section 2.4 to investigate 
expression levels of key pluripotency genes, including the four exogenous reprogramming 
factors Oct4, Sox2, Klf4 and C-Myc, as well as the additional pluripotency-associated genes 
Rex1, Nanog, and Tdgf. Analysis of variance with Fisher’s a priori test was performed to 
determine significant differences between groups. 
Figure 3.4 shows that the partially reprogrammed cells (HFFA and HFFB) both have 
significantly (p = 0.002, n = 3) lower levels of expression of pluripotency genes than either 
an ESC line (H1) or established iPSC line (MRC5I), which both have similar high expression 
levels of pluripotency genes. The expression levels of pluripotency genes in the newly 
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reprogrammed cells are not significantly different from those in the starting fibroblast 
population (HFF1), showing that they have failed to activate endogenous pluripotency genes. 
Characterisation of Completely Reprogrammed iPSCs  
Cells generated in a subsequent reprogramming experiment were fully characterised and 
found to fulfil pluripotency criteria, and these were used in subsequent experiments. All iPS 
cell lines used in these experiments had a stable, ESC-like morphology and growth pattern 
(figure 3.5). They could be expanded in culture for more than 10 passages, and made viable 
frozen stocks.  
 
Figure 3.5 Morphology of stem cell colonies. A) iPSC colony maintained on iSNL feeders, B) iPSC colony 
maintained on Matrigel™, C) ESC colony maintained on iSNL feeders, D) ESC colony maintained on 
Matrigel™.   
 
Immunocytochemistry 
Cells were characterised at an early stage (p2) by TRA-1-60 live cell staining to determine 
whether the colonies generated were true pluripotent stem cell colonies. Figure 3.6 shows 
high levels of TRA-1-60 expression in an ESC line (H1), two established iPSC lines (MRC5I 
and MRC9G) and three newly reprogrammed cell lines (Wild7, Wild12 and Wild17). This 
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indicates that these colonies are likely to be fully reprogrammed. TRA-1-60
+
 colonies were 
selected for further passaging, while TRA-160
-
 colonies were discarded. 
 
 
Figure 3.6. Immunocytochemistry for TRA-1-60 expression using live cell stain in an ESC line (H1), two 
established iPSC lines (MRC5I and MRC9G), and three newly reprogramed iPSC lines (Wild7, Wild12 and 
Wild17).10x magnification, scale bar 100µm.  
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Undifferentiated pluripotent stem cells are also characterised by high levels of alkaline 
phosphatase, an enzyme that is ubiquitously expressed in undifferentiated human pluripotent 
stem cells, embryonic carcinoma cells and embryonic germ cells (Thomson et al, 1998). It 
can be stained using a Napthol/Fast Red Violet staining solution. Figure 3.7 shows that both 
an ESC line (H1) and two iPSC lines (MRC9G and MRC5I) all have high levels of alkaline 
phosphatase, while a differentiated stem cell colony does not.  
 
 
Figure 3.7. Alkaline phosphatase staining in an ES cell line (H1) and two iPS cell lines (MRC5I and MRC9G) 
grown on iSNL feeders. 2x magnification. 
 
Once adequate cell numbers had been obtained, immunocytochemistry for several other 
pluripotency markers could be carried out on cells that had been fixed and permeabalised, as 
described in section 2.4.4. Control dishes were prepared at the same time, using both a 
secondary antibody only and isotype control (data not shown). Cells were counter-stained 
with Hoescht DNA stain. The cells were visualised using a Nikon Eclipse TS100 inverted 
microscope. Figures 3.8, 3.9, 3.10 and 3.11 show immunocytochemistry for several important 
pluripotency markers in four newly reprogrammed iPSC lines, including the transcription 
factors OCT4 and NANOG, as well as two stem cell-specific surface markers, SSEA-3 and 
TRA-1-81. All four cell lines show high expression of all of these markers at the protein 
level, confirming their pluripotency.  





Figure 3.8. Expression of the pluripotency markers OCT4, NANOG, 
SSEA-3 and TRA-1-81 in a newly reprogrammed iPSC line. 10x 
magnification, scale bar 100µm. 
Figure 3.9. Expression of the pluripotency markers OCT4, NANOG, 
SSEA-3 and TRA-1-81 in a newly reprogrammed iPSC line. 10x 
magnification, scale bar 100µm. 
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Figure 3.11 Expression of the pluripotency markers OCT4, NANOG, 
SSEA-3 and TRA-1-81 in a newly reprogrammed iPSC line. 10x 
magnification, scale bar 100µm. 
Figure 3.10. Expression of the pluripotency markers OCT4, NANOG, 
SSEA-3 and TRA-1-81 in a newly reprogrammed iPSC line. 10x 
magnification, scale bar 100µm. 





Expression levels of key pluripotency genes were investigated in undifferentiated ESCs and 
iPSCs using qRT-PCR as described in section 2.4.3. Analysis of variance with Fisher’s a 
priori test was performed to determine significant differences between groups. 
Figure 3.12 shows that all four newly reprogrammed cell lines (Wild7, Wild11, Wild12 and 
Wild17) have significantly (p < 0.005, n = 3) higher expression of several pluripotency-
associated genes, including Oct4, Sox2, Klf4, C-Myc, Nanog, Rex1, and Tdgf, than the 
starting fibroblast line (HFF1). Expression levels in new iPSC lines are not significantly 
different from an ESC line (H9), confirming the pluripotency of these cells.  
Another requirement for a cell line to be considered pluripotent is silencing of the exogenous 
transgenes used in reprogramming (Okita et al, 2007; Wernig et al, 2007), demonstrating that 
the cell line is capable of up-regulating endogenous pluripotency gene expression and 
therefore maintaining pluripotency independently of the exogenous reprogramming factors. 
Expression levels of the factors used in reprogramming were investigated in HFF1 fibroblasts 
(HFF1 uninfected), HFF1 cells that had received both the mouse retrovirus receptor and the 
reprogramming factors (HFF1 mSlc OKSM), HFF1 cells that had received the mouse 
retrovirus receptor only (HFF1 mSlc neg), four new iPSC lines (Wild7, Wild11, Wild12 and 
Wild17) and an ESC line (H9). Figure 3.13 shows that there is little or no expression of 
exogenous OCT4, SOX2, KLF4 and C-MYC in either the untransfected cells or the cells that 
received the receptor alone, but levels in HFF1 cells, 12 days after infection with the 
reprogramming factors, are significantly higher (p < 0.001, n = 3). The transgenes are then 
silenced in the newly reprogrammed iPSC lines at an early passage (cells tested at p12). 
There is also no expression of the transgenes in an ESC line (H9). 





Figure 3.12. qRT-PCR showing expression levels of key pluripotency genes in an ESC line (H9), four newly 
reprogrammed  iPSC lines (Wild7, Wild11, Wild12 and Wild17, and the starting fibroblast cell line HFF1). 
 
 
Figure 3.13. qRT-PCR showing expression levels of exogenous genes used in reprogramming in uninfected 
fibroblasts (HFF1 uninfected), fibroblasts infected with both the mSlc receptor and the OKSM reprogramming 
factors (HFF1 mSlc OKSM), fibroblasts infected with both the mSlc receptor only (HFF1 mSlc neg), four newly 
reprogrammed iPSC lines (Wild7, Wild11, Wild12 and Wild17), and an ESC line (H9).  
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Cell lines were also characterised by their ability to differentiate into cells derived from each 
of the three embryonic germ layers, a defining characteristic of pluripotent stem cells. Cells 
were allowed to spontaneously differentiate over a period of 7 days before RNA isolation.  
Figures 3.14, 3.15 and 3.16 show that four newly generated iPSC lines (Wild7, Wild11, 
Wild12 and Wild17) as well as an ESC line (H9) were able to give rise to all three germ 
layers, as shown by upregulation of genes characteristic of endoderm (Sox17, Cxcr4, Foxa2 
and Cer1), mesoderm (Brachyury) and ectoderm (Nestin, Pax6, and Tubulin) in 
spontaneously differentiated cells compared to undifferentiated cells, confirming their 
pluripotency and ability to differentiate in vitro. Expression of these markers was 
significantly increased in spontaneously differentiated cells compared to undifferentiated 
cells, which showed very low levels of expression of these genes which is likely due to the 
presence of some differentiated cells in the colonies.  
  




Figure 3.14.qRT-PCR data showing expression of marker genes characteristic of endoderm 
 
Figure 3.15. qRT-PCR data showing expression of a marker gene characteristic of mesoderm. 
 
Figure 3.16. RT-PCR data showing expression of marker genes characteristic of ectoderm. 




Initial reprogramming experiments resulted in the production of cells which closely 
resembled iPSCs in terms of their morphology and growth characteristics, and which could 
be maintained in culture over a number of passages, but which, when further characterised, 
showed inadequate expression of pluripotency markers. These cells are likely to represent a 
population of incompletely reprogrammed cells which have been previously described 
(Meissner et al, 2007; Chan et al, 2009). These cells can be maintained in a relatively stable 
state, and can express some stem cell markers such as SSEA-1, and can even occasionally go 
on to give rise to fully reprogrammed cells, either spontaneously or through treatment with 
DNA demethylating agents (Meissner et al, 2008). However in many cases these cells would 
never be able to generate fully pluripotent cells. This shows the importance of fully 
characterising new iPSC lines based on molecular markers rather than cell morphology, as 
these cells are likely to behave very differently to true iPSCs.  
One of the reasons for the appearance of these incompletely reprogrammed populations may 
be due to the reprogramming method used, which relies on delivery of the reprogramming 
factors in four separate viral vectors. This makes it difficult to control the dose of each 
reprogramming factor that each individual cell will receive, and while some will receive an 
adequate dose of all four reprogramming factors and go on to be fully reprogrammed into 
iPSCs, others may receive an inadequate dose of the reprogramming factors to allow them to 
completely alter their cell fate to that of a pluripotent cell, but which may be sufficient to 
allow partial reprogramming. Further complicating matters is the fact that excess expression 
levels of OCT4 (Niwa et al, 2000) or SOX2 (Kopp et al, 2008) are actually detrimental to the 
maintenance of pluripotency. High levels of C-MYC and KLF4 together with low levels of 
SOX2 and OCT4 may lead to the generation of rapidly growing non-iPSCs which have been 
transformed rather than reprogrammed (Yamanaka, 2007). Although a separate vector 
encoding GFP was used in these experiments to monitor efficiency of delivery of the 
reprogramming factors, this is a crude method that simply ascertains whether transfection is 
working, and not the dose of each reprogramming factor that the cells receive. However, this 
method is still one of the most efficient methods of reprogramming, which is why it was 
chosen for this study.  
Early reprogramming studies relied on a selection system where iPSCs were isolated by 
antibiotic selection using a neomycin resistance gene inserted into a pluripotency gene locus. 
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When cells were treated with neomycin, only cells that had reactivated ESC-specific genes 
could survive. Takahashi & Yamanaka (2006) used selection for Fbx15, a gene that is 
specifically expressed in pluripotent stem cells, but that is not essential for maintenance of 
pluripotency. However, although these cells expressed molecular markers of pluripotency, 
and were able to give rise to all three embryonic germ layers as assessed by teratoma 
formation, these cells were not able to give rise to live chimeras, indicating restricted 
developmental potential compared to ESCs. Subsequent studies used selection for genes 
essential to pluripotency, such as Nanog and Oct4 (Maherali et al, 2007; Wernig et al, 2007), 
to select reprogrammed cells, and this was more successful in producing cells that could be 
transmitted through the germline, although all-iPSC mice were not generated through 
tetraploid complementation until later (Okita et al, 2007). While it was initially thought that 
iPSCs could not be isolated without some sort of selection, a study later showed that 
unmodified fibroblasts could be reprogrammed, although the presence of partially 
reprogrammed cells was noticed (Meissner et al, 2007). 
Another technique to eliminate partially reprogrammed colonies is to use doxycycline-
inducible reprogramming factors that can be turned on and off by the addition and removal of 
doxycycline from the medium (Wernig et al, 2008). When doxycycline is removed from the 
medium, fully reprogrammed cells that have started to express pluripotency factors 
endogenously, and therefore do not require expression of the reprogramming factors, can 
continue to grow, but partially reprogrammed cells do not. “Secondary iPSCs” can then be 
generated from the differentiated progeny of these iPSCs simply through the addition of 
doxycycline, allowing high-efficiency, high-throughput reprogramming (Maherali et al, 
2008) However, it is worth noting that cells that have been manipulated in this way, while 
useful for improving reprogramming techniques, are unlikely to ever be considered clinically 
relevant. The same group later generated “reprogrammable mice”, in which genes for 
pluripotency are placed under the control of doxycycline and inserted into a genomic locus 
which is constitutionally active in all tissues of the mouse. These mice allow iPSCs to be 
generated from any tissue by simply isolating the cells and adding doxycycline to the growth 
medium (Hanna et al, 2008). A subsequent study described transgenic mice which carried all 
possible combinations of the four reprogramming factors, allowing further elucidation of the 
role of each factor in reprogramming, as well as allowing screening for chemicals that can 
replace the reprogramming factors (Markoulaki et al, 2009).  
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Reprogramming methods which use a single polycistronic vector to deliver all four 
reprogramming factors (Sommer et al, 2009; Carey et al, 2009) may reduce the number of 
incompletely reprogrammed cells, as all the cells which are successfully transfected will 
receive all the factors, making it more likely that the cells will be fully reprogrammed. This 
method also reduces the number of integration sites of the viral vector into the host genome, 
as this can also affect reprogramming efficiency. The method used in our study results in 
random integration of viral vectors into the host cell genome, usually at several different loci. 
Genomic integration has been shown to alter gene function (Kustikova et al., 2005), and 
random integration may influence the molecular signature of iPSCs by disrupting regulatory 
regions in the genome. Transcriptional analysis has showed that transgene expression from 
incompletely silenced viral vectors could perturb global gene expression in iPSCs (Soldner et 
al, 2009). In addition, vectors which integrate into the genome are retained when the cells 
divide. For this reason, non-integrating methods of reprogramming (summarised in table 1.1) 
may provide an advantage over early retroviral and lentiviral reprogramming techniques in 
terms of the generation of fully reprogrammed cells, in addition to their advantages in terms 
of safety, which is an important consideration for generating clinically-relevant iPSC lines. 
The presence of these incompletely reprogrammed cells show the importance of fully 
characterising new iPSC lines before they are used in subsequent experiments to ensure the 
quality of the lines used. Guidelines for the characterisation of iPSCs have now been well-
established (Maherali & Hochedlinger, 2008), and are largely based on guidelines first used 
for the characterisation of ESCs (Brivanlou et al, 2003). The first step in identifying cells that 
have been successfully reprogrammed is observation of morphological changes, although as 
these results show, this is an inadequate way of assessing whether cells have been fully 
reprogrammed, and further characterisation of molecular and cellular markers is needed. 
These markers include the transcription factors OCT4 and NANOG, which are essential for 
the maintenance of pluripotency. The results described here showed that these genes are 
expressed in newly reprogrammed iPSCs both at the mRNA and the protein level. Expression 
of several other pluripotency-associated genes, including Sox2, Klf4, c-Myc, Tdgf and Rex1 
were also assessed by qRT-PCR, and were found to be expressed at high levels in new iPSC 
lines as well as in an ESC line, confirming the pluripotency of these cell lines. These markers 
were chosen as they are known to be expressed in pluripotent stem cells, but ideally a high-
throughput method would be used to screen for expression of a larger panel of pluripotency-
associated genes. The presence of the stem cell surface antigens TRA-1-60, TRA-1-81 and 
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SSEA-3 was also assessed by immunocytochemistry, and all markers were expressed in both 
iPSCs and ESCs, confirming their pluripotency. Expression levels of pluripotency genes were 
analysed throughout the culture of these cells, and figure 3.17 shows that two iPSC lines 
(MRC5I and MRC9G) maintained expression of these genes at later passages, with no 
significant difference in the expression of OCT4 and NANOG in either cell line (p = 0.378 
for MRC5I, p = 0.931 for MRC9G) at any passage number.  
 
Figure 3.17 qRT-PCR data showing the expression of the pluripotency genes OCT4 and NANOG in two 
iPSC lines (MRC5I and MRC9G) at several different passages. 
 
The newly reprogrammed iPSCs were assessed for silencing of the transgenes used in 
reprogramming, an essential criteria of truly reprogrammed cells. Transgene expression was 
high in fibroblasts at day 17 of the reprogramming process, but was subsequently silenced in 
iPSCs at early passages (~p10), showing that these iPSCs are capable of self-renewal in 
culture independent of transgene expression. Expression of endogenous Oct4, Sox2, Klf4 and 
c-Myc was found to be high in iPSC lines, suggesting that they have successfully reactivated 
the network of gene expression necessary for the maintenance of pluripotency.  
Finally, an in vitro assessment of the differentiation potential of iPSCs was carried out. Cells 
were allowed to spontaneously differentiate for 7 days and the expression of germ layer-
specific genes was assessed. All iPSC lines and an ESC line showed expression of genes 
representative of each embryonic germ layer, confirming their pluripotency and ability to 
differentiate.  
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The most stringent test of pluripotency available for human pluripotent stem cells is the 
teratoma assay. However, this is an expensive and time-consuming assay, and there has been 
debate over how useful it actually is, with many pointing out the qualitative nature of this 
assay, and the fact that it does not accurately assess whether the iPSCs are able to give rise to 
every cell in the body, nor does it assess the contribution of the iPSCs to the germline: many 
mouse iPSC lines are able to give rise to teratomas containing cells derived from all three 
germ layers, but are not able to contribute to all-iPSC mice. In terms of this study, it was 
decided that an in vitro differentiation assay was sufficient to determine the pluripotency of 
these cell lines, as the cells were subsequently to be used for investigation of in vitro 
differentiation. There has been a shift in recent years towards an increased focus on in vitro 
testing of new iPSC lines: the TaqMan® hPSC Scorecard developed by Life Technologies 
aims to allow researchers to fully characterise their pluripotent stem cell lines in a single 
PCR-based assay, which allows measurement of gene expression in order to determine 
whether cell lines are able to give rise to all three embryonic germ layers. In addition, 
PluriTest (www.pluritest.org), an open access resource, allows researchers to compare their 
gene expression data with a large panel of established pluripotent stem cell lines (Muller et al, 
2008). These methods are particularly relevant for lines which are generated primarily for 
research use, where the requirement for pluripotency is less stringent than in cells which 
could potentially be used in a therapeutic setting.  
There are several other considerations to be taken into account before iPSCs can be 
considered for clinical applications. These include the starting cell type, the reprogramming 
factors used, and the method of delivering those reprogramming factors. In addition to these 
considerations, there are still numerous technical difficulties standing in the way of 
generating clinical-grade iPSCs, such as the requirement for GMP conditions and reagents, 
and the need for large-scale production. These factors are discussed further in chapter 1.  
In conclusion, this chapter demonstrates the stochastic nature of the reprogramming process, 
and the requirement for robust characterisation of new iPSC lines. In addition, this chapter 
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Chapter 4: Differentiation of Pluripotent 
Stem Cells into Definitive Endoderm 
 
4.1 Introduction 
Transplantation of both whole pancreas and islets has shown proof of principle for cell 
replacement therapy to treat T1DM. There are numerous different sources of tissue that could 
potentially be used, but there are certain requirements in order for them to be suitable for 
transplantation: first, they must be able to synthesise and store insulin, and release sufficient 
amounts in response to various secretagogues, including circulating glucose. Second, any 
source of replacement β-cells will also need to be able to generate large numbers of cells in 
vitro to meet the requirement of transplantation therapy, but this proliferative capacity must 
be tightly regulated to avoid post-transplantation expansion. Thirdly, the replacement β-cells 
must show persistent engraftment and survival. Lastly, they must satisfy safety concerns. 
Much of the focus has been on pluripotent stem cells, as they have the capacity to self-renew 
indefinitely in culture and can potentially give rise to any cell in the body, but directing stem 
cells to differentiate in vitro into a pancreatic lineage has proved challenging.  
To date, the most successful protocols for generating insulin-expressing cells in vitro have 
been those which recapitulate the signalling pathways which are important during in vivo 
pancreatic development, including TGF-β, Wnt, Hedgehog and Notch signalling (see section 
1.3). The first step in the differentiation of pluripotent stem cells into β-cells is the production 
of definitive endoderm (DE), and this has been shown to be a critical stage in the 
differentiation process, demonstrating the need for protocols which generate DE at a high 
efficiency (Courtney et al., 2010). One of the most widely adopted protocols for the 
differentiation of ESCs into DE was published in 2005, and involved treatment with high 
concentrations of Activin A and low serum levels, resulting in production of a population 
containing approximately 80% SOX17-expressing cells. Other markers of DE, including 
FOXA2, CXCR4, and CER1 were also upregulated, while SOX7, a marker of visceral 
endoderm, was not (D’Amour et al, 2005). Other studies (particularly Nostro et al., 2011) 
have gone on to further elucidate the signalling molecules and exposure times required for the 
most efficient differentiation into DE in vitro.  
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While most differentiation protocols have relied on recombinant growth factors to provide the 
necessary signals to the differentiating cells, the use of small molecules which may be able to 
replace some or all of these factors has been of great interest, as they can be chemically 
synthesised and purified. This could potentially result in less variability in biological activity 
than is seen with growth factors. In addition, they are cheaper to produce, which is an 
important consideration given that these cells will need to be produced on a large scale if they 
are to be used for clinical applications to treat a large number of patients. A study by 
Borowiak et al. (2009) described the use of the small molecules IDE1 and IDE2, which are 
thought to be activators of the TGF-β signalling pathway, to improve the efficiency of DE 
formation in comparison to an Activin A-based protocol (D’Amour et al, 2005).  
 
  




Given the large numbers of protocols published for the differentiation of pluripotent stem 
cells into DE, the aim of this chapter is to evaluate three widely quoted protocols to 
determine which results in the highest yield of DE. This is an important consideration for 
subsequent experiments, since these will be focussed on the DE stage of the differentiation 
process. If the yield of DE is low then results may be affected by the presence of large 
numbers of other cell types in the differentiated samples. In addition, high differentiation 
efficiency at the DE stage is important for the successful differentiation of stem cells into 
insulin-expressing cells (Courtney et al., 2010).  This chapter will also compare the 
differentiation propensities of several ESC and iPSC lines in order to determine whether there 
are any differences between these two cell types.  
 
4.2.1 Differentiation of Pluripotent Stem Cells into Definitive Endoderm  
The use of small molecules in directed differentiation protocols is of great interest, as they 
can be chemically synthesised and purified, making them cheaper to produce. A study by 
Borowiak et al. (2009) described the use of the small molecules IDE1 and IDE2 to improve 
the efficiency of DE formation from several ESC lines in comparison to an Activin A-based 
protocol. Following on from this, I have investigated the effect of IDE1 on the efficiency of 
DE formation in iPSC and ESC lines. In 2011, Nostro et al. reported an optimised protocol 
for the differentiation of pluripotent stem cells into DE, and I have also investigated the 
efficiency of this protocol for DE formation in iPSC and ESC lines. Both of these protocols 
were compared with the protocol described in the initial report by D’Amour et al (2005).  
Stem cells were maintained in culture as previously described in section 2.2. Before the start 
of the differentiation protocol on day 1, samples of undifferentiated colonies were taken. 
Colonies undergoing differentiation were washed with PBS before being exposed to either 
the D’Amour protocol, the Nostro protocol, or IDE1 according to the time scale shown in 
table 4.1. Cells that were allowed to spontaneously differentiate over the same timescale were 
also included in the comparison as a control and were treated with RPMI only, to show 
whether the protocols for directed differentiation result in a higher efficiency of DE 
formation than cells which were not treated with a differentiation protocol.  
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 Stage 1 
Formation of DE 








Activin A (100ng/ml) 









Wnt3A  (3ng/ml)  





Table 4.1. Reagents and concentrations used to direct differentiation of stem cells to DE. 
 
4.2.2. Characterisation of Differentiated Cells 
 
Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) 
RNA was isolated from undifferentiated and differentiated cells by mechanical dissection of 
colonies into 350μl lysis buffer containing Buffer RLT and 1% (v/v) β-mercaptoethanol. 
Total RNA was isolated using the RNeasy mini kit before being reverse transcribed into 
cDNA. 9.5μl total RNA, 1μl Oligo(dT)15 primers (0.5μg/μl) and 1μl random primers 
(0.5μg/μl) were mixed and incubated at 70°C for 5min then immediately cooled on ice for 
5min. A master mix was prepared according to table 4.2 and 8.5μl was added to each sample. 
The samples were then incubated for 50min at 42°C, followed by 15min at 70°C. 
Reverse Transcription Mix 
Reagent Volume Needed For 1 Reaction (µl) 
5x Reaction Buffer 4 
10mM dNTPs 1 
40U/µl RNAsin 2 
400mM DTT 0.5 
MMLV-RT 1 
Total 8.5 
Table 4.2. Reagents and volume needed for the reverse transcription reaction. 
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PCR reactions were set up in 20μl reactions as shown in table 4.3. Serial dilutions of a 
standard cDNA were prepared as described in section 2.4.2 and run together with the samples 
of interest to allow quantification of gene expression. A negative control in which the cDNA 
was replaced with H2O was also included in each reaction. PCR reactions were carried out on 
the Qiagen Rotor-Gene™ 6000 using the following PCR cycling conditions: 10min at 95°C; 
followed by 40 repeated cycles of 5sec at 95°C, 15sec at 58°C and 10sec at 72°C. The 
fluorescence was acquired at the end of the elongation step. A melt curve analysis was carried 
out to ensure amplification of a single product, and the products were run on a gel to confirm 
the amplicon was the correct size (table 2.12). 
qRT-PCR Reaction Mix 
Reagent 
Volume Needed For 1 
Reaction (µl) 
2x Sensimix Plus 
(containing reaction buffer, heat-activated Taq Polymerase, dNTPs, 6mM MgCl2, internal 
reference and stabilisers, and SYBR green intercalating dye) 
10 
10µM Forward Primer 1 
10µM Reverse Primer 1 
cDNA 2 
PCR-grade H2O 6 
Total 20 
Table 4.3. qRT-PCR reaction mix. 
 
Immunocytochemistry 
Medium was aspirated and the cell colonies were washed twice with PBS. The cells were 
fixed with 500µl of 4% paraformaldehyde and incubated for 20min at room temperature 
before being washed 3 times with PBST, and then incubated in PBST at room temperature for 
15min. 500μl of primary antibody diluted appropriately in PBST (table 2.16), was added to 
the cells which were then incubated in the dark overnight at 4°C. The cells were washed 3 
times with PBST and 500μl secondary antibody at the appropriate dilution (table 2.16) was 
then added to the cells and left to incubate at room temperature for 1 hour. 200µl of 5µg/ml 
Hoescht DNA stain solution was added to the cells and incubated for 1min at room 
temperature. The cells were then washed twice in PBST. Control dishes were also prepared, 
by omitting the primary antibody to ascertain the specificity of the antibody, and also using 
an isotype control together with the secondary antibody to ascertain the degree of non-
specific binding. The cells were visualised using a Nikon Eclipse TS100 inverted microscope.  





4.3.1 Comparison of Differentiation Protocols 
Given that the successful generation of pancreatic progenitors, and subsequently the 
development of more mature hormone-expressing cells, is critically dependent on the 
efficiency of DE formation, I have compared three differentiation protocols, together with 
spontaneously differentiated cells, for their ability to form DE. Borowiak et al. (2009) used 
the small molecule IDE1 to improve the efficiency of DE formation in comparison to an 
Activin A-based protocol, while in 2011, Nostro et al. reported an optimised protocol for the 
differentiation of pluripotent stem cells into DE. Differentiated cells and undifferentiated 
cells were characterised using immunocytochemistry and qRT-PCR.  
 
 
Figure 4.1.Immunocytochemistry for SOX17 was carried out on an iPSC line (MRC5I) directed to differentiate 
into DE using one of three differentiation protocols published by D’Amour et al, 2005; Nostro et al, 2011; or 
Borowiak et al, 2009. 10x magnification, scale bar 100µm.  
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Immunocytochemistry was used to determine the levels of SOX17, an early marker of DE, in 
differentiated cells. A representative example using the MRC5I iPSC line is shown in figure 
4.1, which shows that immunofluorescence of the SOX17 protein was highest in cells 
differentiated using the D’Amour protocol (~70%), less in those differentiated using the 
Nostro protocol (~59%) and lowest in the cells differentiated using the Borowiak protocol 
(~18%), indicating that the D’Amour protocol results in the highest efficiency of 
differentiation into DE.  
qRT-PCR was used to investigate gene expression in five cell lines: two iPS (MRC5I and 
MRC9G) and three ES (H1, H7 and H9). Four genes were used as markers of DE: Sox17, 
Cxcr4, Foxa2 and Cer1. Gene expression was compared in cells which had been directed to 
differentiate using the D’Amour, Nostro or Borowiak protocols, or which had been allowed 
to spontaneously differentiate. Fold change in gene expression between differentiated and 
undifferentiated cells was calculated and analysis of variance with Fisher’s a priori test was 
used to determine statistical differences between protocols.  
Figure 4.2 shows the fold change in Sox17 expression in differentiated cells compared to 
undifferentiated cells harvested at the start of the differentiation protocol. Gene expression is 
significantly (p < 0.001, n = 5) higher in cells treated with the D’Amour protocol than with 
either the Nostro or Borowiak protocols, which do not result in significantly higher gene 
expression than seen in the spontaneously differentiated cells, although some upregulation is 
noticeable in cells treated with the Nostro protocol. Sox17 is one of the earliest markers of 
DE (Lewis & Tam, 2006), and is essential for endoderm formation, as mice lacking SOX17 
do not develop gut endoderm from DE (Kanai-Azuma et al., 2002). 
Figure 4.3 shows the fold change in Cxcr4 expression in differentiated cells compared to 
undifferentiated cells. Gene expression is significantly (p < 0.001, n = 5) higher in both the 
D’Amour and Nostro protocols than in the Borowiak protocol or spontaneously differentiated 
cells. There is no significant difference in gene expression between either the D’Amour and 
Nostro protocols, or the Borowiak protocol and spontaneously differentiated cells. The 
expression of Cxcr4 is observed on the cell surface of DE cells (McGrath et al., 1999; Nair & 
Schilling, 2008), but not visceral endoderm cells (Yasunaga et al, 2005).  





Figure 4.2.Expression of Sox17 assessed by qRT-PCR in iPS (MRC5I and MRC9G) and ES (H1, H7 and H9) 




Figure 4.3. Expression of Cxcr4 assessed by qRT-PCR in iPS (MRC5I and MRC9G) and ES (H1, H7 and H9) 
cell lines either directed to differentiate using the D’Amour, Nostro or Borowiak protocols, or allowed to 
spontaneously differentiate. 





Figure 4.4. Expression of Cer1 assessed by qRT-PCR in iPS (MRC5I and MRC9G) and ES (H1, H7 and H9) 




Figure 4.5.Expression of Foxa2 assessed by qRT-PCR in iPS (MRC5I and MRC9G) and ES (H1, H7 and H9) 
cell lines either directed to differentiate using the D’Amour, Nostro or Borowiak protocols, or allowed to 
spontaneously differentiate.  
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Figure 4.4 shows the fold change in Cer1 expression in differentiated cells compared to 
undifferentiated cells. Gene expression is significantly (p < 0.001, n = 5) higher in both the 
D’Amour and Nostro protocols than in the Borowiak protocol or spontaneously differentiated 
cells. There is no significant difference in gene expression between either the D’Amour and 
Nostro protocols, or the Borowiak protocol and spontaneously differentiated cells. Cer1 is 
another early marker of DE, and its expression is transient and restricted to anterior DE (Belo 
et al., 1997; Biben et al., 1998). 
Figure 4.5 shows the fold change in Foxa2 expression in differentiated cells compared to 
undifferentiated cells. Gene expression is significantly (p < 0.001, n = 5) higher in cells 
treated with the D’Amour protocol than with either the Nostro or Borowiak protocols, which 
do not result in significantly higher gene expression than seen in the spontaneously 
differentiated cells. FOXA2 is essential for DE formation, as homozygous knockout in mice 
is lethal due to a lack of endoderm (Sasaki & Hogan, 1993; Monaghan et al., 1993). 
Together, these results clearly show that the D’Amour protocol consistently results in the 
most upregulation of DE-associated genes compared to any of the other protocols, and 
significantly more than in spontaneously differentiated cells. Although the Nostro protocol 
results in similar upregulation of the Cxcr4 and Cer1 genes to the D’Amour protocol, the fact 
that Sox17 and Foxa2 expression are not significantly upregulated in cells treated with this 
protocol suggests that differentiation to DE may be less complete. These results are in 
contrast to those published by Nostro et al (2011), when they reported that this protocol 
produced a population of cells containing approximately 70% SOX17-expressing cells. Cells 
treated with the Borowiak protocol fail to upregulate any DE-associated genes at a higher 
efficiency than spontaneously differentiating cells, suggesting that this protocol is having 
little or no effect in directing the cell lines used in this study towards an endodermal fate.   
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4.3.2 Comparison of Cell Lines 
During experiments carried out to compare the efficiency of different protocols in forming 
DE, it became evident that different cell lines had different propensities to form DE, which 
were consistent over several experiments, with some cell lines showing higher upregulation 
of DE genes than others. To investigate this further, differentiation of individual cell lines 
using the D’Amour protocol, was compared. Differentiated cells and undifferentiated cells 
were characterised using immunocytochemistry and qRT-PCR for Sox17, Cxcr4, Cer1 and 
Foxa2. Fold change in gene expression between differentiated and undifferentiated cells was 
calculated and analysis of variance with Fisher’s a priori test was performed to determine 
significant differences between groups. 
Figure 4.6 shows images of two iPSC lines (MRC5I and MRC9G) and three ESC lines (H1, 
H7 and H9) taken at the beginning (undifferentiated) and end (D’Amour and spontaneous) of 
differentiation. Undifferentiated colonies have a characteristic morphology, and are typically 
smooth, round and largely homogenous in appearance. The cells are small and round, with a 
large nucleus, and are densely packed. In contrast, after differentiation to DE, the 
morphology changes and colonies appear grainy, and are less homogenous. The cells are 
sparser, which is probably due to the large amounts of cell death noticed after the start of 
differentiation. The cells have begun to change shape and increase in size. In addition, 
spontaneously differentiated colonies are distinguishable from colonies induced to 
differentiate using the D’Amour protocol. There is no obvious difference in morphology 
between different cell lines, either ESCs (H1, H7 and H9) or iPSCs (MRC5I and MRC9G), or 
between colonies grown on feeders (MRC5I, MRC9G and H1) and those grown on 
Matrigel™ (H7 and H9). 
Figure 4.7 shows immunocytochemistry for SOX17 expression in two iPSC lines (MRC5I 
and MRC9G) and three ESC lines (H1, H7 and H9) induced to differentiate into DE using the 
D’Amour protocol. While H1 shows noticeably lower levels of SOX17 expression, there is 
no obvious difference between the other cell lines, which all show high expression of SOX17, 
indicating a high efficiency of differentiation. The approximate percentage of SOX17-
expressing cells in the each cell line is: MRC5I = 75%, MRC9G = 74%, H1 = 42%, H7 = 
62%, H9 = 69%.   




Figure 4.6.Change in colony morphology during differentiation to DE. Images of ESCs (H1, H7 and H9) and 
iPSCs (MRC5I and MRC9G) were taken at the start and end of differentiation in order to observe changes in 
colony morphology. 2x magnification. 
  




Figure 4.7.Immunocytochemistry for SOX17 expression was carried out on two iPSC lines (MRC5I and 
MRC9G) and three ESC lines (H1, H7 and H9) induced to differentiate into DE using the D’Amour protocol. 
10x magnification, scale bar 100µm. 




Figure 4.8. Comparison of gene expression in cell lines directed to differentiate into DE.  
 
Figure 4.8 shows the expression of genes characteristic of DE (Sox17, Cxcr4, Cer1 and 
Foxa2) in two iPSC lines (MRC5I and MRC9G) and three ESC lines (H1, H7 and H9). There 
is variability between cell lines in the expression of these genes which is most noticeable in 
the H1 cell line, which shows significantly lower (p = 0.004, n = 5) expression of DE genes 
than any of the other cell lines tested, suggesting that this cell line is more resistant to 
differentiation into DE. 
Initial experiments were carried out using two iPSC lines generated at NIBSC, MRC5I and 
MRC9G, and a well-characterised ESC line (H9). However, the iPSC lines are grown on 
iSNL feeders, and the H9 line is grown on Matrigel™. For this reason, the H1 cell line was 
included in differentiation experiments, as this is an ESC line grown on iSNL feeders, and 
was therefore expected to represent an ESC line grown in a comparable culture format to the 
available iPSC lines. However, data from my own results (figure 4.8) and others (Bock et al, 
2011; Nostro et al, 2011) indicate that this line has a low propensity for forming DE. The H7 
ESC line, also grown on Matrigel™, was also included in differentiation experiments.  
 




Figure 4.9. Expression of Sox17, CXCR4, CER-1 and FOXA2 in H9 cells cultured on either iSNL feeders or 
Matrigel™ and directed to differentiate using the D’Amour protocol. 
 
Investigation of whether the low differentiation efficiency observed in the H1 cell line was a 
result of the culture conditions (i.e. being grown on feeders, compared to the other ESC lines 
which were all grown on Matrigel™) could not be carried out, as the H1 cell line could not be 
maintained on Matrigel™. For this reason, the differentiation efficiency of the H9 ESC line 
grown on both feeders and Matrigel™ was compared to determine whether growing ESC 
lines on feeders was generally detrimental to their ability to differentiate into DE. 
Differentiation into DE was carried out using the D’Amour protocol as described above, and 
the cells were assessed for their expression of Sox17, Cxcr4, Foxa2, and Cer-1. Figure 4.9 
shows that there is no significant difference (p = 0.789, n = 3) in the differentiation efficiency 
between cells cultured on feeders and cells cultured on Matrigel™. Expression of DE genes is 
significantly upregulated in cells treated with the D’Amour protocol, in both culture formats 
(p < 0.001, n = 3), indicating that H9 is capable of differentiating into DE whether cultured 
on iSNL feeders or Matrigel™. There is no significant difference in expression of these genes 
in spontaneously differentiated samples compared to undifferentiated samples, although 
CXCR4 is upregulated in these samples. However, this gene is not specific to DE and is 
upregulated in many other tissue types.     





The aim of the work described in this chapter was to compare three differentiation protocols 
in order to optimise the yield of DE for further experiments. Numerous protocols have been 
developed for the differentiation of pluripotent stem cells into DE, and subsequently insulin-
expressing cells (see section 1.7.1), but the most successful protocols have been those which 
have recapitulated the signalling pathways which are important during in vivo pancreatic 
development, including the influential protocol originally published by D’Amour et al (2005) 
and later optimised by Kroon et al (2008).  
However, there are limitations to these protocols. The cells produced are frequently 
polyhormonal and unable to release insulin in response to glucose (although they can release 
insulin in response to other secretagogues). These features are indicative of an immature 
phenotype, a common problem for many different in vitro differentiation protocols. While 
increasing the length of time in culture did allow the cells to mature somewhat, they were still 
very different from the equivalent adult cells, suggesting that increased time in culture alone 
is not enough to drive maturation, and that additional signals are needed (Patterson et al., 
2012). However, Kroon et al. (2008) succeeded in producing a population of pancreatic 
progenitor cells which, several weeks after transplantation into immunodeficient mice, were 
shown to release C-peptide and insulin in response to glucose, demonstrating that unknown 
factors in the in vivo environment were capable of inducing these cells to complete 
differentiation into a more mature β-cell phenotype. This result was confirmed by another 
group using a different protocol (Shim et al., 2007). Since then, there have been efforts to 
elucidate the factors needed for β-cell maturation (Blum et al, 2012; Xie et al, 2013). 
However, the precise factors involved in β-cell maturation remain unknown, and, until they 
are elucidated, it is unlikely that fully functional mature β-cells will be generated in vitro.  
Another problem facing in vitro differentiation protocols is the variability in the cells 
produced. One factor affecting variability is the fact that many of the published protocols rely 
on the use of recombinant growth factors to direct differentiation. These can vary 
considerably in their biological activity from batch to batch, and in addition are very 
expensive to produce. Both of these problems render these protocols unsuitable for large-
scale production of differentiated cells for cell replacement therapy. For this reason, there has 
been a large amount of research carried out on the use of low molecular weight, cell 
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permeable, bioactive small molecules to enhance the activity of, or replace, growth factors in 
differentiation protocols. These have the advantages of being specific and dose-dependent. 
They have rapid and reversible effects, and synthetic chemistry allows almost unlimited 
diversity to control molecular interactions. 
There have been several reports of small molecules which can increase the efficiency of 
growth factor-directed differentiation into a pancreatic lineage, but which are not able to 
replace growth factors in the protocol. LY294002 and TKT-II inhibit PI3K signalling (which 
is important for maintaining pluripotency), increasing the efficiency of differentiation to DE 
when used in combination with Activin A (McLean et al., 2007). However these chemicals 
were not able to replace Activin A in this protocol but only enhance its effects. This study 
also described the link between serum levels and Activin signalling, suggesting that 
components of serum, such as IGF or insulin, block differentiation through increased PI3K 
signalling. Another study showed that sodium butyrate could increase the efficiency of 
endoderm formation in cells treated with Activin A, but that it was insufficient to induce 
differentiation itself (Jiang et al, 2007). This is likely to be due to its effects on the 
epigenetics of the cells, making them more receptive to differentiation signals. Shim et al 
(2007) used retinoic acid in combination with Activin A to increase the efficiency of 
differentiation.  
Borowiak et al (2009) carried out a large-scale screen of over 4000 compounds in the absence 
of Activin A signalling in an attempt to identify chemicals that could induce DE formation, 
rather than simply enhance it. They identified two compounds, termed inducer of DE (IDE)-1 
and IDE-2, which were reported to give a yield of DE of over 80%. These small molecules 
are thought to act through activation of the TGF-β pathway, as Smad phosphorylation was 
observed following exposure of cells to both IDE1 and IDE2. Unfortunately, despite these 
promising results, I did not observe any upregulation of DE markers when using IDE1 
beyond what is seen in spontaneously differentiating cells, suggesting that this protocol had 
little or no effect on differentiation on the cell lines used in this study. This may be due to the 
different cell lines used, which may have different abilities to respond to these chemicals, as 
the study by Borowiak et al (2009) used three ESC lines (HUES4, HUES8 and HUES9), 
while I used three different ESC lines (H1, H7 and H9) in addition to two iPSC lines (MRC5I 
and MRC9G). It is worth mentioning that I only tested IDE-1 and not IDE-2, although they 
are very similar compounds which are thought to act in the same way. Culture conditions 
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were very similar between the two studies, with both using cells grown on mouse feeders in 
KOSR medium, although I also used cell lines grown on Matrigel™. Another recent study 
comparing the effects of several small molecules in DE formation also found IDE1 and IDE2 
to be ineffective (Tahamtani et al, 2013), and to date there are no other reports that I am 
aware of using these compounds to successfully induce endoderm differentiation, which 
suggests that other researchers have not found them to be efficient either. Indeed, a more 
recent publication by the same group that published the IDE results used Activin A to induce 
differentiation into DE, not IDE1 or IDE2 (Chetty et al, 2013).  
Since then, several other groups have reported small molecules which can enhance or replace 
growth factors in differentiation. Kunisada et al. (2012) replaced Wnt3A with CHIR00921 (a 
GSK3β inhibitor) in DE formation, while Sekine et al (2012) reported increased efficiency of 
endoderm formation using media supplemented with B27. Norrman et al (2012) reported that 
endodermal cells produced using this protocol were the most functionally mature when 
comparing gene expression in single cells differentiated using three different Activin A-based 
protocols. Another study reported enhancement of differentiation efficiency by priming cells 
with Rapamycin prior to differentiation (Tahamtani et al, 2013). In addition to small 
molecules which induce endoderm differentiation, some small molecules promote 
differentiation generally through down-regulation of pluripotency, such as stauprimide, 
which results in increased DE formation in both mouse and human ESCs (Zhu et al, 2009).   
Another problem facing these differentiation protocols is the low yield of cells obtained. In 
an attempt to increase the efficiency of differentiation, Nostro et al (2011) optimised 
differentiation conditions. They further elucidated the temporal requirements for TGF-β, Wnt 
and BMP4 signalling, and showed that BMP4, bFGF and VEGF could replace serum in 
differentiation protocols. Being able to carry out differentiation in serum-free conditions is an 
advantage, both in terms of reproducibility and in being more clinically relevant. However, 
my results show that although treatment with the protocol developed by Nostro et al (2011) 
results in significant upregulation of Cer1 and Cxcr4 to a level comparable to that seen when 
using the D’Amour protocol, there is no significant upregulation of Sox17 and Foxa2 over 
what is seen in spontaneously differentiating cells, suggesting that these cells may not be 
fully representative of DE. This in in contrast to the results published by Nostro et al (2011), 
who reported over 70% of cells expressing Sox17. This study used two of the same cell lines 
used here (H1 and H9), as well as the HES2 and HES3 ESC lines and an iPSC line, and used 
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very similar culture methods. Interestingly, they also noticed the poor differentiation of H1 
into a pancreatic lineage, suggesting that this is a property inherent to this stem cell line.  
Culture conditions also play an important role in differentiation to DE, as demonstrated by 
Kubo et al (2004), who showed that high serum concentrations resulted in a lower efficiency 
of differentiation into DE, due to the presence of undefined growth factors and hormones in 
serum. Reduction of serum concentration to 0.2-0.5% was shown to be the most successful 
for generating DE (D’Amour et al, 2005). Whether the cells are differentiated in monolayer 
culture or as embryoid bodies is also likely to affect the differentiation process, and alter the 
necessary dose and timing of signalling factors (Sulzbacher et al, 2009). In an attempt to 
recreate more physiological conditions, and improve the quality of the cells produced, Van 
Hoof et al (2011) developed a protocol for the differentiation of ESCs into DE in adherent, 
size-controlled, clusters, which were able to give rise to homogenous clusters of pancreatic 
progenitors. However, Nostro et al (2011) found that differentiation kinetics were faster in 
monolayer cultures vs. embryoid bodies, with endodermal gene expression arising by day 3 
in monolayer culture but not until day 5 in embryoid bodies, although embryoid body culture 
has the advantage of being more easily scaled up. Chetty et al (2013) found that the 
differentiation efficiency varied depending on the density of the cells at the start of the 
protocol, with cells plated at higher densities forming more DE than those at low densities, 
suggesting that contact-mediated growth inhibition might improve the cells’ response to 
differentiation signals. Treating low density cells with DMSO prior to differentiation 
improved the efficiency of differentiation to a level comparable with high-density cells, 
through its effects on the cell cycle. This was true for differentiation into several lineages, 
including DE, and should be taken into consideration when optimising differentiation 
protocols. Even when efficiency of differentiation into DE is high, cell yield is generally low 
due to the high levels of cell death during differentiation. One explanation for this is that 
differentiation occurs in a selective manner, where only a few cells in the starting population 
are competent to respond to exogenous signals and so differentiate, while other cells are not 
competent to differentiate and so die. This model is supported by a study carried out by 
Ungrin et al (2012), who monitored cell proliferation during differentiation, and found that 
differentiation resulted in an initial wave of cell death followed by proliferation and 
differentiation of a sub-population of cells. They then went on to identify ways in which this 
initial wave of cell death could be prevented in order to increase the yield of differentiated 
cells, and found that optimising initial embryoid body formation resulted in a 36-fold increase 
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in yield during differentiation to DE.  This method may also allow scale-up of production to 
the levels needed to produce adequate numbers of differentiated cells for cell therapy. 
In an attempt to make differentiation protocols more reproducible, as well as allowing for 
scale up, commercial products for differentiation are now becoming available. These have the 
additional advantages of being both fully defined, as well as serum- and animal product-free, 
making them more clinically applicable. While these products will not change the fact that 
different cell lines have different propensities for differentiation, they should cut down on 
experimental variation arising from the reagents used.  
Although protocols have now been developed which allow the production of DE at high 
efficiencies, it is still difficult to achieve a completely pure population. This is important both 
for efficiency of the later stages of pancreatic differentiation and for studying DE without 
contamination by other cell types. Cell sorting based on expression of extracellular markers 
to achieve a pure population requires the use of a combination of markers in order to select 
for DE cells alone, as many markers are expressed by other cell types, and results in loss of 
cells and reduced cell function. Efforts have been made to further characterise DE cells in an 
attempt to identify better markers that will allow purification of an endoderm population 
(Wang et al, 2012).  
An appealing alternative may be the generation of stable endodermal progenitor cell lines 
from pluripotent stem cells. An early study by Tada et al (2005) used a mouse ESC line with 
a GFP reporter in the locus of the Goosecoid gene to identify DE cells which could be 
expanded in culture while still maintaining expression of endodermal markers. However, 
although some further differentiation was observed, these cells could not give rise to mature 
pancreatic or hepatic cells, suggesting that they are functionally restricted. A subsequent 
study, also in mice, used a reporter gene in the Hex locus to purify endodermal cells, and 
demonstrated that these could be expanded in culture and could give rise to AFP-expressing 
hepatic cells, as well as pancreatic progenitors (Morrison et al, 2008). More recently, self-
renewing endodermal progenitor cell lines have been generated from human ESCs and 
iPSCs, which express key endodermal genes such as Foxa2 and Sox17 and are able to 
differentiate in vitro into hepatic, pancreatic and intestinal lineages. Despite their extensive 
proliferative capacity in vitro, when injected into immunodeficient mice they did not form 
teratomas (Cheng et al, 2012). Another report demonstrated that endoderm cells derived from 
both mouse and human ESCs could be expanded in culture by co-culturing with mouse 
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mesenchymal cells. These cells could spontaneously give rise to glucose-responsive insulin-
producing cells after transplantation into mice (Sneddon et al, 2012). 
Another strategy for differentiation into DE is to overexpress transcription factors known to 
be important at this stage of development, such as SOX17 (Qu et al, 2008; Seguin et al, 
2008). One of these studies used SOX17 overexpression to establish a stable endoderm 
progenitor line which could be maintained in culture over several passages, and retained the 
ability to differentiate into hepatic and pancreatic cells (Seguin et al, 2008). While this cell 
line is likely to be useful to study definitive endoderm, it is unlikely that cells which have 
been genetically manipulated in this way will ever be considered for clinical use. 
 
During the comparison of differentiation protocols, it was noticed that different cell lines had 
different propensities to differentiate into DE. To investigate this further, a comparison of 
both ESCs and iPSCs was carried out and it was found that in all experiments, the H1 ESC 
line gave rise to significantly lower amounts of DE than any of the other cell lines. There 
were also statistically non-significant differences between other cell lines tested, with the 
iPSC line MRC5I and the ESC line H9 both differentiating to DE at high efficiencies. These 
differences were consistent over several experiments, suggesting that they are due to intrinsic 
properties of the cell line, and not random variation. This variability between cell lines has 
been described before (Abeyta et al, 2004; Martinez et al, 2012; Osafune et al, 2008). 
However, while some studies have shown that iPSCs have lower efficiencies of 
differentiation into haematopoietic, neuroepithelial, neuronal and cardiac lineages than ESCs 
(Feng et al, 2010; Hu et al, 2010; Narsinh et al, 2011), this was not found with differentiation 
into DE in this study. Although there was a significant difference in DE gene expression 
between ESCs and iPSCs (p = 0.049), this is likely to be due to the very low levels of gene 
expression in the H1 ESC line, which has previously been noticed to be inefficient at 
endoderm formation (Bock et al, 2011), as when this cell line was excluded from the analysis 
there was no longer a significant difference between the two cell types (p = 0.672). In this 
study, iPSCs were able to form DE at least as well as ESCs. This suggests that differences 
between cell lines may not be due to systematic differences between ESCs and iPSCs, but are 
instead a result of inherent variability between pluripotent stem cell lines. One study has 
suggested that variability between cell lines in their ability to differentiate into endoderm is 
due to their differing levels of endogenous Wnt signalling, with cells that have high levels 
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forming predominantly endodermal and cardiac cells, and cells that have low levels forming 
predominantly ectodermal cells. It has been reported that manipulating the levels of Wnt 
signalling removes much of the heterogeneity observed between different cell lines 
(Blauwkamp et al, 2012). Others have suggested that differences in BMP4 signalling may 
influence differentiation into DE (Christodoulou et al, 2011; Nostro et al, 2011).  
To investigate whether the low differentiation efficiency observed in the H1 cell line was a 
result of the culture conditions (i.e. being grown on feeders, compared to the other ESC lines 
which were all grown on Matrigel™), or an inherent property of the cell line itself, I wanted 
to compare the differentiation efficiency of H1 cultured on both feeders and Matrigel™. 
However, I was unable to maintain H1 on iSNL feeders, so I tested the differentiation 
efficiency of the H9 ESC line grown on both feeders and Matrigel™ to determine whether 
growing ESC lines on feeders was generally detrimental to their ability to differentiate into 
DE. I found no differences in differentiation efficiency between H9 cells cultured on feeders 
and H9 cultured on Matrigel™, although there was some variability in gene expression 
between them. There was significant upregulation of DE genes in the treated samples 
compared to the undifferentiated samples, demonstrating that the H9 cell line can 
differentiate into DE at high efficiencies irrespective of the culture conditions used. 
The subject of whether there are any systematic differences between ESCs and iPSCs has 
been hotly debated. While early studies comparing the gene expression signatures of ESCs 
and iPSCs found that they were very similar, and distinct from other cell types (Muller et al, 
2008),  more recent studies have identified numerous subtle differences between the two cell 
types, including differences in differentiation propensity, gene expression,  miRNA 
expression, and epigenetics (see section 1.9). In addition, iPSCs are generally less successful 
in generating high percentage chimaeras and live mice through tetraploid complementation 
than ESCs (Stadtfeld et al, 2010). These studies have led to questions about whether iPSCs 
are indeed identical to ESCs, and if they are not, what the functional implications of this 
might be for the use of iPSCs for in vitro applications such as disease modelling and drug 
screening, as well as their in vivo use for cell replacement therapy. One study has been 
carried out to investigate whether the differences observed between mouse ESCs and iPSCs 
affect their differentiation into DE. This study compared 4 iPSC lines and 2 ESC lines, and 
found considerable variability between cell lines in their propensity to form DE, although no 
overall difference between ESCs and iPSCs (Christodoulou et al, 2011). In addition, they 
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compared genetically identical mouse ESCs and iPSCs, and tried to link aberrant imprinting 
of the Dlk1-Dio3 region of chromosome 12, which has been previously described as a 
difference commonly seen between genetically identical ESCs and iPSCs (Stadtfeld et al, 
2010), with differences in endoderm formation. Although they found significant differential 
expression of BMP4 between ESCs and iPSCs during differentiation, possibly linked to this 
aberrant imprinting, this did not appear to be associated with any reduction in differentiation 
propensity (Christodoulou et al, 2011). This suggests that although transcriptional differences 
may exist between ESCs and iPSCs, they may not adversely affect the function of the cells.  
It is becoming clear that the heterogeneity and behaviour of pluripotent stem cells is more 
complex than previously thought, and that iPSCs and ESCs are neither identical nor 
completely distinct populations; instead, they seem to overlap, with greater variability within 
each population than is observed between the populations. This variability is likely to have 
functional implications for the cells, so it may be more useful to consider each cell line in 
terms of its quality and utility, in order to choose the best cell line for the application. With a 
view to this end, some researchers have generated a bioinformatics assay for pluripotency 
(Soldner et al, 2009), while others have produced a ‘scorecard’ to evaluate the character of 
both iPSCs and ESCs, and to predict the quality and utility of any pluripotent cell in a high-
throughput manner: a large-scale study by Bock et al (2011) used gene expression profiling, 
DNA methylation mapping, and a high-throughput quantitative differentiation assay to 
establish  genome-wide reference maps for patterns of gene expression and DNA methylation 
in order to provide a baseline against which comparisons of new ES and iPS cell lines can be 
made in order to assess their quality and utility. 
In conclusion, comparison of several differentiation protocols demonstrated that the protocol 
published by D’Amour et al (2006) was the most efficient, and this was used in all further 
experiments. In addition, this chapter demonstrated that both ESCs and iPSCs are able to give 
rise to DE, although at varying efficiencies. The mechanisms underlying these differences 
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Chapter 5: Identification of miRNAs that play a 
Role in the Formation of Definitive Endoderm 
  
5.1 Introduction  
MicroRNAs (miRNAs) are small (18-25 nucleotides), non-coding RNAs that regulate gene 
expression post-transcriptionally. Over 21,000 miRNAs have now been identified in 
numerous different species, according to miRBase version 19 (www.mirbase.org), and they 
are involved in almost every biological process, including development, metabolism, and 
ageing, as well as in many diseases (Slack, 2010). Cells express a miRNA signature 
characteristic of their lineage and developmental state (Strauss et al., 2006). Although the 
number of miRNAs is small compared to that of mRNAs (the human genome is thought to 
encode around 1,000 miRNAs, while the number of mRNAs is estimated to be around 
30,000), a single miRNA is able to target hundreds of mRNAs, and one mRNA may be 
targeted by several miRNAs. As a result, the potential for fine tuning of mRNA translation by 
miRNAs is enormous. 
 
5.1.1 The role of miRNAs in Pluripotency and Differentiation 
The importance of miRNAs in the maintenance of stem cell pluripotency and the control of 
cellular proliferation and differentiation was first identified through experiments disrupting 
the miRNA processing enzymes DICER and DGCR8, as DICER- and DGCR8-null ESCs 
show defects in proliferation and differentiation (Kanellopoulou et al., 2005; Wang et al., 
2007). Sequencing experiments have since shown that a small number of miRNAs are 
specifically expressed in pluripotent stem cells, and these are quickly down-regulated upon 
differentiation. These miRNAs are highly conserved between mice and humans, and include 
the miR-290 family (miR-290, miR-291a, miR-291b, miR-292, miR-293, miR-294, miR-
295) in mice (Houbaviy et al. 2003), its human homologues the miR-371 family (miR-371, 
miR-372, miR-373), and the miR-302 cluster (miR-302a, miR-302b, miR-302c, miR-302d, 
miR-367) which is present in both mice and humans (Suh et al. 2004). Many stem cell-
specific miRNAs are co-transcribed as polycistronic transcripts, suggesting common 




upstream regulation and co-ordinated expression patterns and, like the miR-520 and miR-302 
clusters (Ren et al., 2009), they often have similar seed sequences, suggesting common 
mRNA targets (Martinez & Gregory, 2010). Such a high degree of functional redundancy 
suggests that they play a critical role in maintaining the pluripotent state, and the targets of 
these miRNAs include many genes with promoters bound by the stem cell-associated 
transcription factors NANOG, SOX2 and OCT4, suggesting an important role in the 
regulation of gene expression to maintain pluripotency and self-renewal.  
Although capable of continuous self-renewal and maintenance of pluripotency, pluripotent 
stem cells are permanently poised to differentiate when the appropriate cues arise. This 
massive transformation of phenotype poses a major challenge to the cell, as the entire 
network of transcription factors and signalling pathways must be changed within a short 
developmental window. The ability of miRNAs to regulate hundreds of target genes post-
transcriptionally makes them ideally suited to bring about rapid transformations in cell 
phenotype. The switch from pluripotency to differentiation requires down-regulation of 
pluripotency-associated genes, a reduction in the signalling for self-renewal and the 
activation of early lineage-specific gene expression. These changes can be rapidly effected by 
miRNAs through the silencing of pluripotency genes and the inhibition of genes that 
negatively regulate early differentiation. Indeed, the first miRNAs to be discovered, let-7 and 
lin-4 (the mammalian homologue of which is miR-125), have been shown to play a key role 
in the transition from pluripotency to differentiation. Thus, let-7 promotes the exit from the 
cell cycle by the repression of a number of cell cycle-regulating genes (Mallanna & Rizzino, 
2010) and directly targets the 3’UTR of pluripotency genes such as c-Myc and Lin28 in order 
to regulate their expression negatively (Melton et al., 2010).  Subsequent studies have 
identified an increasing number of miRNAs that repress components of the stem 
cell/pluripotency control network. These include miR-34, miR-134, miR-145, miR-296 and 
miR-470 which, through a range of interactions, target the pluripotency genes Oct4, Sox2, 
Klf4 and Nanog (Tay et al., 2008; Xu et al., 2009). Cells express a miRNA signature 
characteristic of their lineage and developmental state, with an overall trend of increasing 
complexity in miRNA expression during differentiation, with pluripotent stem cells 
expressing relatively few miRNAs, and more differentiated cells expressing an increased 
number of miRNAs. This is in contrast to the pattern of mRNA expression, which has been 
shown to be restricted with increasing development, with fewer genes expressed in more 
mature cells (Strauss et al., 2006).  




A number of studies have now demonstrated the importance of miRNAs in commitment to a 
specific embryonic germ layer during development. In mouse ESCs, elevated levels of miR-
296 and miR-134 enhanced the expression of genes associated with differentiation toward 
ectoderm (Tay et al., 2008). In human ESCs, members of the miR-30 family have been 
shown to regulate the embryonic ectoderm development protein which is important in the 
development of the neural tube (Song et al., 2011), and miR-125 isoforms have been shown 
to potentiate early neural specification (Boissart et al., 2012). The miR-302 family is 
expressed in undifferentiated ESCs and has been shown to be critical in the maintenance of 
pluripotency but a study by Rosa et al. (2011) demonstrated that this family also plays a role 
in the earliest stages of differentiation, as in humans, repression of the Lefty1 and Lefty2 
genes by miR-302 results in increased TGF-β signalling, leading to increased endoderm and 
mesoderm formation, and decreased neuroectoderm formation (Rosa & Brivanlou,  2011). 
The miR-17-92 cluster plays an important role in mesoderm differentiation and knockout in 
mouse embryos results in severe developmental defects affecting the heart and lungs 
(Ventura et al. 2008). Foshay et al. (2009) demonstrated the importance of one member of 
this cluster, miR-93, in the regulation of both endoderm and mesoderm differentiation 
through its targeting of Stat3. miR-124 is highly expressed in human ESCs and targets two 
regulators of cytoskeletal rearrangement important in cell migration during mesodermal 
differentiation (Berardi et al., 2012). Another cluster of pluripotency-associated miRNAs, the 
miR-290 cluster, regulates Pax6 expression in early lineage commitment, and knockout of 
these miRNAs in mice resulted in an increased propensity to form ectoderm at the expense of 
mesoderm and endoderm (Kaspi et al,. 2013). 
One early event that is critical in the commitment of differentiating cells to an endodermal or 
mesodermal lineage is epithelial-to-mesenchymal transition (EMT). EMT is important in 
multiple events during early embryogenesis such as the formation of the placenta and the 
primitive streak. It ultimately leads to the generation of mesendoderm, which then gives rise 
to both the mesoderm and the endoderm. Members of the miR-200 family of miRNAs have 
been implicated in EMT and, as an example, have been shown to be important in targeting 
SIP1 (Chng et al., 2010; Korpal & Kang, 2008), which promotes neuroectoderm formation at 
the expense of mesendoderm. Therefore, the inhibition of SIP1 by the miR-200 family has a 
positive effect on the commitment to mesendoderm (Chng et al., 2010). In addition, 
downregulation of miR-200a is important in definitive endoderm formation, as it results in 
reduced repression of ZEB2, leading to downregulation of E-cadherin and subsequently 




allowing EMT (Liao et al., 2013). Other miR-200 family members also regulate EMT 
through their targets ZEB1 and ZEB2 (Gregory et al., 2008). 
 
5.1.2 The Role of miRNAs in Definitive Endoderm Formation  
Numerous miRNAs have been identified as playing a role in pancreatic development. A 
limited number of studies have investigated miRNA expression at the definitive endoderm 
(DE) stage using an Activin A-based protocol to induce pluripotent stem cells to differentiate. 
These studies have shown that DE is characterised by a unique miRNA expression signature 
(Tzur et al., 2008; Hinton et al., 2010; Tsai et al., 2010; Kim et al., 2011; Porciuncula et al., 
2013). Although there is relatively little overlap in the miRNAs identified in these studies, 
which is likely to be due to the wide range of cell lines and differentiation protocols used, 
some miRNAs, including miR-375, miR-708 and miR-744, were identified in several of the 
studies, providing strong evidence for their involvement in DE formation (Hinton et al., 
2010). However, few of these studies went on to elucidate a function for these miRNAs in 
DE formation. early study identified Timm8a as a target of miR-375 but didn’t elucidate a 
function for this pathway in the formation of endoderm (Hinton et al., 2010) and more 
recently, a study identified a direct relationship between miR-200a and Sox17 (Liao et al., 
2013) which is known to be critical in the development of DE. 
 
5.1.3 Differences in miRNA Expression between ESCs and iPSCs 
There have been several studies which have investigated differences in miRNA expression 
between ESCs and iPSCs, but although there has been some overlap in the miRNAs 
identified, so far there is little evidence for consistent differences between ESCs and iPSCs. 
Wilson et al. (2009) demonstrated that, although ESCs and iPSCs had very similar miRNA 
expression profiles, there were subtle differences between the two cell types. Specifically, 
although some stem cell-specific miRNAs were highly expressed in both ESCs and iPSCs, 
others, including the miR-520 and miR-371 clusters, were more highly expressed in ESCs 
than in iPSCs. In addition, some miRNAs, including miR-886-5p and let-7a, which are 
associated with differentiated cells, were more highly expressed in iPSCs than ESCs, 
suggesting that these miRNAs may be incompletely silenced during reprogramming. This 




study observed a downward trend in miRNA expression when transitioning from fibroblast to 
iPSC, but the expression levels of many miRNAs do not decrease to the levels observed in 
ESCs. However, this study did not report the passage numbers of the cells used. Other studies 
have reported that these differences may be alleviated after extended passaging (Chin et al., 
2009).  
In a meta-analysis focussing on differences in gene expression between ESCs and iPSCs, 
Chin et al. (2009) also carried out miRNA profiling, and found little difference in miRNA 
expression between ESCs and iPSCs; however a few miRNAs were consistently 
differentially expressed between ESCs and iPSCs. These included some of the miRNAs 
identified by Wilson et al. (2009). Another study, using a larger sample group found that 
pluripotent stem cells could be divided into two distinct groups based on their miRNA 
expression levels. However, this  segregation was not dependent on cell type as both iPSCs 
and ESCs were present in both groups:  one group consisted of mainly ESCs with some 
virally-reprogrammed  iPSCs, while the other consisted of iPSCs generated in a number of 
other ways, as well as the ESC line H9. This group did not report differences in expression of 
miR-302, miR-371 or miR-502 clusters between ESCs and iPSCs, as reported by the other 
studies mentioned (Chin et al., 2009; Wilson et al., 2009), although there was some 
variability in their expression between cell lines.  
Some of the most compelling evidence of differences in miRNA expression between ESCs 
and iPSCs comes from studies in isogenic murine ESCs and iPSCs investigating the 
imprinted Dlk1-Dio3 region of the genome, which has been shown to be the only conserved 
difference between genetically identical mouse ESCs and iPSCs. This region, containing 26 
miRNAs, is imprinted, and is maternally expressed in mammals. However, it was strongly 
repressed in most iPSCs compared to ESCs, and only iPSC lines that expressed this region 
were capable of giving rise to all-iPSC mice (Stadtfeld et al., 2010; Liu et al., 2010). 
However, it is unclear whether these differences are also seen in human stem cells, as they 
differ significantly from murine stem cells.  
While there have been several studies investigating differences in miRNA expression 
between undifferentiated ESCs and iPSCs, there have been fewer investigating differences in 
their differentiated progeny. Wilson et al. (2009) reported some differences in miRNA 
expression in embryoid bodies derived from ESCs and iPSCs. However, the functional 
significance of these differences is still unclear.  





The aim of this chapter is to investigate miRNAs which a) are up- or down-regulated upon 
differentiation to DE, and which could therefore be involved in this process; and b) are 
differentially expressed between ESCs and iPSCs, and which may lead to differences in the 
propensity of different cell lines to differentiate into DE, with a view to narrowing down the 
pool of candidate miRNAs to take forward into studies of possible function.  






5.2.1. Choice of Cell Lines 
Initial experiments were carried out using two iPSC lines generated at NIBSC, MRC5I and 
MRC9G, and a well-characterised ESC line (H9). However, the iPSC lines are grown on 
iSNL feeders, and the H9 line is grown on Matrigel™. For this reason, the H1 cell line was 
included in differentiation experiments and microarray analysis, as this is an ESC line grown 
on iSNL feeders, and was therefore expected to represent an ESC line grown in a comparable 
culture format to the available iPSC lines. 
 
5.2.2 In Vitro Differentiation of Pluripotent Stem Cells into Definitive Endoderm 
Stem cells were maintained in culture as previously described in section 2.2. Before the start 
of the differentiation protocol on day 1, samples of colonies containing undifferentiated cells 
were taken. Colonies undergoing differentiation were washed with PBS before the medium 
was changed to medium 1A (table 5.1). On day 2, the medium was changed to medium 1B, 
and differentiated colonies were harvested at the end of day 3.  
 
Stage 1 
Formation Of Definitive Endoderm 










Activin A (100ng/ml) 
Foetal Calf Serum (0.2%) 
Table 5.1. Reagents and concentrations used to direct differentiation of stem cells to definitive endoderm, as 
described in D’Amour et al (2006). 
 
5.2.3 Microarray Analysis 
Microarray analysis was used to analyse microRNA expression in samples of undifferentiated 
ESCs and iPSCs, as well as in ESCs and iPSCs that had undergone differentiation to the DE 




stage. Samples were taken in triplicate, and total RNA, including the small RNA fraction, 
was isolated as described in section 2.5.2. Microarray hybridisation and image scanning were 
carried out by Exiqon Services, Denmark, who then supplied the raw data to be analysed at 
NIBSC. Background correction, normalisation and miRNA expression analysis was carried 
out using Nexus Expression software as described in section 2.5.1. 
 
5.2.4 qRT-PCR For miRNA Expression 
Microarray results were confirmed by qRT-PCR, which is highly recommended given the 
high chance of false positive results occurring during microarray analysis, even when a 
multiple testing correction is performed. Isolation of total RNA, reverse transcription and 
qRT-PCR for the analysis of miRNA expression were carried out as described in 2.4.3.  
In order to select a suitable reference 
RNA to normalise the expression of the 
miRNAs of interest, the quantitation data 
from PCR analysis of several potential 
reference RNAs were compared and 
analysed using GenEx software across a 
range of samples from both 
differentiated and undifferentiated ES 
and iPS cells. SNORD43 was found to 
have the least variability between 
samples (figure 5.1, highlighted in red), 
so was chosen as a reference gene. 
SNORA66 was analysed in 2 separate 
assays (16.06.2011 and 17.06.2011), and 
had similar variation in both. miR-367, a pluripotency-associated miRNA, which is expected 
to vary between undifferentiated and differentiated samples, has the highest variation. This 
demonstrates the validity of this approach for choosing a reference gene for miRNA analysis. 
Figure 5.1 A plot of the standard deviation of quantitation 
data for miRNAs, analysed using GenEx software 
(Exiqon).  





5.3.1 Analysis of Microarray Results 
 
 
Figure 5.2.Principal component analysis allows identification of the factors associated with differences in 
miRNA expression between different samples. Samples which cluster closely together have more similar miRNA 
expression profiles, while samples which are further apart have more dissimilar miRNA expression profiles. 
 
Principal component analysis (PCA) is a way of looking at variance between samples. If 
biological differences between the samples are pronounced, this will be a principal 
component of the variation and the samples will separate along the axis accordingly. PCA 
allows visual identification of differences in miRNA expression related to biological or 
technical factors, providing a useful summary of the microarray data. For example, in figure 
5.2, differentiated cells (circles) cluster together, separately from undifferentiated cells 
(triangles). ESCs (red) and iPSCs (blue) also cluster separately. H9 cells cluster separately 
from the other cell lines (H1, MRC5I and MRC9G). Although the possibility exists that H9 
cells genuinely have a significantly different miRNA expression profile to other pluripotent 
stem cells, it is important to note that these cells are grown on Matrigel™ rather than iSNL 
feeders which support the growth of H1, MRC5I and MRC9G cell lines, which suggests that 
culture conditions may also have an impact on miRNA expression.  





Figure 5.3. Unsupervised hierarchical clustering analysis based on the expression of the 50 miRNAs with the 
highest variation between samples. miRNAs which are expressed at lower levels than in the reference sample 
are shown in red, while miRNAs which are expressed at higher levels are shown in green. 
 
Unsupervised hierarchical clustering analysis (figure 5.3) looks at the 50 miRNAs with the 
highest variation between samples to see how either samples (horizontal clusters) or miRNAs 
(vertical clusters) cluster together based on this variance. Hierarchical clustering treats each 
data point as a single cluster, and then successively merges clusters based on their similarity 
until all points have been merged into a single cluster. This is represented by the 




dendrograms.  This allows quick visual identification of the samples which are most similar 
in terms of their miRNA expression profile.  
Figure 5.3 shows that the two iPSC lines (MRC5I and MRC9G) cluster together, with 
undifferentiated samples distinct from differentiated samples. This shows that these iPSC 
lines are highly similar in terms of their miRNA expression, both at the undifferentiated and 
the DE stage. The H1 ESC line, which is grown on feeders, is the most similar to these iPSC 
lines, but clusters separately from them, indicating differences in miRNA expression. The H9 
cell line, which is grown on Matrigel™, clusters separately both from the iPSC lines and the 
ESC line on feeders, again suggesting that different culture conditions may result in 
differences in miRNA expression patterns in this cell line. Figure 5.3 clearly shows that many 
of the 50 miRNAs shown are differentially expressed in H9 compared to the other cell lines, 
confirming the likely distinctions identified in the PCA.  
Figure 5.3 also shows that miRNAs from the same family cluster together: for example, miR-
373-3p, miR-371a-3p, and miR-371a-5p cluster together at the top of the list. These miRNAs 
are all part of the same family, whose members are highly expressed in pluripotent stem cells, 
where they play an important role in maintaining pluripotency (Suh et al, 2004). Several 
members of the let-7 family, which play a role in differentiation (Morin et al., 2008) are also 
seen to cluster together. Several members (miR-17-5p, miR-106a-5p, miR-20b-5p, miR-19b-
3p, miR-20a-5p) of the miR-17~25 cluster, composed of two miRNA families, which are 
involved in maintaining pluripotency and controlling differentiation (Laurent et al., 2008), 
also cluster together at the bottom of the list. These results suggest that miRNAs from the 
same families, which are likely to be present in the same regions of the genome, and to be co-
regulated and co-transcribed, have similar expression patterns in these samples. In addition, 
the 3p and 5p forms of some miRNAs also cluster together e.g. miR-371a-3p and -5p; miR-
135a-3p and -5p. These different forms of the miRNA are derived from different ends of the 
same pre-miRNA molecule, and are separated as the miRNAs are processed (see figure 1.10), 
which means that their expression patterns are highly similar, although they are likely to have 
different target genes. This indicates that the results of the microarray follow expected 
biological patterns and offers confidence in the validity of the results. 




miRNAs Differentially Expressed Between Undifferentiated & Differentiated Samples 
 
Table 5.2. Comparison of miRNA expression in differentiated vs. undifferentiated samples, allowing 
identification of the 10 miRNAs most highly up- (upper table, highlighted in green) or down- (lower table, 
highlighted in red) regulated during differentiation of ESCs and iPSCs to definitive endoderm. Individual 
comparisons were carried out for ESCs, iPSCs and each individual cell line included in the microarray 
analysis. Lighter shades denote miRNAs with a p-value of < 0.1, darker shades denote miRNAs with a p-value 
of < 0.05  
 
Comparison of differentiated and undifferentiated samples was carried out between ESCs, 
iPSCs and for each individual cell line included in the microarray analysis. A total of 82 
miRNAs were identified as being differentially expressed between differentiated and 
undifferentiated ESCs (shown in supplementary table 1) and 86 miRNAs were differentially 
expressed between differentiated and undifferentiated iPSCs (shown in supplementary table 
2). These miRNAs may play a role in differentiation to DE. As it is not practical to further 
investigate so many results, the miRNAs were ranked by p-value, and the top 10 miRNAs 
which were most highly up- or down-regulated in ESCs and iPSCs were selected for further 




analysis and are shown in table 5.2. The expression of these miRNAs in each individual cell 
line included in the microarray analysis is also shown in table 5.2, showing some variability 
in expression of these miRNAs between cell lines, but also that the pattern of up- or down-
regulation is similar in many of the cell lines. For example, miR-375 is consistently 
upregulated in all the cell lines tested, although this upregulation is not statistically significant 
in MRC9G. The same is true for miR-708, which is strongly upregulated in most cell lines, 
and moderately upregulated in H1. The patterns are less strong for miRNAs which are down-
regulated in DE formation, perhaps because this is such an early stage of differentiation. 
Several miRNAs on the list have been previously described as being expressed at the DE 
stage, including miR-375 (Poy et al., 2004; Kloosterman et al., 2007; Tzur et al; 2008; 
Hinton et al, 2009; Kim et al, 2011), miR-708-5p (Hinton et al, 2009; Kim et al, 2011), and 
miR-744 (Kim et al, 2011), suggesting that the DE generated in these studies is similar to that 
generated by other researchers with respect to its miRNA expression profile. 
However, the very different propensities of H1 and H9 to give rise to DE (see chapter 4), and 
the fact that the different culture formats (feeders vs. Matrigel™) may well result in 
significant differences in miRNA expression, means that combining the data for these cell 
lines in order to identify miRNAs involved in DE formation could potentially lead to 
important candidate miRNAs being overlooked for further study. For this reason, the analysis 
was repeated, firstly excluding H1, which has a low propensity for DE formation, and then 
excluding H9, which has a unique miRNA expression pattern. The top 10 miRNAs most 
highly up- and down-regulated in each analysis are shown in tables 5.3 and 5.4, respectively. 
miRNAs also identified in table 5.2 are shown in bold. 
  





Table 5.3 Comparison of differentiated vs. undifferentiated samples from iPSCs and H9 showing the 10 
miRNAs most highly up- (left table, highlighted in green) or down- (right table, highlighted in red) regulated 
during differentiation of H9 and iPSCs to definitive endoderm. Lighter shades denote miRNAs with a p-value 
of < 0.1, darker shades denote miRNAs with a p-value of < 0.05. miRNAs which also appear on the top 10 list 
when all cell lines are included in the analysis are shown in bold. 
 
Table 5.3 shows the top 10 miRNAs most highly up- or down-regulated upon DE formation 
when H1 is excluded from the analysis. There are considerable differences between iPSCs 
and H9, with several miRNAs that are strongly upregulated in iPSCs being downregulated in 
H9 (e.g. miR-302c-3p, miR-4791) and vice versa (e.g. miR-491-3p, miR-9-3p), with the 
result that several of these miRNAs appear on both the lists of miRNAs most strongly 
upregulated in DE formation and most strongly downregulated. These miRNAs are clearly 
candidates for further study and again shows that differentiating iPSC lines exhibit a distinct 
miRNA expression pattern to differentiating H9 cells, even though the differentiation 
propensity is not manifestly different from analyses of mRNA expression (see chapter 4). 
miRNAs which also appear in table 5.2 are shown in bold, and include miR-708-5p, miR-375 
and miR-4530, which are strongly upregulated in both iPSC lines and H9. 
 




Table 5.4. Top 10 miRNAs most highly up- (left table, highlighted in green) or down- (right table, highlighted 
in red) regulated during differentiation of H1 and iPSCs to definitive endoderm. Lighter shades denote 
miRNAs with a p-value of < 0.1, darker shades denote miRNAs with a p-value of < 0.05. miRNAs which also 
appear on the top 10 list when all cell lines are included are shown in bold. 
 
Table 5.4 shows the top 10 miRNAs most highly up- or down-regulated upon DE formation 
when H9 is excluded from the analysis. There is considerably more overlap between this 
analysis and the analysis including all the cell lines than in the analysis excluding H1 (table 
5.3), suggesting that, as expected from the PCA and hierarchical clustering, iPSCs and H1 
ESCs exhibit more similarity in their miRNA expression patterns than iPSCs vs. H9 ESCs, 
possibly as a result of both populations being grown on feeders. This is particularly true for 
miRNAs that are downregulated in DE formation, including miR-4732-3p, miR-3941, miR-
4436b-5p, miR-124-5p, and miR-4284. Once again, the miRNAs that are consistently 
upregulated include miR-708-5p and miR-375, further suggesting a role for these miRNAs in 
DE formation.  
Comparisons of differentiated and undifferentiated samples were also carried out for each 
individual cell line. 28 miRNAs were significantly upregulated in MRC5I, while 5 were 
downregulated (supplementary table 3). 24 miRNAs were significantly upregulated in 
MRC9G, while 34 were downregulated (supplementary table 4). 106 miRNAs were 
significantly upregulated in H9, while 48 were downregulated (supplementary table 5). 52 
miRNAs were significantly upregulated in H1, while 16 were downregulated (supplementary 
table 6). The top 10 most highly up- and down-regulated miRNAs for each cell line are 
shown in tables 5.5, 5.6, 5.7 and 5.8. miRNAs also identified in table 5.2 are shown in bold. 




Once again, the miRNAs that appear most frequently on the lists of miRNAs up-regulated in 
DE formation include miR-708-5p and miR-375, which is a strong indication that these 
miRNAs play an important role in DE formation. Many of the miRNAs downregulated in DE 
formation also appear in these individual analyses, although these are less consistent between 
cell lines. This suggests that the combined analysis is an adequate starting point for the 
identification of miRNA species for validation by qRT-PCR and ultimately for further studies 
of function. In addition, miRNA species which are differentially expressed in iPSCs when 
compared to the ESC cell lines individually (i.e. H1 or H9) will also be investigated by qRT-
PCR, e.g. miR-302c-3p, miR-4791, and miR-491-3p.   
  
Table 5.8. Comparison of 
differentiated vs. undifferentiated 
samples, showing the top 10 miRNAs 
up- and down-regulated upon 
endoderm formation in the MRC5I 
cell line. Lighter shades denote 
miRNAs with a p-value of < 0.1, darker 
shades denote miRNAs with a p-value 
of < 0.05. miRNAs which also appear 
on the top 10 list when all cell lines are 
included are shown in bold. Only 5 
miRNAs were significantly down-
regulated in this cell line.  
 
 
Table 5.5. Comparison of 
differentiated vs. undifferentiated 
samples, showing the top 10 miRNAs 
up- and down-regulated upon 
endoderm formation in the H9 cell 
line. Lighter shades denote miRNAs 
with a p-value of < 0.1, darker shades 
denote miRNAs with a p-value of < 
0.05. miRNAs which also appear on the 
top 10 list when all cell lines are 
included are shown in bold. Only 9 
miRNAs were significantly down-





Table 5.7. Comparison of 
differentiated vs. undifferentiated 
samples, showing the top 10 miRNAs 
up- and down-regulated upon 
endoderm formation in the MRC9G 
cell line. Lighter shades denote 
miRNAs with a p-value of < 0.1, darker 
shades denote miRNAs with a p-value 
of < 0.05. miRNAs which also appear 
on the top 10 list when all cell lines are 
included are shown in bold. 
Table 5.6. Comparison of 
differentiated vs. undifferentiated 
samples, showing the top 10 miRNAs 
up- and down-regulated upon 
endoderm formation in the H1 cell 
line. Lighter shades denote miRNAs 
with a p-value of < 0.1, darker shades 
denote miRNAs with a p-value of < 
0.05. miRNAs which also appear on 
the top 10 list when all cell lines are 
included are shown in bold. 
 
  
miRNAs Differentially Expressed Between iPSCs & ESCs: Undifferentiated Samples 
When undifferentiated iPSCs and undifferentiated ESCs were compared, there were no 
miRNAs that were significantly differently expressed, suggesting that starting populations of 
these cell populations are equivalent in terms of their miRNA expression. This was a rather 
surprising result and is in contrast to several previous studies (Wilson et al, 2009; Chin et al, 
2009; Neveu et al, 2010), which reported miRNAs that were differentially expressed between 
undifferentiated iPSCs and ESCs. Since this result was unexpected, and since we know that 
H9 and H1 ESC lines exhibit different miRNA expression profiles, undifferentiated iPSCs 
were also compared with undifferentiated H1 and H9 ESC lines individually.  
When undifferentiated iPSCs were compared to undifferentiated H1, only 5 miRNAs were 
significantly differentially expressed: 3 were down regulated in iPSCs compared to H1, and 2 
were upregulated (supplementary table 7). The fact that so few miRNAs are differentially 
expressed between H1 and the two iPSC lines suggest that they are very similar in the 
undifferentiated state. However, when undifferentiated iPSCs were compared to 
undifferentiated H9, 186 miRNAs were differentially expressed: 107 were downregulated in 
iPSCs compared to H9 and 79 were upregulated (supplementary table 8). The large number 
of miRNAs differentially expressed between H9 and the iPS cell lines suggests that even in 
the undifferentiated state, culture conditions can influence miRNA expression levels. This is 
despite the extensive characterisation carried out on these cells which showed that these cell 
lines are equivalent in terms of their expression of pluripotency genes (see chapter 3). 
 
miRNAs Differentially Expressed Between iPSCs & ESCs: Differentiated Samples 
91 miRNAs were significantly (p < 0.05) differentially expressed between differentiated 
iPSCs and ESCs (table 5.9). 61 miRNAs were downregulated in iPSCs vs. ESCs (red), while 
30 were upregulated (green). Several of these miRNAs were also identified as being up- or 
down-regulated in differentiated samples compared to undifferentiated samples (table 5.2), 
and these are shown in bold. 
  




Comparison of miRNA Expression in  
Differentiated iPSCs vs. Differentiated ESCs 
miRNA p-value LogFC 
hsa-miR-151a-5p 0.0035 -0.737 
hsa-miR-151b 0.0035 -1.3088 
hsa-miR-99b-5p 0.0035 -1.3789 
hsa-miR-125a-5p 0.0036 -0.8069 
hsa-miR-130a-3p 0.0043 -0.6481 
hsa-miR-181a-5p 0.0043 -2.0135 
hsa-miR-191-5p 0.0043 -0.6342 
hsa-miR-197-3p 0.0043 -0.3174 
hsa-miR-30b-5p 0.0043 -0.9451 
hsa-miR-30c-5p 0.0043 -0.8929 
hsa-miR-320a 0.0043 -0.6468 
hsa-miR-320c 0.0043 -0.9285 
hsa-miR-335-5p 0.0043 -0.9878 
hsa-miR-3653 0.0043 -0.5547 
hsa-miR-3685 0.0043 0.2931 
hsa-miR-423-3p 0.0043 -0.8026 
hsa-miR-20a-5p 0.0046 -0.9107 
hsa-miR-27b-3p 0.005 -0.9839 
hsa-miR-15b-5p 0.0054 -0.4956 
hsa-miR-320b 0.0054 -0.7598 
hsa-miR-181d 0.0056 -1.9588 
hsa-miR-30d-5p 0.0056 -0.5706 
hsa-miR-204-3p 0.0064 0.7034 
hsa-miR-4419b 0.0064 0.4019 
hsa-miR-4505 0.0064 0.7786 
hsa-miR-454-3p 0.0064 -0.8979 
hsa-miR-92a-3p 0.0064 -0.6663 
hsa-miR-103a-3p 0.0104 -0.7494 
hsa-miR-151a-3p 0.0104 -0.4902 
hsa-miR-16-5p 0.0107 -0.5991 
hsa-miR-4484 0.0116 1.1915 
hsa-miR-17-5p 0.0122 -0.8922 
hsa-miR-3646 0.0122 0.3478 
hsa-miR-106a-5p 0.0143 -0.8975 
hsa-miR-30e-5p 0.0143 -0.6218 
hsa-miR-4532 0.0143 0.6558 
hsa-miR-93-5p 0.0143 -0.6366 
hsa-miR-130b-3p 0.0149 -1.2139 
hsa-miR-181b-5p 0.0152 -1.446 
hsa-miR-3687 0.0152 -1.0384 
hsa-miR-26b-5p 0.0154 -0.4076 
hsa-miR-4299 0.0154 0.4855 
hsa-miR-711 0.0165 0.9775 
hsa-miR-107 0.018 -0.7897 
hsa-miR-19a-3p 0.0183 -0.6169 
hsa-miR-106b-5p 0.0191 -0.8247 
hsa-miR-1587 0.0191 0.7501 
hsa-miR-34a-5p 0.0191 -0.6565 
hsa-miR-378a-3p 0.0191 0.23 
hsa-miR-4780 0.0191 -0.3121 
hsa-miR-135b-5p 0.0193 -1.6118 
hsa-miR-4284 0.0195 -0.2847 
hsa-miR-17-3p 0.0197 -0.7416 
hsa-miR-513a-5p 0.0199 0.4952 
hsa-miR-342-3p 0.0218 -0.9452 
hsa-miR-19b-3p 0.0219 -0.8428 
hsa-miR-4657 0.0248 -0.6466 
hsa-miR-331-3p 0.0255 -0.6998 
hsa-miR-4792 0.0255 0.8258 
hsa-miR-150-5p 0.0261 0.1916 
hsa-miR-4286 0.0263 -0.6974 
hsa-miR-4301 0.0263 -0.5148 
hsa-miR-9-3p 0.0263 -2.1832 
hsa-miR-335-3p 0.0277 -0.2762 
hsa-miR-92b-3p 0.0277 -0.9395 
hsa-miR-18b-5p 0.0284 -0.8408 
hsa-miR-1273g-3p 0.0305 -0.334 
hsa-miR-4417 0.0305 -1.487 
hsa-miR-4714-5p 0.0305 -0.3333 
hsa-miR-4530 0.0314 0.7268 
hsa-miR-4289 0.0321 -0.9101 
hsa-miR-4508 0.0338 0.8684 
hsa-miR-4726-5p 0.0343 0.4853 
hsa-miR-1909-3p 0.035 0.2531 
hsa-let-7c 0.036 0.8174 
hsa-miR-149-3p 0.0378 0.5623 
hsa-miR-25-3p 0.0378 -0.4055 
hsa-miR-548an 0.0378 -0.2313 
hsa-miR-9-5p 0.0378 -2.257 
hsa-miR-654-3p 0.0394 0.7269 
hsa-miR-3201 0.0413 0.6605 
hsa-miR-15a-5p 0.0427 -0.6342 
hsa-miR-936 0.0433 0.9696 
hsa-miR-4747-5p 0.0434 0.8154 
hsa-miR-4667-5p 0.0447 0.328 
hsa-miR-30c-1-3p 0.0465 0.3686 
hsa-let-7g-5p 0.0475 1.1879 
hsa-miR-4712-3p 0.0479 -0.2099 
 
Table 5.9. miRNAs significantly (p < 0.05) differentially expressed between iPSCs and ESCs that had been 
directed to differentiate into definitive endoderm, ranked in order of significance. miRNAs that are upregulated 
in iPSCs vs. ESCs are highlighted in green, while miRNAs that are downregulated in iPSCs vs. ESCs are 
highlighted in red. The miRNAs that are also included on the lists of miRNAs most highly up- or down-regulated 
during endoderm formation are in bold.  
 
 




However, given the very different propensities of H1 and H9 to give rise to DE, and the fact 
that the different culture methods appear to result in significant differences in miRNA 
expression, combining the data for these cell lines in order to identify miRNAs differently 
expressed between ESCs and iPSCs is problematic. For this reason, the analysis was 
repeated, firstly excluding H9 to eliminate any differences derived from culture methods 
(table 5.10), and secondly excluding H1, which does not have a high propensity for DE 
formation (table 5.11). Finally, a comparison of differentiated H1 and H9 was carried out 
(table 5.12). 
Comparison of miRNA Expression in 
Differentiated iPSCs vs. Differentiated H1 
miRNA LogFC P-Value 
hsa-miR-371a-5p 1.8662 0.018 
hsa-miR-4288 0.4336 0.018 
hsa-miR-3653 0.6953 0.018 
hsa-miR-23b-3p 1.4598 0.018 
hsa-miR-24-3p 1.1901 0.018 
hsa-miR-23a-3p 1.428 0.018 
hsa-miR-181a-5p 1.0852 0.018 
hsa-miR-27b-3p 1.2984 0.019 
hsa-miR-34a-5p 1.0237 0.019 
hsa-miR-125a-5p 0.9247 0.0213 
hsa-miR-222-3p 0.4793 0.0213 
hsa-miR-363-3p -0.8662 0.0213 
hsa-miR-373-3p 1.7474 0.0213 
hsa-miR-151a-5p 0.6916 0.0213 
hsa-miR-27a-3p 1.2937 0.0213 
hsa-miR-2355-3p 0.756 0.0359 
hsa-miR-371a-3p 1.6578 0.0403 
hsa-miR-708-5p -0.6927 0.0408 
hsa-miR-30c-5p 0.5951 0.0408 
hsa-miR-22-3p 0.7858 0.042 
hsa-miR-99b-5p 1.1732 0.042 
hsa-miR-30b-5p 0.7343 0.042 
hsa-miR-1909-3p -0.3628 0.042 
hsa-miR-518b -0.3893 0.042 
hsa-miR-151a-3p 1.2359 0.042 
hsa-miR-302d-5p -0.2972 0.042 
hsa-miR-181d 1.0152 0.0426 
hsa-miR-21-5p 1.117 0.0478 
 
Table 5.10.miRNAs significantly (p < 0.05) differentially expressed between differentiated iPSCs and 
differentiated H1.  miRNAs that are upregulated in iPSCs vs. H1 are highlighted in green, while miRNAs that 
are downregulated in iPSCs vs. H1 are highlighted in red. The miRNAs that are also included on the lists of 









Comparison of miRNA Expression in   
Differentiated iPSCs vs. Differentiated H9 
miRNA LogFC P-Value 
hsa-miR-29a-3p -3.3296 0 
hsa-miR-17-5p 1.2259 0 
hsa-miR-200c-3p -2.6019 0 
hsa-miR-181a-5p 2.6324 0 
hsa-miR-106a-5p 1.2456 0 
hsa-miR-107 1.1469 0 
hsa-miR-130b-3p 1.7291 0 
hsa-miR-92b-3p 1.4253 0 
hsa-miR-31-5p -1.7119 0 
hsa-miR-92a-3p 0.8751 0 
hsa-let-7d-5p -1.5536 0 
hsa-miR-4288 -0.6438 0 
hsa-miR-3687 1.4838 0 
hsa-miR-20b-5p 1.2647 0 
hsa-miR-1827 -1.9765 0 
hsa-miR-151a-5p 0.7672 0 
hsa-miR-4747-5p -1.2849 0 
hsa-miR-181d 2.5878 0 
hsa-miR-4501 -3.2632 0 
hsa-miR-4289 1.3984 0 
hsa-miR-93-5p 0.8917 0 
hsa-miR-936 -1.517 0 
hsa-miR-103a-3p 0.9847 0 
hsa-miR-363-3p 1.5835 0 
hsa-miR-9-3p 3.2816 0 
hsa-miR-423-3p 0.993 0 
hsa-let-7g-5p -1.9037 0 
hsa-miR-199a-3p -1.7248 0 
hsa-miR-22-3p -1.5781 0 
hsa-miR-135b-5p 2.3319 0 
hsa-miR-30c-5p 1.0914 0 
hsa-miR-373-3p -2.6799 0.0001 
hsa-miR-106b-5p 1.1741 0.0001 
hsa-miR-320c 1.1126 0.0001 
hsa-miR-4500 -0.488 0.0001 
hsa-miR-20a-5p 1.1417 0.0001 
hsa-miR-342-3p 1.373 0.0001 
hsa-miR-135a-5p 2.1674 0.0001 
hsa-miR-361-5p 0.9664 0.0001 
hsa-miR-124-3p 1.533 0.0001 
hsa-miR-17-3p 1.0524 0.0001 
hsa-miR-513a-5p -0.6881 0.0001 
hsa-miR-30b-5p 1.0857 0.0001 
hsa-let-7i-5p -1.6503 0.0001 
hsa-miR-34c-5p -1.0879 0.0001 
hsa-let-7c -1.2486 0.0001 
hsa-miR-9-5p 3.494 0.0001 
hsa-miR-130a-3p 0.7934 0.0001 
hsa-miR-18b-5p 1.249 0.0001 
hsa-miR-4484 -1.5818 0.0001 
hsa-miR-371a-5p -1.8858 0.0001 
hsa-miR-454-3p 1.0835 0.0001 
hsa-miR-25-3p 0.6245 0.0001 
hsa-miR-141-3p -1.5852 0.0001 
hsa-miR-214-3p -1.3622 0.0001 
hsa-miR-221-3p -0.8206 0.0002 
hsa-miR-4419b -0.5062 0.0002 
hsa-miR-199a-5p -1.6738 0.0002 
hsa-miR-181b-5p 2.0125 0.0002 
hsa-miR-19b-3p 1.1852 0.0002 
hsa-miR-320a 0.7557 0.0003 
hsa-miR-4532 -0.8479 0.0004 
hsa-miR-222-3p -0.5013 0.0004 
hsa-miR-99b-5p 1.5161 0.0004 
hsa-miR-331-3p 1.0019 0.0005 
hsa-miR-29b-3p -2.0941 0.0005 
hsa-miR-30e-5p 0.8051 0.0006 
hsa-miR-877-5p 0.4864 0.0006 
hsa-miR-27b-3p 0.7742 0.0007 
hsa-miR-320b 0.8703 0.0007 
hsa-let-7b-5p -1.1435 0.0007 
hsa-miR-4299 -0.6563 0.0007 
hsa-miR-4284 0.3662 0.0007 
hsa-miR-151a-5p 1.3574 0.0008 
hsa-miR-371a-3p -1.8188 0.0008 
hsa-miR-335-5p 1.0916 0.0008 
hsa-miR-4726-5p -0.6872 0.0009 
hsa-miR-191-5p 0.7445 0.001 
hsa-miR-340-5p 0.9998 0.0011 
hsa-miR-18a-3p 0.6234 0.0017 
hsa-miR-15b-5p 0.5813 0.0017 
hsa-miR-2355-3p -0.6624 0.0018 
hsa-let-7a-5p -0.778 0.002 
hsa-miR-3653 0.4609 0.002 
hsa-miR-302a-3p 0.4046 0.0022 
hsa-miR-4521 0.8567 0.0022 
hsa-miR-15a-5p 0.9395 0.0023 
hsa-miR-197-3p 0.353 0.0023 
hsa-miR-19a-3p 0.7923 0.0024 




hsa-miR-125a-5p 0.7283 0.0026 
hsa-miR-16-5p 0.7372 0.0026 
hsa-miR-302c-3p 0.415 0.0028 
hsa-miR-424-5p -0.6669 0.0038 
hsa-miR-4505 -0.8631 0.0039 
hsa-miR-151a-3p 0.4639 0.0041 
hsa-miR-302b-5p 0.4751 0.0042 
hsa-miR-4687-3p 0.4767 0.0042 
hsa-miR-21-5p -0.9605 0.0043 
hsa-miR-3201 -0.8782 0.0044 
hsa-miR-4417 2.0142 0.0046 
hsa-miR-711 -1.1984 0.0048 
hsa-miR-3685 -0.2898 0.0057 
hsa-miR-4800-5p -0.9898 0.0066 
hsa-miR-365a-3p -0.2632 0.0067 
hsa-miR-548an 0.3144 0.008 
hsa-miR-205-5p -0.9881 0.008 
hsa-miR-3611 -0.8365 0.0083 
hsa-miR-106b-3p 0.5294 0.0085 
hsa-miR-30d-5p 0.5454 0.009 
hsa-miR-4475 -0.7388 0.0091 
hsa-miR-34a-5p 0.4117 0.01 
hsa-miR-204-3p -0.6755 0.01 
hsa-miR-4780 0.3391 0.0102 
hsa-miR-26b-5p 0.4187 0.0102 
hsa-miR-659-3p -0.3752 0.0104 
hsa-miR-302d-5p 0.2053 0.0108 
hsa-miR-302f 0.2863 0.0109 
hsa-miR-4508 -1.1427 0.0112 
hsa-miR-585 0.5165 0.0126 
hsa-miR-302a-5p 0.3851 0.0131 
hsa-miR-378a-3p -0.2707 0.0142 
hsa-miR-1587 -0.8565 0.0154 
hsa-miR-148b-3p 0.5833 0.0154 
hsa-miR-374b-5p 0.7289 0.0167 
hsa-miR-520c-3p 0.4135 0.0167 
hsa-miR-3646 -0.3297 0.0193 
hsa-miR-155-5p -0.5876 0.0194 
hsa-miR-548ap-5p 0.3937 0.02 
hsa-miR-3924 -0.5755 0.0203 
hsa-miR-5002-5p -0.3993 0.0203 
hsa-miR-299-5p 0.5036 0.0206 
hsa-miR-1275 -0.4743 0.0235 
hsa-miR-302e 0.3684 0.0246 
hsa-miR-1285-3p 0.3768 0.0262 
hsa-miR-4657 0.6929 0.0263 
hsa-miR-4478 0.3008 0.0273 
hsa-miR-1915-3p 0.4853 0.0284 
hsa-miR-143-3p -0.7689 0.0297 
hsa-miR-3183 0.3325 0.0327 
hsa-miR-302b-3p 0.3255 0.0333 
hsa-miR-4530 -0.795 0.0348 
hsa-miR-182-5p -0.3582 0.0349 
hsa-miR-4792 -0.8801 0.0358 
hsa-miR-3656 0.282 0.0359 
hsa-miR-634 0.1949 0.0359 
hsa-miR-665 0.4129 0.0396 
hsa-miR-335-3p 0.2642 0.0421 
hsa-miR-4286 0.7085 0.0425 
hsa-miR-4714-5p 0.3298 0.0473 
hsa-miR-3182 0.7784 0.0486 
hsa-miR-3156-3p 0.2378 0.0486 
hsa-miR-4301 0.4719 0.0488 
hsa-miR-140-3p 0.5838 0.0488 
hsa-miR-23a-3p -0.2527 0.0488 
Table 5.11. miRNAs significantly (p < 0.05) differentially expressed between differentiated iPSCs and 
differentiated H9. miRNAs that are upregulated in iPSCs vs. H9 are highlighted in green, while miRNAs that 
are downregulated in iPSCs vs. H9 are highlighted in red. The miRNAs that are also included on the lists of 
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Comparison of miRNA Expression in 
Differentiated H1 vs. Differentiated H9 
miRNA Log FC p-value 
hsa-miR-340-3p -0.4991 0.0017 
hsa-miR-31-5p 1.9208 0.0053 
hsa-miR-363-3p -2.4497 0.0053 
hsa-miR-371a-3p 3.4766 0.0053 
hsa-miR-373-3p 4.4272 0.0053 
hsa-miR-584-5p -1.0799 0.0053 
hsa-miR-371a-5p 3.752 0.0053 
hsa-miR-4288 1.0774 0.0053 
hsa-miR-3941 0.2222 0.0053 
hsa-miR-642b-3p -1.235 0.0053 
hsa-miR-29a-3p 3.4275 0.0053 
hsa-miR-4454 0.7002 0.0053 
hsa-miR-375 -0.4237 0.0053 
hsa-miR-135a-5p -2.5126 0.0062 
hsa-miR-22-3p 2.3639 0.0063 
hsa-miR-221-3p 1.034 0.0063 
hsa-miR-3116 -0.5492 0.0063 
hsa-miR-664-3p -0.3895 0.0067 
hsa-miR-34c-5p 1.3234 0.0071 
hsa-miR-29b-3p 2.0456 0.0075 
hsa-miR-361-5p -0.966 0.0078 
hsa-miR-200c-3p 3.0395 0.0091 
hsa-miR-1908 -0.4547 0.0098 
hsa-miR-21-5p 2.0775 0.0104 
hsa-miR-665 -0.6988 0.0105 
hsa-miR-518b -0.2902 0.0106 
hsa-miR-1915-3p -1.1319 0.0118 
hsa-let-7g-5p 1.7895 0.0118 
hsa-miR-1827 1.9613 0.0118 
hsa-miR-182-5p 0.8887 0.0121 
hsa-miR-4687-3p -0.723 0.0121 
hsa-miR-3158-5p -0.6867 0.0123 
hsa-miR-574-3p 0.4143 0.0123 
hsa-miR-302c-3p -0.7537 0.0127 
hsa-miR-302b-5p -0.555 0.0127 
hsa-miR-4788 -0.931 0.0134 
hsa-miR-423-5p -0.1657 0.0134 
hsa-let-7i-5p 1.5926 0.0134 
hsa-miR-141-3p 2.0581 0.014 
hsa-miR-3195 -1.0326 0.014 
hsa-miR-23a-3p 1.6807 0.014 
hsa-miR-424-5p 0.935 0.014 
hsa-miR-205-5p 2.0712 0.014 
hsa-miR-199a-3p 1.9192 0.0151 
hsa-miR-222-3p 0.9806 0.0151 
hsa-miR-92b-3p -1.2144 0.0151 
hsa-miR-4289 -1.2209 0.0151 
hsa-miR-2355-3p 1.4183 0.0151 
hsa-miR-4750 -0.6062 0.0151 
hsa-miR-4732-5p -1.3053 0.0154 
hsa-miR-214-3p 1.6785 0.0158 
hsa-miR-124-3p -1.8288 0.0158 
hsa-miR-3924 1.1683 0.0158 
hsa-miR-3656 -0.6829 0.0158 
hsa-miR-4674 -0.9545 0.0158 
hsa-miR-4501 3.4363 0.0158 
hsa-miR-99b-3p -0.3322 0.0158 
hsa-miR-4725-3p -0.6959 0.0166 
hsa-miR-130b-3p -1.2881 0.0174 
hsa-miR-4429 0.51 0.0174 
hsa-miR-4707-5p -0.6952 0.0174 
hsa-let-7b-5p 1.0822 0.0179 
hsa-miR-181b-5p -1.4162 0.0183 
hsa-miR-3940-5p -0.7796 0.0183 
hsa-miR-199a-5p 1.9867 0.0183 
hsa-miR-492 -0.5573 0.0183 
hsa-miR-4436b-5p 0.2129 0.0189 
hsa-miR-107 -0.893 0.019 
hsa-miR-155-5p 1.145 0.019 
hsa-miR-18b-5p -1.0206 0.019 
hsa-miR-3687 -1.1135 0.019 
hsa-miR-3621 -0.8171 0.019 
hsa-miR-454-3p -0.7424 0.019 
hsa-miR-4475 0.6704 0.019 
hsa-miR-93-5p -0.6378 0.019 
hsa-miR-9-5p -3.0924 0.019 
hsa-miR-25-3p -0.5475 0.019 
hsa-miR-181a-5p -1.5472 0.019 
hsa-miR-302f -0.4464 0.019 
hsa-miR-135b-5p -1.8001 0.0198 
hsa-miR-4500 0.5582 0.0198 
hsa-miR-663a -1.2821 0.0198 
hsa-let-7d-5p 1.4661 0.0201 
hsa-miR-585 -0.7841 0.0203 
hsa-miR-302b-3p -0.4837 0.0206 
hsa-miR-4747-5p 1.1736 0.0206 
hsa-miR-15a-5p -0.7632 0.0207 
hsa-miR-24-3p 1.1876 0.0211 
hsa-miR-943 -0.6964 0.0217 
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hsa-miR-302a-5p -0.542 0.0221 
hsa-miR-299-5p -0.5708 0.0225 
hsa-miR-181d -1.5727 0.023 
hsa-miR-3162-3p -0.7361 0.0233 
hsa-miR-23b-3p 1.2015 0.0236 
hsa-miR-516b-5p -0.1073 0.0238 
hsa-miR-20b-5p -1.1864 0.0238 
hsa-miR-302e -0.5172 0.0238 
hsa-miR-302d-5p -0.5025 0.0238 
hsa-miR-96-5p 0.4278 0.0244 
hsa-miR-3591-5p 0.4059 0.0244 
hsa-miR-520c-3p -0.5002 0.0247 
hsa-miR-3183 -0.6093 0.0247 
hsa-miR-9-3p -2.7459 0.0254 
hsa-miR-193b-3p 0.6602 0.0265 
hsa-miR-4299 0.427 0.0272 
hsa-miR-936 1.3686 0.0272 
hsa-miR-660-3p -0.287 0.0273 
hsa-miR-4768-5p -0.7331 0.0273 
hsa-miR-5100 0.7137 0.0273 
hsa-miR-1323 -0.2217 0.0276 
hsa-let-7c 1.078 0.028 
hsa-miR-331-3p -0.7551 0.0289 
hsa-miR-877-5p -0.4579 0.0292 
hsa-miR-4451 -0.1507 0.0303 
hsa-miR-25-5p -0.8015 0.0303 
hsa-miR-140-3p -0.2999 0.0305 
hsa-miR-27a-3p 1.3614 0.0305 
hsa-miR-342-3p -1.0695 0.0307 
hsa-miR-1299 0.1187 0.0312 
hsa-miR-106b-3p -0.4973 0.0313 
hsa-miR-574-5p 0.2894 0.0314 
hsa-miR-340-5p -0.9276 0.0314 
hsa-miR-4258 -0.4585 0.0322 
hsa-miR-874 -1.0039 0.0322 
hsa-miR-302a-3p -0.6523 0.0323 
hsa-miR-1285-3p -0.3082 0.033 
hsa-miR-106b-5p -0.8736 0.0333 
hsa-miR-638 -0.6155 0.0333 
hsa-miR-5572 -0.3801 0.0339 
hsa-miR-552 -0.5116 0.0345 
hsa-miR-17-3p -0.777 0.0357 
hsa-miR-365a-3p 0.6473 0.037 
hsa-miR-1290 -0.6166 0.037 
hsa-miR-4516 -0.6803 0.037 
hsa-miR-483-5p 0.3528 0.0373 
hsa-miR-4417 -1.3181 0.0388 
hsa-miR-373-5p 0.7357 0.039 
hsa-miR-148b-3p -0.4799 0.0405 
hsa-miR-652-5p -0.5021 0.0408 
hsa-miR-548ap-5p -0.6468 0.0422 
hsa-miR-4795-3p -0.2856 0.0429 
hsa-miR-3679-3p 0.328 0.0433 
hsa-miR-1184 -0.7149 0.0434 
hsa-miR-106a-5p -0.8702 0.0438 
hsa-miR-5187-3p -0.4782 0.0439 
hsa-miR-4508 0.6858 0.0448 
hsa-miR-634 -0.3676 0.0448 
hsa-miR-4632 -0.5121 0.045 
hsa-miR-675-5p 0.2231 0.045 
hsa-miR-19b-3p -0.8562 0.0456 
hsa-miR-4653-3p -0.4738 0.0456 
hsa-miR-17-5p -0.8343 0.0456 
hsa-miR-4800-5p 0.8808 0.0456 
hsa-miR-4484 0.9759 0.0456 
hsa-miR-708-5p -0.8074 0.0456 
hsa-miR-18a-3p -0.5474 0.0486 
 
 
Table 5.12 miRNAs significantly (p < 0.05) differentially expressed between differentiated H1 and 
differentiated H9. miRNAs that are upregulated in H1 vs. H9 are highlighted in green, while miRNAs that are 
downregulated in H1 vs. H9 are highlighted in red. The miRNAs that are also included on the lists of miRNAs 
most highly up- or down-regulated during endoderm formation are in bold.
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Table 5.10 shows the comparison of differentiated iPSCs with differentiated H1 (excluding 
H9). 28 miRNAs are significantly differentially expressed between iPSCs and H1: 23 are 
expressed at a lower level in iPSCs than in H1 (red), and 5 are expressed at a higher level 
(green). Interestingly, miR-708-5p, which was identified as one of the miRNAs strongly 
upregulated in DE formation, is expressed at higher levels in iPSCs than in H1. This may 
partially explain why the H1 cell line has a lower propensity to form DE. However, miR-27b, 
also identified as potentially being involved in DE formation, is expressed at lower levels in 
iPSCs than in H1.  
Table 5.11 shows the comparison of differentiated iPSCs with differentiated H9 (excluding 
H1). 154 miRNAs were significantly differentially expressed between iPSCs and H9, with 60 
expressed at a higher level in iPSCs compared to H9 (green) and 94 expressed at a lower 
level (red). The fact that a much greater number of miRNAs are differentially expressed 
between iPSCs vs. H9 compared to iPSCs vs. H1 again suggests that culture conditions have 
having an effect on miRNA expression.  
Several miRNAs, including miR-151a-3p, miR-151a-5p, and miR-27b were identified in both 
the overall comparison of iPSC vs. ESC, as well as the individual comparison of iPSC vs. H1 
and iPSC vs. H9. These miRNAs are more likely to represent conserved differences between 
iPSCs and ESCs which are not cell line-specific, although this is difficult to determine in an 
analysis of only four cell lines.  
 Table 5.12 shows the comparison of differentiated H1 with differentiated H9.156 miRNAs 
were significantly differentially expressed between the two cell lines, with 98 miRNAs 
downregulated in H1 vs. H9 (red), and 58 miRNAs upregulated in H1 vs. H9 (green). Two 
miRNAs identified as being strongly upregulated in DE formation, miR-375 and miR-708-
5p, are expressed at lower levels in H1 than in H9, which again may partly explain the 
reduced propensity for differentiation into DE observed in the H1 cell line. The miRNAs 
identified as being differentially expressed between iPSCs and ESCs were not differentially 
expressed between H1 and H9.   
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5.3.2 Validation of Microarray Results by qRT-PCR 
As microarray analysis is prone to give false positive results due to the high numbers of 
comparisons being performed in parallel, even when a statistical correction is used, it is 
important to validate the results using qRT-PCR, as this is a more reliable method of 
analysing miRNA expression levels. The expression levels of miRNAs were analysed in 
undifferentiated samples, samples directed to differentiate into DE, and samples that were 
allowed to spontaneously differentiate. Spontaneously differentiated cells were not included 
in the microarray analysis, as it was thought that they would result in too much background 
noise and make data analysis too complicated, but were included in qRT-PCR analysis, 
allowing investigation of whether changes in miRNA expression are specific to DE 
formation, or are also involved in more general differentiation. Samples were taken in 
triplicate and at least two separate differentiation experiments were analysed for expression 
of each miRNA. In addition to the four cell lines investigated using microarray (MRC5I, 
MRC9G, H1 and H9), an additional ESC line (H7) was included in qRT-PCR analysis. This 
is another ESC line grown on Matrigel™, and was included to provide additional information 
as to whether the differences noticed in miRNA expression between cell lines grown on 
feeders and the H9 cell line grown on Matrigel™ were due to the culture methods. Including 
another cell line also indicates whether the array results are applicable to other cell lines than 
those analysed in the array. miRNA expression was analysed using Students’ T-test to 
determine whether the fold change in miRNA expression in differentiated samples from 
undifferentiated samples was significant. 




Figure 5.4. qRT-PCR results showing log2 fold change in expression levels of miR-375 in differentiated 
samples compared to undifferentiated samples. miR-375 is significantly (p = 0.006, n = 3) upregulated in cells 
directed to differentiate using the D’Amour protocol, but not in spontaneously differentiated cells. 
 
Figure 5.5. qRT-PCR results showing log2 fold change in expression levels of miR-708-5p in differentiated 
samples compared to undifferentiated samples. miR-708-5p is significantly (p = 0.006, n = 2) upregulated in 
cells directed to differentiate using the D’Amour protocol, but not in spontaneously differentiated cells. 




Figure 5.6 qRT-PCR results showing log2 fold change in expression levels of miR-744-5p in differentiated 
samples compared to undifferentiated samples. miR-744-5p is significantly upregulated in both cells directed 
to differentiate using the D’Amour protocol (p = 0.008, n = 3) and spontaneously differentiated cells (p = 
0.016, n = 3). 
 
Figure 5.7. qRT-PCR results showing log2 fold change in expression levels of miR-27b-3p in differentiated 
samples compared to undifferentiated samples. miR-27b-3p is significantly upregulated in both samples 
differentiated using the D’Amour protocol (p = 0.003, n = 2) and spontaneously differentiated cells (p = 0.013, 
n = 2). 




Figure 5.8. qRT-PCR results showing log2 fold change in expression levels of miR-26b-5p in differentiated 
samples compared to undifferentiated samples. miR-26b-5p is significantly upregulated in spontaneously 
differentiated samples (p = 0.012, n = 3) but not in cells directed to differentiate using the D’Amour protocol. 
 
Figure 5.9. qRT-PCR results showing log2 fold change in expression levels of miR-30b-5p in differentiated 
samples compared to undifferentiated samples. miR-30b-5p is significantly upregulated in spontaneously 
differentiated samples (p = 0.012, n = 4) but not in cells directed to differentiate using the D’Amour protocol. 




Figure 5.10. qRT-PCR results showing log2 fold change in expression levels of miR-4530 in differentiated 
samples compared to undifferentiated samples. miR-4530 is significantly upregulated in spontaneously 
differentiated samples (p = 0.025, n = 3) but not in cells directed to differentiate using the D’Amour protocol.  
 
Figure 5.11. qRT-PCR results showing log2 fold change in expression levels of miR-151a-3p in differentiated 
samples compared to undifferentiated samples. miR-151a-3p is significantly (p = 0.006, n = 3) upregulated  in 
three ESC lines (H1, H7 and H9, shown in red) but downregulated in two iPSC lines (MRC5I and MRC9G, 
shown in blue). 




Figure 5.12. qRT-PCR results showing log2 fold change in expression levels of miR-151a-5p in differentiated 
samples compared to undifferentiated samples. miR-151a-5p is significantly (p = 0.018, n = 3) upregulated  in 
three ESC lines (H1, H7 and H9, shown in red) but downregulated in two iPSC lines (MRC5I and MRC9G, 
shown in blue). 
 
Figure 5.13. qRT-PCR results showing log2 fold change in expression levels of miR-191-5p in differentiated 
samples compared to undifferentiated samples. miR-191-5p is not significantly upregulated  in either cells 
directed to differentiate using the D’Amour protocol or cells allowed to spontaneously differentiate.  




Figure 5.14. qRT-PCR results showing log2 fold change in expression levels of miR-3148 in differentiated 
samples compared to undifferentiated samples. miR-3148 is significantly (p = 0.001, n = 3) upregulated in 
spontaneously differentiated cells but not in cells directed to differentiate using the D’Amour protocol. 
 
Figure 5.15. qRT-PCR results showing log2 fold change in expression levels of miR-124-5p in differentiated 
samples compared to undifferentiated samples. miR-124-5p is significantly (p = 0.046, n = 3) upregulated in 
cells directed to differentiate using the D’Amour protocol, but not in spontaneously differentiated cells. 




Figure 5.16. qRT-PCR results showing log2 fold change in expression levels of miR-4285 in differentiated 
samples compared to undifferentiated samples. miR-4285 is not significantly upregulated  in either cells 
directed to differentiate using the D’Amour protocol or cells allowed to spontaneously differentiate. 
 
Figure 5.17. qRT-PCR results showing log2 fold change in expression levels of miR-3935 in differentiated 
samples compared to undifferentiated samples. miR-3935 is not significantly upregulated  in either cells 
directed to differentiate using the D’Amour protocol or cells allowed to spontaneously differentiate. 




Figure 5.18. qRT-PCR results showing log2 fold change in expression levels of miR-378a-3p in differentiated 
samples compared to undifferentiated samples. miR-378a-3p is not significantly upregulated  in either cells 
directed to differentiate using the D’Amour protocol or cells allowed to spontaneously differentiate. 
 
 
Figure 5.19. qRT-PCR results showing log2 fold change in expression levels of miR-4451 in differentiated 
samples compared to undifferentiated samples. miR-4451 is significantly upregulated only in cells grown on 
Matrigel™ (H7 and H9), but not those grown on feeders (MRC5I, MRC9G and H1), which are directed to 
differentiate into definitive endoderm. miR-4451 is also significantly downregulated in spontaneously 
differentiated samples.  




Figure 5.20. qRT-PCR results showing log2 fold change in expression levels of miR-516b-5p in differentiated 
samples compared to undifferentiated samples. miR-516b-5p is significantly (p = 0.004, n = 3) downregulated 
in cells directed to differentiate using the D’Amour protocol, but not spontaneously differentiated cells.  
 
 
Figure 5.21. qRT-PCR results showing log2 fold change in expression levels of miR-4436b-5p in 
differentiated samples compared to undifferentiated samples. Levels of miR-4436b-5p expression are not 
significantly changed in either cells directed to differentiate using the D’Amour protocol or cells allowed to 
spontaneously differentiate. 




Figure 5.22. qRT-PCR results showing log2 fold change in expression levels of miR-4732-3p in differentiated 
samples compared to undifferentiated samples. miR-4732-3p is significantly upregulated only in cells grown 
on Matrigel™ (H7 and H9), but not those grown on feeders (MRC5I, MRC9G and H1), which are directed to 
differentiate into definitive endoderm. There is no significant change in miRNA expression in spontaneously 
differentiated samples.  
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miRNAs Involved in Endoderm Formation 
The expression of the top ten miRNAs that were predicted to be the most highly up- or down-
regulated during DE formation by microarray analysis was investigated using qRT-PCR. Of 
the ten miRNAs predicted to be upregulated in DE formation, only two (miR-375 and miR-
708-5p) were confirmed to be specifically upregulated in cells undergoing differentiation to 
DE, and not in spontaneously differentiated cells (figures 5.4 and 5.5, respectively). Although 
there was some upregulation of these miRNAs in spontaneously differentiated samples, 
perhaps suggesting a role in more general differentiation, this was not statistically significant. 
These miRNAs are strongly upregulated in differentiated cells, and their expression mirrors 
that of DE marker genes such as Sox17, with much lower expression in the H1 cell line, 
which my results have previously shown to have a lower propensity for forming DE (see 
chapter 4). In addition, both miR-375 (Tzur et al, 2008; Hinton et al, 2010;  Kim et al, 2011) 
and miR-708 (Hinton et al, 2010; Kim et al, 2011) have been previously described to be 
upregulated in DE formation.  
Similarly, of the ten miRNAs predicted to be downregulated in DE formation, only one (miR-
516b-5p) was confirmed to be significantly downregulated in cells undergoing differentiation 
to DE, and not in spontaneously differentiated cells (figure 5.20). This miRNA is strongly 
downregulated in all five cell lines tested, and its expression inversely mirrors that of DE 
marker genes such as Sox17, with a much reduced downregulation of expression in the H1 
cell line which has been previously shown to have a lower propensity for forming DE. miR-
3148 was significantly downregulated in spontaneously differentiated cells, but not cells 
directed to differentiate using the D’Amour protocol (figure 5.14). Expression of miR-3941, 
predicted to be downregulated in DE formation by the microarray results, could not be 
detected in any samples analysed by qRT-PCR. miR-124-5p, which was predicted by the 
array data to be downregulated in DE formation actually appeared to be significantly 
upregulated when assessed using qRT-PCR (figure 5.15), although the expression levels were 
highly variable between experiments and the p-value was approaching non-significance (p = 
0.046).  
Two miRNAs, miR-744 and miR-27b, that were predicted by the microarray analysis to be 
upregulated in DE formation were confirmed by qRT-PCR, but were also found to be 
significantly upregulated in spontaneously differentiated cells (figure 5.6 and 5.7, 
respectively). There were no miRNAs that were significantly downregulated in both DE and 
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spontaneously differentiated cells. Some miRNAs, including miR-26b-5p, miR-30b-5p, and 
miR-4530, were significantly upregulated only in spontaneously differentiated samples, 
although some upregulation was seen in samples directed to differentiate into DE (figures 
5.8, 5.9 and 5.10, respectively). These results show the importance of including 
spontaneously differentiated samples in the comparison as a control, as they allow 
identification of the miRNAs which are specifically upregulated in DE formation. The 
miRNAs which are also up- or down-regulated in spontaneously differentiated samples may 
play a more general role in differentiation, rather than in DE formation specifically. 
miR-191-5p, which was predicted to be upregulated in DE formation by microarray analysis, 
showed no significant upregulation in either samples directed to differentiate into DE or 
spontaneously differentiated samples (figure 5.13). This was also true of some miRNAs 
predicted to be downregulated in DE formation, including miR-4285, miR-3935, miR-378a-
3p, and miR-4436b (figures 5.16, 5.17, 5.18, and 5.21). This shows the importance of 
validating microarray results with a more robust method such as qRT-PCR, but may also 
reflect the variability of differentiation efficiency between experiments.  
Differential expression of miRNAs between cells grown under different conditions were also 
noticed during validation of microarray results, with miR-4451and miR-4732-3p  upregulated 
in cells grown on Matrigel (H7 and H9) and downregulated in cells grown on iSNL feeders 
(MRC5I, MRC9G and H1) (figure 5.19 and 5.22). This again suggests that the culture 
conditions have some influence on the expression of miRNAs, in support of the microarray 
results. These differences were not apparent in undifferentiated cells. 
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miRNAs Differentially Expressed Between ESCs & iPSCs 
Differential expression of miRNAs between ESCs and iPSCs was also investigated using 
qRT-PCR to confirm the microarray results. Of the 91 miRNAs reported to be differentially 
expressed between DE derived from ESCs and iPSCs, 7 were also on the top ten lists of 
miRNAs up- or down-regulated during DE formation, including miR-151a-5p, miR-30b-5p, 
miR-27b-3p, miR-151a-3p, miR-26b-5p, miR-378a-3p, and miR-4530. Of these 7 miRNAs, 
only two (miR-151a-3p and miR-151a-5p) were found to be significantly differently 
expressed in either ESCs or iPSCs directed to differentiate into DE (figure 5.11 and 5.12). 
These miRNAs are upregulated upon differentiation to DE in ESCs and downregulated in 
iPSCs. There are no differences in the expression of these miRNAs in undifferentiated ESCs 
and iPSCs. 
Because of the apparent differences between the H1 and H9 ESC lines, the expression levels 
of several other miRNAs which were identified as being significantly differentially expressed 
in iPSCs when compared to the ESC cell lines individually (i.e. H1 or H9) were also 
investigated by qRT-PCR. Several miRNAs that are strongly upregulated in iPSCs were 
predicted to be downregulated in H9 (e.g. miR-302c-3p, miR-4791) and vice versa (e.g. miR-
491-3p). However, as no significant differences could be seen in the expression of any of 
these miRNAs between the different cell lines, these miRNAs were not investigated further.  
Something that became quickly apparent from the microarray results was that the culture 
methods have an impact on miRNA expression pattern, with the principal component 
analysis (figure 5.2) and hierarchical clustering (figure 5.3) showing that the H9 cell line 
clusters separately from the other three cell lines included in the analysis. Although the 
possibility exists that H9 cells genuinely have a significantly different miRNA expression 
profile to other ESCs, these differences in miRNA expression are more likely to be a result of 
the different culture conditions. However, no functional effects of these differences were 
noticed in the analysis of either pluripotency genes (chapter 3) or definitive endoderm genes 
(chapter 4), indicating that these differences in miRNA expression do not have a significant 
functional impact on the pluripotency or differentiation of H9 cells. In addition, during PCR 
validation of microarray results, two miRNAs (miR-4451 and miR-4732-3p; figures 5.19 and 
5.22, respectively) were identified as being upregulated in DE formation only in the cell lines 
cultured on Matrigel (H7 and H9), and not those on iSNL feeders, although these differences 
were not apparent in undifferentiated cells.  
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To investigate these culture-specific differences further, H9 cells were grown on both 
Matrigel™ and iSNL feeders, and subjected to the differentiation protocol described in 
section 5.2.1. Comparison of these two methods in the same cell line allows us to elucidate 
differences in miRNA expression that are specific to the culture conditions. The expression of 
miRNAs identified by qRT-PCR as being a) upregulated in DE formation; b) downregulated 
in DE formation or c) differentially expressed between cells grown on iSNL feeders and cells 
grown on Matrigel™ were investigated in H9 cells cultured using both methods. Analysis of 















Figure 5.23. Comparison of expression of miRNAs upregulated in DE formation in H9 cells cultured on 
iSNL feeders or Matrigel™ 
 
Figure 5.24 Comparison of expression of miRNAs downregulated in DE formation in H9 cells cultured on 
iSNL feeders or Matrigel™ 
 
Figure 5.25. Comparison of expression of miRNAs differentially expressed between cells cultured on iSNL 
feeders or Matrigel™ 
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Figure 5.23 shows the expression of miR-375, miR-708-5p, miR-744-5p, miR-27b, miR-
151a-3p and miR-151a-5p in H9 cells cultured on iSNL feeders or Matrigel. These miRNAs 
have all been previously demonstrated to be consistently upregulated in DE formation in 
several ESC and iPSC lines, and figure 5.23 shows that they are upregulated in both culture 
conditions, with no significant difference between them (p = 0.792, n = 3). In addition, the 
patterns of expression are similar to those previously observed, with miR-375 and miR-708-
5p upregulated only in cells directed to differentiate using the D’Amour protocol, and miR-
744-5p, and miR-27b upregulated in both directed and spontaneous differentiation.  
Figure 5.24 shows the expression of miR-124-5p and miR-516b. miR-516b was previously 
demonstrated to be downregulated in DE formation, and this is true for H9 grown on both 
feeders and Matrigel™. There are no significant differences (p = 0.638, n = 3) in the 
expression of these two miRNAs between feeders and Matrigel. Interestingly, miR-124-5p 
expression was predicted by the microarray to be downregulated in DE formation, and this 
has been the finding of other studies as well (Tzur et al., 2008; Hinton et al., 2010). However, 
previous qRT-PCR validation of the microarray results indicated that miR-124-5p expression 
was in fact upregulated in those samples (figure 5.15), although there was high variability 
between experiments, and the upregulation was close to being non-significant. In contrast to 
these findings, the comparison of differentiation on different culture methods again 
demonstrated downregulation of miR-124-5p in the H9 cell line, despite the use of the same 
differentiation protocol.  
Figure 5.25 shows the expression of miR-4732 and miR-4451. These miRNAs were shown in 
qRT-PCR validation of microarray results to be differentially expressed between cell lines 
grown on feeders and Matrigel. Both were upregulated in DE formation only in the cell lines 
grown on Matrigel, and not those on feeders. This is reflected in the comparison of H9 on 
feeders and Matrigel, as both miRNAs are expressed at lower levels in H9 grown on feeders, 
but this is not statistically significant (p =  0.211, n = 3).  
  




In this chapter, I used microarray analysis to identify miRNAs differentially expressed 
between undifferentiated and differentiated cells, and which may therefore play a role in DE 
formation. A comparison of undifferentiated and differentiated cells was carried out for ESCs 
(H1 and H9 combined), iPSCs (MRC5I and MRC9G combined), as well as for individual cell 
lines. Although there are some differences in the miRNAs which are up- or down-regulated 
in these comparisons, several miRNAs show consistency between several cell lines, most 
notably miR-375 and miR-708-5p, which are consistently and significantly upregulated in all 
cell lines. These microarray results were validated using qRT-PCR, which confirmed the 
upregulation of miR-375 and miR-708-5p, suggesting a role for these miRNAs in DE 
formation. Both of these miRNAs have been previously reported to be upregulated in DE 
formation (Tzur et al., 2008; Hinton et al., 2010; Kim et al., 2011), although their exact 
mechanism of action has not been fully elucidated. There was less consistency in the 
miRNAs predicted to be downregulated in DE formation by the microarray, and this was 
reflected in the PCR validation, as only one of the ten miRNAs investigated, miR-516b, was 
found to be significantly downregulated.  
For the purpose of narrowing down the candidate miRNAs to focus on a more manageable 
number to investigate further, only miRNAs which were significantly up- or down-regulated 
in all cell lines were considered. Other miRNAs are strongly up- or down-regulated in some 
cell lines but not all e.g. miR-26b-5p, which is strongly upregulated in H9; miR-4436b-5p, 
which is strongly downregulated in MRC5I. These miRNAs may still be involved in 
endoderm formation, and may provide information about the different propensities of 
individual cell lines to form DE, but were disregarded in this study in favour of candidates 
likely to have a more general role in differentiation to DE.  
Interestingly, miR-124-5p, which was predicted by the array data to be downregulated in DE 
formation, and which has been previously described as being downregulated in DE formation 
(Tzur et al., 2008; Hinton et al., 2010) actually appeared to be significantly upregulated when 
assessed using qRT-PCR for the validation of the microarray results. Upregulation was only 
seen in cells directed to differentiate, and not in spontaneously differentiating cells, but there 
was high variation between experiments and the level of upregulation was only just 
statistically significant. This miRNA is strongly associated with the neuronal lineage, and its 
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expression in these samples might reflect contamination of endodermal tissue with ectoderm 
due to inefficient differentiation, but the pattern of expression, with the highest expression in 
the cell lines with the highest efficiency of making DE, and the lowest in H1, which is poor at 
making DE, suggests that this may not be the case. miR-124-5p is also known to play a role 
in later pancreas development through its target genes Pdx1 and Neurod1 (Baroukh et al., 
2007), which may explain its upregulation in these samples. Interestingly, the comparison of 
miRNA expression in cells cultured on iSNL feeders and Matrigel™ again demonstrated 
downregulation of miR-124-5p in the H9 cell line, despite the use of the same differentiation 
protocol. This is not due to a failure of differentiation in any of the samples, as qRT-PCR 
data shows that DE genes were highly upregulated in all of these samples. However, 
variability between experiments using the same protocol is a well-known issue, and this 
demonstrates the importance of fully elucidating the mechanisms involved in differentiation 
to enable a higher degree of standardisation of differentiation protocols.    
The later stages of pancreatic development have been reasonably well-characterised in terms 
of miRNA expression and the functions of some of the most important of these miRNAs have 
also been elucidated. However, there have been relatively few studies focussing on the DE 
stage. I have identified several miRNAs which are either upregulated (miR-375, miR-708-5p) 
or downregulated (miR-516b) during DE formation and which may therefore play a role in 
this process. While miR-375 (Tzur et al., 2008; Hinton et al., 2010; Kim et al., 2011) and 
miR-708 (Hinton et al., 2010; Kim et al., 2011) have been previously described as being up- 
or down-regulated during DE formation, miR-516b has not. 
A better understanding of the role of miRNAs in DE formation may prove useful both in 
terms of characterisation and in manipulation of cell fate. The expression of miR-375 and 
miR-708 in the cell lines tested in this study mirrored the expression of genes used as markers 
for this germ layer, such as Sox17, with the highest expression of these miRNAs in the cell 
lines previously noted to give rise to DE at higher efficiency, and with the lowest expression 
in the H1 cell line, which has a poor efficiency of differentiation into DE. In addition to 
analysis of gene expression, analysis of miRNA expression may also be helpful when 
characterising the differentiated progeny of stem cells.  
Another way in which a better understanding of the miRNA expression patterns during 
differentiation may be useful is in their potential to influence cell fate, either through 
replacing transcription factors and signalling molecules, or enhancing differentiation 
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efficiency. The use of miRNAs for this purpose is appealing, as they have the potential to 
directly and immediately alter gene transcription, which may reduce the time needed for in 
vitro differentiation and increase the efficiency of differentiation and the yield of the desired 
cell type. The ability of miRNAs to post-transcriptionally regulate hundreds of target genes 
makes them ideally suited to bring about rapid transformations in cell phenotype. They can 
be transiently expressed in a cell, and therefore do not permanently alter gene expression in 
the target cells, which has been a concern with other methods of altering cell fate, such as the 
use of lentiviral vectors to overexpress transcription factors. In addition, miRNAs are 
inherently less variable than the recombinant growth factors commonly used in 
differentiation protocols.  
 
qRT-PCR was also used to validate differences in miRNA expression between ESCs and 
iPSCs, with a view to identifying any differences in miRNA expression  which may have a 
functional impact on their ability to differentiate into a pancreatic lineage. Initial comparison 
of undifferentiated ESCs and iPSCs did not identify any miRNAs differentially expressed 
between the two cell types. When undifferentiated H1 samples were compared with 
undifferentiated iPSC samples, only 5 miRNAs were significantly differentially expressed. 
This suggests that these samples are highly similar in terms of their miRNA expression. 
However, when undifferentiated H9 samples were compared with undifferentiated iPSC 
samples, 186 miRNAs were differentially expressed, suggesting either that this cell line 
genuinely exhibited a significantly different miRNA expression profile, or that the culture 
conditions have a significant effect on miRNA expression levels. A similar phenomenon was 
noticed when comparing differentiated samples. When differentiated H9 were compared with 
differentiated iPSCs, 154 miRNAs were differentially expressed, but when differentiated H1 
were compared with differentiated iPSCs, only 28 miRNAs were significantly differentially 
expressed. The fact that a greater number of miRNAs are differentially expressed between H9 
and iPSCs compared to H1 and iPSCs again suggests that culture conditions have having an 
effect on miRNA expression.  
The differences in miRNA expression which were observed in the H9 cell line were not 
anticipated from either the pluripotency characterisation data (chapter 3) or the differentiation 
data (chapter 4). For this reason, another cell line grown on Matrigel™ (H7) was included in 
the PCR validation studies. These experiments identified two miRNAs that appeared to show 
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differences in their expression possibly as a result of the culture method: miR-4451and miR-
4732 were upregulated in cells grown on Matrigel (H7 and H9) and downregulated in cells 
grown on iSNL feeders (MRC5I, MRC9G and H1). To investigate these differences in 
miRNA expression, a further differentiation experiment was carried out using H9 cells grown 
on both iSNL feeders and Matrigel, and the expression of miRNAs previously demonstrated 
by qRT-PCR validation of the microarray results to be up- or down-regulated in DE 
formation was investigated in these samples. There were no significant differences in 
expression of any of these miRNAs between H9 cells grown on iSNL feeders and H9 cells 
grown on Matrigel. There were some differences in the expression of miR-4732 and miR-
4451, which had been previously indicated by the PCR validation result, but this was not 
statistically significant. These miRNAs may represent conserved differences between cell 
lines cultured in different ways, but a larger experiment including more cell lines would be 
needed to investigate this further.  
Despite observed dissimilarities between the cell lines and between culture methods, some 
miRNAs, including miR-151a-3p, miR-151a-5p and miR-27b, previously identified as 
potentially playing a role in endoderm formation, were also identified as being differentially 
expressed in both the overall comparison of iPSC vs. ESC, as well as the individual 
comparison of H1 vs. iPSC and H9 vs. iPSC. These miRNAs are more likely to represent 
conserved differences between ESCs and iPSCs which are not specific to certain cell lines, 
although this is difficult to determine in an analysis of only five cell lines. The strongest 
contrast was seen in expression of miR-151a-3p and miR-151a-5p, which are upregulated 
upon differentiation to DE in ESCs, and downregulated in iPSCs. This pattern of expression 
is not seen in spontaneously differentiated samples. These two miRNAs are derived from the 
same pre-miRNA stem loop, and are therefore likely to be co-regulated and co-transcribed, 
although as their sequence is different they are likely to have different target genes and 
therefore different mechanisms of action. The function of these miRNAs will be further 
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Chapter 6: Investigation of the Function of miRNAs 
in Differentiation to Definitive Endoderm 
 
6.1 Introduction 
The roles of miRNAs in the later stages of pancreatic development, as well as in mature 
pancreatic function, have been reasonably well described (section 1.10.4). However, 
relatively few studies (Tzur et al., 2008; Hinton et al., 2010; Tsai et al., 2010; Kim et al., 
2011) have investigated miRNA expression at the definitive endoderm (DE) stage. Although 
there is relatively little overlap in the miRNAs identified in these studies, which is likely to 
be due to the different cell lines and differentiation protocols used, some miRNAs, including 
miR-375, miR-708 and miR-744, were identified in several of the studies, providing strong 
evidence for their involvement in DE formation. However, few of these studies went on to 
elucidate a function for these miRNAs in DE formation. An early study in ESCs investigated 
the effect on differentiation of overexpressing miR-122, but found that, rather than increasing 
differentiation efficiency into an endodermal lineage, this actually resulted in an overall delay 
in differentiation (Tzur et al, 2008). A subsequent study identified TIMM8A as a target of 
miR-375 but didn’t elucidate a function for this pathway in DE formation (Hinton et al, 
2010). Fu et al. (2011) showed that overexpression of a panel of miRNAs in differentiating 
mouse ESCs resulted in upregulation of the definitive endoderm genes Sox17 and Foxa2, 
suggesting an increase in differentiation efficiency.  
miR-375 was also identified as upregulated in DE formation by my own microarray analysis 
(chapter 5). A role for this miRNA in DE formation has been suggested in ESCs (Hinton et 
al, 2010), but it is unknown whether this mechanism also applies to iPSCs. In addition, the 
study carried out by Hinton et al (2010) only investigated the ectopic expression of miR-375, 
and not inhibition. This can result in false results due to supraphysiological levels of 
miRNAs, which have the potential to saturate RISC complexes and displace other 
endogenous miRNAs, consequently causing low affinity target sites to appear functionally 
important. These problems may be overcome by the use of miRNA silencing with an 
inhibitor to influence mRNA expression within physiological levels, although this approach 
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has its own limitations, as miRNAs often exist in families of highly related sequences and 
this high degree of redundancy poses challenges for loss-of-function analyses, as other family 
members may compensate for the loss of the miRNA of interest. Ideally, both overexpression 
and inhibition approaches should be used when investigating the function of miRNAs. In 
addition, this study only investigated the levels of TIMM8A mRNA following manipulation 
of miR-375 levels, and did not show any effect on protein levels. This is important as 
miRNAs do not always mediate translational repression through degradation of target 
mRNA, they may simply prevent its transcription. For these reasons, the functional 
relationship between miR-375 and TIMM8A was investigated in both ESCs and iPSCs. As 
this relationship has already been established, it was thought that this would also be a useful 
way of validating the new techniques used in this chapter to study miRNA function.  
In addition to identifying miRNAs important in DE formation, microarray analysis and 
subsequent qRT-PCR was also used to identify miRNAs that were also differentially 
expressed between ESCs and iPSCs, and which may therefore have an impact on their ability 
to differentiate into DE. Two miRNAs fulfilled this criteria, miR-151a-3p and miR-151a-5p. 
These miRNAs were shown to be upregulated in DE formation in ESCs, but downregulated 
in iPSCs. These miRNAs have not been previously implicated in DE formation, although 
their expression has been noted in foetal liver (Fu et al, 2005) and their function remains 
unknown, although a few gene targets have been identified 
(mirtarbase.mbc.nctu.edu.tw/index.php, accessed 03/12/2013). For this reason, these 
miRNAs were identified for further study through identification of gene targets, 
computationally and experimentally through the use of a luciferase assay, and through 
manipulation of miRNA expression levels in ESCs and iPSCs.  
  





6.2.1 Identification of Gene Targets of miRNAs 
None of the currently available existing target prediction software tools has been able to 
include all the currently known features of miRNA-target interactions. For this reason, three 
algorithms were used to generate lists of predicted miRNA targets: TargetScan 
(www.targetscan.org), miRDB (www.mirdb.org) and Pictar (www.pictar.mdc-berlin.de/cgi-
bin/PicTar_vertebrate.cgi). The results are shown in appendix 2.   
 
6.2.2 Luciferase Assay in 293FT Cells 
In order to determine whether miRNAs were acting directly by binding to genes which had 
been identified as putative targets, a luciferase assay was carried out in which a miRNA 
mimic or inhibitor were co-transduced using lentiviral vectors into 293FT cells together with 
a reporter plasmid carrying a Gaussia luciferase gene and the 3’UTR of the gene of interest, 
which is where the majority of miRNA-target interactions occur.  
 
Plate Map 



































Vector + Mimic 
+ Inhibitor 
Untreated Untreated Untreated Untreated 
Figure 6.1. Plate map used in luciferase assays. 
 
293FT cells were maintained in culture as described in section 2.1.1. 24hrs prior to infection, 
293FT cells were trypsinised and counted before being plated at a density of 3x10
4
 cells per 
well of a 24-well plate in 293FT medium, giving a confluency of 60-70%. After 24hrs, the 
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medium was removed from the cells, and they were washed once with Opti-MEM reduced 
serum medium. 0.5ml of Opti-MEM supplemented with 4µg/ml Polybrene was added to each 
well, and 10µl of lentivirus or 1µl of control lentivirus (giving a MOI of approximately 10) 
was added to each well according to the plate map shown in table 6.1. After 5-6 hours, the 
medium on the cells was replaced with 293FT medium.  
72hrs after infection with lentivirus, cells were transfected with the 3’UTR-containing 
plasmid. Cells were washed once with Opti-MEM and 0.5ml of Opti-MEM was added to the 
cells. 2.5µl of Lipofectamine 2000 transfection reagent was diluted in 25µl of Opti-MEM per 
well. 500ng of plasmid DNA was diluted in 50µl of Opti-MEM per well, and the DNA and 
Lipofectamine were combined and incubated at room temperature for 5mins. The DNA-
Lipofectamine mixture was then added dropwise to each well according to the plate map 
shown in table 6.1. The cells were incubated for 5-6hrs at 37C, 5% CO2 before the medium 
on the cells was replaced with 293FT medium. 72hrs after plasmid transfection, the culture 
medium was collected and analysed for luminescence using the SecretePair™ Dual 
Luminescence Assay Kit as described in section 2.5.4. 
 
6.2.3 Manipulation of miRNA Expression 
In order to determine what effects the miRNAs identified in this study might have on 
differentiation to definitive endoderm, their levels of expression were manipulated using 
lentiviral vectors carrying either miRNA mimics to overexpress the miRNA of interest, or 
miRNA inhibitors, to knock down the miRNA of interest. The different protocols used are 
described in more detail in section 6.3.4.  
  




6.3.1 Identification of Gene Targets of miRNAs 
The results of the target prediction algorithms for miR-151a-3p and miR-151a-5p are shown 
in appendix 2. There was considerably more overlap in the target predictions from 
TargetScan and miRDB than from PicTar, which did not overlap with the results from the 
other two algorithms at all for either of these miRNAs. This is likely to be due to the different 
criteria measured by each algorithm, as TargetScan and miRDB are more similar to each 
other than PicTar (see section 2.5.3).  
Interestingly, Sox17 appeared on the list of predicted targets for miR-151a-5p in the results 
from both TargetScan and miRDB. This gene is one of the earliest markers of DE (Lewis & 
Tam, 2006), and is essential for endoderm formation, as mice lacking SOX17 do not develop 
gut endoderm from DE (Kanai-Azuma et al., 2002). It is possible that miR-151a-5p has an 
effect on endoderm formation through regulation of Sox17 expression, and this was selected 
for further investigation in this chapter. 
 
6.3.2 Investigation of the Function of miR-375 in Definitive Endoderm Formation 
There is strong evidence for the involvement of miR-375 in pancreatic development, both at 
the DE stage and at later stages. A role for this miRNA in DE formation has been suggested 
in ESCs (Hinton et al, 2010), but it is unknown whether this mechanism also applies to 
iPSCs. In addition, this study didn’t investigate whether changing levels of miR-375 had an 
effect on the efficiency of DE formation. For this reason, this miRNA was chosen for further 
study. As a miRNA-target relationship has already been established, it was thought that this 
would also be a useful way of validating the new techniques used in this chapter to study 
miRNA function.  
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Luciferase Assay in HFF1 Cells 
The fibroblast line HFF1 was initially chosen to carry out luciferase assays to determine the 
miRNA-target relationships, as it is known from earlier reprogramming experiments that this 
cell line is amenable to transduction using viral vectors. Lentiviral transduction in this cell 
line was successful (figure 6.2), with the highest expression of GFP/mCherry in the cells 
infected with the highest amounts of lentivirus and expression reaching maximum levels at 
72 hours post-infection. However, attempts to transfect these cells with the plasmid 
containing the luciferase reporter gene were unsuccessful. For this reason, 293FT cells were 
selected as an alternative cell line for these experiments, as they were found to be amenable 
to both lentiviral transduction and plasmid transfection.   
 
Figure 6.2. Transduction of HFF1 cells with the lentiviral vectors encoding the miR-375 miRNA mimic, the 
scrambled miRNA mimic, the miR-375 inhibitor or the scrambled miRNA inhibitor. Pictures taken 72hrs post-
infection, 10x magnification, scale bar 100μm. 
 
Luciferase Assay in 293FT Cells 
Figure 6.3 shows that 293FT cells could be successfully transduced with the lentiviral vectors 
encoding the miR-375 mimic, miR-375 inhibitor, scrambled control mimic or scrambled 
control inhibitor, as shown by the expression of the fluorescent reporter genes GFP (mimic 
and scrambled mimic) and mCherry (inhibitor and scrambled inhibitor). An MOI of 10, 
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achieved using 10µl of lentiviral particles, was determined to give the highest infection 
efficiency and was therefore used in subsequent experiments.  




Figure 6.3.Expression of the GFP and mCherry reporter genes in 293FT cells which have been transduced 
with lentiviral vectors carrying a miR-375 mimic, a miR-375 inhibitor, a scrambled control mimic or a 
scrambled control inhibitor. Pictures taken 72hrs post-infection, 10x magnification, scale bar 100µm. 




Figure 6.4 qRT-PCR data showing miR-375 expression in transduced 293FT cells 
 
Figure 6.5. qRT-PCR data showing expression of the 3’UTR reporter plasmid in transfected 293FT cells 
 
Figure 6.6. Luciferase expression in transduced 293FT cells 
P = 0.55 
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Figure 6.4 shows that transduction of 293FT cells with the lentiviral vectors results in altered 
expression levels of miR-375 in 293FT cells. There is a significant increase over the 
untreated cells in miR-375 expression in cells which have been transduced with either 5ul (p 
= 0.005, n = 2) or 10μl (p = 0.001, n = 2) of the miR-375 mimic, with the greatest increase in 
the cells receiving the highest amount of lentivirus. The cells transduced with 1μl of 
lentivirus showed a slight increase in miR-375 expression, although this was not statistically 
significant. There is no miR-375 expression in cells transduced with the scrambled control 
mimic. As there is no endogenous miR-375 expression in 293FT cells, no reduction in miR-
375 levels could be seen in cells transduced with the miR-375 inhibitor alone. However, cells 
transduced with both the miR-375 mimic and inhibitor show lower levels of miR-375 
expression than cells transduced with the miR-375 mimic alone, although this difference is 
not statistically significant (p = 0.738, n = 2), confirming  the activity of the inhibitor 
lentiviral vector. Figure 6.5 shows qRT-PCR data showing expression of the luciferase 
plasmid in 293FT cells. There is significantly higher (p = 0.003, n = 2) expression of the 
plasmid in transfected cells than in the untreated cells or the cells treated with the transfection 
reagents only. Figure 6.6 shows luminescence in transfected 293FT cells. There is a 
significant increase in luciferase levels in cells transfected with the plasmid at both 48hrs and 
72hrs (p < 0.001, n = 4) compared with untreated cells, although luciferase is highest at 
72hrs. These results confirm successful transfection of the luciferase plasmid into the 293FT 
cells.  
Once experimental conditions had been optimised, luciferase assays were carried out in 
293FT cells to determine whether we could also detect a direct relationship between miR-375 
and its target gene Timm8a, as has been previously described (Hinton et al, 2010). 293FT 
cells were transduced with lentiviral vectors containing the miR-375 mimic, inhibitor or 
scrambled controls. After 72 hours, the cells were transfected with a vector containing the 
3’UTR region of the Timm8a gene, together with a luciferase reporter gene. As a control, 
some cells were transfected with a plasmid containing a scrambled 3’UTR which does not 
correspond to any known gene sequence. Cells were analysed using a luciferase assay and 
qRT-PCR. Analysis of variance with Fisher’s a priori test was used to determine differences 
between sample groups.  
 





Figure 6.7. Expression of GFP and mCherry reporter genes in 293FT cells transduced with lentiviral vectors 
carrying a miR-375 mimic, miR-375 inhibitor, scrambled control mimic or scrambled control inhibitor. Cells 
were also transfected with a luciferase reporter plasmid containing either the Timm8a 3’UTR or a scrambled 









Figure 6.8 qRT-PCR data showing expression of miR-375 in transduced 293FT cells. 
 
Figure 6.9 qRT-PCR data showing expression of the 3’UTR vector in transfected 293FT cells. 
 
 
Figure 6.10.Luciferase expression in transduced 293FT cells. 
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Figure 6.7 shows successful transduction of 293FT cells with lentiviral vectors carrying a 
miR-375 mimic, miR-375 inhibitor, scrambled control mimic or scrambled control inhibitor, 
as demonstrated by the expression of the GFP or mCherry reporter genes. Untreated cells, as 
well as cells treated with reagents only or vector only, were included as negative controls. 
Figure 6.8 shows expression of miR-375 in transduced 293FT cells. There is a significant 
(p=0.008, n=2) increase in miR-375 expression in cells infected with the lentiviral vector 
encoding the miR-375 mimic compared with untreated cells. The levels of miR-375 
expression are reduced in 293FT cells also infected with the lentiviral vector encoding the 
miR-375 inhibitor, confirming its activity, although this reduction is not statistically 
significant (p = 0.711, n = 2). There is no increase in miR-375 expression in cells treated with 
the scrambled control lentivirus. Figure 6.9 shows expression of the 3’UTR vector in 
transfected 293FT cells. There is a significant increase (p = 0.005, n = 2) in 3’UTR vector 
expression in wells transfected with either the TIMM8A 3’UTR plasmid or the scrambled 
control plasmid compared to the untransfected cells. Although there is some variability in the 
expression of the 3’UTR vector between wells, this is not statistically significant, and the use 
of a dual reporter luciferase assay system means that the luminescence reading can be 
normalised between samples. Figure 6.10 shows luminescence readings from transduced 
293FT cells. There is high luciferase in cells transfected with either the TIMM8A 3’UTR 
vector or the scrambled control vector. The luciferase levels are significantly (p = 0.005, n = 
2) reduced in cells infected with the miR-375 lentivirus compared to cells treated with the 
3’UTR vector only. This demonstrates a direct binding relationship between miR-375 and the 
3’UTR region of the TIMM8A gene, confirming the reliability of this assay. There is no 
reduction in luciferase in cells transduced with the scrambled control vector when the miR-
375 lentiviral vector is added, showing that this is not due to non-specific effects, and there is 
also no reduction when scrambled control lentiviral vectors are used. There is some reduction 
in luciferase in cells transduced with both the miR-375 mimic and inhibitor vectors, showing 
that the inhibitor is not present in sufficient amounts to entirely prevent miR-375 binding to 
the TIMM8A 3’UTR, but this is less than in the cells transduced with the miR-375 mimic 
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6.3.3 Investigation of the Function of miR-151a-5p in Definitive Endoderm Formation 
Luciferase assay in 293FT Cells 
 
Figure 6.11. Expression of the GFP and mCherry reporter genes in 293FT cells which have been transduced 
with lentiviral vectors carrying a miR-151a-5p mimic, a miR-151a-5p inhibitor, a scrambled control mimic or 
a scrambled control inhibitor. Cells were also transfected with a luciferase reporter plasmid containing either 
the Sox17 3’UTR or a scrambled control sequence.  Pictures taken 72hrs post-infection, 10x magnification, 
scale bar 100µm. 
 




Figure 6.12. qRT-PCR data showing expression of miR-151a-5p in transduced 293FT cells. 
 
Figure 6.13. qRT-PCR data showing expression of the 3’UTR vector in transduced 293FT cells. 
 
Figure 6.14. Luciferase assay in transduced 293FT cells. 
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The luciferase assay was next used to determine whether there was a direct relationship 
between miR-151a-5p and its predicted target gene Sox17.  Following transduction with the 
lentiviral vectors and 3’UTR plasmid as described previously, cells were analysed using a 
luciferase assay and qRT-PCR. Analysis of variance with Fisher’s a priori test was used to 
determine differences between sample groups. 
Figure 6.11 shows successful transduction of 293FT cells with lentiviral vectors carrying a 
miR-151a-5p mimic, miR-151a-5p inhibitor, scrambled control mimic or scrambled control 
inhibitor, as demonstrated by their expression of the GFP or mCherry reporter genes. 
Untreated cells, as well as cells treated with reagents only or vector only, were included as 
negative controls. Figure 6.12 shows expression levels of miR-151a-5p in transduced 293FT 
cells. There is a significant (p < 0.001, n = 2) increase in miR-151a-5p expression in cells 
treated with the miR-151a-5p mimic compared to untreated cells. The levels of miR-151a-5p 
expression are reduced in 293FT cells also infected with the lentiviral vector encoding the 
miR-151a-5p inhibitor, confirming its activity, although this difference is not statistically 
significant (p = 0.094, n = 2). There is no significant increase in miR-151a-5p expression in 
cells treated with the scrambled control mimic. Figure 6.13 shows expression levels of the 
3’UTR in transfected 293FT cells. There is a significant increase (p = 0.002, n = 2) in 3’UTR 
vector expression in wells transfected with either the SOX17 3’UTR plasmid or the 
scrambled control plasmid compared to the untransfected cells. Although there is some 
variability in the expression of the 3’UTR vector between wells, this is not statistically 
significant, and the use of a dual reporter luciferase assay system means that the 
luminescence reading can be normalised between samples. Figure 6.14 shows luminescence 
readings from transduced 293FT cells. There is high luciferase in cells transfected with either 
the SOX17 3’UTR vector or the scrambled control vector. However, there is no reduction in 
luciferase in cells treated with the miR-151a-5p mimic, indicating that there is no direct 
binding relationship between miR-151a-5p and its predicted target Sox17. 
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6.3.4 Manipulation of miRNA Expression in Pluripotent Stem Cells 
Several different protocols were tested to determine which would give the most efficient 
transduction of pluripotent stem cells with the lentiviral vectors carrying either the miRNA 
mimic or inhibitor. In the first protocol, cells were passaged on Matrigel™ as previously 
described. 24hrs prior to lentiviral infection, H9 ESCs were treated with Accutase™ to obtain 
a single cell suspension. This was added to a Matrigel™-coated 24-well plate at a 
concentration of 1x10
5
 cells per well in mTesr-1 medium supplemented with Y-27632 ROCK 
inhibitor at a concentration of 10µM, as this has been previously shown to prevent 
dissociation-induced apoptosis of stem cells (Watanabe et al, 2007). After 24hrs, the medium 
was changed to 50% Opti-MEM low serum medium and 50% mTeSR-1, supplemented with 
4µg/ml Polybrene. 10µl of lentivirus was added to each well, and the cells were incubated at 
37°C for 6hrs. As a control, untreated cells and cells treated with the transfection reagents 
only were included in the experiment. The medium was then changed to mTeSR-1. However, 
24hrs post-infection, there was a large amount of cell death (figure 6.15), despite the presence 
of the Rock inhibitor, which was not seen in the untreated cells, and there was no expression 




Figure 6.15 Images before (0hr) and after (24hr) lentiviral transfection show poor cell survival.4x 
magnification.  
 
Chapter 6: Investigation of the Function of miRNAs in Differentiation to Definitive Endoderm 
264 
 
In an attempt to try and optimise this protocol for use with pluripotent stem cells, an 
experiment was carried out in which the multiplicity of infection (MOI) used and the time for 
which the cells were treated with the lentivirus were varied, as shown in figure 6.16.  
 
Plate Map 
MOI Treatment Time 
5 10 20 50 6 hrs 
5 10 20 50 12hrs 
5 10 20 50 24hrs 
Figure 6.16. Plate map used in lentiviral transduction of stem cells. 
 
As ESCs and iPSCs are known to be vulnerable to increased apoptosis following dissociation 
into a single-cell suspension (Watanabe et al, 2007), whole colonies were treated instead. H9 
ESCs were passaged as normal into a 24-well Matrigel-coated plated approximately 5 days 
prior to transduction. On the day of infection, cells were washed, and the medium was 
replaced with 50% Opti-MEM low serum medium and 50% mTeSR-1, supplemented with 
4µg /ml Polybrene. The amount of lentivirus indicated in figure 6.16 was added to each well, 
and the cells were incubated at 37°C for the time shown. As a control, untreated cells and 
cells treated with the reagents only were included in the experiment. Cell pictures were taken 
prior to infection, and then at 24, 48 and 72hrs post-infection. While cell viability was 
improved using this method, there was still a significant amount of cell death at 72hrs post-
infection (see figure 6.17)  which was not seen in either the untreated cells or the cells treated 
with the reagents alone, and there was no expression of the fluorescent reporter gene at any 
time point.  
In case the lack of transduction observed was due to the cell line used, this experiment was 
repeated with the Wild7 iPSC line. However, the results were very similar to those seen when 
using H9 cells (figure 6.18), with increased cell death in the wells treated with the lentivirus, 
and no expression of the fluorescent reporter gene at any time point. This suggests that the 
inefficiency is not due to the cell lines used, but instead due to inadequate protocol 
optimisation.  
 




Figure 6.17 Images of H9 ES cells treated with different MOI of lentivirus for different time periods taken 
72hrs post-infection.4x magnification. 




Figure 6.18. Images of Wild7 iPS cells treated with different MOI of lentivirus for different time periods 
taken 72hrs post-infection.4x magnification. 
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In a further attempt to transduce the stem cells with the lentiviral vectors, a different protocol 
was used (published by Sigma-Aldrich, available online at http://www.sigmaaldrich.com/life-
science/functional-genomics-and-rnai/shrna/learning-center/hesc-transduction.html, accessed 
23/02/2014). The cells were passaged as normal in a Matrigel-coated 6-well plate. Prior to 
infection, the medium on the cells was replaced with mTeSR-1 supplemented with 10µM Y-
27632 ROCK inhibitor. The cells were incubated at 37°C for 1hr. Next, the cells were 
washed twice with DMEM and 1ml of either Accutase™ (to give a single cell suspension) or 
Dispase (to passage the cells in clumps) was added to the cells, as per the manufacturer’s 
instructions. Once the cells had detached, they were transferred to 15ml tubes and centrifuged 
at 480 x g for 3min, and the supernatant was removed. The cells were resuspended in 1ml 
mTeSR-1 supplemented with 4µg/ml Polybrene, and 10µl of lentivirus was added to each 
tube. The cells were incubated at 37°C for 1 hr, before being washed with mTeSR-1, 
centrifuged at 480 x g for 3min, resuspended in mTeSR-1 supplemented with 10µM  Y-
27632 ROCK inhibitor and transferred to a Matrigel-coated 6-well plate. Cell pictures were 
taken prior to infection, and then at 24hrs, 48hrs and 72hrs post-infection. The amount of cell 
death was significantly reduced using this protocol (figure 6.19); however, no expression of 




Figure 6.19. Images of cells 72hrs following lentiviral transduction.4x magnification. 
 
Unfortunately, due to time constraints, further optimisation of these protocols was not 
possible, and the functional effects of manipulation of miRNA expression in pluripotent stem 
cells remain as work to be continued after this PhD.    




miR-151a-5p was previously identified using microarray analysis as being upregulated during 
DE formation, as well as being differentially expressed between ESCs and iPSCs (see chapter 
5). The aim of this chapter was to elucidate a role for this miRNA in DE formation through 
identification of its target genes, and to discover whether manipulation of its expression 
levels in both ESCs and iPSCs had an effect on differentiation to DE. Although several 
miRNAs have been previously identified as playing a role in DE formation (Tzur et al., 2008; 
Hinton et al., 2010; Tsai et al., 2010; Kim et al., 2011), few of these studies went on to 
elucidate a function for these miRNAs in endoderm formation, and the target genes of many 
of these miRNAs are still largely unknown.  
Identifying miRNA targets is challenging, largely due the limited complementarity between 
miRNAs and their target mRNAs, and the fact that the interactions between miRNAs and 
their target genes are still not entirely understood. The lack of high throughput experimental 
methods for miRNA target identification means there is a reliance on target prediction 
algorithms. Several independent groups have established computational algorithms designed 
to predict target genes of miRNAs (reviewed in Rajewsky, 2006). Target prediction software 
was used to identify potential target genes of both miR-151a-3p and miR-151a-5p, the results 
of which can be seen in appendix 2. TargetScan, miRDB and Pictar were chosen, as in a 
comparison of target prediction programs, these three used either alone or in combination had 
the best trade-off between sensitivity and specificity (Witkos et al., 2011). There was 
considerably more overlap in the target predictions from TargetScan and miRDB than from 
PicTar, which did not overlap with the other two algorithms at all for either of these miRNAs. 
This is likely to be due to the different criteria measured by each algorithm, as TargetScan 
and miRDB have more similar requirements to each other than PicTar. Interestingly, Sox17 
appeared on the list of predicted targets for miR-151a-5p in the results from both TargetScan 
and miRDB. This gene is one of the earliest markers of DE (Lewis & Tam, 2006), and is 
essential for endoderm formation, as mice lacking Sox17 do not develop gut endoderm from 
DE (Kanai-Azuma et al., 2002). It is possible that miR-151a-5p has an effect on endoderm 
formation through regulation of Sox17 expression, and that the differences in expression of 
miR-151a-5p between ESCs and iPSCs may be important in DE formation through a pathway 
involving the regulation of Sox17 expression. 
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Although few miRNA-target relationships have been identified in the context of DE 
formation, Hinton et al (2010) previously identified Timm8a as a target of miR-375. This 
known relationship was used to optimise the experimental conditions of the luciferase assay. 
Initial experiments demonstrated that although HFF1 cells could be transduced using the 
lentiviral vectors encoding the miRNA mimic or inhibitor, as demonstrated by their 
expression of the GFP and mCherry reporter genes, transfection of the 3’UTR plasmid was 
unsuccessful. For this reason, 293FT cells were used for further experiments, as they were 
amenable to transduction with the lentiviral vectors encoding the miRNA mimic or inhibitor, 
as demonstrated by their expression of the GFP and mCherry reporter genes, as well as by 
qRT-PCR demonstrating upregulation of miRNA expression. In addition, transfection of the 
3’UTR plasmid could be carried out at high efficiency, as demonstrated by qRT-PCR and 
luciferase measurements.  Co-transfection of the miR-375 mimic and a luciferase reporter 
plasmid containing the Timm8a 3’UTR (where the majority of miRNA binding occurs) 
demonstrated that this assay could be used to identify miRNA-gene target binding, as a 
reduction in luciferase was evident in the presence of the miR-375 mimic.  
Subsequently, the luciferase assay was used to determine whether there was a direct 
interaction between miR-151a-5p and the Sox17 3’UTR. However, no such interaction could 
be identified, as no reduction in luciferase was seen in the presence of the miR-151a-5p 
mimic. This demonstrates the importance of using experimental approaches to validate 
predicted target genes of miRNAs, as algorithms used for predicting targets typically predict 
large numbers of target genes for each miRNA, most of which are not true targets (Thomas et 
al., 2010). The false positive rate of prediction algorithms has been variously reported as 
between 24-70% (Thomson et al., 2011).  
It is possible that there is an indirect relationship between miR-151a-5p and Sox17 through a 
larger regulatory network of miRNAs and genes. This could be investigated further through 
manipulation of miR-151a-5p expression levels, as this would demonstrate whether the 
expression levels of Sox17 are affected by changes in miR-151a-5p expression levels. This 
experiment would be best carried out in ESCs or iPSCs, as they are known to express both 
miR-151a-5p and Sox17.  Alternatively, there may be no relationship between miR-151a-5p 
and Sox17, and miR-151a-5p may mediate its effects on DE formation through another 
mechanism. One way to investigate this further would be to use microarray analysis to 
identify changes in gene expression that inversely correlate with experimentally induced 
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changes in miR-151a-5p expression levels, as this would indicate gene silencing by miRNA 
binding to its target genes. This would also be useful for identifying target genes not 
predicted by target prediction algorithms, as many genes identified by overexpression or 
silencing of miRNAs in combination with microarray analysis were not predicted by target 
prediction software (Krutzfeldt et al., 2006). 
The second aim of this chapter was to investigate the effects of manipulating miR-151a-5p 
expression in pluripotent stem cells using lentiviral vectors encoding a miRNA mimic and a 
miRNA inhibitor, to determine whether changes in the expression of miR-151a-5p result in 
changes in endodermal gene expression, particularly Sox17, or altered differentiation 
efficiency. As miR-151a-5p is differentially expressed between ESCs and iPSCs, it would be 
interesting to see how manipulating expression of miR-151a-5p affects each cell type. 
Unfortunately, attempts to transduce human pluripotent stem cells with the lentiviral vectors 
encoding the miRNA mimic and inhibitor were unsuccessful, demonstrating a need for 
further optimisation of the experimental conditions, which, due to time constraints, could not 
be investigated as part of this study. 
Several previous studies have attempted to manipulate miRNA expression in order to identify 
their roles in DE formation. The overexpression of a panel of miRNAs in mouse ESCs 
resulted in the up-regulation of the DE markers Sox17 and Foxa2, suggesting an increase in 
differentiation efficiency (Fu et al., 2011). Another study, using human ESCs, attempted to 
influence endodermal, and particularly hepatic, differentiation using miR-122, which is 
known to be important in liver development and function. While its overexpression did result 
in the up-regulation of some hepatic genes, the overall effect was to delay differentiation 
(Tzur et al., 2008). Hinton et al. (2010), again using human ESCs, showed that manipulation 
of miR-375 resulted in altered expression of TIMM8A, although these authors did not observe 
any change in differentiation efficiency. Similarly, Wei et al. (2013) elucidated the temporal 
expression of several miRNAs known to be involved in pancreatic development, and 
correlated these with genes known to be expressed at specific stages of differentiation. The 
latter study showed that manipulation of miR-375 expression in human ESCs resulted in 
altered expression of Hnf1β and Sox9, transcription factors important in pancreatic 
development, but the authors did not demonstrate whether this was a direct interaction 
between miR-375 and these genes. More recently, miR-375 overexpression has been shown 
to promote pancreatic endocrine differentiation in human ESCs and iPSCs in the absence of 
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any extrinsic factors (Lahmy et al., 2013; Lahmy et al, 2014). These results demonstrate the 
importance of miRNAs in pancreatic differentiation, and demonstrate their potential for 










7.1 Generation and Characterisation of iPSCs ............................................................................. 273 
7.2 Differentiation of Pluripotent Stem Cells into Definitive Endoderm .................................... 275 
7.3 Investigation of miRNA Expression in DE Formation ........................................................... 278 
7.4 Investigation of Differential miRNA Expression between ESCs and iPSCs ........................ 280 
7.5 Investigation of the Function of miRNAs in DE Formation .................................................. 283 
7.6 Concluding Remarks ................................................................................................................. 287 
 
  
Chapter 7 Discussion 
273 
 
Chapter 7: General Discussion 
 
The aim of this study was to identify whether iPSCs are a viable alternative to ESCs for generating 
β-cells in vitro for cell replacement therapy to treat type 1 diabetes. In order to achieve this, new 
iPSC lines were first generated and characterised. Secondly, the differentiation potential of iPSCs 
and ESCs to give rise to definitive endoderm (DE), a key early step in pancreatic differentiation, was 
compared. Finally, the role of miRNAs in differentiation to DE, and differences in miRNA 
expression between ESCs and iPSCs which may have an effect on the differentiation process, were 
investigated.  
 
7.1 Generation and Characterisation of iPSCs 
The first aim of this study was to generate new iPSC lines, and characterise them to assess their 
pluripotency. Although several iPSC lines were already available in the lab for use in differentiation 
experiments, generating and characterising my own iPSC lines allowed me to gain technical 
expertise and a greater understanding of the reprogramming process. A table showing all the iPSC 
and ESC lines used in these experiments is included in chapter 3.  
Initial reprogramming experiments resulted in the production of cells which closely resembled 
pluripotent stem cells in terms of their morphology and growth characteristics, and which could be 
maintained in culture over a number of passages, but which, when further characterised, showed 
inadequate expression of pluripotency markers. These cells are likely to represent a population of 
incompletely reprogrammed cells which have been previously described (Meissner et al, 2007; Chan 
et al, 2009). One of the reasons for the appearance of these incompletely reprogrammed populations 
may be due to the reprogramming method used, which relies on delivery of the reprogramming 
factors in four separate viral vectors. This makes it difficult to control the dose of each 
reprogramming factor that each individual cell will receive, and while some will receive an adequate 
dose of all four reprogramming factors and go on to be fully reprogrammed into iPSCs, others may 
receive an inadequate dose of the reprogramming factors to allow them to completely alter their cell 
fate to that of a pluripotent cell, but which may be sufficient to allow partial reprogramming. Further 
complicating matters is the fact that excess levels of OCT4 (Niwa et al, 2000) or SOX2 (Kopp et al, 
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2008) are actually detrimental to the maintenance of pluripotency. High levels of C-MYC and KLF4 
together with low levels of SOX2 and OCT4 may lead to the generation of rapidly growing “non-
iPSCs” which have been transformed rather than reprogrammed (Yamanaka, 2007). Although a 
separate vector encoding GFP was used in these experiments to monitor efficiency of delivery of the 
reprogramming factors, this is a crude method that simply ascertains whether transfection is working, 
and not the dose of each reprogramming factor that the cells receive. However, this method of 
reprogramming is still one of the most efficient, which is why it was chosen for this study. The 
presence of incompletely reprogrammed cells show the importance of fully characterising new iPSC 
lines before they are used in subsequent experiments to ensure the quality of the lines used. 
Guidelines for the characterisation of iPSCs have now been well-established (Maherali & 
Hochedlinger, 2008), and are largely based on guidelines first used for the characterisation of ESCs 
(Brivanlou et al, 2003).  
Subsequent reprogramming experiments resulted in iPSCs that closely resembled ESCs in terms of 
their expression of pluripotency genes as assessed by qRT-PCR and immunocytochemistry, their 
expression of alkaline phosphatase, and their ability to spontaneously differentiate into cells derived 
from all three embryonic germ layers. iPSCs were also shown to silence the exogenous transgenes 
used in reprogramming, demonstrating that they have successfully reactivated the network of gene 
expression necessary for the maintenance of pluripotency. Although several pluripotency genes were 
assessed using qRT-PCR and immunocytochemistry, a high-throughput method that could be used to 
screen for expression of a larger number of pluripotency-associated genes would give a more robust 
characterisation of new iPSC lines and their ability to spontaneously differentiate into lineages from 
all three germ layers. In addition, the most stringent test of pluripotency available for human 
pluripotent stem cells is the teratoma assay. However, this is an expensive and time-consuming 
assay, and there are ethical concerns over the use of animals for a routine test which would need to 
be carried out for every iPSC line generated. There has also been debate over how useful it actually 
is, with many pointing out the qualitative nature of this assay, and the fact that it does not accurately 
assess whether the iPSCs are able to give rise to every cell in the body, nor does it assess the 
contribution of the iPSCs to the germline. Many mouse iPSC lines are able to give rise to teratomas 
containing cells derived from all three germ layers, but are not able to contribute to all-iPSC mice. 
There has been an increased focus in recent years on in vitro testing of new iPSC lines: for example, 
the TaqMan® hPSC Scorecard developed by Life Technologies aims to allow researchers to fully 
characterise their pluripotent stem cell lines in a single PCR-based assay. In addition, PluriTest 
(www.pluritest.org), an open access resource, allows researchers to compare their gene expression 
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data with a large panel of established pluripotent stem cell lines (Muller et al, 2008). These methods 
are particularly relevant for lines which are generated primarily for research use, where the 
requirement for pluripotency is less stringent than in cells which could potentially be used in a 
therapeutic setting. In terms of this study, it was decided that an in vitro differentiation assay was 
sufficient to determine the pluripotency of these cell lines, as the cells were subsequently to be used 
for investigation of in vitro differentiation.  
 
7.2 Differentiation of Pluripotent Stem Cells into Definitive Endoderm 
The next stage of the study was to investigate the differentiation efficiency of the ESC and iPSC 
lines. The first step in the differentiation of pluripotent stem cells into β-cells is the production of 
definitive endoderm (DE), and this has been shown to be a critical stage in the differentiation 
process, demonstrating the need for protocols which generate DE at a high efficiency (Courtney et 
al., 2010). Differences in differentiation efficiency between ESCs and iPSCs at this stage are likely 
to impact the differentiation efficiency of later stages of the differentiation process. In addition, the 
full differentiation protocol for the generation of insulin-expressing cells in vitro is a lengthy (17 
days) and inefficient process, in contrast to the generation of DE, which takes 3 days and routinely 
results in a yield of around 70% Sox17-expressing cells (D’Amour et al, 2006). For these reasons, 
comparison of the differentiation propensities of ESCs and iPSCs was compared at the DE stage 
rather than the insulin-expressing stage of differentiation.  
Given the large numbers of protocols published for the differentiation of pluripotent stem cells into 
DE, the second aim of this part of the study was to evaluate three widely applied protocols to 
determine which results in the highest yield of DE in our cells. Obtaining a high yield of DE was 
important for subsequent experiments, as contamination of DE samples with high levels of other cell 
types could affect the results of further experiments. These experiments demonstrated that the 
protocol published by D’Amour et al (2005) resulted in the highest yield of DE compared to any of 
the other protocols tested, or to spontaneously differentiated cells. Although the protocol published 
by Nostro et al (2011) results in similar upregulation of the Cxcr4 and Cer1 genes to the D’Amour 
protocol, the fact that Sox17 and Foxa2 expression are not significantly upregulated suggests that 
differentiation to DE may be less complete in the cell lines used in these experiments. These results 
are in contrast to those published by Nostro et al (2011), where they reported that this protocol 
produced a population of cells containing approximately 70% Sox17-expressing cells. Cells treated 
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with the protocol published by Borowiak et al (2009) fail to upregulate any DE-associated genes at a 
higher efficiency than spontaneously differentiating cells, suggesting that this protocol is having little 
or no effect in directing the cell lines used in this study towards an endodermal fate. This may be due 
to the use of different cell lines in this study than in the Borowiak or Nostro protocols, and the 
D’Amour protocol may result in a higher yield simply because it is more applicable across stem cell 
lines. However, other researchers (Tahamtani et al, 2013; Massumi et al, 2014) have also found the 
Borowiak protocol to be ineffective. As the D’Amour protocol gave the highest efficiency of 
differentiation for the cell lines used in these experiments, this was used in all subsequent 
differentiation experiments.  
During the course of these investigations, it was noticed that different cell lines had different 
propensities to form DE, with one ESC line (H1) forming significantly less DE than any other cell 
line. These differences between cell lines were consistent over several experiments, suggesting that 
they are due to intrinsic properties of the cell lines, and not random variation in differentiation 
efficiency due to other factors. However, a limitation of this study is that the cell lines used are not 
all cultured in the same way. Initial experiments were carried out using two iPSC lines generated at 
NIBSC, MRC5I and MRC9G, and a well-characterised ESC line (H9). However, the iPSC lines are 
grown on iSNL feeders, and the H9 line is grown on Matrigel™. For this reason, the H1 cell line was 
included in differentiation experiments and microarray analysis, as this is an ESC line grown on 
iSNL feeders, and was therefore expected to represent an ESC line grown in a comparable culture 
format to the available iPSC lines. However, data from my own results and others (Bock et al, 2011; 
Nostro et al, 2011) subsequently indicated that this line has a low propensity for forming DE. The H7 
ESC line, also grown on Matrigel™, was also included in differentiation comparisons to provide 
additional supportive data for ESC lines grown on Matrigel™. To investigate whether the low 
differentiation efficiency observed in the H1 cell line was a result of being grown on iSNL feeders, 
compared to the other ESC lines which were all grown on Matrigel™, I tested the differentiation 
efficiency of the H9 ESC line grown on both feeders and Matrigel™. I found no significant 
differences in differentiation efficiency between H9 cells cultured on feeders vs. Matrigel™, 
although there was some slight variability in gene expression between them. There was significant 
upregulation of DE genes in the treated samples compared to the undifferentiated samples, 
demonstrating that the H9 cell line can differentiate into DE at high efficiencies irrespective of the 
culture conditions used. 
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The subject of whether there are any systematic differences between ESCs and iPSCs has been hotly 
debated. Disparities were first observed in the differentiation abilities of ESCs and iPSCs, in both 
teratoma formation and in vitro differentiation assays. Just like ESC lines, iPSC lines have 
considerable heterogeneity and show different propensities for differentiation (Abeyta et al, 2004; 
Martinez et al, 2012; Osafune et al, 2008), with some studies showing that iPSCs have lower 
efficiencies of differentiation into haematopoietic, neuroepithelial, neuronal and cardiac lineages 
compared to ESCs (Feng et al, 2010; Hu et al, 2010; Narsinh et al, 2011). While some researchers 
argued that these results show that iPSCs have an intrinsically lower capacity to differentiate into 
certain lineages in vitro than ESCs, others have argued that the cell of origin might have an effect on 
the differentiation propensity of the iPSCs. A study by Boulting et al (2011) found that, although 
there was variation between cell lines in their ability to differentiate, iPSCs were as good as ESCs at 
generating motor neurones, and that the differentiated cells produced were functionally equivalent. 
The differences in differentiation propensities could not be correlated with pluripotency markers, 
karyotype, reprogramming method, or transgene expression, and although some donor-specific 
differences in gene expression were noticed, these were not statistically significant. A more recent 
large-scale study compared the propensity of 49 iPSC lines and 10 ESC lines to differentiate into a 
neural lineage, and found that 7 iPSC lines showed significantly reduced differentiation capacity, 
which corresponded to differences in the expression levels of several genes. However, the majority 
of iPSC lines could not be distinguished from ESC lines (Koyanagi-Aoi et al, 2013). In contrast, 
Kwon et al (2014) found that iPSCs differentiated into dopaminergic neurons at a higher efficiency 
than ESCs. These studies have led to questions about whether iPSCs are indeed identical to ESCs, 
and if they are not, what the functional implications of this might be for the use of iPSCs for in vitro 
applications such as disease modelling and drug screening, and in vivo use for cell replacement 
therapy.  
My results showed that the two iPSC lines used in these experiments did not show a lower 
propensity for differentiating into DE than the 3 ESC lines. In fact, the lowest differentiation 
efficiency was seen in the H1 cell line. However, there was variability in differentiation efficiency 
between the cell lines used. These results are similar to a study carried out in mice, which compared 
4 iPSC lines and 2 ESC lines, and found considerable variability between cell lines in their 
propensity to form DE, although no overall differences between ESCs and iPSCs. Although this 
study found significant differential expression of BMP4 during differentiation, this did not appear to 
be associated with any reduction in differentiation propensity (Christodoulou et al, 2011). This 
Chapter 7 Discussion 
278 
 
suggests that although differences may exist between ESCs and iPSCs, they may not have a 
functional impact on the cells.  
 
7.3 Investigation of miRNA Expression in DE Formation 
MicroRNAs are now known to be important in controlling pluripotency and differentiation of ESCs 
and iPSCs, and there have been suggestions that there are differences in miRNA expression between 
these cell types which may have an impact on their ability to differentiate into DE. To investigate 
this further, miRNA expression patterns in ESCs and iPSCs were investigated at the undifferentiated 
and DE stage.  
There are three main techniques used for profiling miRNA expression: microarray, high-throughput 
RNA sequencing, and qRT-PCR, each with their own advantages and disadvantages. Microarray 
analysis has the advantage of being a high-throughput method for profiling miRNA expression, 
allowing investigation of thousands of miRNAs in parallel. It is also relatively inexpensive. 
However, limitations of this approach include the fact that the labelling reaction can result in the 
addition of a large and variable number of nucleotides, and other RNA species may also be labelled, 
contributing to background noise, and may cross-hybridise with miRNA probes. The variation in the 
CG content of miRNAs can lead to different annealing temperatures for different miRNAs. To avoid 
this problem, LNA (locked nucleic acids) can be incorporated into the arrays, as they have an 
increased affinity for complementary miRNA sequences. In addition, a limited range of 
quantification, imperfect specificity for some closely related miRNAs, and the inability to absolutely 
quantify miRNA means that this technique is most suited to carrying out comparisons between two 
states e.g. differentiated and undifferentiated stem cells. Due to the high chance of false positives 
occurring during microarray analysis, the results need to be validated by qRT-PCR, as this the most 
reliable method of analysing miRNA expression. In addition, qRT-PCR is also the cheapest, 
although the large numbers of miRNAs now known to exist means that this technique is more suited 
to validation than discovery. 
For absolute quantification of miRNAs in a sample, next generation RNA sequencing can be used. 
This technique has the clear advantage of being the only method allowing discovery of new miRNAs 
and post-transcriptional modifications of miRNAs. In addition, this method is not adversely affected 
by variability in melting temperatures, co-expression of nearly identical miRNA family members, or 
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post-transcriptional modifications. The disadvantages of this method include the high cost; the 
requirement for high performance bioinformatic infrastructure for data analysis; and the fact that the 
RNA ligation and PCR amplification steps of sample preparation can lead to bias. Studies comparing 
microarray and RNA sequencing for analysis of miRNA expression have found that for 
quantification of miRNAs in a sample, microarray analysis surpasses next generation sequencing in 
terms of specificity and sensitivity (Willenbrock et al, 2009). For this reason, as well as the cost of 
the experiments, microarray analysis was chosen to analyse the expression of miRNAs during 
differentiation to DE. However, it would be interesting to analyse the same samples using RNA 
sequencing to see if any novel miRNAs could be identified in these samples, and to compare the 
results of both microarray and RNA sequencing.  
Although the later stages of pancreatic development have been reasonably well-characterised in 
terms of miRNA expression, there have been relatively few studies focussing on the DE stage. 
Microarray analysis was carried out to identify miRNAs differentially expressed between 
undifferentiated and differentiated cells, and which may therefore play a role in DE formation. This 
comparison was carried out for ESCs and iPSCs, as well as for individual cell lines. Although there 
are some differences in the miRNAs which are up- or down-regulated in these comparisons, several 
miRNAs show consistency between cell lines, most notably miR-375 and miR-708-5p, which are 
consistently and strongly upregulated in differentiating cells. These microarray results were validated 
using qRT-PCR, which again confirmed the strong upregulation of miR-375 and miR-708-5p, 
suggesting a role for these miRNAs in DE formation. Both of these miRNAs have been previously 
reported to be upregulated in DE formation (Tzur et al, 2008; Hinton et al, 2010; Kim et al, 2011), 
although their exact mechanism of action has not been fully elucidated. One study identified 
TIMM8A as a target of miR-375 but did not elucidate the role of this pathway in DE formation 
(Hinton et al, 2010). There was less consistency in the miRNAs predicted to be downregulated in DE 
formation by the microarray, and this was reflected in the PCR validation, as only one of the ten 
miRNAs investigated (miR-516b) was found to be significantly downregulated.  
A better understanding of the role of miRNAs in DE formation may prove useful both in terms of 
characterisation and in manipulation of cell fate. In addition to analysis of gene expression, analysis 
of miRNA expression may also be helpful when characterising the differentiated progeny of stem 
cells. The expression of miR-375 and miR-708 in the cell lines tested in this study mirrored the 
expression of genes routinely used as markers for this germ layer, such as Sox17, with the highest 
expression of these miRNAs in the cell lines previously noted to give rise to DE at higher efficiency, 
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and with the lowest expression in the H1 cell line, which has a poor efficiency of differentiation into 
DE. 
 
7.4 Investigation of Differential miRNA Expression between ESCs and iPSCs 
There have been several studies which have investigated differences in miRNA expression between 
ESCs and iPSCs (Chin et al, 2009; Wilson et al, 2009; Neveu et al, 2010; Razak et al., 2013), with 
some studies finding differences between the two cell types, and others finding no differences 
(Koyanagi-Aoi et al, 2013). Although there has been some overlap in the miRNAs identified as 
differentially expressed between ESCs or iPSCs, so far there is little evidence for consistent 
differences between ESCs and iPSCs. In addition, most of these studies focussed on miRNA 
expression only in undifferentiated cells. For these reasons, the functional significance of differences 
between ESCs and iPSCs is still unclear, although as miRNAs are now known to play a significant 
role in controlling differentiation, differences in miRNA expression between ESCs and iPSCs may 
affect the cells’ ability to differentiate into a pancreatic lineage, rendering them less suitable for use 
in cell replacement therapy to treat T1DM. With this in mind, microarray analysis was used to 
investigate differences between ESCs and iPSCs with the aim of identifying any differences in 
miRNA expression which may have a functional impact on the cells’ ability to differentiate into a 
pancreatic lineage at the DE stage.  
Initial comparison of undifferentiated ESCs and iPSCs did not identify any miRNAs differentially 
expressed between the two cell types. However, when miRNA expression was compared in DE 
derived from ESCs and iPSCs, several miRNAs were identified as being differentially expressed 
between the two cell types. In addition, several of these differentially expressed miRNAs, including 
miR-151a-3p, miR-151a-5p, miR-26b-5p, miR-27b-3p, miR-30b-5p, miR-378a-3p, and miR-4530, 
were also identified as potentially playing a role in DE formation, as they were also significantly up- 
or down-regulated in differentiated cells compared to undifferentiated cells. Validation of these 
results by qRT-PCR identified miR-151a-3p and miR-151a-3p as being significantly differently 
expressed between ESCs and iPSCs. These two miRNAs are derived from the same pre-miRNA 
stem loop, and are therefore likely to be co-regulated and co-transcribed, although as their sequence 
is different they are likely to have different target genes and therefore different mechanisms of 
action.  
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Another factor identified by the microarray as having an effect on miRNA expression is the culture 
conditions that the cells are grown in. Initial experiments were carried out using two iPSC lines 
generated at NIBSC (MRC5I and MRC9G) and a well-characterised ESC line (H9). However, the 
iPSC lines are grown on iSNL feeders, and the H9 line is grown on Matrigel™. For this reason, the 
H1 cell line was also included in differentiation experiments and microarray analysis, as this is an 
ESC line grown on iSNL feeders, and was therefore expected to represent an ESC line grown in a 
comparable culture format to the available iPSC lines. However, subsequent experiments 
demonstrated that this cell line was poor at differentiating into DE. At the time, these were the only 
cell lines available with which to carry out the analysis, and an obvious improvement to this part of 
the study would be to include an ESC line cultured on iSNL feeders which was not similarly limited 
in the efficiency with which it was able to differentiate into DE. During the microarray analysis, it 
quickly became apparent that the difference in culture conditions may have an effect on miRNA 
expression, as the H9 cell line was clearly segregated from the other cell lines in the principal 
component analysis and hierarchical clustering. This was also evident from the comparisons of 
individual cell lines. When undifferentiated H1 samples were compared with undifferentiated iPSC 
samples, only 5 miRNAs were significantly differentially expressed. This suggests that these samples 
are highly similar in terms of their miRNA expression. However, when undifferentiated H9 samples 
were compared with undifferentiated iPSC samples, 186 miRNAs were differentially expressed. A 
similar phenomenon was noticed when comparing differentiated samples. When differentiated H9 
were compared with differentiated iPSCs, 154 miRNAs were differentially expressed. When 
differentiated H1 were compared with differentiated iPSCs, only 28 miRNAs were significantly 
differentially expressed, despite the fact that the H1 cell line has a lower propensity to form DE than 
the two iPSC lines. In order to ensure that we were not missing any candidate miRNAs which may 
be differentially expressed between ESCs and iPSCs, the expression of several other miRNAs which 
were identified as being significantly differentially expressed in iPSCs when compared to the ESC 
cell lines individually (i.e. H1 or H9) were further investigated further. However, when these 
miRNAs were assessed using qRT-PCR in five pluripotent stem cell lines, no significant differences 
in miRNA expression were seen between any of the cell lines tested. While it remains possible that 
there are differences in the expression of these additional miRNAs due to the different culture 
conditions, as well as to cell line-specific differences, they were not identified in this study, and these 
miRNAs were not investigated further.  
These differences in miRNA expression in the H9 cell line were not predicted either by the 
pluripotency characterisation data (chapter 3) or by the differentiation data (chapter 4), as the H9 cell 
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line showed very similar expression of pluripotency and DE genes to the other cell lines analysed. 
For this reason, another ESC line (H7) grown on Matrigel™ was included in the PCR validation of 
the microarray data. These analyses identified two miRNAs that appeared to show differences in 
their expression depending on the culture method: miR-4451and miR-4732 were upregulated in cells 
grown on Matrigel (H7 and H9) and downregulated in cells grown on iSNL feeders (MRC5I, 
MRC9G and H1). To further investigate the possibility that differences in culture conditions had an 
effect on miRNA expression, a further differentiation experiment was carried out using H9 cells 
grown on both iSNL feeders and Matrigel™. The expression of miRNAs previously demonstrated by 
qRT-PCR validation of the microarray results to be a) upregulated in DE formation; b) 
downregulated in DE formation; or c) differentially expressed between cells grown on iSNL feeders 
and cells grown on Matrigel™ were investigated. However, there were no significant differences in 
expression of any of these miRNAs when H9 cells were grown using both culture methods.  
The differences observed in miRNA expression in these analyses may be due to a number of factors, 
including cell type, individual cell lines, culture conditions, and differentiation status. The purpose of 
this experiment was not to draw any definitive conclusions about differences in miRNA expression 
between individual cell lines or between different culture conditions, but instead to try to identify 
miRNAs which may be involved in DE formation, and which are differentially expressed between 
ESCs and iPSCs. A more complete analysis of global patterns of miRNA expression would require 
access to a larger number of different ESC and iPSC lines. Furthermore, to elucidate the effects of 
different culture conditions on miRNA expression, it would be necessary to have access to these cell 
lines grown on both feeders and Matrigel™, which in many cases, because of specific cell lines 
requiring certain culture conditions, would not always be possible. For example, despite repeated 
attempts, we were not able to grow the H1 cell line on Matrigel™, as transfer from iSNL feeders 
resulted in a failure to grow and loss of pluripotency gene expression. 
However, despite the dissimilarities between the cell lines, some miRNAs, including miR-151a-3p, 
miR-151a-5p and miR-27b, previously identified as potentially playing a role in DE formation, were 
also identified as being differentially expressed in both the overall comparison of iPSC vs. ESC, as 
well as the individual comparison of H1 vs. iPSC and H9 vs. iPSC. These miRNAs are more likely 
to represent conserved differences between ESCs and iPSCs which are not specific to certain cell 
lines, although this is difficult to determine in an analysis of only four cell lines. The strongest 
contrast was seen in expression of miR-151a-3p and miR-151a-5p, which are upregulated upon 
differentiation in ESCs, and downregulated in iPSCs. miR-27b did show differential expression 
Chapter 7 Discussion 
283 
 
between the two cell types, being more strongly upregulated in ESCs than in iPSCs, but this 
difference was not statistically significant in the qRT-PCR validation data.  
 
7.5 Investigation of the Function of miRNAs in DE Formation 
miR-375 is known to be essential both for embryonic pancreatic development and mature β-cell 
function (reviewed in Francis et al., 2014). It has also been reported to be upregulated in DE 
formation (Tzur et al., 2008; Hinton et al., 2010; Tsai et al., 2010; Kim et al., 2011; Porciuncula et 
al., 2013) and was also found to be strongly upregulated by my own microarray analysis, but its 
exact function remains unclear. Hinton et al (2010) demonstrated a direct relationship between miR-
375 and its target Timm8a, although they did not elucidate a role for this pathway in DE formation. 
As this relationship has already been established, it was thought that this would be a useful way of 
validating the methods used to study miRNA function, and indeed, the relationship between miR-375 
and its target gene Timm8a was confirmed using a luciferase assay.  
In addition to identifying miRNAs important in DE formation, microarray analysis and subsequent 
qRT-PCR was also used to identify miRNAs that were differentially expressed between ESCs and 
iPSCs, and which may therefore have an impact on the cells’ ability to differentiate into DE. Two 
miRNAs fulfilled this criteria, miR-151a-3p and miR-151a-5p. These miRNAs were shown to be 
upregulated in DE formation in ESCs, but downregulated in iPSCs. These miRNAs have not been 
previously implicated in DE formation, although their expression has been noted in foetal liver (Fu et 
al, 2005) and their function remains unknown, although a few gene targets have been confirmed 
(mirtarbase.mbc.nctu.edu.tw/index.php, accessed 03/12/2013), although not in the context of 
pancreatic differentiation. For this reason, these miRNAs were identified for further study.  
First, target prediction algorithms were used to identify potential gene targets of miR-151a-3p and 
miR-151a-5p. The results are included in appendix 2. TargetScan, miRanda and Pictar were chosen, 
as in a comparison of target prediction programs, these three used either alone or in combination had 
the best trade-off between sensitivity and specificity (Witkos et al., 2011). Interestingly, Sox17 
appeared on the list of predicted targets for miR-151a-5p in the results from both TargetScan and 
miRanda. This gene is one of the earliest markers of DE (Lewis & Tam, 2006), and is essential for 
endoderm formation, as mice lacking Sox17 do not develop gut endoderm from DE (Kanai-Azuma et 
al., 2002). A luciferase assay was used to determine whether there is a direct relationship between 
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miR-151a-5p and Sox17, but no binding of this miRNA to the 3’UTR of the Sox17 mRNA could be 
detected. Identifying miRNA targets is challenging, largely due the limited complementarity between 
miRNAs and their target mRNAs, and the fact that the interactions between miRNAs and their target 
genes are still not entirely understood. This demonstrates the importance of using experimental 
approaches to validate predicted target genes of miRNAs, as algorithms used for predicting targets 
typically predict hundreds if not thousands of target genes for each miRNA, most of which are not 
true targets (Thomas et al., 2010). The false positive rate of prediction algorithms has been variously 
reported as between 24-70% (Thomson et al., 2011). It is possible that there is an indirect 
relationship between miR-151a-5p and Sox17 through a larger regulatory network of miRNAs and 
genes. This could be investigated further through manipulation of miR-151a-5p expression levels, as 
this would demonstrate whether the expression levels of Sox17 are affected by changes in miR-151a-
5p expression levels. This experiment would be best carried out in ESCs or iPSCs, as they are known 
to express both miR-151a-5p and Sox17.  Alternatively, there may be no relationship between miR-
151a-5p and Sox17, and miR-151a-5p may mediate its effects on DE formation through another 
mechanism. One way to investigate this further would be to use microarray analysis to identify 
changes in gene expression that inversely correlate with changes in miR-151a-5p expression levels, 
as this would demonstrate gene silencing by miRNA binding to its target genes. This would also be 
useful for identifying target genes not predicted by target prediction algorithms, as many genes 
identified by overexpression or silencing of miRNAs in combination with microarray analysis were 
not predicted by target prediction software, which can largely be explained by the application of 
stringent criteria regarding the evolutionary conservation of putative binding sites (Krutzfeldt et al., 
2006). 
The second aim of this chapter was to investigate the effects of manipulating miR-151a-5p 
expression in pluripotent stem cells using lentiviral vectors encoding a miRNA mimic and a miRNA 
inhibitor, to determine whether changes in the expression of miR-151a-5p result in changes in 
endodermal gene expression, particularly Sox17, or altered differentiation efficiency. As miR-151a-
5p is differentially expressed between ESCs and iPSCs, it would be interesting to see how 
manipulating expression of miR-151a-5p affects each cell type. However, despite repeated attempts 
to optimise experimental conditions, successful lentiviral transduction of the cells could not be 
achieved within the allocated time frame for inclusion in this thesis. Further optimisation of these 
experiments would include testing lentiviral vectors with different promoters driving gene 
expression, as a study has demonstrated that different promoters result in differential transgene 
expression in human ESCs, with some expression from some promoters being suppressed more than 
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others (Xia et al, 2007). A promising alternative may be the use of lentiviral vectors whose 
expression is driven by the EF1α promoter, as this has been shown to drive transgene expression 
more efficiently than the CMV promoter that I used in these experiments (Kim et al, 2007). It is also 
likely that the experimental conditions, including time of infection and multiplicity of infection, will 
need to be further optimised.  
 
7.6 Future Perspectives 
In recent years, our understanding of the role that miRNAs play in pluripotency and differentiation 
has greatly increased, and this is a field of research that is likely to continue to expand rapidly in 
coming years. Increased knowledge of the role of miRNAs in differentiation to different lineages 
may improve differentiation protocols, as each stage of differentiation is characterised by a unique 
miRNA signature which can be characterised in the same way that gene expression is currently used 
for characterisation. In addition, recent studies have demonstrated the ability of miRNAs to influence 
cell fate.  
One of the clearest indications of the power of miRNAs to influence cell fate is through the 
demonstration that pluripotency-associated miRNAs are able to reprogram somatic cells to iPSCs 
without the need for additional reprogramming factors (Anokye-Danso et al., 2011). However, 
miRNAs can also be used to induce differentiation. One of the earliest studies to investigate these 
effects demonstrated that the overexpression of miRNAs associated with a specific lineage, e.g. miR-
1 (muscle) or miR-124 (neurons) in HeLa cells resulted in a shift in gene expression towards those 
specific lineages (Lim et al., 2005). Since then, there have been a number of similar studies 
demonstrating, for example, miR-124-mediated conversion of fibroblasts into functional neurons 
(Ambasudhan et al., 2011; Yoo et al., 2011; Xue et al., 2013) and miRNA-mediated conversion of 
cardiac fibroblasts into cardiomyocytes, both in vivo and in vitro, using a combination of the 
miRNAs miR-1, miR-133, miR-208, and miR-499 (Jayawardena et al., 2012). 
To date, there have been few examples of the use of miRNAs to drive or influence pancreatic 
development, which perhaps reflects the current incomplete understanding of the role of miRNAs in 
this process. However, miRNAs have been used to drive differentiation into a pancreatic lineage in 
the absence of any other factors in both ESCs (Lahmy et al, 2013) and iPSCs (Lahmy et al, 2014), 
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highlighting the potentially important role that miRNAs may play in reaching the ultimate goal of a 
β-cell replacement therapy for type 1 diabetes. 
The use of miRNAs to influence cell fate is appealing for a number of reasons. Firstly, they have the 
potential to directly and immediately alter gene expression, which may reduce the time required for 
in vitro differentiation of cells and thereby lead to increased efficiency and reduced costs for the 
manufacture of cell therapy products. Secondly, they can be transiently expressed in a cell and so do 
not permanently integrate into the cellular genome, which is appealing from a safety perspective. In 
addition, miRNAs are inherently less variable than the recombinant growth factors commonly used 
in differentiation protocols. As a result, their use has the potential to reduce the variability currently 
observed in the differentiation of pluripotent stem cells for cell therapy applications, including the 
generation of pancreatic β-cells for a therapy for T1DM. However, if the full potential of miRNAs to 
modulate cellular differentiation is to be realised, a better understanding of the specific role of each 
miRNA is required. With this in mind, it is likely that the continued development of powerful, high-
throughput technologies, such as next generation sequencing and related technologies for identifying 
miRNAs bound to their targets, such as HTS-CLIP (high-throughput sequencing of RNA isolated by 
cross-linking immunoprecipitation), are likely to have a significant impact over the next few years. 
The potential of miRNAs to alter entire gene networks which are dysregulated in certain disease 
states also makes them appealing targets for the development of new therapeutics. Based on lessons 
learned from siRNA technologies, very potent chemically-modified oligonucleotides to repress 
miRNA expression, as well as synthetic miRNA mimics, are being developed. Despite the short time 
since the discovery of miRNAs in humans (Pasquinelli et al., 2000), several miRNA therapeutic 
products have already entered clinical trials (reviewed in van Rooij et al, 2012). Many miRNA 
therapeutics are currently focussed on the treatment of cancer. However, numerous miRNAs have 
been identified as playing a role in diabetes and its related complications (reviewed in Kumar et al., 
2012), and these may provide targets for the future development of therapeutic miRNAs. At present, 
however, strategies to achieve cell type-specific delivery of miRNAs into the β-cell are lacking, 
though the identification of β-cell surface-enriched markers (Stutzer et al. 2012) may provide the 
basis of new selective delivery approaches in the future.  
Finally, miRNAs may also have therapeutic potential when combined with gene therapy. Proof-of-
principle has recently been demonstrated in a recent study by Jayawardena et al. (2012), in which 
delivery of cardiomyocyte-associated miRNAs into ischemic mouse myocardium resulted in the 
direct conversion of cardiac fibroblasts to cardiomyocytes in situ. While this study did not address 
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any improvement in cardiac function, it does demonstrate the potential of miRNAs to alter cell fate 
in vivo, which may prove a useful therapeutic tool in the future. 
 
7.7 Concluding Remarks 
This study demonstrates that iPSC lines are able to form definitive endoderm as well as ESC lines, 
but that there is variability in efficiency between cell lines. I have investigated the role of miRNAs in 
differentiation to the definitive endoderm stage, and identified a number of miRNAs as being up- or 
down-regulated during this process. In addition, I have shown that some of these miRNAs are also 
differentially expressed between ESCs and iPSCs, and gone on to further investigate the role of one 
of these, miR-151a-5p. I have confirmed that there is no direct relationship between this miRNA and 
one of its putative target genes, Sox17, demonstrating that this is not the mechanism through which 
this miRNA is involved in DE formation. The true targets of this miRNA and their role in DE 
formation have yet to be elucidated. In addition, the functional impact of these differences in miRNA 
expression on the differentiation of iPSCs and ESCs into a pancreatic lineage requires further 
investigation. A previous study which identified differences in BMP4 expression levels between 
ESCs and iPSCs during pancreatic differentiation found that these differences did not appear to be 
associated with any reduction in differentiation propensity (Christodoulou et al, 2011). This suggests 
that although differences may exist between ESCs and iPSCs, they may not adversely affect the 
function of the cells, suggesting that iPSCs may be considered an alternative to ESCs for cell 
replacement therapy.  
It is becoming clear that the heterogeneity and behaviour of stem cells is more complex than had 
previously been thought, and that iPSCs and ESCs are neither identical nor distinct populations; 
instead, they seem to overlap, with greater variability within each population than is observed 
between the populations. This variability is likely to have functional implications for the cells. It may 
be more useful to consider each cell line in terms of its quality and utility, in order to choose the best 
cell line for the desired application. With a view to this end, some researchers have produced a 
‘scorecard’ to evaluate the character of both iPSCs and ESCs, and to predict the quality and utility of 
any pluripotent cell in a high-throughput manner: a large-scale study by Bock et al (2011) used gene 
expression profiling, DNA methylation mapping, and a high-throughput quantitative differentiation 
assay to establish  genome-wide reference maps for patterns of gene expression and DNA 
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methylation in order to provide a baseline against which comparisons of new ES and iPS cell lines 
can be made in order to assess their quality and utility.  
However, even with a better understanding of the differences between ESCs and iPSCs, and the 
functional consequences of these differences, there are still numerous hurdles to be overcome before 
pluripotent stem cells can offer a cure for T1DM. These include the source of the cells used, whether 
ESC or iPSC. Recently, human ESCs have been generated through somatic cell nuclear transfer 
(SCNT), providing an alternative source of pluripotent stem cells that does not require the use of 
fertilised human embryos, although it does still require the use of human oocytes (Tachibana et al, 
2014). It is likely that these cells will provide many of the advantages currently associated with 
iPSCs, including the ability to derive them from donors with known phenotypes, such as specific 
diseases, as well as providing a source of patient-matched pluripotent stem cells. In addition, these 
cells could be useful for treating mitochondrial diseases through cell replacement therapy, as the 
mitochondria in SCNT-ESCs are derived from the donor oocyte. However, careful evaluation of 
these cells in comparison with traditional ESCs and iPSCs is needed, as iPSCs have demonstrated 
how different two types of pluripotent stem cell can be. The use of iPSCs for cell replacement 
therapy requires careful consideration of the cell source and method used for reprogramming (see 
section 1.8), and the cell lines will need to be derived in a GMP-compliant manner.   
There are also issues facing the differentiation protocols used to direct the pluripotent stem cells 
towards a desired cell fate in vitro. While some cell types have proved relatively easy to generate in 
vitro, others, such as pancreatic β-cells, have proved more difficult, with problems of inefficiency of 
differentiation and limited function in comparison to their in vivo counterparts. However, this is the 
topic of much current research, with steps being made towards a full understanding of the 
differentiation signals. In addition, the use of small molecules in differentiation has the potential to 
increase efficiency and reproducibility, and steps have been made towards GMP-compliant culture, 
expansion and differentiation of cells in vitro. Furthermore, it has been shown that pancreatic 
progenitors derived from pluripotent stem cells undergo further maturation following transplantation, 
and these cells will form the basis of clinical trials being carried out by Viacyte for the treatment of 
T1DM (viacyte.com/press-releases/jdrf-to-provide-additional-support-for-upcoming-clinical-trial-of-
viacytes-encapsulated-cell-therapy-for-type-1-diabetes, accessed 16/04/2014).  
Finally, there are concerns over the safety of transplanted cells derived from pluripotent stem cells. 
Undifferentiated cells remaining in the graft may result in teratomas, so efforts have been made to 
exclude these cells (see section 1.8), although a recent study found that even autologous 
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undifferentiated ESCs were efficiently rejected following transplantation through natural killer cell-
mediated killing, due to their low expression of MHC class I molecules (Perez-Cunningham et al, 
2014). However, a recent study in rhesus macaques demonstrated that transplantation of 
undifferentiated iPSCs did result in teratoma formation, although only when administered in high 
doses, and there was some evidence of an inflammatory immune response (Hong et al, 2014). 
Another safety concern is the risk of immunogenicity, as recent research has shown that even 
autologous iPSCs may be subject to immune rejection (Zhao et al, 2011), although other studies  
have since cast doubt on these findings (Araki et al, 2013; Guha et al, 2013), including one very 
recent study in a non-human primate model, the first of this type of study not carried out in mice 
(Hong et al, 2014). However, due to the time it takes to derive and differentiate a patient’s own cells 
for cell replacement therapy, and the expense of making these cells, it may be more appropriate to 
turn to banking of iPSCs. With the diversity of starting material available from blood donors, it is 
considerably easier to generate cell lines of a known genetic background that would provide a 
beneficial immunological match for most of the population, although it is unlikely that even the best 
possible match from an iPSC bank will be able to entirely escape immune recognition following 
transplant, making it likely that some form of immunosuppressive treatment may be needed. In 
addition, the autoimmune nature of T1DM means that if the transplanted cells are not protected in 
some way from immune attack, perhaps through immune modulation or encapsulation (see section 
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Appendix 1: Supplementary miRNA Tables 
Supplementary Table 1 
ESCs: Differentiated vs. Undifferentiated 
miRNA p-value logFC 
hsa-miR-124-5p 0.015 -0.207 
hsa-miR-99b-5p 0.019 1.579 
hsa-miR-483-5p 0.019 0.729 
hsa-miR-375 0.019 0.502 
hsa-miR-5572 0.019 0.398 
hsa-miR-30d-5p 0.019 0.442 
hsa-miR-4530 0.019 0.687 
hsa-miR-4795-5p 0.021 -0.273 
hsa-miR-26b-5p 0.021 0.574 
hsa-miR-181d 0.021 2.007 
hsa-miR-378a-3p 0.021 -0.309 
hsa-miR-185-5p 0.023 0.251 
hsa-miR-191-5p 0.023 0.453 
hsa-miR-181a-5p 0.023 2.261 
hsa-miR-3182 0.026 0.850 
hsa-miR-484 0.027 0.129 
hsa-miR-3202 0.028 0.571 
hsa-miR-342-3p 0.028 0.680 
hsa-miR-181b-5p 0.029 1.497 
hsa-miR-4306 0.029 0.519 
hsa-miR-4472 0.029 0.247 
hsa-miR-744-5p 0.029 0.471 
hsa-miR-3149 0.029 -0.311 
hsa-miR-197-3p 0.029 0.256 
hsa-miR-135b-5p 0.029 1.366 
hsa-miR-4792 0.030 0.321 
hsa-miR-4516 0.035 1.078 
hsa-miR-4451 0.035 -0.351 
hsa-miR-27b-3p 0.036 0.846 
hsa-miR-1247-5p 0.038 0.127 
hsa-miR-516b-5p 0.039 -0.232 
hsa-miR-4800-3p 0.042 0.822 
hsa-miR-1587 0.044 0.319 
hsa-miR-4285 0.045 -0.555 
hsa-miR-15a-5p 0.045 0.449 
hsa-miR-5581-3p 0.046 0.204 
hsa-miR-24-3p 0.050 0.943 
hsa-miR-125a-5p 0.050 1.373 
hsa-miR-708-5p 0.050 1.066 
hsa-miR-151a-5p 0.050 0.764 
hsa-miR-3935 0.050 -0.236 
hsa-miR-30b-5p 0.050 0.699 
hsa-miR-218-5p 0.050 0.778 
hsa-miR-4297 0.051 -0.150 
hsa-miR-454-3p 0.054 0.510 
hsa-miR-16-5p 0.055 0.396 
hsa-miR-320a 0.056 0.737 
hsa-miR-320c 0.058 0.852 
hsa-miR-519d 0.061 -0.244 
hsa-miR-99b-3p 0.065 0.211 
hsa-miR-5002-5p 0.065 -0.475 
hsa-miR-4301 0.065 0.632 
hsa-miR-3941 0.065 -0.480 
hsa-miR-193b-3p 0.066 0.525 
hsa-miR-151a-5p 0.066 0.507 
hsa-miR-4639-3p 0.066 -0.439 
hsa-miR-3148 0.066 -0.302 
hsa-miR-3136-3p 0.066 -0.274 
hsa-miR-150-5p 0.066 -0.146 
hsa-miR-30e-3p 0.066 0.556 
hsa-miR-378c 0.066 -0.147 
hsa-miR-301a-3p 0.066 0.888 
hsa-miR-149-5p 0.066 0.503 
hsa-miR-877-5p 0.070 0.314 
hsa-miR-331-3p 0.072 0.761 
hsa-miR-340-5p 0.073 0.391 
hsa-miR-1825 0.073 -0.123 
hsa-miR-374a-5p 0.075 0.630 
hsa-miR-4644 0.077 0.295 
hsa-miR-23a-3p 0.077 1.047 
hsa-miR-320b 0.077 0.739 
hsa-miR-1249 0.077 -0.265 
hsa-miR-3178 0.077 -0.454 
hsa-miR-27a-3p 0.078 0.716 
hsa-miR-149-3p 0.079 0.530 
hsa-miR-4284 0.084 -0.427 
hsa-miR-4292 0.088 0.152 
hsa-miR-23b-3p 0.090 1.181 
hsa-miR-151a-3p 0.094 0.406 
hsa-miR-9-5p 0.096 2.705 
hsa-miR-943 0.099 0.454 




Supplementary Table 2 
iPSCs: Differentiated vs. Undifferentiated 
miRNA p-value logFC 
hsa-miR-708-5p 0.000 1.702 
hsa-miR-4732-3p 0.005 -0.719 
hsa-miR-32-3p 0.005 -0.719 
hsa-miR-106a-5p 0.008 0.569 
hsa-miR-302c-5p 0.009 0.420 
hsa-miR-107 0.010 0.372 
hsa-miR-93-5p 0.011 0.631 
hsa-miR-18a-5p 0.011 0.209 
hsa-miR-17-5p 0.011 0.544 
hsa-miR-92a-3p 0.011 0.464 
hsa-miR-9-3p 0.011 -0.331 
hsa-miR-659-3p 0.011 -0.331 
hsa-miR-103a-3p 0.013 0.633 
hsa-miR-4289 0.017 0.236 
hsa-miR-106b-5p 0.019 0.438 
hsa-miR-151a-3p 0.019 0.188 
hsa-miR-151a-5p 0.020 0.181 
hsa-miR-4791 0.020 0.373 
hsa-miR-302c-3p 0.020 0.558 
hsa-miR-302f 0.020 0.339 
hsa-miR-205-3p 0.020 -0.306 




hsa-miR-3591-5p 0.035 -0.406 
hsa-miR-4436b-5p 0.037 -0.371 
hsa-miR-4532 0.037 0.589 
hsa-miR-18a-3p 0.037 0.154 
hsa-miR-744-5p 0.038 0.655 
hsa-miR-302a-5p 0.039 0.350 
hsa-miR-3201 0.039 0.405 
hsa-miR-3148 0.041 -0.216 
hsa-miR-20a-5p 0.041 0.487 
hsa-miR-375 0.042 0.876 
hsa-miR-3941 0.042 -0.376 
hsa-miR-148b-3p 0.042 0.209 
hsa-miR-4505 0.042 0.755 
hsa-miR-361-5p 0.042 0.239 
hsa-miR-25-3p 0.042 0.250 
hsa-miR-4484 0.042 0.803 
hsa-miR-363-3p 0.042 0.477 
hsa-miR-199a-5p 0.042 0.509 
hsa-miR-491-3p 0.043 -0.679 
hsa-miR-3611 0.044 0.634 
hsa-miR-2116-5p 0.044 -0.242 
hsa-miR-92b-3p 0.050 0.145 
hsa-miR-4530 0.051 0.929 
hsa-miR-1587 0.058 0.679 
hsa-miR-149-3p 0.059 0.960 
hsa-miR-4508 0.059 0.858 
hsa-miR-3183 0.059 -0.214 
hsa-miR-124-5p 0.063 -0.148 
hsa-miR-4507 0.063 0.508 
hsa-miR-3656 0.063 0.439 
hsa-miR-26b-5p 0.066 0.356 
hsa-miR-4285 0.066 -0.578 
hsa-miR-130a-3p 0.066 0.342 
hsa-miR-18b-5p 0.066 0.335 
hsa-miR-30b-5p 0.068 0.252 
hsa-miR-711 0.068 0.620 
hsa-miR-620 0.068 -0.101 
hsa-miR-155-5p 0.068 -0.450 
hsa-miR-4646-3p 0.068 -0.266 
hsa-miR-27b-3p 0.070 0.307 
hsa-miR-320a 0.071 0.225 
hsa-miR-1285-3p 0.071 -0.259 
hsa-miR-638 0.071 0.364 
hsa-miR-30c-5p 0.074 0.250 
hsa-miR-191-5p 0.081 0.304 
hsa-miR-423-3p 0.081 0.190 
hsa-miR-2355-3p 0.081 -0.604 
hsa-miR-361-3p 0.081 -0.272 
hsa-miR-675-5p 0.081 -0.287 
hsa-miR-302e 0.082 0.445 
hsa-miR-20b-5p 0.089 0.404 
hsa-miR-3676-3p 0.090 0.630 
hsa-miR-302d-3p 0.091 0.426 
hsa-miR-1976 0.092 -0.114 
hsa-miR-3924 0.098 -0.485 
hsa-miR-187-3p 0.098 0.124 
hsa-miR-3651 0.098 0.306 
hsa-miR-1255a 0.098 -0.265 
hsa-miR-5701 0.098 0.380 
hsa-miR-19b-3p 0.099 0.352 





Supplementary Table 3 
MRC5I: Differentiated vs. Undifferentiated 
miRNA p-value logFC 
hsa-miR-3676-3p 0.004 1.357 
hsa-miR-4707-5p 0.004 0.776 
hsa-miR-1469 0.009 0.761 
hsa-miR-585 0.046 0.829 
hsa-miR-4488 0.046 1.029 
hsa-miR-4463 0.046 0.812 
hsa-miR-708-5p 0.048 1.464 
hsa-miR-4792 0.048 0.975 
hsa-miR-638 0.048 0.707 
hsa-miR-664-3p 0.048 0.193 
hsa-miR-1909-3p 0.048 0.524 
hsa-miR-652-5p 0.049 0.662 
hsa-miR-3195 0.052 0.925 
hsa-miR-1184 0.056 0.841 
hsa-miR-4436b-5p 0.056 -0.439 
hsa-miR-1290 0.056 0.786 




hsa-miR-1321 0.063 -0.169 
hsa-miR-4791 0.072 0.141 
hsa-miR-4449 0.074 0.617 
hsa-miR-744-5p 0.085 0.713 
hsa-miR-9-3p 0.085 -0.494 
hsa-miR-659-3p 0.085 -0.494 
hsa-miR-5681b 0.087 0.561 
hsa-miR-4726-5p 0.089 0.218 
hsa-miR-204-3p 0.089 0.993 
hsa-miR-492 0.089 0.699 
hsa-miR-634 0.089 0.536 
hsa-miR-4674 0.089 0.757 
hsa-miR-4532 0.094 0.766 
hsa-miR-25-5p 0.094 1.321 









Supplementary Table 4 
MRC9G: Differentiated vs. Undifferentiated 
miRNA p-value logFC 
hsa-miR-708-5p 0.020 1.835 
hsa-miR-4791 0.079 0.512 
hsa-miR-361-5p 0.079 0.335 
hsa-miR-106a-5p 0.079 0.546 
hsa-miR-93-5p 0.079 0.667 
hsa-miR-3183 0.079 -0.318 
hsa-miR-4732-3p 0.079 -0.789 
hsa-miR-32-3p 0.079 -0.789 
hsa-miR-103a-3p 0.079 0.678 
hsa-miR-106b-5p 0.079 0.415 
hsa-miR-4456 0.079 -0.572 
hsa-miR-4417 0.079 -0.404 
hsa-miR-302c-3p 0.079 0.674 
hsa-miR-4768-5p 0.079 -0.661 







hsa-miR-302a-5p 0.079 0.415 
hsa-miR-302f 0.079 0.467 
hsa-miR-302e 0.079 0.688 
hsa-miR-302d-3p 0.079 0.648 
hsa-miR-107 0.084 0.433 
hsa-miR-302c-5p 0.084 0.388 
hsa-miR-27b-3p 0.085 0.308 
hsa-miR-3158-5p 0.085 -1.273 
hsa-miR-665 0.091 -0.551 
hsa-miR-17-5p 0.092 0.505 
hsa-miR-375 0.092 0.479 
hsa-miR-18a-5p 0.092 0.200 
hsa-miR-3915 0.092 0.422 
hsa-miR-210 0.092 0.257 
hsa-miR-18b-5p 0.092 0.477 
hsa-miR-26b-5p 0.092 0.499 
hsa-miR-320a 0.092 0.344 





Supplementary Table 5 
H9: Differentiated vs. Undifferentiated 
miRNA p-value logFC 
hsa-miR-4800-3p 0.008 1.007 
hsa-miR-302a-3p 0.015 -0.903 
hsa-miR-4451 0.015 -0.442 
hsa-miR-302b-3p 0.015 -0.727 
hsa-miR-4516 0.015 1.423 
hsa-miR-99b-5p 0.015 2.187 
hsa-miR-3162-3p 0.015 0.613 
hsa-miR-4532 0.015 0.670 
hsa-miR-125a-5p 0.015 2.040 
hsa-miR-181d 0.015 2.631 
hsa-miR-125b-5p 0.015 3.228 
hsa-miR-181b-5p 0.016 2.074 
hsa-miR-483-5p 0.017 0.702 
hsa-miR-520c-3p 0.017 -0.778 
hsa-miR-181a-5p 0.017 3.151 
hsa-miR-375 0.017 0.620 
hsa-miR-4484 0.017 1.043 
hsa-miR-943 0.017 0.676 
hsa-miR-218-5p 0.017 1.227 
hsa-miR-3202 0.017 0.658 
hsa-miR-3687 0.017 1.083 
hsa-miR-30c-1-3p 0.017 0.386 
hsa-miR-99b-3p 0.017 0.304 
hsa-miR-542-5p 0.017 0.460 
hsa-miR-4324 0.019 1.349 
hsa-miR-3651 0.019 -0.338 
hsa-miR-9-5p 0.019 4.018 
hsa-miR-518b 0.019 -0.280 
hsa-miR-512-3p 0.020 -0.966 
hsa-miR-4508 0.020 0.895 
hsa-miR-4780 0.020 -0.354 
hsa-miR-4534 0.020 0.637 
hsa-miR-708-5p 0.021 1.082 
hsa-miR-302c-3p 0.021 -0.654 
hsa-miR-4530 0.025 0.742 
hsa-miR-1469 0.025 0.341 
hsa-miR-675-5p 0.026 0.599 
hsa-miR-4792 0.026 0.310 
hsa-miR-4306 0.026 0.579 
hsa-miR-491-3p 0.029 0.731 
hsa-miR-3656 0.029 0.360 
hsa-miR-4714-5p 0.029 -0.555 
hsa-miR-5572 0.029 0.460 
hsa-miR-135a-5p 0.029 1.653 
hsa-miR-4725-3p 0.029 0.316 
hsa-miR-4791 0.030 -0.419 
hsa-miR-5701 0.030 -0.395 
hsa-miR-23b-3p 0.030 1.200 
hsa-miR-301a-3p 0.030 1.053 
hsa-miR-23a-3p 0.031 1.089 
hsa-miR-454-3p 0.031 0.556 
hsa-miR-4728-3p 0.031 -0.209 
hsa-miR-5002-5p 0.032 -0.347 
hsa-miR-340-3p 0.032 0.226 
hsa-miR-4459 0.033 0.190 
hsa-miR-19b-3p 0.037 -0.774 
hsa-miR-519b-3p 0.037 -0.774 
hsa-miR-135b-5p 0.037 1.584 
hsa-miR-24-3p 0.037 1.095 
hsa-miR-1825 0.037 -0.197 
hsa-miR-1247-5p 0.037 0.207 
hsa-miR-4472 0.039 0.287 
hsa-miR-1184 0.039 0.317 
hsa-miRPlus-G1246-3p 0.039 -0.479 
hsa-miR-485-3p 0.040 0.141 
hsa-miR-652-5p 0.041 0.165 
hsa-miR-4301 0.042 0.871 
hsa-miR-331-3p 0.043 0.702 
hsa-miR-4726-5p 0.044 0.428 
hsa-miR-197-3p 0.044 0.245 
hsa-miR-335-5p 0.044 0.887 
hsa-miR-4732-5p 0.045 0.687 
hsa-miR-96-5p 0.045 -0.332 
hsa-miR-3621 0.050 -0.392 
hsa-miR-302e 0.051 -0.449 
hsa-miR-371a-5p 0.051 -0.474 
hsa-miR-320c 0.051 0.700 
hsa-miR-4531 0.051 0.373 
hsa-miR-22-3p 0.052 0.677 
hsa-miR-4289 0.053 0.570 
hsa-let-7a-5p 0.053 0.599 
hsa-miR-483-3p 0.053 0.537 
hsa-miR-4429 0.055 0.593 
hsa-let-7e-5p 0.056 0.690 
hsa-miR-302f 0.057 -0.554 
hsa-miR-638 0.057 0.344 
hsa-miR-204-3p 0.057 0.339 
hsa-miR-30e-3p 0.057 0.608 
hsa-miR-4657 0.057 -0.415 
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hsa-miR-519d 0.057 -0.440 
hsa-miR-3607-3p 0.057 -0.692 
hsa-miR-484 0.057 0.138 
hsa-miR-193a-3p 0.057 0.327 
hsa-miR-340-5p 0.060 0.579 
hsa-miR-30d-5p 0.060 0.424 
hsa-miR-3611 0.060 0.740 
hsa-miR-320a 0.062 0.614 
hsa-miR-27a-3p 0.062 0.536 
hsa-miR-15a-5p 0.062 0.706 
hsa-miR-374a-5p 0.063 0.580 
hsa-miR-148b-3p 0.064 0.369 
hsa-miR-711 0.064 0.144 
hsa-miR-1275 0.064 0.470 
hsa-miR-744-5p 0.064 0.548 
hsa-miR-342-3p 0.064 0.809 
hsa-miR-585 0.064 0.212 
hsa-miR-3607-5p 0.064 -0.530 
hsa-miR-874 0.064 -0.268 
hsa-miR-200b-3p 0.064 -0.496 
hsa-miR-26b-5p 0.065 0.569 
hsa-miR-302a-5p 0.065 -0.606 
hsa-miR-149-3p 0.065 0.482 
hsa-miR-30b-5p 0.065 0.719 




hsa-miR-877-5p 0.065 0.357 
hsa-miR-185-5p 0.066 0.184 
hsa-miR-93-5p 0.066 0.829 
hsa-miR-9-3p 0.066 0.257 
hsa-miR-659-3p 0.066 0.257 
hsa-miR-551b-3p 0.066 0.831 
hsa-miR-4417 0.066 -0.315 
hsa-miR-1915-3p 0.067 -0.912 
hsa-miR-4644 0.069 0.474 
hsa-miR-516b-5p 0.072 -0.276 
hsa-miR-106b-5p 0.073 0.852 
hsa-miR-4739 0.073 0.302 
hsa-miR-25-3p 0.073 0.560 
hsa-miR-3182 0.073 1.413 
hsa-miR-4497 0.073 -0.276 
hsa-miR-182-5p 0.073 -0.393 
hsa-miR-4284 0.076 -0.616 
hsa-miR-149-5p 0.077 0.552 
hsa-miR-27b-3p 0.077 0.550 
hsa-miR-4795-5p 0.078 -0.202 
hsa-miR-3178 0.082 -0.291 
hsa-let-7i-5p 0.083 -0.443 
hsa-miR-4776-3p 0.086 -0.501 
hsa-miR-378a-3p 0.086 -0.356 
hsa-miR-5100 0.090 0.522 
hsa-miR-373-3p 0.092 -0.385 
hsa-miR-664-3p 0.092 -0.098 
hsa-miR-1587 0.092 0.401 
hsa-miR-200c-3p 0.092 -0.295 
hsa-miR-3124-3p 0.092 0.358 
hsa-miR-4698 0.093 0.383 
hsa-miR-4708-3p 0.094 0.355 
hsa-miR-16-5p 0.096 0.643 
hsa-miR-4421 0.096 0.341 
hsa-miR-4787-5p 0.096 0.249 
hsa-miR-29a-3p 0.096 -0.326 
hsa-miR-4292 0.096 0.232 





Supplementary Table 6 
H1: Differentiated vs. Undifferentiated 
miRNA p-value logFC 
hsa-miR-3158-5p 0.048 -0.849 
hsa-miR-375 0.048 0.404 
hsa-miR-4639-3p 0.063 -0.443 
hsa-miR-107 0.075 0.807 
hsa-miR-3621 0.075 -0.799 
hsa-miR-125a-5p 0.075 0.706 
hsa-miR-378a-3p 0.075 -0.184 
hsa-miR-181a-5p 0.075 1.216 
hsa-miR-193b-3p 0.075 1.116 
hsa-miR-3941 0.077 -0.462 
hsa-miR-708-5p 0.083 1.095 
hsa-miR-93-5p 0.083 0.538 
hsa-miR-4732-3p 0.083 -0.864 
hsa-miR-320a 0.083 0.859 
hsa-miR-23a-3p 0.083 1.284 
hsa-miR-181d 0.083 1.284 
hsa-miR-23b-3p 0.083 1.370 
hsa-miR-4436b-5p 0.083 -0.446 
hsa-miR-24-3p 0.083 0.984 
hsa-miR-4285 0.083 -0.868 
hsa-miR-99b-5p 0.083 0.973 
hsa-miR-331-3p 0.083 0.861 
hsa-miR-877-5p 0.083 0.237 
hsa-miR-103a-3p 0.084 1.001 
hsa-miR-20a-5p 0.084 0.759 
hsa-miR-27b-3p 0.084 1.400 
hsa-miR-17-5p 0.084 0.807 
hsa-miR-18b-5p 0.084 0.783 
hsa-miR-26b-5p 0.084 0.659 
hsa-miR-27a-3p 0.084 1.278 
hsa-miR-4289 0.084 0.635 
hsa-miR-151a-3p 0.084 0.780 
hsa-miR-302b-3p 0.084 -0.278 
hsa-miR-9-3p 0.084 0.933 
hsa-miR-483-5p 0.084 0.896 
hsa-miR-151a-5p 0.084 0.824 
hsa-miR-135b-5p 0.084 0.946 
hsa-miR-181b-5p 0.084 0.774 
hsa-miR-30d-5p 0.084 0.576 




hsa-miR-744-5p 0.084 0.430 
hsa-miR-423-3p 0.084 0.643 
hsa-miR-191-5p 0.084 0.511 
hsa-miR-130a-3p 0.084 0.571 
hsa-miR-5701 0.084 0.640 
hsa-miR-320c 0.084 1.068 
hsa-miR-5572 0.084 0.367 
hsa-miR-124-5p 0.084 -0.438 
hsa-miR-1255a 0.084 -0.347 




hsa-miR-320b 0.086 0.890 
hsa-miR-92a-3p 0.088 0.624 
hsa-miR-5002-5p 0.088 -0.454 
hsa-miR-374a-5p 0.088 0.768 
hsa-miR-200c-3p 0.088 1.019 
hsa-miR-516b-5p 0.088 -0.190 
hsa-miR-4306 0.088 0.501 
hsa-miR-4429 0.088 0.318 
hsa-miR-106a-5p 0.088 0.804 
hsa-miR-149-3p 0.088 0.581 
hsa-miR-3651 0.088 0.560 
hsa-miR-3935 0.089 -0.336 
hsa-miR-361-5p 0.090 0.313 
hsa-miR-32-3p 0.090 -0.361 
hsa-miR-4472 0.098 0.358 




Supplementary Table 7 
H1 Undifferentiated vs. iPSC Undifferentiated 
miRNA LogFC p-value 
hsa-miR-363-3p -0.7661 0.0288 
hsa-miR-371a-3p 1.9052 0.0288 
hsa-miR-3183 -0.287 0.0288 
hsa-miR-4417 1.1804 0.0288 




Supplementary Table 8 
Undifferentiated H9 vs. iPSC Undifferentiated 
miRNA LogFC p-value 
hsa-miR-4726-5p -0.7851 0 
hsa-miR-4534 -1.5359 0 
hsa-miR-92a-3p 1.1306 0 
hsa-miR-302a-3p 1.3641 0 
hsa-miR-29a-3p -2.866 0 
hsa-miR-5701 0.8753 0 
hsa-miR-302a-5p 1.2003 0 
hsa-miR-200c-3p -2.1629 0 
hsa-miR-423-3p 1.2172 0 
hsa-miR-4417 2.492 0 
hsa-miR-92b-3p 1.3856 0 
hsa-miR-17-5p 1.4209 0 
hsa-miR-675-5p -1.067 0 
hsa-miR-302f 1.2158 0.0001 
hsa-miR-106a-5p 1.4449 0.0001 
hsa-miR-4714-5p 1.1868 0.0001 
hsa-miR-130b-3p 1.4614 0.0001 
hsa-miR-363-3p 1.7939 0.0001 
hsa-miR-18b-5p 1.308 0.0001 
hsa-miR-20a-5p 1.2902 0.0001 
hsa-miR-22-3p -2.0891 0.0001 
hsa-miR-29b-3p -2.0441 0.0001 
hsa-miR-302c-3p 1.4419 0.0001 
hsa-miR-4289 1.1549 0.0001 
hsa-miR-3651 0.8524 0.0001 
hsa-miR-659-3p -0.9603 0.0001 
hsa-miR-4501 -2.7858 0.0001 
hsa-miR-30c-1-3p -0.7297 0.0001 
hsa-miR-4780 1.0119 0.0001 
hsa-miR-425-5p 0.7575 0.0001 
hsa-miR-125b-5p -2.8101 0.0001 
hsa-miR-361-5p 0.8992 0.0001 
hsa-miR-17-3p 1.1663 0.0001 
hsa-miR-4451 0.4071 0.0001 
hsa-miR-4657 0.9052 0.0002 
hsa-miR-103a-3p 1.2669 0.0002 
hsa-miR-3175 0.7094 0.0002 
hsa-miR-4508 -1.1411 0.0002 
hsa-miR-20b-5p 1.3988 0.0002 
hsa-miR-302d-5p 0.6607 0.0002 
hsa-miR-199a-3p -1.8071 0.0002 
hsa-miR-3156-3p 0.3042 0.0002 
hsa-miR-3654 0.628 0.0002 
hsa-miR-4791 0.7508 0.0002 
hsa-miR-106b-5p 0.95 0.0002 
hsa-miR-3607-3p 1.0385 0.0003 
hsa-miR-199a-5p -1.5709 0.0003 
hsa-miR-4532 -0.891 0.0003 
hsa-miR-19b-3p 1.2728 0.0003 
hsa-miR-151a-5p 0.7496 0.0003 
hsa-miR-107 1.1011 0.0003 
hsa-miR-151a-3p 0.5477 0.0003 
hsa-miR-4484 -1.7824 0.0003 
hsa-miR-767-5p 0.5764 0.0003 
hsa-miR-5684 0.5542 0.0004 
hsa-miR-302b-3p 1.209 0.0005 
hsa-miR-4419b -0.4261 0.0005 
hsa-miR-3607-5p 0.8728 0.0006 
hsa-miR-4747-5p -1.325 0.0006 
hsa-miR-1275 -0.763 0.0006 
hsa-miR-31-5p -1.2817 0.0007 
hsa-miR-936 -1.4002 0.0007 
hsa-miR-491-3p -1.1362 0.0007 
hsa-miR-302e 1.1314 0.0007 
hsa-miR-130a-3p 0.878 0.0008 
hsa-miR-708-5p 0.9549 0.0009 
hsa-miR-151a-5p 0.9931 0.001 
hsa-miR-302d-3p 0.903 0.001 
hsa-miR-30c-5p 0.6628 0.001 
hsa-miR-214-3p -1.3979 0.0011 
hsa-miR-141-3p -1.197 0.0011 
hsa-miR-148b-3p 0.5392 0.0011 
hsa-miR-30b-5p 0.7513 0.0012 
hsa-miR-302b-5p 0.8361 0.0013 
hsa-let-7g-5p -1.345 0.0013 
hsa-miR-4324 -1.3979 0.0014 
hsa-miR-25-3p 0.4876 0.0014 
hsa-miR-18a-3p 0.6839 0.0014 
hsa-let-7d-5p -1.3636 0.0014 
hsa-miR-493-5p 0.8346 0.0014 
hsa-miR-320c 0.6394 0.0014 
hsa-miR-520c-3p 1.0857 0.0014 
hsa-let-7a-5p -1.1651 0.0014 
hsa-miR-3133 0.5877 0.0014 
hsa-miR-135b-5p 1.34 0.0016 
hsa-miR-200b-3p 0.8383 0.0017 
hsa-miR-93-5p 0.8043 0.0017 
hsa-miR-135a-5p 0.7005 0.0017 
hsa-miR-3201 -0.7565 0.0017 
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hsa-miR-1827 -1.5736 0.0018 
hsa-miR-320a 0.4886 0.0021 
hsa-miR-3611 -0.9106 0.0023 
hsa-miR-19a-3p 0.7899 0.0024 
hsa-miR-1323 1.1581 0.0027 
hsa-miR-124-3p 0.9673 0.0028 
hsa-miR-4299 -0.8917 0.0029 
hsa-miR-34c-5p -0.8611 0.0031 
hsa-miR-4279 -0.4803 0.0032 
hsa-miR-1915-3p 1.53 0.0032 
hsa-miR-3124-3p -0.5258 0.0032 
hsa-miR-320b 0.5851 0.0032 
hsa-miR-4698 -0.4379 0.0033 
hsa-miR-4732-3p -0.7974 0.0033 
hsa-let-7e-5p -0.5298 0.0034 
hsa-miR-21-5p -0.9867 0.0034 
hsa-miR-3653 0.6117 0.0034 
hsa-miR-155-5p -1.0108 0.0034 
hsa-miR-335-3p 0.3802 0.0037 
hsa-miR-4800-5p -1.1052 0.0038 
hsa-miR-106b-3p 0.6589 0.0041 
hsa-miR-4284 0.7562 0.0044 
hsa-miR-340-5p 0.3042 0.0044 
hsa-miR-342-3p 0.7927 0.0045 
hsa-miR-4467 -0.5179 0.0046 
hsa-miR-3960 -0.4991 0.0046 
hsa-miR-3976 -0.2943 0.0049 
hsa-miR-373-3p -1.9053 0.005 
hsa-miR-4473 -0.7435 0.0052 
hsa-miR-4459 -0.3123 0.0052 
hsa-miR-193a-3p -0.6587 0.0058 
hsa-miR-191-5p 0.7436 0.006 
hsa-miR-454-3p 0.5659 0.006 
hsa-miR-34a-5p 0.6457 0.006 
hsa-let-7i-5p -0.9706 0.006 
hsa-miR-367-3p 0.7045 0.0061 
hsa-miR-4421 -0.3504 0.0062 
hsa-miR-371a-3p -1.4247 0.0064 
hsa-miR-4285 -0.6305 0.0064 
hsa-miR-302c-5p 0.4494 0.0065 
hsa-miR-4436b-5p -0.4399 0.0069 
hsa-miR-3687 0.4422 0.0072 
hsa-miR-23a-3p -0.9405 0.0074 
hsa-miR-4429 -0.6818 0.0075 
hsa-miR-424-5p -0.4962 0.0075 
hsa-miR-3195 1.0117 0.0081 
hsa-miR-3676-3p 0.9271 0.0081 
hsa-miR-5100 -0.6512 0.0081 
hsa-miR-483-3p -0.7586 0.0081 
hsa-miR-4787-5p -0.4608 0.0087 
hsa-miR-4454 -0.6105 0.0089 
hsa-miR-711 -0.6411 0.0093 
hsa-miR-331-3p 0.4765 0.01 
hsa-miR-518b 0.3005 0.0112 
hsa-miR-3924 -0.9507 0.0118 
hsa-miR-143-3p -0.8403 0.0119 
hsa-miR-1264 -0.1717 0.0122 
hsa-let-7c -0.8383 0.0123 
hsa-miR-197-3p 0.239 0.0123 
hsa-miR-30e-5p 0.4951 0.0144 
hsa-miR-516b-5p 0.2407 0.0144 
hsa-miR-1273g-3p 0.361 0.0144 
hsa-miR-4521 0.6734 0.0144 
hsa-miR-2355-3p -1.0654 0.0158 
hsa-miR-15b-5p 0.5924 0.0158 
hsa-miR-183-5p 0.679 0.016 
hsa-miR-642b-5p -0.4632 0.0174 
hsa-miR-1285-3p 0.3901 0.018 
hsa-miR-585 0.6848 0.0184 
hsa-miR-874 1.0185 0.0198 
hsa-miR-4708-3p -0.438 0.0215 
hsa-miR-27b-3p 0.5597 0.0226 
hsa-miR-96-5p 0.2815 0.0248 
hsa-miR-140-3p 0.6235 0.027 
hsa-miR-27a-3p -0.4178 0.0274 
hsa-miR-15a-5p 0.4883 0.0274 
hsa-miR-548an 0.4548 0.0277 
hsa-miR-638 0.3622 0.0278 
hsa-miR-3656 0.5232 0.0278 
hsa-miR-4531 -0.2953 0.0283 
hsa-miR-664-3p 0.2758 0.0285 
hsa-miR-5193 0.3082 0.0302 
hsa-miR-16-5p 0.5091 0.0308 
hsa-miR-4712-3p 0.2608 0.0311 
hsa-miR-4716-5p 0.1746 0.0323 
hsa-miR-548ap-5p 0.5216 0.0333 
hsa-miR-374b-5p 0.8743 0.0337 
hsa-miR-4784 -0.3031 0.0358 
hsa-miR-4500 -0.4531 0.0363 
hsa-miR-24-3p -0.6587 0.0369 
hsa-miR-1587 -0.4785 0.0382 
hsa-miR-205-3p -0.3022 0.0383 
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hsa-miR-4530 -0.5563 0.0416 
hsa-miR-374c-5p 0.7103 0.0437 
hsa-miR-99b-5p -0.5374 0.0464 
hsa-miR-371a-5p -1.1702 0.0466 
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Appendix 3: List of Reagents 
Reagent Supplier 
100% Ethanol Sigma 
100bp DNA Ladder Promega 
1kbp DNA Ladder Promega 
2x Sensimix Plus Bioline 
5x PCR Reaction Buffer Promega 
5x Reverse Transcription Reaction Buffer Promega 
6x Blue/Orange Loading Dye Promega 
Accutase™ Stem Cell Technologies 
Activin A R & D Systems 
Agarose Sigma 
Alkaline Phosphatase Detection Kit Millipore 
AllPrep DNA/RNA/Protein mini kit Qiagen 
B27® Supplement Invitrogen 
bFGF Invitrogen 
Blasticidin Sigma 
BMP4 R & D Systems 
Chloroform Sigma 







Ethidium Bromide Sigma 
Ethylene Glycol Sigma 
Exendin4 R & D Systems 
FuGENE® 6 Transfection Reagent Promega 
Geneticin Invitrogen 
Glycerol Stocks Of E. Coli Containing pMX Plasmids Addgene 
Goat Anti-Human Oct4 IgG Abcam 
Goat Anti-Human Sox17 IgG Abcam 
Goat Anti-Mouse IgG + IgM (FITC) Abcam 
Goat IgG Abcam 
GoTaq Polymerase Promega 
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HEPES Buffer Invitrogen 
HGF R & D Systems 




IGF-1 R & D Systems 
KAAD-Cyclopamine Millipore 
KGF R & D Systems 
Knockout Serum Replacement Invitrogen 
L-Glutamine Invitrogen 
Lipofectamine 2000 ® Invitrogen 
Matrigel™ BD 
MgCl2 Promega 
miArrest™/miExpress™ miRNA Lentiviral Vectors Genecopoeia 
miRNeasy™ Mini Kit Qiagen 
miScript™ Reverse Transcription Kit Qiagen 
miScript™ SYBR Green PCR Kit Qiagen 
miTarget ™ 3’UTR-Luciferase Reporter Constructs Genecopoeia 
Mitomycin C Sigma 
MMLV Reverse Transcriptase Promega 
Mouse Anti-Human TRA-1-81 IgM UK Stem Cell Bank 
Mouse IgG Abcam 
mTeSR-1™ Stem Cell Technologies 
Nanog Antibody Abcam 
Noggin R & D Systems 
Non-Essential Amino Acids Invitrogen 
Oligo(DT)15 Primers Promega 
Opti-MEM Invitrogen 
PCR-Grade Water Sigma 
Penicillin-Streptomycin Invitrogen 
pLenti6-mSlc7a1 Plasmid AddGene 
Polybrene Sigma 
Puromycin Sigma 
QIAquick Gel Extraction Kit Qiagen 
Rabbit Anti-Goat Alexafluor® 488 Abcam 
Random Primers Promega 
Retinoic Acid Sigma 
RNA 6000 Nano Bioanalyzer Chips Agilent 
RNA 6000 Nano Bioanalyzer Reagents Agilent 
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RNase-Free DNase Kit Qiagen 
RNAsin Promega 
RNeasy Mini Kit Qiagen 
RPMI Invitrogen 
SecretePair™ Dual Luminescence Assay Kit Genecopoeia 
SNAP Midiprep Kit Invitrogen 
Sodium Pyruvate Invitrogen 
TRA-1-60 StainAlive Dye Stemgent 
Trypan Blue Sigma 
Trypsin/EDTA Sigma 
Valproic Acid Sigma 
VEGF R & D Systems 
Virapower Lentiviral Expression System Invitrogen 
Wnt3A R & D Systems 
Y-27632 Sigma 
β –Mercaptoethanol (50mM) Invitrogen 
β-Mercaptoethanol Sigma 
 
